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1. Introduction and aims of the present thesis work 
 
Psychiatric disorders are ‘complex diseases’ (Meyer-Lindenberg et al. 2006, Craddock et al. 
2007). They do not segregate in a Mendelian manner within families and are influenced by 
both genetic and environmental factors (Visscher et al. 2012). As has been revealed by twin 
and adoption studies, a large proportion of the phenotypic variation of psychiatric conditions 
like schizophrenia and autism can be attributed to additive genetic effects (80%-90%) 
(Cardno et al. 1999, Sullivan et al. 2003). The methodological approaches to unravel the 
genetic architecture of common psychiatric conditions range from candidate gene studies 
(Gurling 1986), over linkage studies (Risch et al. 1993) to hypothesis-free designs such as 
genome-wide association studies (GWAS) (Cichon et al. 2009, Bondy 2011). Although being 
the most widely applied genetic paradigm in the past decade, GWA studies have lagged 
behind high expectations (Girard et al. 2012, Visscher et al. 2012). 
 
GWAS rely on the artificial dichotomization of multi-dimensional quantitative traits  
GWA studies compare the allele frequency of genetic markers like single nucleotide 
polymorphisms (SNPs) between unrelated individuals carrying a clinical diagnosis (cases) 
and healthy subjects (controls) (Cichon et al. 2009, Bondy 2011). These studies draw on the 
principle of linkage disequilibrium (LD), which refers to the non-random association between 
alleles at different loci. Although 90% of human genetic variation is ancient, new mutations 
contributing to an increase or decrease in disease risk constantly emerge in populations 
(McClellan et al. 2010). By random drift or natural selection some of these mutations can 
become more frequent in the population (Kimura 1976, Hartl et al. 1997). These causal 
variants will be associated by LD with SNPs that are contained on SNP arrays produced by 
commercial companies. The included ‘tag SNPs’ capture a major part of the common 
genomic variation in the human population. The scientific community hoped for a majority of 
causal variants across the entire genome to be accounted for by the ‘SNP chips’(Visscher et 
al. 2012). Thus, GWA studies were expected to explain a major part of the heritability of 
psychiatric disorders such as schizophrenia (Visscher et al. 2012). This chronic disorder, 
characterized by bizarre delusions as its unique feature but also by hallucinations, negative 
symptoms and cognitive decline, affects about one person in 100 and usually strikes in late 
adolescence or early adulthood (Bleuler 1979). Although not long ago scientists sought to 
discover the ‘schizophrenia gene’ (Slater 1958), results in support of the polygenic theory of 




have been found to be differentially distributed between schizophrenic cases and controls. 
The number of detected variants per study increased with augmenting sample sizes. 
Disappointingly, only few results could be replicated across studies (Visscher et al. 2012). 
Among the most replicated GWAS results are markers in the major histocompatibility 
complex region and in TCF4, ZNF804A and neuregulin1 genes (Stefansson et al. 2009, 
Steinberg et al. 2011, Steinberg et al. 2011). The limited reproducibility of GWAS results can 
be partially attributed to odds ratios (OR) below 1.5 (as they are generally identified by 
GWAS) which can be explained by cryptic population stratification (McClellan et al. 2010). 
As a result, the most replicated major ‘GWAS hits’ together explain less than 1% of the 
variance in liability to schizophrenia (Visscher et al. 2012).  
 
Unclear biological relevance of common genetic variants associated with schizophrenia   
GWAS are by design biased towards detection of association with causal genetic variants that 
are relatively common in the population because they are based on the principle of LD 
(Visscher et al. 2012). Besides common genetic variation, highly penetrant rare variants of 
large effect (such as copy number variations) have been reported to be associated with the risk 
for schizophrenia in the past years (Bassett et al. 2010, Owen et al. 2010, Rapoport et al. 
2011). Presently, whether most genetic variation contributing to complex traits is caused by 
rare or common variants is controversially discussed (Risch et al. 1996, Visscher et al. 2012). 
GWA studies were useful in indicating that multiple common SNPs of small effect sizes are 
implicated in common psychiatric conditions (Purcell et al. 2009). In a recent report it was 
estimated that 23% of variation in susceptibility to schizophrenia can be explained when all 
SNPs represented across the current generation of GWAS arrays are considered 
simultaneously (Lee et al. 2012). Findings from GWA studies imply that we all might carry 
some risk variants but our systems are robust to their effects due to compensatory 
mechanisms. In affected individuals, the burden of risk variants might be too high to be 
efficiently compensated for. Consequently, common genetic variation seems to play an 
important role in explaining schizophrenia heritability and will be the focus of the present 
thesis work. Nevertheless, although associated with the endpoint diagnosis of schizophrenia, 
the GWAS ‘top-10’ SNPs individually or upon their accumulation do not seem to modulate 
the severity of lead symptoms of schizophrenia (Papiol et al. 2011) (see attachment, co-
authorship III ). Putative functional implications of genes emerging from GWAS are often 
derived from their involvement in particular molecular networks (Luo et al. 2013). It remains 
unclear, however, how the pathways enriched for genetic variants associated with a 
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schizophrenia diagnosis; modulate particular phenotypic features of the condition. 
Consequently, the vast majority of the variants resulting from GWAS and have no established 
































Figure 1 Example of possible subphenotypes resulting from a decomposition of schizophrenia into 
quantitative traits. When assessed with adequate psychometric measures (i.e. neuropsychological tests, 
questionnaires, behavioral assays) in a non-selected population of individuals, many dimensional phenotypes 
are normally distributed. For some assessment tools, high scores may reflect better function (i.e. cognitive 
variables, first row) whereas as for others low (i.e. neurological signs) or intermediate scores (anxiety 
sensitivity) may be most functional/adaptive. Individuals belonging to different diagnostic categories and 
healthy controls can be allocated along the different behavioral dimensions (every person is assigned a score 
for each ‘micro-phenotype’). Schizophrenic patient 1 and 2 (gray circles) differ substantially in terms of the 
behavioral expression of certain traits exemplifying the tremendous amount of variability within a group of 
schizophrenic cases. Likewise, an individual who does not have a clinical diagnosis (white circle) might score 
towards the dysfunctional end of certain behavioral dimensions. The same holds true for individuals carrying 
an affective or autism spectrum disorder diagnosis suggesting overlapping biological pathways relevant for 
seemingly distinct diagnostic entities. Some of the depicted phenotypes are relevant for the projects included 
in this thesis. 
Healthy control subject
1 Patient 1 with diagnosis of schizophrenia
2 Patient 2 with diagnosis of schizophrenia
3 Patient with diagnosis of major depression
4 Patient with diagnosis of autism spectrum disorder
5
Low score superior function
High score superior function
Intermediate score superior function
Behavioral expression of the dimensional trait
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Phenotypic approaches to the ‘missing heritability’ of schizophrenia 
How can the ‘missing heritability’ of schizophrenia be uncovered? Many researchers suppose 
that genome-wide studies will ultimately lead to a higher amount of explained variance in the 
liability to schizophrenia when sample sizes are increased such that variants of smaller effects 
can be detected (Cichon et al. 2009, Sullivan 2012). Others believe that describing the real 
causal variants using deep-sequencing will substantially contribute to our understanding of 
the genetic architecture of schizophrenia (Duan et al. 2010, Myers et al. 2011). However, 
these approaches neglect the very important fact that schizophrenia is a syndrome comprising 
many different behavioral domains which are differentially pronounced across affected 
individuals. The present thesis work is based on the assumption that a decomposition of 
schizophrenia into single quantitative behavioral dimensions will assist in delineating the 
functional relevance of certain genes by elucidating their influence on particular aspects of the 
phenotype (phenotype-based genetic association study). Additionally, alternatively to ever 
increasing sample sizes, it will lead to a substantial increase in statistical power. 
 
Reducing inter-individual variability by decomposing schizophrenia into quantitative traits 
The tremendous amount of intra-group variability can be partly ascribed to the fact that 
schizophrenia is not a one-dimensional phenomenon. It can be conceptualized as composed of 
various continuous behavioral dimensions which can be assessed quantitatively (Figure 1) 
(Plomin et al. 2009). Schizophrenia is not homogeneous either. Given the manifold inter-
individual phenotypic expressions of schizophrenia symptoms (compare schizophrenia patient 
1 and 2 in Figure 1); the integrity of more than one biological pathway is likely to be 
compromised in this disease (Lee et al. 2013). Thus, certain phenotypically definable 
subgroups of patients likely differ as to the predominant involvement of certain biological 
pathways. As a result, a large amount of ‘noise’ reducing statistical power in GWA studies 
stems from inter-individual heterogeneity in symptom composition. 
 
Achieving genetic inter-group separation by contrasting the extremes of quantitative traits  
GWAS rely on the classification of individuals as cases and controls although this 
dichotomization is rather artificial (Gottesman et al. 1967). Besides the presence of certain 
sets of symptoms, a clinical diagnosis requires a person to experience subjective 
psychological burden or to not function vocationally or socially anymore. This largely 
depends on the degree of misfit between individual and environment and on how well certain 
functions are compensated for by the social network. Along the same lines, population 
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research revealed high rates of psychotic experiences (4-8%) in people who are not 
diagnosable according to the current classification systems (van Os et al. 2012). Literature 
suggests a psychometric continuum in the sense of an extended psychosis phenotype sharing 
etiological factors with the clinical disorder (van Nierop et al. 2011, van Os et al. 2012). 
Consequently, if schizophrenia is conceptualized as composed of various quantitative 
behavioral traits, many of the putative ‘controls’ are nearly cases (Figure 1; e.g. ‘excitability’ 
and ‘compulsivity’) (Plomin et al. 2009). This further diminishes the likelihood of detecting 
etiologically meaningful differences between the groups. Consequently, statistical power can 
be significantly enhanced by comparing the low and high extremes of quantitative phenotypes 
(see projects II and V) or by studying the entire trait distribution with respect to certain 
candidate genes or functional gene complexes (compare projects I; III and IV). 
 
Aims of the present thesis work  
Defining quantitative subphenotypes is indispensable for understanding how common genetic 
variants modulate phenotypes of psychiatric disorders and for how molecular biological 
processes mediate the relationship between genetic and phenotypic variation. My scientific 
work has been devoted to the operationalization, quantification and validation of complex 
phenotypes underlying psychiatric disorder like schizophrenia, using the GRAS (Göttingen 
Research Association for Schizophrenia) data collection (Ribbe et al. 2010) (for a detailed 
description see attachment, co-authorship I). Moreover, I was responsible for the statistical 
analyses of associations of candidate genes with these quantitative phenotypes. Hypotheses 
for specific genotype-phenotype relationships were derived from the genes’ established 
molecular functions and/or from studies with mouse models of loss-and gain-of function of 
the respective proteins. Projects I-IV provide proof-of-concept for our phenotype-based 
genetic association study (PGAS) approach by elucidating the association of certain candidate 
genes with specific continuous behavioral variables in the schizophrenic GRAS sample 
(project I: EPO/EPOR & higher cognition; project II: Neuregulin1 & central olfactory 
processing; project III: GPM6A & claustrophobic anxiety; project IV: MECP2 & impulsive 
aggression). Ultimately, progress in etiological research leading to the development of new 
therapeutic targets will require the definition of more homogeneous disease subgroups based 
on highly intercorrelated quantitative phenotypes. Project V of the present work will give an 
example of the phenotypic definition of an autistic subgroup of patients with schizophrenia 
which will provide the ground for a future definition of a clinically relevant biological 




2. EPO and EPOR variants modulate cognitive performance in 
schizophrenia 
 
2.1 Overview of project I 
 
Besides stimulating erythropoiesis (Adamson 1996), erythropoietin (EPO) and its receptor 
(EPOR) were repeatedly shown to have neurothrophic, angiogenic, anti-oxidative, anti-
inflammatory, anti-apoptotic, and stem cell modulating properties in vitro and in vivo (Brines 
et al. 2005, Sargin et al. 2010). The observation that EPOR receptor (EPOR) is expressed in 
neural cells (Morishita et al. 1997) and that EPO is endogenously produced in the brain in a 
hypoxia-dependent way (Marti 2004), gave rise to the notion that the endogenous EPO/EPOR 
system serves important neuroprotective functions in non-hematopoietic tissues like the brain. 
Indeed, evidence supporting a neuroprotective effect for recombinant human erythropoietin 
(rhEPO) in stroke, schizophrenia, multiple sclerosis and even healthy individuals accumulated 
over the past years (Ehrenreich et al. 2008, Siren et al. 2009). In these studies beneficial 
effects of rhEPO regarding stroke outcome measures, cognition and gray matter loss were 
revealed (Ehrenreich et al. 2002, Ehrenreich et al. 2007, Ehrenreich et al. 2007, Miskowiak et 
al. 2007, Bartels et al. 2008, Ehrenreich et al. 2011, Wüstenberg et al. 2011) (see co-
authorship II). Both in schizophrenic and healthy individuals, the cognitive improvement 
induced by rhEPO was most pronounced in the domains ‘speed of processing’ and 
‘immediate memory’. Importantly, these effects could not be accounted for by an increase in 
hemoglobin (Miskowiak et al. 2007).  
 
Various studies focus on the phenotypic relevance of the endogenous EPO/EPOR system by 
searching for associations of EPO and EPOR genetic markers with myeloprolieferative/-
dysplastic syndromes or diabetic retinopathy. Many of them remain inconsistent, especially 
for the EPO gene (de la Chapelle et al. 1993, Sokol et al. 1993, Sokol et al. 1994, Arcasoy et 
al. 1997, Furukawa et al. 1997, Kralovics et al. 1997, Percy et al. 1997, Watowich et al. 1999, 
Jedlickova et al. 2003, Petersen et al. 2004, Tong et al. 2008, Abhary et al. 2010, Ma et al. 
2010). Although the positive influence of exogenously administered rhEPO on cognition is 
quite established, the modulatory influence of the EPO and EPOR genes on cognitive 





As proof-of-concept of our phenotype-based genetic association study approach, we aimed at 
investigating whether common genetic variants in the EPO and EPOR genes modulate 
cognitive functioning in the schizophrenic GRAS sample. To support our assumption that 
genotype-phenotype relationships are independent of clinical diagnoses, we intended to 
replicate our findings in a phenotyped control population from Munich (van den Oord et al. 
2008). 
 
For the EPO gene, two single nucleotide polymorphisms (SNPs) located in functionally 
interesting regions (5’ upstream and the 3’ regulatory region) were selected and genotyped: 
rs167640 (T/G) and SNP rs56444 (T/G). To cover variability in the EPOR gene, we chose the 
short tandem repeat (STR) STR (GA)n in the EPOR 5’ upstream area. In order to compare 
results in patients and healthy controls, relevant cognitive domains (speed of processing and 
perceptual organization) were operationalized by either using the same test or by using a 
measure previously shown by factor analysis to share a common source of underlying 
statistical variance (Berger 1998). Unfortunately, short-term memory function could only be 
assessed in the patients as no such measure was available for the replicate sample. By 
employing statistical models correcting for possible confounding factors (such as medication 
and negative symptoms), we found carriers of the G allele in the EPO SNP rs167640 and of 
EPOR STR (GA)n low repeat sum to be superior in all selected neuropsychological readouts. 
Interestingly, carriers of one particular combination of EPO and EPOR genotypes (GG 
genotype and 21-35 repeat sums, ‘GG & 21-35’) were found to outperform all other patients. 
In the healthy control sample, essentially all phenotype-genotype associations could be 
reproduced, except for the advantage of the ‘GG & 21-35’ genotype combination. However, 
when analyzing only those healthy subjects cognitively performing at the level of 
schizophrenic patients, a similar tendency of genotype superiority could be revealed. These 
findings suggest that a cognitive advantage of the ‘GG & 21-35’ constellation may only 
become obvious when cognitive capacities are reduced. As a next step we wondered, how this 
phenotype-genotype relationship is biologically mediated. As EPO and EPOR variants are 
located in the promoter regions of the respective genes, they are likely to influence 
transcription factor binding and thus regulability of the system. Mechanistically, we could 
demonstrate that the cognitively superior genotypes were associated with higher 
expression/regulability of gene expression. As a conclusion, thesis project I provides evidence 
for common variants in the EPO/EPOR genes to modulate cognitive performance, especially 
in patients suffering from cognitive decline but also in cognitively inferior healthy subjects. 
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2.2 Original publication 
 
Kästner, A.*, Grube, S.*, El-Kordi, A.*, Stepniak, B., Friedrichs, H., Sargin, D., Schwitulla, 
J., Begemann, M., Giegling, I., Miskowiak, K. W., Sperling, S., Hannke, K., Ramin, A., 
Heinrich, R., Gefeller, O., Nave, K. A., Rujescu, D. and Ehrenreich, H. (2012). "Common 
variants of the genes encoding erythropoietin and its receptor modulate cognitive performance 
in schizophrenia." Mol Med 18: 1029-1040. 
 
*These authors contributed equally to the work.  
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I was responsible for the selection and operationalization of the cognitive readouts for the 
schizophrenic sample and the sample of healthy controls, the statistical analyses combining 
genetic and phenotypic information, and the interpretation of data for schizophrenic patients 
and healthy controls and the design of figures and tables. Moreover, I was involved in the 






Erythropoietin (EPO), originally de-
scribed as a hematopoietic growth factor,
has been found to improve cognition al-
most since its first clinical approval for
the treatment of renal anemia, but this ef-
fect has long been attributed solely to its
indirect action via increased hemoglobin
(1). Over the last 15 years, the importance
of EPO for nonhematopoietic tissues, par-
ticularly the nervous system, has been
recognized increasingly. In addition to di-
rect neuroprotective and neuroregenera-
tive functions of the EPO system, its ef-
fects on neuroplasticity and cognition
have become evident (2–4). EPO treat-
ment has been shown to improve learning
and memory functions, not only in dis-
ease models, but also in healthy rodents
(5–7). In clinical trials on patients suffer-
ing from schizophrenia or multiple sclero-
sis, high-dose rhEPO infusions over sev-
eral months resulted in better cognitive
performance (8,9). Functional magnetic
resonance imaging 1 wk after just a single
high dose of rhEPO revealed an enhance-
ment of the hippocampal response during
memory retrieval in healthy human sub-
jects (10). Importantly, cognitive improve-
ment in these studies was not linked to an
increase in hemoglobin. Still-remaining
concerns that EPO might exert these cog-
nitive effects via enhanced hemoglobin
were further alleviated by the functional
separation of hematopoietic and neuro-
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EPO and EPO receptor (EPOR) genotypes with cognitive functions. To prove this hypothesis, schizophrenic patients (N > 1000) were
genotyped for 5′ upstream–located gene variants, EPO SNP rs1617640 (T/G) and EPOR STR(GA)n. Associations of these variants were
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protective actions using EPO variants, de-
void of hematopoietic properties (11). In
addition, neuroregenerative effects of
EPO in insects, lacking hematopoiesis,
suggest an intrinsic and phylogenetically
ancient significance of EPO for neuroplas-
ticity and cognition (12).
Studies on the role of EPO or EPOR
genotypes have focused on searching for
associations of genetic markers in these
genes with readouts of the hematopoietic
system in healthy individuals and disease
states, such as myeloproliferative or
myelodysplastic syndromes. The results
were mainly negative for EPO genotypes
(13–18), but several associations for EPOR
polymorphisms or rare mutations with
various forms of familial polycythemia
were identified (19,20). Three publications
deal with EPO genotypes in diabetic reti-
nopathy. One turned out negative (21),
whereas the other two found associations,
but the results remain contradictory since
opposing risk genotypes were described
(22,23). Another study reported an associ-
ation of an EPO genotype with age of
onset of amyotrophic lateral sclerosis (24).
No data are available yet on associations
of EPO or EPOR genotypes with brain
functions, including cognition.
We hypothesized that an inherent rele-
vance of EPO for cognitive functioning
and neuroplasticity in humans should be
reflected by associations of EPO and
EPOR genotypes with selected readouts of
cognitive performance and might be un-
covered in a disease characterized by cog-
nitive decline. To test these hypotheses, we
exploited the GRAS (Göttingen Research
Association for Schizophrenia) data collec-
tion, which provides a unique ground for
phenotype-based genetic association stud-
ies (PGAS) with information on over 1,000
well-characterized schizophrenic patients
(25,26). We show here that in this popula-
tion, as well as in a healthy replicate sam-
ple, EPO/EPOR genotypes are associated
with several domains of higher cognition.
Moreover, on the basis of reporter gene as-
says and mouse studies, we propose that
better performance is linked to higher




Disease sample. The GRAS data col-
lection was approved by the ethics com-
mittee of the Georg-August-University
(master committee) and the local internal
review boards of the collaborating cen-
ters. The project complies with the
Helsinki Declaration (27). Patients fulfill-
ing DSM-IV criteria for schizophrenia or
schizoaffective disorder were included
regardless of the stage of the disease
(acute, chronic, residual or remitted). All
study participants and, if applicable,
their legal representatives gave written
informed consent (for detailed informa-
tion on the GRAS sample, see reference
26). A total of N = 1,050 GRAS patients
were successfully genotyped for the EPO
SNP (single nucleotide polymorphism
T/G) rs1617640, N = 1,054 for the EPO
SNP (T/G) rs564449, and N = 1,054 for
EPOR short tandem repeat, STR(GA)n,
and are included in the present genetic
analyses. Most GRAS patients are of Eu-
ropean Caucasian ethnicity (Caucasian
95.4%; other ethnicities 1.8%; unknown
2.8%). Peripheral blood mononuclear
cells (PBMCs) were taken from a sub-
sample of the GRAS cohort (N = 98) to
analyze mRNA expression dependent on
genotype.
Case control sample. Healthy volun-
tary blood donors were recruited by the
Department of Transfusion Medicine at
the Georg-August-University of Göttin-
gen according to national guidelines for
blood donation to serve as control sub-
jects. As such, they widely fulfill health
criteria, ensured by a broad predonation
screening process including standardized
health questionnaires, interviews and as-
sessment of hemoglobin concentration,
blood pressure, pulse and body tempera-
ture. Of the N = 1,141–1,142 successfully
genotyped control subjects, 58.9% were
male (N = 672–673) and 41.1% female (N =
469–470). The average age was 34.61 ±
12.30 y (range 18 to 69). The majority of
the control subjects were of European
Caucasian ethnicity (Caucasian 97.8%;
other ethnicities 2%; unknown 0.2%).
Independent healthy control sample
(replicate sample). Unrelated volunteers
of German descent (that is, both parents
German) were selected randomly from the
general population of Munich, Germany,
and contacted by mail (28). To exclude
subjects with central neurological diseases
and psychotic disorders or individuals
who had first-degree relatives with psy-
chotic disorders, several screenings were
conducted before volunteers were enrolled
in the study. Firstly, subjects who re-
sponded were screened initially by phone
for the absence of neuropsychiatric disor-
ders. Secondly, detailed medical and psy-
chiatric histories were obtained for both
the patients themselves as well as their
first-degree relatives by using a semistruc-
tured interview. Thirdly, if inclusion crite-
ria were fulfilled, the subjects were invited
for a comprehensive interview including
the German version of the structured clini-
cal interview for DSM-IV (SCID I and
SCID II) (29) to confirm the absence of any
lifetime psychotic disorder. Additionally,
the family history assessment module (30)
was conducted to exclude psychotic disor-
ders among first-degree relatives. Further-
more, a neurological examination was
conducted to exclude subjects with current
central nervous system impairment. In
case of volunteers being older than 60
years, the Mini-Mental State Examination
(MMSE; 31) was performed to exclude
subjects with possible cognitive impair-
ment. Written informed consent was ob-
tained from all individuals after providing
them with a detailed description of the
study, which was approved by the local
ethics committee and carried out in accor-
dance with the Helsinki Declaration (27).
Phenotype-Based Genetic
Association Study (PGAS)
Disease sample. On the basis of find-
ings of our previous EPO treatment trial
with schizophrenic patients (9), neu-
ropsychological measures of processing
speed (Digit  Symbol-Coding [Zahlen-
Symbol-Test], a subtest of German ver-
sion of Wechsler Adult Intelligence Scale
[WAIS; 32]) and perceptual organization
(subtests Dotting and Tapping from Mac-
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Quarrie Test for Mechanical Ability; 33)
were selected from the GRAS database
for phenotype–genotype association
analyses (target variables). The “Verbal
Learning and Memory Test” (Verbaler
Lern- und Merkfähigkeitstest [VLMT];
34) was included as another  target vari-
able to cover aspects of short-term mem-
ory. Additionally, to demonstrate the
specificity of genotype associations with
the selected cognitive readouts, sociode-
mographic (that is, age, gender, level of
education) and clinical variables (age at
first episode, duration of disease, med-
ication status, Positive and Negative
Syndrome Scale [PANSS; 35] subscales
and Global Assessment of Functioning
[GAF; 36]) were included in the analysis
(see Table 1 for target and Table 2 for so-
ciodemographic and clinical variables).
Healthy individuals (replicate sample).
To replicate the phenotype–genotype asso-
ciations found in GRAS patients in an in-
dependent group of healthy individuals,
we aimed at covering comparable domains
of processing speed and perceptual organ-
ization. Digit  Symbol-Coding test as mea-
sure of processing speed and Block Design
(Mosaik-Test) as test of perceptual organi-
zation capacities (both from German ver-
sion of WAIS; 32) were employed. Unfor-
tunately, neuropsychological tests
measuring verbal memory were not avail-
able in sufficient numbers for  replication.
Statistical Analyses
Statistical analyses of phenotype–
 genotype associations for healthy and
schizophrenic individuals were per-
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Table 1. Association of EPO and EPOR genotypes with cognitive target variables in schizophrenic patients (GRAS) and healthy individuals.
EPO rs1617640 EPOR STR (GA)n EPO and EPOR
GG and 
Effect Effect 21–35 All other Effect 
GG GT TT (p)a Low sum High sum (p) repeats combinations (p)
Disease sample (GRAS), mean ± SD (95% CI)b,c,d
N = 161–172 N = 408–465 N = 345–381 N = 466–509 N = 448–509 N = 60–63 N = 854–955
Perceptual organization
Dotting and Tapping 0.08 ± 1.98 0.02 ± 1.83 –0.11 ± 1.94 1.492 0.01 ± 1.85 –0.03 ± 1.94 4.402 0.65 ± 1.92 –0.06 ± 1.88 10.259
(–0.22–0.38) (–0.14–0.19) (–0.30–0.09) (0.222) (–0.16–0.16) (–0.20–0.14) (0.045) (0.18–1.13) (–0.18–0.06) (0.001)
Processing speed
Digit Symbol-Coding (WAIS)e 40.13 ± 14.19 37.62 ± 12.73 36.93 ± 13.42 8.868 37.80 ± 13.20 37.77 ± 13.38 1.893 43.57 ± 14.46 37.40 ± 13.12 16.166
(38.0–42.3) (36.5–38.8) (35.6–38.3) (0.003) (36.7–38.9) (36.6–38.9) (0.169) (40.0–47.1) (36.6–38.2) (<0.001)
Cognition compositef 0.08 ± 0.94 –0.01 ± 0.88 –0.07 ± 0.92 3.327 –0.00 ± 0.89 –0.02 ± 0.93 4.274 0.37 ± 0.90 –0.04 ± 0.90 13.891
(–0.07–0.22) (–0.09–0.08) (–0.16–0.03) (0.036) (–0.09–0.07) (–0.11–0.06) (0.039) (0.14–0.59) (–0.10–0.02) (<0.001)
Verbal learning and 42.74 ± 13.22 42.22 ± 12.84 40.62 ± 12.69 0.852 42.22 ± 13.00 41.18 ± 12.82 5.298 46.72 ± 12.49 41.36 ± 12.83 9.063
memory (VLMT)g (40.7–44.8) (41.0–43.5) (39.3–42.0) (0.356) (41.1–43.4) (40.0–42.4) (0.022) (43.6–49.9) (40.5–42.2) (0.003)
Healthy individuals, mean ± SD (95% CI)h
N = 332 N = 1095 N = 859 N = 447 N = 434 N = 50 N = 831
Perceptual organization
Block Design (WAIS)e 31.78 ± 9.24 30.32 ± 9.43 30.32 ± 9.58 7.263 32.83 ± 9.18 30.99 ± 8.76 9.815 33.46 ± 9.23 31.83 ± 9.00 1.068
(30.8–32.8) (29.8–30.9) (29.7–31.0) (0.007) (32.0–33.7) (30.2–31.8) (0.002) (30.9–36.0) (31.2–32.4) (0.302)
Processing speed
Digit Symbol-Coding (WAIS)e 53.19 ± 13.22 51.74 ± 12.96 51.34 ± 13.33 4.116 54.29 ± 12.08 54.13 ± 12.12 0.004 56.56 ± 10.68 54.07 ± 12.16 1.678
(51.8–54.6) (51.0–52.5) (50.5–52.2) (0.043) (53.2–55.4) (53.0–55.3) (0.953) (53.6–59.5) (53.2–54.9) (0.196)
Cognition compositef 0.12 ± 0.88 –0.01 ± 0.88 –0.03 ± 0.89 7.768 0.22 ± 0.84 0.11 ± 0.79 4.142 0.34 ± 0.81 0.16 ± 0.82 2.025
(0.02–0.21) (–0.07–0.04) (–0.09–0.03) (0.005) (0.14–0.29) (0.04–0.19) (0.043) (0.11–0.56) (0.10–0.21) (0.155)
aEffects for GG versus T carriers.
bAnalysis of covariance (ANCOVA) with age, negative symptoms (PANSS), medication status (chlorpromazine equivalents) and duration of
disease as covariates, and Blom-transformed single targets.
cOwing to missing data upon phenotyping and the exclusion of nonnative German speakers for language-dependent readouts (VLMT),
sample size varies between N = 914–1018 in the total GRAS sample.
dCI, confidence interval.
eTest from German version of WAIS (32).
fCognition composite represents mean of Dotting and Tapping subtests and Digit Symbol-Coding test (both tests Blom transformed).
gExclusion of nonnative German speakers (N = 92).
hAnalysis of covariance (ANCOVA) with age as covariate and Blom-transformed single targets.
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Table 2. Sociodemographic and disease-related variables in schizophrenic patients and healthy controls are not associated with
EPO/EPOR genotypes.
EPO rs1617640 EPOR STR (GA)n EPO and EPOR
GG and 
Effect Effect 21–35 All other Effect 
Basic variables GG GT TT (p)a Low sum High sum (p) repeats combinations (p)
Disease sample (GRAS) (95% CI)b,c,d
N = 165-171 N = 452-483 N = 366-388 N = 496-519 N = 484-520 N = 60-63 N = 920-976
Age, mean ± SD, y 40.32 ± 12.48 39.15 ± 12.43 39.69 ± 12.74 (0.316) 39.67 ± 12.39 39.42 ± 12.71 (0.540) 37.34 ± 12.50 39.69 ± 12.55 (0.166)
(38.4–42.2) (38.0–40.3) (38.4–41.0) (38.6–40.7) (38.3–40.5) (34.23–40.5) (38.9–40.5)
Gender, no. (%), male 110 (63.6%) 332 (67.9%) 260 (67%) 1.002 352 (67.2%) 350 (66.4%) 0.094 43 (68.3%) 659 (66.8%) 0.059
(54.6–72.6) (62.9–72.9) (61.3–72.7) (0.317) (62.4–72.2) (61.5–71.4) (0.759) (54.3–82.2) (63.2–70.4) (0.808)
Ethnicity, no. (%), Caucasiane 171 (98.8%) 461 (94.3%) 368 (94.8%) 1.916 499 (95.4%) 501 (95.1%) 1.691 63 (100.0%) 937 (94.9%) 1.276
(97.2–100.4) (92.2–96.4) (92.6–97.1) (0.384) (93.6–97.2) (93.2–97.0) (0.429) (–) (93.5–96.3) (0.528)
Years of education, mean ± SDf 12.40 ± 3.15 12.11 ± 2.93 11.95 ± 3.23 (0.208) 12.16 ± 3.06 12.05 ± 3.10 (0.528) 12.75 ± 3.25 12.06 ± 3.07 (0.143)
(11.9–12.9) (11.8–12.4) (11.6–12.3) (10.7–14.5) (12.0–15.7) (11.9–13.6) (11.9–12.3)
Current occupation, no. (%), 30 (17.3%) 77 (15.7%) 59 (15.2%) 0.275 75 (14.3%) 91 (17.3%) 1.805 14 (22.2%) 152 (15.4%) 1.915
unemployed (3.8–30.9) (7.6–23.9) (6.0–24.4) (0.600) (6.4–22.3) (9.5–25.0) (0.179) (0.4–44.0) (9.7–21.1) (0.166)
Age at first episode, mean ± SD, y 26.72 ± 9.30 25.73 ± 8.21 26.75 ± 8.94 (0.742) 26.35 ± 8.71 26.19 ± 8.66 (0.654) 25.12 ± 9.30 26.35 ± 8.64 (0.101)
(25.3–28.1) (25.0–26.5) (25.9–27.6) (25.6–27.1) (25.5–26.9) (22.8–27.4) (25.8–26.9)
Duration of disease (first episode), 13.25 ± 11.48 13.28 ± 10.71 12.83 ± 10.34 (0.811) 13.27 ± 10.44 12.94 ± 10.96 (0.365) 11.80 ± 11.27 13.19 ± 10.66 (0.161)
mean ± SD, y (11.5–15.0) (12.3–14.2) (11.8–13.9) (12.4–14.2) (12.0–13.9) (9.0–14.6) (12.5–13.9)
Smoker status, no (%), smoker 57 (33.7) 128 (27.2) 113 (30.5) 2.776 148 (29.1) 154 (30.5) 0.244 22 (35.5) 276 (29.1) 1.135
(20.6–40.8) (23.2–31.2) (25.8–35.2) (0.250) (25.2–33.0) (26.5–34.5) (0.621) (23.6–47.4) (26.2–32.0) (0.287)
Chlorpromazine equivalents, 637.1 ± 514.8 724.29 ± 792.18 671.7 ± 647.5 (0.957) 751.5 ± 727.3 680.6 ± 674.2 (0.486) 542.6 ± 427.9 713.1 ± 714.2 (0.174)
mean ± SD (559.5–714.7) (653.6–794.9) (607.0–736.4) (637.9–736.1) (622.5–738.7) (436.9–648.3) (655.3–754.0)
PANSS positive, mean ± SD 13.49 ± 6.17 14.30 ± 6.75 13.16 ± 5.75 (0.669) 13.95 ± 6.45 13.53 ± 6.16 (0.355) 13.98 ± 6.59 13.72 ± 6.30 (0.805)
(12.6–14.4) (13.7–14.9) (12.6–13.7) (13.4–14-5) (13.0–14.1) (12.3–15.6) (13.3–14.1)
PANSS negative, mean ± SD 17.69 ± 7.78 18.68 ± 8.11 18.09 ± 7.73 (0.286) 18.80 ± 8.30 17.78 ± 7.49 (0.106) 18.18 ± 7.98 18.30 ± 7.92 (0.863)
(16.5–18.9) (17.9–19.4) (17.3–18.9) (18.1–19.5) (17.1–18.4) (16.2–20.2) (17.8–18.8)
PANSS general, mean ± SD 33.37 ± 11.17 34.56 ± 12.51 32.88 ± 11.28 (0.809) 34.10 ± 12.43 33.36 ± 11.25 (0.610) 33.20 ± 12.29 33.77 ± 11.83 (0.570)
(31.7–35.1) (33.4–35.7) (31.7–34.0) (33.0–35.2) (32.4–34.4) (30.1–36.3) (33.0–34.5)
PANSS total, mean ± SD 64.34 ± 22.53 67.43 ± 24.72 64.03 ± 22.08 (0.484) 66.89 ± 24.96 64.38 ± 21.73 (0.284) 65.30 ± 24.95 65.67 ± 23.36 (0.733)
(60.9–67.8) (65.2–69.7) (61.8–63.3) (64.7–69.1) (62.4–66.3) (59.0-71.6) (64.2–67.2)
GAF, mean ± SD 45.88 ± 18.48 45.30 ± 17.26 46.40 ± 16.67 (0.934) 46.09 ± 17.78 45.51 ± 16.72 (0.836) 47.02 ± 18.60 45.72 ± 17.16 (0.749)
(43.1–48.7) (43.7–46.9) (44.7–48.1) (44.5–47.6) (44.1–47.0) (42.4–51.7) (44.6–46.8)
Healthy individuals (95% CI)b
N = 335 N = 1,111 N = 869 N = 449 N = 437 N = 50 N = 836
Age, mean ± SD, y 51.12 ± 16.37 51.91 ± 15.45 52.18 ± 15.42 (0.686) 47.97 ± 14.16 48.52 ± 14.42 (0.427) 46.88 ± 15.14 48.32 ± 14.24 (0.605)
(49.4–52.9) (51.0–52.8) (51.2–53.2) (46.7–49.3) (47.2–49.9) (42.7–51.1) (47.4–49.3)
Gender, no. (%), male 160 (47.8%) 547 (49.2%) 416 (47.9%) 0.088 221 (44.6%) 198 (40.2%) 1.359 23 (46.0%) 396 (47.4%) 0.035
(40.0–55.5) (45.1–53.4) (43.1–52.7) (0.767) (38.1–51.2) (33.3–47.0) (0.244) (25.6–66.4) (42.5–52.3) (0.851)
Education, no. (%),low levelg 60 (20.6%) 287 (25.8%) 224 (25.8%) 4.316 101 (20.4%) 90 (18.3%) 1.108 7 (14.0%) 184 (22.0%) 3.386
(11.0–30.1) (20.8–30.9) (20.1–31.5) (0.116) (12.5–28.3) (10.3–26.2) (0.575) (–11.7–39.7) (16.0–28.0) (0.184)
aEffects for GG versus T carriers.
bMethods used: Mann-Whitney U tests and χ2 tests.
cOwing to missing data upon phenotyping, sample size varies between N = 771–1,049 in the total GRAS sample.
dCI, confidence interval.
eExploratory exclusion of non-Caucasian subjects did not appreciably alter any of the main findings of the paper.
fRating according to graduation/certificate; patients currently in school or in educational training are excluded.
gLow level education: equal or less than nine years of academic formation.
formed using SPSS for Windows version
17.0 (SPSS Inc., Chicago, IL, USA;
http:// www.spss.com). GraphPad Prism,
version 5.01 (La Jolla, CA, USA) was used
to analyze expression and mouse data.
Case control study (disease sample
versus healthy blood donors or repli-
cate sample). For EPOR STR (GA)n, the
sum of repeat lengths of both alleles was
analyzed. To account for intraindividual
allelic heterogeneity (that is, the degree
of heterogeneity between the two alle-
les), the difference between allelic repeat
lengths was calculated. Distributions of
single allele lengths, allelic repeat sum,
allelic heterogeneity and of EPO SNP
genotypes (SNPs rs1617640 and
rs564449) between schizophrenic subjects
and healthy controls were assessed by
χ2 tests with (EPOR) and without (EPO)
Monte Carlo sampling (1,000 runs).
PGAS. For the phenotype–genotype 
association analysis using the EPO SNP
rs1617640 as independent variable, T car-
riers (GT and TT) were aggregated and
contrasted with individuals homozygous
for the G allele. Group comparisons for
the EPOR repeat were based on median
splits (21–36 versus 37–54; for the first
PGAS approach, Tables 1 and 2) or tercile
splits (21–35 versus 36–38 versus 39–54;
for more detailed subgroup comparisons,
see Figure 1F) of allelic repeat sums. Data
on cognitive target variables are presented
such that higher values always indicate
better performance. They were standard-
ized to mean zero and variance one by
Blom transformation (37). In language-
 dependent tests (VLMT), nonnative Ger-
man speakers (N = 92) were excluded for
analyses. A cognition composite score was
calculated for each individual represent-
ing the mean of the Blom-transformed
data for processing speed and perceptual
organization. Genotype differences were
assessed by analysis of covariance includ-
ing covariates age (both healthy individu-
als and disease controls), duration of dis-
ease, chlorpromazine equivalents and
severity of negative symptoms (PANSS;
the latter three covariates only for the dis-
ease sample) as they are known to influ-
ence performance on neuropsychological
tests. Genotype differences with respect to
sociodemographic and clinical readouts
were tested using χ2 (nominal variables)
or Mann-Whitney U tests (continuous
variables). The impact of EPO and EPOR
genotypes on mRNA levels and expres-
sion differences dependent on EPOR
genotype were tested nonparametrically
using Kruskal-Wallis and Mann- Whitney
U tests in the subsample of patients of
whom PBMCs were available (N = 98).
DNA Extraction and Normalization
Disease sample and healthy blood
donors. Genomic DNA was purified
from whole blood using JETQUICK
Blood & Cell Culture DNA Spin Kit
(Genomed GmbH, Löhne, Germany) ac-
cording to the manufacturer’s protocol.
Resulting DNA samples were aliquoted
and stored at –80°C. For further analysis,
DNA was normalized to 50ng/μL with
an automated robotic platform (Microlab
Star, Hamilton, Bonaduz, Switzerland).
For quality control, each sample was an-
alyzed with a 0.8% agarose gel.
Healthy individuals (replicate sam-
ple). DNA extraction was done with the
QIAamp Blood Maxi Kit (Qiagen,
Hilden, Germany). DNA concentration
was adjusted using the PicoGreen quan-
titation reagent (Invitrogen, Karlsruhe,
Germany).
Genotyping—Analysis of SNPs in the
hEPO Gene
Disease sample and healthy blood
donors. The selected SNPs (rs1617640
and rs564449) in the EPO gene were ana-
lyzed using Simple Probes (TIB Molbiol,
Berlin, Germany) and called using the
LightCycler 480 Genotyping Software im-
plemented in the LightCycler 480 system
(Roche, Mannheim, Germany). The reac-
tion mixture (10 μL) was prepared with
20 ng of DNA in 384 well plates accord-
ing to standard protocols (Roche). In each
run, eight positive controls (hgDNA, Bio-
line, Luckenwalde, Germany) and nega-
tive water blanks were included for qual-
ity and internal control purposes.
Overall, successfully genotyped markers
amounted to 99.7–99.9%.
Healthy individuals (replicate sam-
ple). The SNP rs1617640 was genotyped
using the iPLEX assay on the Mass -
ARRAY MALDI-TOF mass spectrometer
(Sequenom, Hamburg, Germany). Geno-
typing call rates were all >95%.
Genotyping—Analysis of GA Repeats
(Both Disease Sample and Healthy
Individuals)
The polymorphic GA repeat in the pro-
moter region of hEPOR was amplified
from genomic DNA by PCR. Primers
were chosen from de la Chapelle et al.,
1993 (38): hEPOR_(GA)n forward: 5′-FAM
GGTGA CAGAG CAACA CCCTG-3′;
hEPOR_(GA)n reverse: 5′-ATCAG CATCT
CTTCC CAGCC-3′ resulting in a PCR
fragment of ~186bp. Due to the presence
of GGAA repeats in the same region (20),
we likely obtained aggregates of all re-
peats, that is, GGAA as well as GA. Since
we assume that the aggregates as a whole
are important for modulating function,
we did not further analyze the exact com-
position of the aggregates. In fact, our
data validate this assumption. For each
sample, the reaction mixture (20 μL) was
prepared in 384 well plates, each contain-
ing 20 ng of human genomic DNA,
125 μmol/L dNTPs each, 200 nmol/L
FAM-labeled forward primer and the re-
verse primer and 1U Phire polymerase
(Finnzymes, Espoo, Finland). The ampli-
cons were separated using size elec-
trophoresis on the ABI 3730 XL DNA Ana-
lyzer (Applied Biosystems, Foster City,
CA, USA). For this, samples were diluted
1:50 with 0.3 mmol/L EDTA and 4 μL
were mixed with 6 μL LIZ-500 Size Stan-
dard (Applied Biosystems). Raw data
were processed using the Gene Mapper
 Software 4.0 (Applied Biosystems).
Analysis of Peripheral Blood
Mononuclear Cells (PBMCs)
Blood was collected in CPDA (citrate
phosphate dextrose adenine) tubes from
schizophrenic patients with different
genotypes at the selected markers.
PBMCs were isolated applying the stan-
dard Ficoll-Paque Plus isolation proce-
dure (GE Healthcare, München, Ger-
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many). RNA was prepared using Qiagen
miRNeasy Mini Kit (Qiagen). 1 μg of
RNA per sample was used to synthesize
cDNA (SuperScriptIII, Invitrogen). The
qRT-PCR was performed with the aid of
SYBR Green detection on the LightCycler
480 system (Roche). The starting amount
of cDNA was 20 ng; the number of PCR
cycles was 30–34 for EPO and 27–31 for
EPOR. Primers were added at 0.5 pMol.
CT (cycle threshold) values for EPO and
EPOR were standardized to CT values of
GAPDH. hEPO_qRT-PCR forward: 5′-
TCCCA GACAC CAAAG TTAAT
TTCTA-3′; hEPO_qRT-PCR reverse: 5′-
CCCTG CCAGA CTTCT ACGG-3′;
hEPOR_qRT-PCR forward: 5′-TTGGA
GGACT TGGTG TGTTT C-3′;
hEPOR_qRT-PCR reverse: 5′-AGCTT
CCATG GCTCA TCCT-3′; hGAPDH_qRT-
PCR forward: 5′-CTGAC TTCAA CAGCG
ACACC-3′; hGAPDH_qRT-PCR reverse:
5′-TGCTG TAGCC AAATT CGTTG T-3′.
Cloning and Transfection Studies
Constructs. The EPO promoter con-
structs were built according to Tong and
coworkers (23). Briefly, the promoter site
(1.5 kb) including either G or T at
rs1617640 was PCR amplified from respec-
tive human samples and cloned into the
pGL3 basic vector (Promega, Mann heim,
Germany). In addition, constructs includ-
ing the 3′ region of human EPO, as this is
known to be of major importance for the
regulation of EPO expression, were de-
signed. For this, the following primers in-
cluding XbaI sites were used: hEPO_3′ for-
ward: 5′-GCGTC TAGAC CAGGT GTGTC
CACCT-3′; hEPO_3′ reverse: 5′-GCGTC
TAGAA TGACA ATCTC AGCGC-3′.
All constructs were verified by restric-
tion enzyme digestion and complete
bidirectional DNA sequencing.
Luciferase Assays. Neuro2a (N2a) cells
(LGC Standards GmbH, Wesel, Germany)
were plated in 96-well cell culture plates
(NUNC, Langenselbold, Germany) at
15,000 cells per well in DMEM supple-
mented with 5% FCS without antibiotics.
At 16–18 h after plating, cells were trans-
fected with Lipofectamine 2000 (Invitro-
gen) using the manufacturer’s protocol. Of
the different EPO constructs, 30 ng (con-
taining G or T) and 1 ng of pRL-TK-
 control vector (Promega) were cotrans-
fected. For each treatment, six replicates
were performed. At 24 h after transfection,
cobalt chloride (CoCl2), a well known
mimetic of hypoxic EPO induction (39,40),
was added in different concentrations to
induce chemical hypoxia to the transfected
cells. Concentrations were selected such
that after the CoCl2 exposure, no signs of
toxicity or increased cell death were ob-
served (Trypan blue counts <1% in all con-
ditions, including normoxic controls). At
48 h after transfection, cells in each well
were lysed, using 30 μL passive lysis
buffer (Promega). The dual-luciferase re-
porter assay (Promega) was used accord-
ing to the manufacturer’s protocol. Prior
to measurement, lysates were transferred
into a black plastic microtiter plate. Meas-
urements were performed with the micro -
plate reader Mitras LB940 (Berthold Tech-
nologies, Regensdorf, Switzerland) and
associated software MicroWin 2000. Firefly
values were divided by the corresponding
Renilla readings producing values ex-
pressed as relative luciferase units (RLU).
Mouse Studies
The generation and characterization of
cEPOR transgenic mice have been re-
ported in detail elsewhere (7). Briefly,
EPORR129C (cEPOR) bears a single point
mutation at nucleotide 484, that is, in the
exoplasmic domain, causing a substitu-
tion of cysteine for arginine at codon 129
of the N terminus (R129C). The cDNA se-
quence of cEPOR, containing a hemagglu-
tinin (HA; YPYDVPDY) tag inserted five
residues downstream of the signal pepti-
dase cleavage site (41,42) was excised
with PacI and SalI from the pMX-HA-
cEPOR plasmid. The HA-cEPOR cDNA
was inserted into pNN265 plasmid, with
a modified multiple cloning site, that car-
ries a 5′ hybrid intron and a 3′ intron plus
poly-A signal from SV40 through PacI
and SalI sites. Finally, the entire DNA
fragment of HA-cEPOR, flanked by a hy-
brid intron at the 5′ end and a polyadeny-
lation signal from SV40 at the 3′ end was
cut out from pNN265 vector using NotI
and placed downstream of the 8.5kb α-
CaMKII promoter. The TG founders were
produced by pronuclear injection of the
linearized DNA into C57BL6/N (TG1) or
FvB/N (TG2) zygotes. The analysis of line
TG1 mice was performed after 4–7 back-
crosses with C57BL6/N wild type mice
(that is, all results reported in this study
were obtained from generations 4–7 of the
TG1 line). The TG1 line was used (be-
cause of its clean C57BL6/N background)
for the behavioral experiments presented
here. Analysis of line TG2 mice was per-
formed after 8–9 backcrossings to
C57BL6/N mice. The genotype of trans-
genic offspring was analyzed by PCR of
tail genomic DNA using primers specific
for the 3′ end of the α-CaMKII promoter
sequence (5′-GGGAG GTAGG AAGAG
CGATG-3′) and the 5′ end of the HA-
cEPOR cDNA sequence (5′-CACCC
TGAGT TTGTC CATCC-3′) yielding a 769
bp product. PCR amplification of the tail
DNA was carried out with the following
conditions: 2 min at 94°C (1 cycle); 30 s at
94°C, 30 s at 60°C and 1 min at 72°C (35
cycles), followed by final extension at
72°C for 10 min.
Behavioral Testing
All experiments were approved by the
local animal care and use committee in
accordance with the German Animal
Protection Law. For behavioral testing,
mice were housed in groups of 3–5 in
standard plastic cages, food and water ad
libitum (except for the 5-choice [water
deprivation] and T-maze [food depriva-
tion] training periods). The temperature
in the colony room was maintained at
20°–22°C, with a 12 h light:dark cycle
(light on at 7 AM). Behavioral experi-
ments were conducted during the light
phase of the day (between 8 AM and 
5 PM). Mouse data were analyzed using
repeated measures analysis of variance
(ANOVA) and Mann-Whitney U tests.
Five-choice serial reaction time task 
(5-CSRTT). The 5-CSRTT measures higher
brain functions, ranging from various dis-
crete learning/memory to attentional par-
adigms (43,44). A detailed description of
the procedure and training steps is given
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elsewhere (7). In the present study, we re-
port only the results obtained in interven-
tion phase 3 (variable, short stimulus du-
ration, indicative of speed of processing).
Novel object recognition task. Briefly,
mice are habituated for 20 min to a gray
plastic arena (45 × 45 cm, 35 cm high)
with no objects. Next, for the training
session, an object is placed in the arena,
and the time the mouse spends exploring
the object (that is, nose ≤15 mm to the
object) is recorded for 10 min (video
tracking software Viewer 2; Biobserve,
Bonn, Germany). Next, a new, second ob-
ject is added to the arena and exploration
recorded for 10 min (testing session). The
whole procedure is repeated several days
later with a different set of objects and a
30 min interval between training and
testing session. We use plastic objects of
similar size (around 3 cm in diameter)
but different shape, texture, and color
(pilot experiments had confirmed that
mice show no spontaneous preference
for any of the objects).
T-maze. The T-maze consists of three
arms (clear plexiglas, 7 cm wide, 12.5 cm
high with the start arm 43.5 cm long, and
the goal arms 32.5 cm each). The goal
arms contain distinct visual cues on the
outer side of the walls; the start arm is
plain. A plastic pellet cup (2.2 cm high, 
3.5 cm in diameter) is situated in the rear
of each goal arm. To have equal olfactory
reward cues in both arms, we use pellet
cups consisting of two parts separated by
a perforated floor: the lower part contains
12 food pellets, which are inaccessible for
mice; the accessible upper part holds one
food pellet as reward. Before starting the
habituation procedure, mice are food de-
prived (1 h/day access to food in the home
cage) for 3 d. Another 3 d of habituation to
apparatus and reward (5 min of exposure
to the maze each day, with reward placed
at both ends of the T-maze) are followed
by training for 12 d, six trials/day. On the
first (sample) run of each trial, both goal
arms are baited, but the mouse is forced to
choose one of the goal arms (the other
being closed by a removable wooden
block: 16 cm × 6.9 cm). After entering the
preselected goal arm, the mouse is al-
lowed to consume the reward for 20 s and
then placed back in the start box. On the
second (choice) run, which during the ac-
quisition phase of training follows 20 s
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Figure 1. EPO and EPOR genotype analyses in schizophrenic patients of the GRAS data collection and healthy controls (blood donors). (A)
Genetic overview of EPO/EPOR including analyzed genetic markers. (B,C) A case control study reveals comparable distribution of EPO
SNP genotypes in schizophrenic and healthy control subjects, thus excluding EPO genotypes as risk factors for schizophrenia. (D,E) Case
control analysis of EPOR STR (GA)n repeat lengths shows comparable results for both samples, again excluding a risk constellation of EPOR
genotypes. (F) Grouping of genotype combinations with respect to Digit Symbol-Coding test performance uncovers one genotype highly
superior to all others: GG&21–35 (lowest) repeat sum. Mean ± standard error of the mean (SEM) given; χ2 tests and analysis of covariance
(ANCOVA) applied.
after the sample run, both goal arms are
open, and the mouse is rewarded for
choosing the previously unvisited arm.
The location of the sample arm (left or
right) is varied pseudorandomly across
trials so that mice received equal numbers
of left and right presentations, but no
more than two consecutive trials with the
same sample location. The mice are run in
squads of 6–8 (including both transgenic
and littermate control animals) to mini-
mize variation in intertrial intervals (12
min for all mice throughout the 12 d of
training). No-delay trials: Mice are trained
for 14 d in sample and choice runs with
20-s interval (10 trials on d 1; 6 trials/day
from d 2–14). Delay trials: After finishing
the no-delay procedure, mice are tested in
the delay procedure using two different
time intervals between sample and choice
run: 2 min and 6 min (3 d per delay; six
trials/ day containing three delay and
again three no-delay trials each—in an al-
ternating manner—to rule out motiva-
tional decrement and to obtain an internal
control condition).
Note: All experiments in this manu-
script were conducted in a blinded fash-
ion that is, with the respective investiga-
tor/rater being unaware of sample
assignment.




EPO SNPs rs1617640 (T/G) and
rs564449 (T/G), as well as EPOR STR
(GA)n, are not associated with schizo-
phrenia. When conducting phenotype-
based genetic association studies (PGAS)
to evaluate the contribution of certain
genotypes to defined subphenotypes, a
potential role of these genotypes as genetic
risk factors for schizophrenia should first
be explored. Therefore, we performed a
case control study on SNP rs1617640
(T/G) and SNP rs564449 (T/G), located in
the 5′ upstream region and in the 3′ regu-
latory region of the EPO gene, respec-
tively, as well as the STR (GA)n in the
EPOR 5′ upstream area (Figure 1A). To as-
sess the EPOR genotype, the repeat
lengths sum of both alleles was employed.
No significant difference in the distribu-
tion of EPO genotypes (Figures 1B, C; χ2 =
1.897 and p = 0.397; χ2 = 0.058 and p =
0.972) or of EPOR repeat lengths sum (Fig-
ure 1D; χ2 = 23.85, p = 0.917, evaluated
with Monte Carlo sampling on 1,000 runs)
between cases (N = 1,050–1,054) and
healthy controls (blood donor sample; N =
1,141–1,142) was found (for details see Fig-
ure 1 and Supplementary Table S1). An as-
sociation analysis of single allele repeat
lengths instead of allelic repeat lengths
sum between cases and controls also failed
to yield significant distribution differences
(χ2 = 32.15, p = 0.114, evaluated with
Monte Carlo sampling on 1,000 runs). Fur-
thermore, the intraindividual difference of
repeat lengths as a measure of marker het-
erogeneity did not vary between cases and
controls (Figure 1E; χ2 = 8.54, p = 0.967,
1000 Monte Carlo simulations). Thus, we
could not find any evidence for a role of
EPO/EPOR genotypes regarding the risk
to develop schizophrenia. For the follow-
ing phenotype analyses, the EPO SNP
rs564449 (T/G) had to be excluded due to
its low minor allele frequency (MAF~11%).
Phenotype-Based Genetic
Association Study (PGAS)
EPO SNP rs1617640 (T/G) and EPOR
STR (GA)n are associated with higher
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Figure 2. Mice with transgenic expression of constitutively active EPOR (cEPOR) driven by
the α-calcium/calmodulin-dependent protein kinase II (α-CaMKII) promoter demonstrate
highly superior cognitive performance compared with their wild type littermates. (A) Con-
struct used for transgenic expression. (B) Significant reduction of reaction time in the at-
tentional testing part of the 5-Choice Serial Reaction Time Task (5-CSRTT) reflects superior
speed of cognitive processing in transgenic mice. (C–F) Transgenic mice perform better in
Novel Object Recognition (NOR) (depicted is the number of visits of the new object) and
T-maze tests with or without delay, illustrating their supremacy in memory tasks. Exact N
numbers of all experiments are given directly in the bars or the line graph; all male mice,
5–8 month old at the time point of testing; mean ± standard error of the mean (SEM) pre-
sented; two-way ANOVA for repeated measures and Mann-Whitney U tests applied.
cognition in schizophrenia. In a previous
treatment trial, we showed that high-dose
EPO, infused weekly over 12 wks, im-
proves cognitive functions and reduces
cortical gray matter loss in chronic schizo-
phrenic patients. The domains most
prominently influenced by EPO were
speed of cognitive processing and short-
term memory (Repeatable Battery for the
Assessment of Neuropsychological Status
(RBANS™): subtests coding, digit span
and figure recall) (9). Assuming that an in-
fluence of genetic variation within the
EPO system on cognitive function would
be detectable targeting these domains, we
selected of the tests available within the
GRAS database those closest to the above
(same test or similar test regarding do-
main or loading on the same factor, that is,
tests leading to similar results in an indi-
vidual due to joint variation in response to
the same unobserved latent variable):
Digit Symbol-Coding test, VLMT, and
 Dotting/ Tapping (45). Indeed, significant
associations were detected for both, EPO
SNP rs1617640 (T/G) and EPOR STR(GA)n
low versus high repeat sum (Table 1): car-
riers of G at EPO SNP rs1617640 and of
EPOR STR(GA)n low repeat sum showed
superior performance. In contrast, none of
the relevant  sociodemographic or basic
disease variables revealed any significant
associations (Table 2). To see whether cer-
tain combinations of genotypes of the EPO
and EPOR genes would lead to better per-
formance in the sense of a potential inter-
action effect, we grouped them accord-
ingly. For EPOR genotypes, we assigned
all individuals to three equally sized
groups of allelic repeat sum carriers from
low to high (Figure 1F). Surprisingly, we
found one particular genotype combina-
tion, GG&21–35 (lowest) repeat sum, to be
highly superior compared with all others
with respect to performance in Digit
 Symbol-Coding test (p < 0.0001; see Fig-
ure 1F) but also in the other tests, where
associations had been found for either EPO
or EPOR or both (all p ≤ 0.003; Table 1).
In contrast to the clear associations with
cognitive parameters found here, and in
agreement with previous work by others,
for example (14), we did not see any evi-
dence of a potential association of
EPO/EPOR genotypes with blood indices.
In fact, we screened a total of 94 patients
(Göttingen participants of the GRAS
study) where comprehensive information
on blood data was available. Repeated de-
terminations over the year in these pa-
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Figure 3. Genotype-dependent EPO/EPOR expression differences using reporter gene assays and PBMCs. (A) Reporter gene constructs:
5′ upstream region of the EPO gene with either G or T at rs1617640 (left) and in addition with the 3′ regulatory region of EPO (right).
(B) G at SNP rs1617640 leads to significantly higher basal gene expression than T (baseline control). Addition of the 3′ regulatory region to
the construct induces downregulation of gene expression. This suppression is stepwise alleviated by increasing doses of CoCl2 (100 μmol/L
and 400 μmol/L). (C) In all conditions shown in (B), the suppressability (regulability) of gene expression compared with the baseline con-
trol (that is, normoxic control condition of B) is highest for the G genotype. (D) EPOR mRNA levels in peripheral blood mononuclear cells
(PBMCs) of patients, determined by qRT-PCR and normalized to GAPDH as the housekeeper, show that the lowest EPOR STR (GA)n repeat
length sum is associated with the highest EPOR expression. Gender distribution among the three repeat groups is well balanced
(males/all: 24/37, 18/31, 20/30; χ2 test p = 0.628). (E) Even when considering the individual EPO mRNA levels (which by themselves do not
reveal differences; data not shown) in form of an EPO/EPOR expression ratio, the significant difference between different STR length carri-
ers remains. N = 28–37 per group; mean ± standard error of the mean (SEM) presented; Mann-Whitney U tests applied.
tients (between 2–48 times each) allowed
a first step to substantiate each individ-
ual’s normal values (considering also the
reason for hospitalization, for example,
exclusion of values obtained after blood
loss due to a suicide attempt). These in
turn delivered the basis of the mean val-
ues given in Supplementary Table S2. As
shown there, all parameters are highly
similar among genotypes. Interestingly, in
this small cohort of individuals (N = 94)
with information on blood indices, N = 6
subjects carried the GG&21–35 (low) re-
peat sum genotype and could be checked
against all other genotype combinations.
Group comparison by Mann-Whitney U
test did not reveal any difference between
groups for hemoglobin levels (p = 0.413),
whereas the cognitive composite score al-
ready yielded a nearly significant result 
(p = 0.093) (Supplementary Figure S2).
cEPOR Expression in Pyramidal
Neurons of Cortex and Hippocampus
Increases Speed of Cognitive
Processing and Memory Functions in
Mice
On the basis of the above findings, we
speculated that the best performing geno-
type combination should be characterized
by higher EPO/EPOR expression. This
hypothesis is further supported by (i) the
cognition- improving effect of high-dose
EPO in clinical trials (8,9) and in mouse
studies (5,6) and (ii) our previous data on
mice with transgenic expression of consti-
tutively active EPOR (cEPOR) driven by
the α-calcium/calmodulin-dependent
protein kinase II (α-CaMKII) promoter
(Figure 2A). These mice show better per-
formance in higher cognitive tasks (7). We
reexamined these mice and specifically
conducted/ analyzed tests measuring
speed of cognitive processing and short-
term memory, analogous to our neuropsy-
chological findings in humans. In fact, we
found a clearly reduced reaction time in
the phase addressing selective attention in
the 5-CSRTT (2-way ANOVA for repeated
measures, F(1,14) = 6.159; p = 0.026; Figure
2B) as well as superior performance in
short-term memory tasks, that is, novel
object recognition (no-delay trials p =
0.038; 30-min delay trials p = 0.026; Mann-
Whitney U test) and T-maze (2-way
ANOVA for repeated measures, no-delay
trials F(1,22) = 19.61, p = 0.0002; 2-min delay
trials F(1,22) = 4.668, p = 0.042; Figures
2C–F). These data further support the hy-
pothesis of higher expression/activity of
the EPO system being associated with
better cognitive functioning.
Mechanistic Insight: Genotype-
 Dependent EPO/EPOR Expression
Differences
To better understand a potential influ-
ence of the EPO SNP rs1617640 on gene
expression, we used reporter gene assays
based on the 5′ upstream region of the
EPO gene with G or T at the respective
position. Additionally, we designed con-
structs including the 3′ regulatory region
of human EPO, as this is known to be
highly homologous between species and
thus of major importance for the complex
regulation of EPO gene expression (39,46)
(Figure 3A). As illustrated in Figure 3B, 
G at SNP rs1617640 leads to significantly
higher basal gene (luciferase) expression
than T. Upon addition of the 3′ regulatory
region to the construct, a remarkable
downregulation of gene expression can be
observed that is likely due to the interac-
tion with the 5′ region which is essential
for hypoxia-related EPO regulation (39,40).
This suppression is stepwise alleviated by
increasing doses of CoCl2 as an inducer of
chemical hypoxia. In all conditions, the
suppressability (regulability) of gene ex-
pression as compared with baseline is
highest for the G genotype (Figure 3C).
To explore the role of the EPOR STR
(GA)n repeat length sum on gene expres-
sion, we determined EPOR and EPO
mRNA in peripheral blood mononuclear
cells. The results show that the lowest re-
peat sum is associated with the highest
EPOR expression as well as with the
highest EPO/EPOR ratio as readout of
the interplay between the two genes
(Figures 3D, E). EPO mRNA levels per se
did not differ significantly between
EPOR repeat sum groups (data not
shown). The exact mechanisms explain-
ing the observed effects on quantitative
gene expression are still unclear. Both,
EPO and EPOR gene variants investi-
gated here are located in the promoter
areas of the respective genes, where they
may, for instance, directly or indirectly
influence transcription factor binding. In-
deed, regulation of these genes is highly
complex and involves many different
transcription and cofactors, the roles of
which are still widely obscure (46,47).
Replication of the EPO and EPOR
Genotype Associations with Cognitive
Performance in a Healthy Control
Sample
Having obtained associations of geno-
types in the EPO system with cognition in
a disease population, that is, individuals
suffering from schizophrenia with known
disease-typical cognitive deterioration, we
wanted to know whether similar findings
would be obtained in healthy controls.
Fortunately, a phenotyped control popula-
tion from Munich was available for com-
parison. Again, a case control study on
EPO SNP rs1617640 (T/G) as well as
EPOR STR (GA)n did not reveal differ-
ences between these healthy controls and
the GRAS subjects (Supplementary Table
S1, Supplementary Figure S1). This
healthy control population, however, has
several confines with respect to the GRAS
sample: (1) Of the relevant cognitive do-
mains, only one has been evaluated with
the same test, the other one just with a
similar test loading on the same factor
(that is, producing similar results in an in-
dividual based on a common underlying
source of variance); (2) The population is
considerably older on average; (3) The
sample has a different gender distribution
(Table 2). Despite these limitations, the as-
sociations are essentially reproduced
(Table 1), pointing to very robust effects.
Interestingly, having the GG&21–35 re-
peat sum genotype does not yield an ad-
vantage for healthy individuals who gen-
erally perform much better on all
cognitive tests as compared with schizo-
phrenic individuals (Table 1). This obser-
vation suggests that only subjects with an
inferior cognitive performance may bene-
fit from this specific genotypic constella-
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tion. We wondered whether the superior-
ity of the GG&21–35 group would be re-
vealed when selecting the subgroup of
healthy individuals with an average per-
formance equal to the mean performance
of the schizophrenic sample on the Digit
Symbol-Coding test. Indeed, the low per-
former group of healthy individuals
(Digit Symbol-Coding test performance
threshold ≤50) displays a similar tendency
of genotype superiority (p = 0.089) which
is not detectable in the high performer
group (Digit Symbol-Coding test per-
formance threshold >50, p = 0.809). These
results suggest that the GG&21–35 geno-
type may disclose its benefits particularly
in situations of reduced cognitive capacity
or (relative) cognitive impairment (Sup-
plementary Figure S3).
DISCUSSION
In the present hypothesis-driven study,
we identified novel associations of EPO
and EPOR genotypes with cognition,
namely speed of processing, short-term
memory and tasks requiring distinct fine
motor components, both in schizo-
phrenic patients and in a healthy control
population (replicate sample). On a mo-
lecular/cellular level, we demonstrate
that the cognitively more beneficial geno-
types are associated with higher expres-
sion/stronger regulability of expression.
In supporting preclinical experiments,
we show that mice with transgenic ex-
pression of constitutively active EPOR in
pyramidal neurons of cortex and hip-
pocampus (7) perform better in cognitive
domains reminiscent of those influenced
by EPO/EPOR genotypes in humans.
Interestingly, in the schizophrenic pop-
ulation that is defined by overall reduced
cognitive performance, one discrete
genotype combination (GG&21–35 repeat
sum) achieves highly superior cognitive
outcome, whereas this same combination
in healthy individuals has only the ten-
dency of an advantage. This advantage is
restricted to subjects with lower cogni-
tive capacity. Thus, higher EPO/EPOR
activity appears to be most beneficial in
situations of compromised function. We
note that in disease states, such benefit is
likely achieved by the upregulation of
the endogenous EPO system in the brain,
as seen for example, in stroke, schizo-
phrenia or Alzheimer’s disease (48–50).
In fact, this EPO/EPOR upregulation is
further potentiated by rhEPO treatment,
resulting in lasting cognitive improve-
ment (8,9,51,52).
The selection of the cognitive domains
reported here to show associations with
EPO/EPOR genotypes strictly followed
hypotheses derived from the results of
earlier rhEPO treatment studies (9).
Therefore, multiple testing issues do not
apply here. On the other hand, also for a
purely hypothesis-driven, exploratory
study, it is reassuring to obtain replica-
tion of the results in an independent
sample, in the present paper, a healthy
control population.
Limitations of the present work are
particularly (1) the incomplete availabil-
ity of identical neuropsychological tests
in the two populations studied (forcing to
use tests loading on the same factor, that
is, resulting in highly correlated readouts
in a given individual due to shared vari-
ance produced by a common underlying
variable), and (2) the different age/gen-
der distribution. Despite all these short-
comings, a similar pattern of associations
arose, pointing to robust effects and con-
firming the significance of EPO/EPOR
genotypes for higher  cognition.
We are aware that the use of transfec-
tion studies/reporter gene assays and of
PBMCs cannot answer all questions re-
lated to genotype-dependent brain ex-
pression of the EPO system. Especially
PBMCs are a heterogeneous population of
cells. There may be variations in the com-
position of mononuclear cells such as cir-
culating erythroid progenitor or precursor
cells, megakaryocytes, mast cells and
macrophages, lymphocytes, and endothe-
lial progenitor cells from sample to sam-
ple. Many of these cell types potentially
may serve as source of EPO expression in
the peripheral blood. We cannot exclude,
however, that our data on EPO and EPOR
mRNA mainly derive from a small frac-
tion of erythroid progenitors that express
these genes. Nevertheless, the pragmatic
approach to analyze PBMCs was the only
choice presently available for us to study
quantitative gene expression in a reason-
able number of humans with defined
genotype. To obtain further support for
increased expression/activation of the
EPO system leading to better cognition,
we additionally performed mouse studies
in a model of targeted upregulation of
EPOR in neuronal populations that are
known to play a pivotal role in the func-
tions of interest (7). The superiority of
these mice included essentially the same
cognitive domains as those found to be
influenced by EPO/EPOR genotypes in
human populations.
CONCLUSION
To conclude, we identified an intrinsic
role of the EPO system for higher cogni-
tion, reflected by associations of
EPO/EPOR genotypes with cognitive per-
formance, which may be of particular sig-
nificance in disease states. These findings
further suggest the EPO system as target
for treating human brain diseases that are
characterized by cognitive  decline.
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Supplementary Table S2. Blood indices of a total of 94 patients (Göttingen participants of the GRAS study) with comprehensive
information on blood data available.
EPO (mean ± SD) EPOR (mean ± SD)
GG GT TT Low sum High sum
N=13 N=47 N=34 N=50 N=44
Hemoglobin (g/dl) 14.751 ±1.317 14.703 ±0.923 14.657 ±1.329 14.748 ±1.112 14.631 ±1.157
Hematocrit (%) 43.765 ±3.877 43.484 ±2.611 43.288 ±3.892 43.661 ±3.187 43.166 ±3.384
Erythrocytes (x0^6/μl) 4.860 ±0.439 4.902 ±0.391 4.831 ±0.488 4.894 ±0.442 4.844 ±0.423
Thrombocytes (x0^3/μl) 271.166 ±54.047 254.554 ±44.449 271.043 ±71.662 261.442 ±59.959 264.376 ±54.015
Repeated determinations over the years in these patients (between 2-48 times each) allowed in a first step to substantiate each
individual’s ‘normal’ blood values (considering also the reason for hospitalization, e.g. exclusion of values obtained after blood loss due to
a suicide attempt). These in turn delivered the basis of the mean values given in the Table.
Supplementary Table S1. Case control study: genotype frequencies of EPO SNPs in
schizophrenic patients (GRAS sample) versus healthy blood donors and versus healthy
replicate sample.
(SCZ, GRAS subjects: N=1050 for rs1617640 and N=1054 for rs564449; CON1, healthy blood
donors: N=1142; CON2, healthy replicate sample: N=2315).
Genotypic frequencies
EPO SNPs GG GT TT χ2 (p)a HWE (p)
rs1617640 SCZ (N=1050) 16.5% 46.5% 37.0% (.368)
CON1b (N=1142) 15.6% 49.5% 34.9% 1.897 (.397) (.357)
CON2c (N=2315) 14.5% 48.0% 37.5% 2.297 (.317) (.508)
GG GT TT
rs564449 SCZ (N=1054) 79.6% 19.5% 0.9% (.628)
CON1b (N=1142) 79.5% 19.4% 1.1% .058 (.972) (.877)
aComparison of genotype distribution between the respective control group (CON1 or
CON2) and the GRAS sample of schizophrenic patients (SCZ); bCON1= blood donors,
cCON2= healthy replicate sample
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Supplementary Figure S1. Case control study: frequency distribution of EPOR STR (GA)n re-
peat lengths sum and repeat lengths difference in the GRAS sample of schizophrenic pa-
tients versus subjects of a healthy replicate sample. An association analysis of single allele
repeat lengths instead of allelic repeat lengths sum between cases and controls also
failed to yield significant distribution differences (χ2=14.71, p=.903, evaluated with Monte
Carlo sampling on 1000 runs).
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Supplementary Figure S2. Subgroup analysis: hemoglobin and cognition composite val-
ues in GG&21-35 (low) repeat sum genotype carriers versus all other genotype combina-
tions. Of the cohort of patients with blood values available (Supplementary Table 2), N=6
individuals carried the GG&21-35 (low) repeat sum genotype and could be tested
against all other genotype combinations. Group comparison by Mann-Whitney U test did
not reveal any difference between groups for hemoglobin levels (p=.413). In contrast, de-
spite the small number of high performers (GG&21-35 (low) repeat sum carriers), the cog-
nitive composite score (available for most but not all of the patients with blood informa-
tion - see N numbers) yielded already a nearly significant result (p=.093) (mean±SEM
presented).
Supplementary Figure S3. The superiority of the ‘GG&21-35 repeat sum’ genotype versus
all other combinations is most prominent in individuals with low performance. Comparison
of the Digit Symbol-Coding (DSC) performance of individuals carrying the genotype
combination ‘GG&21-35 (lowest) repeat sum’ versus subjects with all other combinations.
Given are good (raw score > 50) and bad DSC performer groups (raw score <= 50).
Mean±SEM of raw scores presented, p-values from ANOVA with Blom-transformed DSC
score and age (schizophrenic sample and healthy controls), severity of negative symp-




3. A neuregulin1 risk genotype is associated with performance in central 
olfactory measures in a schizophrenic sample 
 
3.1 Overview of project II 
 
Central neural circuits underlying olfactory function can be mapped to temporolimbic and 
frontal brain regions (Benarroch 2010). Dysfunctional connectivity in these olfactory 
structures has been consistently implicated in the affective and cognitive symptomatology of 
schizophrenic patients (Turetsky et al. 2009). Consequently, olfactory tasks serve as 
behavioral probes to assess the functional integrity of neural substrates underlying disturbed 
sensory-cognitive and emotional processing in schizophrenia (Turetsky et al. 2009). Olfactory 
input triggers cognitive events, often in form of autobiographical memories (Savic 2001, 
Larsson et al. 2009, Turetsky et al. 2009). Tests measuring olfactory cognition address the 
integration of olfactory input into cognitive processing (Atanasova et al. 2008). The 
spontaneous identification of odorants (odor naming) is a complex task requiring correct 
smell encoding, semantic memory, and selection of the most appropriate denomination 
(Schab 1990). First evidence from a very small sample of male schizophrenic patients 
supports an odor naming deficit in this patient group (Saoud et al. 1998). Likely due to the 
small sample size, clinical variables did not correlate with odor naming ability (Saoud et al. 
1998). The first aim of our study was to build on these findings by evaluating odor naming 
performance and its relationship with clinical and cognitive variables in a large sample of 
schizophrenic patients. 
 
Olfactory stimuli do not only induce cognitive activity, they immediately evoke emotional 
reactions (Soudry et al. 2011). To explore the nature of affective states in response to different 
scents, available olfactory function tests require the judgement of the hedonic quality of given 
odors. Schizophrenic subjects are less accurate when deciding whether an odor is edible, 
pleasant or familiar as compared to healthy controls (Hudry et al. 2002, Moberg et al. 2003, 
Kamath et al. 2011, Kamath et al. 2011). No study has ever investigated whether 
schizophrenic patients have difficulties in judging gustatory or semantic properties of odors 
beyond familiarity, hedonicity and edibility ratings (odor interpretation). Moreover, it has not 
been evaluated how the inability to accurately interpret olfactory stimuli relates to 




As a part of the very comprehensive phenotyping of the GRAS cohort (Ribbe et al. 2010) we 
modified and extended existing odor interpretation and naming tasks as a basis for a time-
economic exploration of the clinical relevance of olfactory processing deficits in our sample. 
Odor naming and interpretation performance was evaluated in 881 schizophrenic patients and 
102 healthy matched controls using 6 semantically diverse odors derived from the University 
of Pennsylvania Smell Identification Test (Doty et al. 1984) as well as 7 attributes. 
Statistically, we first analyzed the entire distribution of olfactory performance and then, to 
clinically characterize the subgroup of patients with a central olfactory impairment, compared 
the low and high extremes of the odor interpretation phenotype with respect to cognitive and 
clinical measures and a neuregulin1 marker, a well replicated risk genotype for schizophrenia 
(Stefansson et al. 2002).  
 
Schizophrenic patients underperformed healthy controls in odor naming and interpretation. 
Applying multiple linear regression analysis to both olfactory target measures and clinical 
variables revealed strong relative associations with alertness. Additionally, odor naming was 
found to depend on the integrity of higher cognitive processing whereas odor interpretation 
was associated with the severity of positive symptoms. Extreme groups of odor interpretation 
performance were compared with respect to additional symptomatic parameters. The 
subgroup of schizophrenic patients defined by a central olfactory dysfunction was found to be 
characterized by a more severe psychopathology, and extreme cognitive deficits resulting in 
an overall inferior functional outcome as compared to all other schizophrenic patients. 
Moreover, the risk genotype (TT) of neuregulin1 SNP8NRG243177, previously shown to be 
associated with the severity of positive symptoms (Papiol et al. 2011), was found to be 
overrepresented in the subgroup of patients with extreme odor interpretation impairments. 
Interestingly, brain regions structurally and functionally altered in individuals carrying the 
risk allele (T) of SNP8NRG243177 (Hall et al. 2006, Plailly et al. 2006, Barnes et al. 2012) 
and regions implicated in olfactory processing largely overlap. Thus, the influence of this 
genotype on odor interpretation may well be (co-)mediated by its effect on brain structure, 
which was observed to depend on gene expression differences (Law et al. 2006). Together, 
our findings suggest a central integration deficit in sensory-cognitive networks in a subgroup 
of schizophrenic patients. Future studies should aim at replicating and refining present 
findings by using psychometrically improved odor naming and interpretation tasks. 
____________________________________________________________________Project II 
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ABSTRACT (187 words) 
 
Background: The clinical relevance of central olfactory measures has not been 
comprehensively studied in schizophrenia. 
Aims: We modified and extended existing odor naming and interpretation tasks and 
applied them to a large sample of schizophrenic subjects to explore the association 
with clinical outcome and with a schizophrenia risk genotype, the neuregulin1 marker 
SNP8NRG243177. 
Method: During comprehensive phenotyping of the GRAS (Göttingen Research 
Association for Schizophrenia) cohort, odor naming (active memory retrieval) and odor 
interpretation (attribute assignment) were evaluated in 881 schizophrenic patients and 
102 healthy controls, and associations with emotional processing, disease outcome 
and SNP8NRG243177 studied.  
Results: Patients underperformed controls. Odor naming deficits were correlated with 
compromised cognition, odor interpretation deficits with positive symptom severity and 
general alertness. SNP8NRG243177 (neuregulin1) was associated with poor odor 
interpretation.   
Limitations: The psychometric properties of the olfactory measures used here in an 
exploratory fashion in a large sample have to be improved by e.g. increasing the number 
of odors for future establishment of a solid clinical test.  
Conclusions: The strong association of odor naming and interpretation with disease 
outcome and a genetic schizophrenia risk factor highlights their clinical and scientific 
significance.  
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Olfactory information processing in the brain integrates complex neuronal networks with 
particular relevance of temporolimbic and frontal regions1. In schizophrenia, essentially 
all facets of this information processing are found to be affected, ranging from 
peripheral receptor insufficiency to disturbances in passive odor identification, odor 
memory, odor naming and odor interpretation2-10. The associations of these deficits with 
disease severity 9, 11-15, however, have mostly remained incomplete or unclear. The 
present study has been designed to (I) assess odor naming and interpretation abilities 
in a large number of schizophrenic patients (N=881) and in healthy matched controls 
(N=102), (II) evaluate the relationship of olfactory task performance with specific 
symptom domains, (III) explore extreme groups of odor interpretation regarding 
determinants of disease severity, and (IV) test for genetic association of odor 
interpretation with the neuregulin1 marker SNP8NRG243177, a known risk genotype 
for schizophrenia16. 
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The present study (GRAS project) was approved by ethics committees of the Georg-
August-University Göttingen (master committee) and collaborating centers. Detailed 
phenotyping of the GRAS sample17 contained odor naming and odor interpretation 
tasks (figure 1A), administered to 999 schizophrenic patients after written informed 
consent. Present analyses excluded all non-native German speakers (N=89), all 
patients with known anosmia (N=14, neurological conditions e.g. head injury, or cold) 
and 6 patients with missing data. Nine patients were excluded as non-admissible based 
on performance in entry and odor naming tasks (figure 1B). Data analyses were based 
on the remaining 881 patients. 
 
Healthy controls 
As comparison group, 103 healthy subjects matched for age, gender and smoking 
status (smoker: yes/no) were recruited by public announcements and gave written 
informed consent. They were free of any physical, neurological and psychiatric disorder, 
and had no relatives with a history of neuropsychiatric diseases. One individual was 
excluded due to his performance in entry and odor naming tasks. Data analyses were 






The University of Pennsylvania Smell Identification Test18 (UPSIT), the clinically and 
scientifically most established test, has been widely used as test validation criterion19. A 
total of 10 different scents (scratch and sniff format) were selected from this battery (for 
detailed description of the administration procedure see3). Odorants were chosen by an 
experienced psychiatrist based on following criteria: (I) For the entry task, odors had to 
be easily identifiable (low item difficulty) to minimize contribution of higher cognition to 
task performance. For the naming task, odorants were selected to cover a broad range 
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of difficulties to differentiate between subjects along the whole spectrum of cognitive 
abilities. For odor interpretation, items of low difficulty were chosen due to the expected 
profound interpretation deficit in schizophrenia. (II) The odors had to be of high 
ecological validity to German subjects. (III) To balance avoidance of redundancy (due 
to time limitations) and reliability, odors were selected to represent diverse associated 
contexts (e.g. rose and gasoline) and attribute overlap (both pineapple and licorice are 
pleasant and sweet). Although this study was not designed to introduce a new ready-to-
be-used olfaction test, preliminary item characteristics and psychometric properties are 
provided in supplemental table 1.  
 
Entry task 
To be able to interpret odor naming and interpretation results as central processing 
deficits, an entry task (figure 1A; maximum score 4) was introduced. A total of 4 
consecutively presented odors are chosen from 4 alternative descriptors each (multiple 
choice, brief passive odor identification3) by pointing to or naming the correct term on 
the scoring sheet. The entry task should identify potentially anosmic subjects unaware 
of their condition or failing to report it prior to performing odor naming and interpretation 
tasks. The 4 odorants lemon, smoke, lilac and paint thinner were chosen to be easily 
identifiable (supplemental table 1) and representative of all attributes contained in the 
odor interpretation task. Lemon was selected to cover the attributes sweet and edible, 
lilac is an odor judged as pleasant and natural, smoke is hot and dangerous and paint 
thinner is often associated with a technical context. Figure 1B shows that theoretical 
binomial probabilities for random guessing (in case of anosmia or pronounced cognitive 
impairment, assuming equal multiple-choice success probabilities of 0.25 for all 4 
odors) markedly differed from relative recognition score frequencies. The vast majority 
of patients and controls recognized 3-4 odors correctly whereas 95% of guessing 
subjects would recognize <3 odors correctly in the entry task. Simultaneously, guessing 
would result in an odor naming score of 0 (free choice test) which is extremely unlikely 
(supplemental figure 1B). Consequently, subjects were excluded from analysis when 
they had less than 3 out of 4 correctly recognized odors in the entry task and an odor 
naming score of 0 (9 schizophrenic subjects, 1 healthy control subject) because of 
potentially experiencing difficulties at the peripheral processing level. Clearly, this 
approach risks excluding cognitively extremely impaired individuals. Indeed, excluded 
individuals cognitively underperformed the 881 schizophrenic subjects (881 subjects: -
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0.03±0.78; 9 excluded subjects: -0.92±0.54; mean±SD of higher cognition composite; 
see below). 
 
Odor naming and odor interpretation 
The odor naming task (maximum score 18) measures the correct naming of the 6 odors 
pineapple, gasoline, mint, rose, natural gas and licorice (free choice; figure 1A). Three 
points were scored for the correct name, 1 point if the subject provided an item 
belonging to the same semantic category (e.g. pineapple: 3 points for ‘pineapple’, 1 
point for ‘fruit’). Before naming an odor, probands had to decide whether it matched the 
7 attributes pleasant, sweet, hot, technical, natural, edible and dangerous (forced 
choice: ‘yes’ or ‘no’ answer; odor interpretation; same set of odors as for naming) 
(figure 1A). One point was scored for each attribute assignment consistent with the 
predefined profile (maximum score 42=6x7). Although task reliability improves with 
number of items20, we had to restrict it to 6 items for time-economic reasons (olfactory 
tasks being only a fraction of the GRAS examination procedure17). Nevertheless, the 
internal consistency of the odor interpretation task, is high for attributes (supplemental 
table 1). 
 
Disease-relevant possible confounders 
As unspecific but disease-relevant (overall severity) possible confounders, duration of 
disease, number of hospitalizations and medication status (chlorpromazine equivalents) 
were selected.  
 
Functional outcome, disease severity, psychopathology, cognition and emotional 
processing 
To address schizophrenia relevant target domains, age-at-prodrome, general 
assessment of functioning (GAF) scale, PANSS (positive and negative syndrome scale) 
subscales, a higher cognition composite (supplemental table 2), and the alertness 
subtest (mean of tonic and phasic alertness) of TAP (Testbatterie für 
Aufmerksamkeitsprüfung) were included. McQuarrie dotting and tapping tests were 
integrated into a fine motor function composite. Mehrfachwahl-Wortschatz-Test covered 
premorbid intelligence. Emotional processing was operationalized as sum score of 
‘blunted affect’, ‘emotional withdrawal’ and ‘poor rapport’ of PANSS. Higher scores 
represent worse outcome in PANSS but better performance in GAF and 
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neuropsychological tests. Healthy controls completed odor naming and interpretation 
tasks and 4 neuropsychological tests (LPS 3; MWTB; McQuarrie Dotting and 
McQuarrie Tapping test). All tests are cited in17. 
 
Schizophrenia severity score 
As integrative measure of overall schizophrenia severity, a score of Blom transformed21 
items: positive, negative symptoms (PANSS), cognition22, neurological symptoms (CNI) 
and age-at-prodrome was created with all single variables scaled such that higher 
values indicate higher symptom severity (figure 2A). 
 
Genetic analysis 
The neuregulin1 marker SNP8NRG243177 was genotyped using HypProbes (TIB 
Molbio, Berlin, Germany) on Light Cycler480 (Roche, Mannheim, Germany). 
 
Statistical analyses 
To test for associations of odor naming and interpretation performance with disease-
relevant symptom domains, multiple linear regression was applied within the 
schizophrenic sample (table 1, displaying mutually adjusted relative association 
strengths interpretable in analogy to Cohen’s d). Sum scores for higher cognition and 
fine motor performance are the mean of standardized neuropsychological measures in 
these domains (larger values represent better performance). Rank-based Blom 
transformation21 was applied to standardize all measures by transforming them into 
standard normally distributed surrogates prior to sum score computation. This 
maintained the order of the data, but removed skewness from variable distributions.  
Group comparisons between healthy and schizophrenic subjects (supplemental figure 
1A-B), and schizophrenic subgroups (figures 1C, 2B-C, tables 2, 3, supplemental figure 
1C, supplemental table 2), or genotype groups (figure 2E-F) were tested by linear 
regression or analysis of covariance (figure 2F) (estimating difference between group 
means for standardized normally distributed quantitative targets, with covariate 
adjustment where indicated), by Fisher’s exact test or Chi-square test (for binary 
targets gender, smoking and genetic risk status), by non-parametric Wilcoxon rank sum 
test (for quantitative targets which could not be standardized to normal distribution). For 
linear model analyses, standardized regression coefficients (with 95% confidence 
limits) were converted to the original variable scale for ease of interpretation by 
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multiplication with the raw data standard deviation of the target variable within the 
respective data. Multiple-testing was accounted for by Bonferroni correction and closed 






Influence of age, smoking and gender on odor naming and interpretation 
Increasing age is associated with a decline in odor naming (average -0.05 points/year, 
p=2.2x10-11, test statistic t978=-6.770) and interpretation performance (average -0.06 
points/year, p=1.6x10-8, t979=-5.697) likewise in schizophrenic and healthy individuals 
(no significant difference). Smoking status had no influence on both central olfactory 
measures. Women proved to be slightly superior to men in odor naming (average 0.42 
points, p=0.043, t978=2.022) but not interpretation.  
 
Odor naming and interpretation are impaired in schizophrenic patients 
The main study results are summarized in figure 1C. Inferior performance of 
schizophrenic patients (N=881) compared to 102 matched healthy controls became 
evident for odor interpretation and naming tasks (supplemental figure 1A,B; 
interpretation: p=4.0x10-10; naming: p=2.9x10-9).  
 
Odor naming and interpretation are differentially associated with psychopathology and 
cognition in schizophrenic patients 
Odor naming and interpretation correlate substantially (Spearman correlation r=0.51, 
95%CI [0.46, 0.56], p<2.2x10-16). To investigate relative association strengths of odor 
naming and interpretation with 3 schizophrenia relevant symptom domains (cognition, 
negative and positive symptoms) and 2 control variables (fine motor function and 
premorbid intelligence) (table 1), multiple linear regression was applied in the 
schizophrenic sample (N=881). Regression coefficients express relative association 
strength (relative to the standard deviation of the target trait). Odor naming and 
interpretation scores were strongly dependent on alertness. Worse naming results were 
additionally linked to impaired higher cognition and more severe negative symptoms 
(PANSS). Deficits in odor interpretation were associated with higher positive symptom 
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severity (PANSS). No link was detected between odor naming or interpretation and fine 
motor function or premorbid intelligence. 
 
Extreme group comparisons based on odor interpretation performance reveal strong 
differences in several symptom domains 
Frequency distribution of interpretation and naming scores (supplemental figure 1A,B) 
show increased probabilities of low scores for schizophrenic patients, especially for 
odor interpretation. This suggests that olfactory deficits are particularly pronounced in a 
subgroup of patients. Odor interpretation covers cognitive and emotional processing 
deficits, both representative of a broad spectrum of schizophrenia symptomatology. To 
explore the informative value of odor interpretation for the domains cognition, 
psychopathology, emotional processing and functional outcome, schizophrenic high 
interpretation performers (HIP, scoring >90th percentile) were contrasted with low 
interpretation performers (LIP, scoring <10th percentile; N=88 each) and compared to 
healthy controls (Con, N=102). The 3 groups did not differ (pairwise comparisons) with 
regard to age, gender and smoking status. Expectedly, a highly significant naming 
deficit became obvious for LIP in comparison to HIP (p=7.0x10-28) and healthy controls 
(p=9.1x10-29) (supplemental figure 1C). In terms of reasoning capabilities, healthy 
controls obtained better results than schizophrenic HIP (p=1.6x10-3) with the latter 
performing superior to LIP (table 2, p=3.4x10-3) (figure 1C). For fine motor function, 
both schizophrenic groups performed comparably and markedly worse than healthy 
controls (HIP/LIP: p=0.015; HIP/Con: p=4.4x10-6; LIP/Con: p=8.1x10-9). For premorbid 
intelligence, a difference was observed between disease groups (HIP/Con: p=0.81; 
LIP/Con: p=0.017; LIP/HIP: p=3.6x10-3) (table 2). 
 
More detailed assessment of group contrast between schizophrenic LIP compared to 
HIP in disease-related domains, revealed higher severity of negative symptoms 
(p=1.7x10-4) and positive symptoms (p=1.6x10-4) for LIP (figure 1C). Additionally, 
strongly impaired cognitive and emotional processing became evident (higher cognition 
composite: p=3.7x10-3; alertness: p=1.4x10-4; emotional processing: p=3.3x10-3), 
resulting in a worse functional outcome (p=6.5x10-6; average difference 12 GAF units) 
for LIP (table 3). No significant differences were observed with regard to possible 
confounders indicating overall disease severity (age-at-prodrome, duration of disease, 
number of hospitalizations and chlorpromazine equivalents, all above the Bonferroni 
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corrected significance threshold p>0.005). Together, the results of the extreme group 
approach indicate that deficits in odor interpretation are accompanied by more severe 
psychopathology, worse cognitive and emotional processing and inferior functional 
outcome. 
 
Schizophrenic carriers of the neuregulin1 SNP8NRG243177 risk allele display high 
symptom load and poor odor interpretation performance 
Employing a composite score of schizophrenia severity (figure 2A) revealed that low 
odor interpretation ability is closely related to higher symptom load (figure 2B-C). This 
observation motivated the inclusion of this measure into the schizophrenia severity 
score for subsequent genetic analyses using the neuregulin1 marker SNP8NRG243177. 
This SNP was associated with odor interpretation and overall schizophrenia severity 
based on different statistical approaches: (I) The relative frequency distribution of the 
schizophrenia severity score including odor interpretation revealed that schizophrenic T 
allele carriers have a higher probability of severe schizophrenic symptoms (figure 2D). 
(II) The risk genotype (TT) is overrepresented in the group of extremely poor 
interpretation performers (figure 2E; Chi-square: 4.380, p=0.036; odds ratio: 2.532 
[confidence interval: 1.049, 6.115]). (III) When contrasting Blom transformed means 
based on SNP8NRG243177 risk status (CC versus T allele), individuals carrying the 
protective genotype (CC) tended to be less affected on all single measures (figure 2F). 
The strongest group differences (withstanding Bonferroni correction) were observed for 
the schizophrenia severity score including odor interpretation (p=0.009) and the odor 
interpretation performance when homozygous genotypes were contrasted (p=0.004).     
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The present study, building on and extending previous work, demonstrates in a large 
sample of subjects that the ability to name and qualitatively interpret odors is markedly 
impaired in schizophrenia. Importantly, it adds new aspects to the available literature by 
showing distinct associations between central olfactory measures and schizophrenia-
relevant clinical variables. Extreme group comparisons as well as an association study 
using a genetic variant of the schizophrenia risk gene neuregulin1, deliver first hints for 
a biological subgroup of patients, defined by their severe olfactory dysfunction. This 
subgroup is characterized by profound abnormalities in higher olfactory processing, 
together with a more severe psychopathology, extreme cognitive deficits across various 
neuropsychological measures and pronounced affective flattening, resulting in an 
overall inferior functional outcome as compared to all other schizophrenic patients.  
 
Odor naming ability relies on higher cognitive processing  
Odor naming but not interpretation was found to depend on the integrity of higher 
cognitive processing. This association was primarily driven by reasoning abilities while 
all other domains appeared less prominent. In contrast to Saoud and coworkers, we 
found odor naming, like almost all neuropsychological tests17, to correlate with PANSS 
negative scores9. This discrepancy is likely explained by the low number of patients 
included in the Saoud study. 
 
Positive symptoms interfere with odor interpretation ability 
Odor interpretation, but not odor naming, was found to be influenced by the severity of 
positive symptoms. In line with the disconnectivity hypothesis in schizophrenia23, we 
hypothesized that the aberrant assignment of hedonic (pleasant), gustatory (sweet, hot) 
and higher-order semantic attributes (e.g. technical, edible) potentially reflects the 
dysfunctional integration of sensory input into cognitive-emotional processing. Thus, 
impaired odor interpretation should reflect positive symptom severity. In fact, while the 
relationship between basic olfactory processing (e.g. passive odor identification) and 
severe negative symptoms is quite well established11, 12, 24, 25, this is the first study to 
provide evidence for psychotic symptoms to interfere with performance in an olfactory 
function test. We even show here that odor interpretation impairments may be slightly 
more marked than deficits in odor naming. Therefore, measuring dysfunctional 
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integration of olfactory (and likely other sensory) input into cognition should be 
complemented by assessment of respective dysregulated emotion processing in this 
patient group.  
 
Alertness modulates performance in central olfactory measures 
The large amount of variance shared by odor naming and interpretation can be partially 
explained by the strong association of both olfactory tasks with the level of alertness. 
The latter represents the intensity aspect of attention and comprises both a state of 
general wakefulness (intrinsic alertness) and the ability to increase the readiness to 
react in response to a cue over a short period of time (phasic alertness)26. Importantly, 
attention is a requirement for assigning the continuous flow of air through the nose to 
either respiration or olfactory exploration27. Non-attended, the olfactory content of 
inhalations is ignored and not processed further. Effects of attentional modulation on 
activity in human primary27 and secondary olfactory cortices28 and amygdala29 support 
this notion. Consequently, the extent to which an individual attends to a presented odor 
and is able to maintain the level of alertness during the completion of a task, likely 
influences the amount of resources provided for higher-order mental operations 
following the perception of an olfactory stimulus. Additionally, it is well established that 
olfactory (spicy, fruity) and gustatory (salty, sweet) judgements lead to the activation of 
associated semantic networks. This results in a facilitation of olfactory naming – at least 
in healthy individuals7. However, as the here applied odor interpretation task was the 
same for all odors, differential depth-of-processing effects, potentially confounding odor 
naming results, can be excluded.  
 
Schizophrenia susceptibility marker associates with odor interpretation performance 
Interestingly, brain regions structurally and functionally altered in individuals carrying 
the T allele of the neuregulin1 variant SNP8NRG24317730-32 and regions implicated in 
higher olfactory processing largely overlap. Therefore, the possibility of a genetic root 
also for the observed olfactory phenomena arises. Neuregulin1 is among the presently 
best established schizophrenia risk genes16. In a previous study, we had found the 
protective genotype of the neuregulin1 marker SNP8NRG243177 (CC) 
underrepresented in schizophrenic patients with most severe positive symptoms33. The 
modulatory effects of this genetic variant on odor interpretation in our schizophrenic 
sample may well be (co-)mediated through its effect on brain structure, which in turn 
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may depend on gene expression differences34. The strong association of the 
SNP8NRG243177 risk allele (T) with compromised odor interpretation and overall 
(positive) symptom severity supports a central olfactory integration deficit in sensory-
cognitive or sensory-emotional networks in a defined biological subgroup of 
schizophrenic patients.  
 
Limitations: 
We are aware of the fact that the psychometric properties of the olfactory measures 
used here in an exploratory fashion have to be improved by e.g. increasing the number 
of odors for future establishment of a solid clinical test.  
 
Conclusions: 
The present work, by simultaneously assessing naming and interpretation deficits in a 
large schizophrenic sample and combining it with a genetic association, defined a 
biological subgroup of the disease and prepared the ground for future test development. 
Importantly, it revealed that both olfactory tasks extract differential information on higher 
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Figure 1: Design of odor tasks and overview of main results. (A) After completion 
of the entry task (passive recognition of 4 odors - multiple choice), subjects were asked 
to assign a set of attributes (odor interpretation) and then to name the respective 
odorant (odor naming), consecutively for 6 odors. (B) The entry task revealed a clear 
contrast between test results (schizophrenic patients, healthy controls) and theoretical 
binomial probabilities for guessing subjects. (C) The main findings of the study are 
summarized. Low interpretation performers (LIP) showed worse reasoning abilities, a 




Figure 2: Association of odor interpretation performance with a genetic risk 
variant of neuregulin1. (A) The internal consistency (Cronbach’s α) of single variables 
integrated into a schizophrenia severity score is slightly improved upon inclusion of 
odor interpretation. (B, C) Schizophrenic subjects performing below the 10th percentile 
(extreme groups) or below the median of odor interpretation performance (total sample) 
have a profoundly increased schizophrenia severity score (corrected for age and 
medication). SEM presented. (D) The relative frequency distribution of schizophrenia 
severity score bins (including odor interpretation) shows dissociation between the 
SNP8NRG243177 CC genotype and T allele carriers. (E) Carriers of the protective 
genotype (CC) are overrepresented in the group of high interpretation performers (Chi-
square test). (F) Carriers of the CC genotype differ consistently from risk allele carriers 
(T) in all Blom transformed single variables integrated into the schizophrenia severity 
scores (all variables except for age-at-prodrome corrected for age and medication). 
Multiple testing adjusted significances (applying Bonferroni: p≤ 0.006) are set in 
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Theoretical binomial probabilities for random guessing
a1 or 2 missing values (out of 4) were imputed for N=21 schizophrenic subjects. All other subjects had complete data in the 
entry task. bStill including the N=9 schizophrenic / N=1 healthy subjects that were identified by the entry task and odor 
naming as non-admissible and excluded from remaining analyses.











































aReasoning: Higher values mean better performance. bPsychopathology and emotional processing deficits: Higher values mean 
more severe symptomatology. Abbreviations: LPS 3=Leistungsprüfsystem (subtest 3); Con=Healthy controls; HIP= High odor 
interpretation performers; LIP= Low odor interpretation performers; PANSS items N1:Blunted affect, N2:Emotional withdrawal, 
N3:Poor rapport.





























Pleasant   Sweet   Hot   Technical   Natural   Edible   Dangerous
Gustatory 










































p=0.039 p=0.039 p=0.245 p=0.872 p=0.457 p=0.044














T allele carriers (N=440-508)
p=0.009




Cronbach’s α excluding odor interpretation=0.592
Neuregulin1 SNP8NRG243177
CC genotype (N=301-339)
T allele carriers (N=440-508)
Neuregulin1 SNP8NRG243177
Odor interpretation:
Comparison of homozygous 
genotypes: p=0.004
Comparison of homozygous 
























































































































































Odor naming is associated with cognition and odor interpretation with severity of positive symptoms and 
alertness in schizophrenic subjects (n=881) 
 
 Odor Naminga Odor Interpretationa
0.165 0.057 Higher cognition composite (t813= 2.347, p=0.019) (t814= 0.789, p=0.430) 
  
0.144 0.196 Alertness (TAP) (t813= 3.401, p=0.001) (t814= 4.635, p=0.000) 
  
-0.112 -0.045 PANSS negative (t813=-2.717, p=0.007) (t814=-1.073, p=0.283) 
  
-0.055 -0.107 PANSS positive 
(t813=-1.407, p=0.160) (t814=-2.701, p=0.007) 
  
-0.010 0.017 Fine motor function composite 
(t813=-0.210, p=0.834) (t814= 0.336, p=0.737) 
  
0.071 0.059 Premorbid intelligence (MWTB) 
(t813= 1.761, p=0.079) (t814= 1.420, p=0.156) 
aRelative association strength of domains with odor naming and odor interpretation (t-statistic tdf with df degrees of 
freedom, p value). Multiple linear regression, adjusted for age (odor naming and odor interpretation) and gender 






   
Table 2 
 
Severely impaired interpretation performers (LIP) show compromised cognition compared to healthy 
controls (Con) and non impaired interpretation performers (HIP) 
 
Trait Descriptive Group Contrast Effect [95% CI] Statistic p 
Basic characteristics 
Age (years)  SZ 39.5 ± 13 (17-78)      
mean ± SD (range)  Con 38.8 ± 14 (18–71) HIP / Con  2.75 [-0.81, 6.31] t275= 1.522a 0.13 
  HIP 41.0 ± 11 (22–64) LIP / Con  1.25 [-2.31, 4.81] t275= 0.693a 0.49 
  LIP 39.7 ± 13 (18–71) LIP / HIP -1.40 [-4.58, 1.77] t174=-0.873a 0.38 
       
Gender (% female)  SZ 33      
  Con 32 HIP / Con OR 1.25 [0.66, 2.38] Fisherb 0.54 
  HIP 38 LIP / Con OR 0.83 [0.42, 1.62] Fisherb 0.64 
 LIP 28 LIP / HIP OR 0.66 [0.33, 1.31] Fisherb 0.26 
  for females   
        
Smoker status (% yes)  SZ 48      
  Con 63 HIP / Con OR 0.45 [0.21, 0.94] Fisherb 0.025 
  HIP 43 LIP / Con OR 0.57 [0.26, 1.23] Fisherb 0.15 
 LIP 49 LIP / HIP OR 1.26 [0.52, 3.05] Fisherb 0.68 
   for smokers    
Disease related higher and basal cognition and premorbid intelligence 
Reasoningc  SZ 20.8 ± 6.6 (2-38)      
mean ± SD (range)  Con 27.2 ± 5.2 (14–38) HIP / Con -3.00 [-4.86, -1.14] t265=-3.180a 1.6x10-3
  HIP 21.5 ± 6.5 (8–38) LIP / Con -5.49 [-7.63, -3.35] t265=-5.058a 7.9 x10-7
  LIP 18.2 ± 6.7 (2–34) LIP / HIP -2.45 [-4.07, -0.82] t164=-2.971a 3.4 x10-3
      
Fine motor function  SZ -0.12 ± 0.91 (-3.22–3.22)      
compositec  Con 0.97 ± 0.68 (-1.09–2.83) HIP / Con -0.53 [-0.75, -0.31] t268=-4.674a 4.7 x10-6
mean ± SD (range)  HIP -0.002 ± 0.87 (-2.40–1.83) LIP / Con -0.78 [-1.03, -0.52] t268=-5.951a 8.3 x10-9
  LIP -0.45 ± 0.93 (-2.89–1.90) LIP / HIP -0.23 [-0.41, -0.05] t167=-2.471a 0.014 
      
Premorbid  SZ 26.2 ± 6.1 (4-37)      
intelligenced  Con 30.9 ± 4.0 (18–37) HIP / Con -0.22 [-2.06, 1.62] t267=-0.236a 0.81 
mean ± SD (range)  HIP 27.8 ± 5.0 (13–37) LIP / Con -2.60 [-4.74, -0.46] t267=-2.393a 0.017 
  LIP 23.8 ± 7.0 (5–35) LIP / HIP -2.51 [-4.19, -0.83] t166=-2.955a 3.6 x10-3
Multiple testing adjusted significances (applying Bonferroni (p≤ 0.007) and the closed testing principle) are set in boldface. All other p-values ≤ 0.05 are set in italic; 
at-Statistic tdf with df degrees of freedom for estimation of difference in means (employing a linear model on Blom-transformed trait); bFisher’s exact test for count 
data; cAdjusted for age at exam and PANSS negative (value 7 for healthy control). Reasoning ability was measured by LPS 3. Fine motor function composite is the 
mean from standardized (by Blom-transform) McQuarrie Dotting and McQuarrie Tapping; dAdjusted for age (age of onset of psychosis for schizophrenic HIP and 
LIP, age at exam for healthy control) and PANSS negative (value 7 for healthy control). Premorbid intelligence was assessed by MWTB. Abbreviations: Con= 
Healthy control (N=102); SZ= Descriptive statistics for whole schizophrenic sample (N=881); HIP= High interpretation performers (N=88); LIP= Low interpretation 





Severely impaired interpretation performers (LIP) show a more severe psychopathology, compromised 
cognition and emotional processing compared to high interpretation performers (HIP) 
  Descriptive LIP compared to HIP 









Disease relevant confounders     
5.4 x10-4Years of education median 12.0 11.0 13.0 -1.55 
(t174=-3.525 a) (years) interquartile [10.0, 13.5] [9.0,13.0] [10.0,15.0] [-2.42, -0.68] 
 range (8.0-27.0) (8.0-20.5) (8.0-24.0)   
       
Duration of disease  median 11.0 13.7 11.1  0.28 
(years) interquartile [4.7, 20.1] [6.4, 21.9] [5.3, 20.9] - ( W=3466b) 
 range (0.008,58.4) (0.1, 47.4) (0.6, 45.3)   
       
Number of  median 3.0 3.0 4.0  0.10 
( W=2532b) hospitalizations interquartile [2.0, 6.0] [2.0, 5.0] [3.0, 6.0] - 
 range (0, 55) (1, 44) (1, 50)   
       
Chlorpromazine  median 500 600 450  0.068 
( W=3216b) equivalents interquartile [250, 900] [300, 1072] [228, 817] - 
 range (0, 7375) (0, 3238) (0, 3064)   
Functional outcome, disease severity and psychopathology 
6.5x10-6General assessment of  mean ± SD 45.6 ± 17.2 38.0 ± 17.1 49.8 ± 17.0 -11.93 
(t171=-4.654a) functioning (GAF) range (5, 90) (10, 85) (20, 90) [-16.99, -6.87] 
       
median  20 19 23 -2.70 0.054 
(t153=-1.942a) interquartile [17, 26] [16, 24] [17, 30] [-5.44, 0.05] Age-at-prodrome  (years) 
range (2, 66) (12, 66) (2, 47)   
       
median 17.0 22.0 15.0 4.54  1.7 x10-4
( t171= 3.840a) interquartile [12.0, 23.0] [14.0, 27.0] [11.0, 21.8] [2.21, 6.88] PANSS negative 
range (7.0, 44.0) (7.0, 40.0) (7.0, 38.0)   
       
1.6 x10-4median  12.0 15.0 11.0 3.96  
( t171= 3.869a) interquartile [9.0, 17.0] [10.0, 22.0] [8.0, 15.8] [1.94, 5.98] PANSS positive 
range (7.0, 38.0) (7.0, 37.0) (7.0, 38.0)   
Disease-related cognition    
4.3 x10-3Higher cognition  mean ± SD -0.03 ± 0.78 -0.41 ± 0.84 0.07 ± 0.83 -0.24 
compositec range (-2.64, 1.93) (-2.64, 1.40) (-1.92, 1.77) [-0.40, -0.07] ( t169=-2.896a) 
       
1.4 x10-4Alertness (TAP)c median -282 -331 -270 -80.75 
( t164=-3.902a) (msec) interquartile [-350, -245] [-479, -270] [-311, -237] [-121.61, -39.89] 
 range (-1288, -163) (-1219, -206) (-878, -192)   
Emotional processing 
 
PANSS negative  median  8.0 10.0 7.0  3.3 x10-3
N1+N2+N3d interquartile [5.0, 11.0] [6.0, 12.3] [4.0, 11.0] - ( W=2883b) 
range (0.0, 21.0) (3.0, 18.0) (0.0, 16.0)    
Multiple testing adjusted significances (Bonferroni: p≤0.0045) are set in boldfaces, all other p-values≤0.05 in italic. at-Statistic tdf with df degrees of freedom for 
estimation of difference in means (employing a linear model on Blom-transformed trait; small differences in degrees of freedom are due to low percentages of 
missing trait values). bWilcoxon rank sum test. cAdjusted for age and PANSS negative. dN1: Blunted affect, N2: Emotional withdrawal, N3: Poor rapport. 
Abbreviations: SZ= Descriptive statistics for whole schizophrenic sample (N=881); HIP= High interpretation performers (N=88); LIP= Low interpretation performers 
(N=88), OR=Odds ratio. 
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Odor interpretation sum score
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High Interpretation Performers (N=88)
Low Interpretation Performers (N=88)
C
0.46 points, 95%CI [-0.27,  1.20], p=0.22a,c 
-4.67 points, 95%CI [-5.41, -3.94], p=9.1x10-29a,d
-5.15 points, 95%CI [-5.92, -4.38], p=7.0x10-28a,e
Supplemental figure 1: Odor naming and interpretation sum scores in patients and healthy controls and extreme group 
comparison based on odor interpretation performance. (A) Schizophrenic subjects experience severe problems in correct 
interpretation of odors compared to matched healthy controls (p<0.000001). (B) Schizophrenic subjects are significantly impaired in 
the odor naming task compared to matched healthy controls (p<0.000001). (C) Extremely poor interpretation performers (LIP) 
perform worse in odor naming compared to high interpretation performers (HIP) and healthy controls.
aLinear regression on Blom-transformed trait, adjusted for age and gender (naming). Smoking status did not significantly influence naming, nor interpretation. 
bSchizophrenic compared to healthy subjects (test statistic t979=-6.318 (interpretation), t978=-5.993 (naming)). cSchizophrenic HIP compared to healthy subjects 
(t273=1.234). dSchizophrenic LIP compared to healthy subjects (t273=-12.533). eSchizophrenic LIP compared to schizophrenic HIP (t172=-13.183). Abbreviations : CI= 
Confidence interval; HIP= High odor interpretation performers; LIP= Low odor interpretation performers.
Supplemental table 1  
Psychometric properties of odor interpretation and odor naming tasks in the schizophrenic sample (N=881) 
 Odor naminga Odor interpretation (odors)b
 
Odor interpretation (attributes)b
Item difficulty (weighted % correct naming ± 95%CI) 
Pineapple 21.71 ± 0.01 73.0 ± 1.7 Pleasant 81.7 ± 1.2 
Gasoline 38.67 ± 0.02 78.2 ± 1.3 Sweet 72.6 ± 1.1 
Mint 76.35 ± 0.03 78.0 ± 1.2 Hot 69.5 ± 1.4 
Rose 39.99 ± 0.02 80.2 ± 1.3 Technical 81.3 ± 1.1 
Natural gas 16.61 ± 0.02 70.9 ± 1.6 Natural 75.1 ± 1.3 
Licorice 54.48 ± 0.03 82.3 ± 1.3 Edible 80.4 ± 1.2 
   Dangerous 79.5 ± 1.1 
Item discrimination,  part-whole corrected [95%CI] 
Pineapple 0.24 [0.18, 0.30] 0.21 [0.15,0.27] Pleasant 0.46 [0.40,0.51] 
Gasoline 0.25 [0.19, 0.31] 0.25 [0.19,0.31] Sweet 0.33 [0.27,0.39] 
Mint 0.30 [0.24, 0.36] 0.27 [0.20,0.33] Hot 0.18 [0.11, 0.24] 
Rose 0.28 [0.21, 0.34] 0.18 [0.11,0.24] Technical 0.58 [0.53, 0.62] 
Natural gas 0.13 [0.07, 0.20] 0.16 [0.09,0.22] Natural 0.45 [0.40,0.50] 
Licorice 0.27 [0.20, 0.33] 0.20 [0.14,0.27] Edible 0.52 [0.47,0.56] 
   Dangerous 0.52 [0.47,0.56] 
Item discrimination,  not part-whole corrected [95%CI] 
Pineapple 0.41 [0.35, 0.46] 0.57 [0.52,0.61] Pleasant 0.63 [0.59,0.67] 
Gasoline 0.50 [0.45, 0.54] 0.53 [0.48,0.58] Sweet 0.52 [0.47,0.56] 
Mint 0.60 [0.55, 0.64] 0.52 [0.47,0.57] Hot 0.44 [0.38,0.49] 
Rose 0.56 [0.51, 0.61] 0.45 [0.40,0.50] Technical 0.72 [0.69,0.75] 
Natural gas 0.33 [0.26, 0.39] 0.50 [0.45, 0.55] Natural 0.64 [0.60,0.68] 
Licorice 0.65 [0.62, 0.69] 0.48 [0.43,0.53] Edible 0.68 [0.64,0.71] 
   Dangerous 0.66 [0.62,0.70] 
Internal consistency (standardized Cronbach´s α, equals average split-half reliability) 
 0.50 [0.47, 0.54] 0.44 [0.40,0.48]  0.72 [0.71,0.74] 
Abbreviations: CI, confidence interval. 
aPsychometric measures were calculated based on Spearman correlation (ordinal data). 
 bPsychometic measures were calculated based on Pearson correlation (metric data). 
 
Supplemental table 2 
 
Presentation of high (HIP) and low (LIP) interpretation performer profiles with respect to higher cognition 
composite components and emotional processing score subscales 
  Descriptive LIP compared to HIP 
Effect   p 
  SZ LIP HIP [95% CI] (Statistic) 
Higher cognition composite components     
mean ± SD 20.8 ± 6.6 18.2 ± 6.7 21.5 ± 6.5 -2.61 3.6x10-3Reasoningc
range (2-38) (2–34) (8–38) [-4.35, -0.86] ( t164=-2.951a) 
       
median  -56.5 -79.0 -47.0 -24.77 0.082 
interquartile [-103.0, -36.0] [-139.0, -47.0] [-122.0, -34.0] [-52.69, 3.15] ( t155=-1.753a) Executive functioningc
range (-868– 40) (-680– -9) (-563– -10)   
       
mean ± SD 13.1 ± 3.9 11.7 ± 4.4 13.6 ± 3.9 -1.25 0.049 
Working memoryc
range (1–24) (4–22) (4–24) [-2.50, -0.00] ( t158=-1.981a) 
       
mean ± SD 38.4 ± 13.2 32.5 ± 13.7 39.3 ± 13.5 -4.52 0.011 
Processing speedc
range (4–88) (5–68) (6–71) [-7.99, -1.04] ( t167=-2.566a) 
       
mean ± SD 42.0 ± 12.6 37.3 ± 12.5 43.0 ± 14.0 -3.38 0.083 
Verbal memoryc range (6–72) (11–62) (6–70) [-7.22, 0.45] ( t161=-1.742a) 
       
median  -725 -764 -714 4.14 0.84 
interquartile [-806, -659] [-833, -651] [-797, -647] [-35.50, 43.78] Divided attentionc
range (-1663– -355) (-1167– -448) (-1160– -416)  
( t158= 0.206a) 
 
Emotional processing subscales    
7.5x10-3Blunted affect median  3 4 3  
( W=2947b) [2, 4] [3, 5] [2, 4] - (PANSS N1) interquartile 
 range (1–7) (1–7) (1–6)   
       
Emotional withdrawal median  3 3 3  0.029 
[1, 4] [1, 4] [1, 4] - ( W=3119b) (PANSS N2) interquartile 
 range (1–7) (1–7) (1–6)   
       
3.1 x10-3Poor rapport median  2 3 2  
[1, 3] [1, 4] [1, 3] - ( W=2875b) (PANSS N3) interquartile 
 range (1–7) (1–6) (1–5)   
Multiple testing adjusted significances are set in boldface (p≤0.0083 for components of higher cognition composite, p≤0.0167 for subscales of emotional processing 
score). All other p-values≤0.05 in italic. at-Statistic tdf with df degrees of freedom for estimation of difference in means (employing a linear model on Blom-transformed 
trait). bWilcoxon rank sum test. cAdjusted for age and PANSS negative. Reasoning ability was measured by LPS3, executive functioning is represented as difference 
of execution times between TMTA and TMTB, working memory was assessed by BZT, processing speed by ZST, verbal memory by VLMT and divided attention by 
negative execution time (-d3mdg) of TAP. In this table, and when building the cognition composite, all measures were presented such that larger values represent 
better cognitive performance.  Abbreviations: SZ= Descriptive statistics for schizophrenic sample (N=881); HIP= High interpretation performers (N=88); LIP= Low 
interpretation performers (N=88). 
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4. Loss-of-function genotypes of the neuronal glycoprotein GPM6a are 
associated with claustrophobia 
 
4.1 Overview of project III 
 
Prolonged exposure to stress leading to dysregulation of the limbic-hypothalamo-pituitary-
adrenal axis (LHPA) has been shown to confer susceptibility to depression and anxiety 
disorders (Shin et al. 2010); two conditions which frequently co-occur (Tronson et al. 2008). 
Besides evoking subjective distress, elevated levels of glucocorticoids induce physiological 
and morphological changes in amygdala and hippocampus (Magarinos et al. 1995, McEwen 
2008). More specifically, it has been demonstrated across different species that dendritic 
branching is increased in amygdala while it is found to be decreased in hippocampus after 
exposure to chronic stress (McEwen 2001, Mitra et al. 2005, Conrad 2006, McEwen 2008). 
Amygdala and hippocampus have been implicated in fear conditioning and extinction 
learning, respectively (Shin et al. 2010). Thus, the reported stress-induced morphological 
alterations might contribute to changes in anxiety-related behaviors, like e.g. facilitation of 
fear conditioning and impaired extinction learning (Eiland et al. 2012). Both processes have 
been suggested to be involved in the etiology of anxiety disorders like specific phobias (Stein 
et al. 2006).  
 
The neuron-specific tetraspan membrane glycoprotein Gpm6a is among the genes identified 
to be down-regulated in hippocampus in response to chronic stress (Alfonso et al. 2004). It 
belongs to the myelin proteolipid protein family (Lagenaur et al. 1992) and is abundantly 
expressed in all subregions of hippocampus (Alfonso et al. 2005). In vitro approaches 
inducing both loss- and gain of function of Gpm6a revealed its putative role in neurite 
outgrowth, and dendritic spine formation in hippocampal neurons (Alfonso et al. 2005, 
Michibata et al. 2009). As a result, glycoprotein M6a likely influences stress-induced 
morphological alterations in hippocampus. Whether the Gpm6a-mediated hippocampal 
neuropathology contributes to the emergence of anxiety-related phenotypes has not been 
studied so far.  
 
To investigate the behavioral consequences of prolonged stress in the absence of Gpm6a, 
Gpm6a null mutant mice were generated and behaviorally characterized. Whereas these mice 




emerged in the null mutants independent of the severity of previously applied stress. Mild 
social isolation stress (i.e. single housing) was sufficient to reveal clear avoidance of the 
closed arms of the elevated plus maze in the mice lacking Gpm6a; a phenotype reminiscent of 
human claustrophobia. Further behavioral assays in several cohorts of mice substantiated the 
claustrophobia-like phenotype in male and female Gpm6a null mutant mice.  
 
Interestingly, the human GPM6A gene is located on chromosome 4q32-q34, a region linked to 
panic disorder (Domschke et al. 2008) but also other anxiety disorders such as agoraphobia or 
specific phobia (Kaabi et al. 2006). These findings support the notion of susceptibility loci 
being shared between different diagnostic categories which are highly co-morbid. Along the 
same lines, depressive symptoms have been shown to be modulated by GPM6A in a subgroup 
of schizophrenic individuals (Boks et al. 2008). To translate our findings in mice to human 
subjects and thus to explore a potential role of GPM6A in human claustrophobia, 115 adult 
subjects (N=47 claustrophobics and N=68 non-claustrophobic controls; matched for age, 
gender, marital status and co-morbid disease state) were recruited and interviewed. After 
validation of claustrophobia status applying DSM-IV criteria (APA 1994), subjects underwent 
detailed claustrophobia relevant phenotyping using the abbreviated German version of the 
Claustrophobia Questionnaire (Radomsky et al. 2001) (Short CLQ-G) which was specifically 
developed and psychometrically evaluated for this project. Claustrophobic cases displayed 
higher ratings on all 10 items of the Short CLQ-G than controls while the prevalence of DSM-
IV anxiety disorders other than claustrophobia did not substantially differ between groups. 
Genomic sequencing of GPM6A covering all exons and flanking noncoding regions identified 
nine rare single-base substitutions in the noncoding regions of GPM6A that were more 
frequent in the affected individuals as compared to the controls. Moreover, one variant in the 
3’ untranslated region was found to be genetically linked to claustrophobia in two small 
pedigrees. Mechanistically, this variant is in an interesting position as it is located in the seed 
sequence of microRNA (miR) 124. The latter is brain expressed and upregulated in 
amygdalae of mice in response to restraint stress. Overexpression of miR124 in peripheral 
blood mononuclear cells of human subjects revealed a down-regulation of GPM6A mRNA in 
carriers of the variant not associated with claustrophobia. As a conclusion, we suggest that 
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B Stepniak1, J Patzig3, P de Monasterio-Schrader3, N Strenzke5, G Flügge2,6, HB Werner3, R Pawlak7, K-A Nave2,3
and H Ehrenreich1,2
Claustrophobia, the well-known fear of being trapped in narrow/closed spaces, is often considered a conditioned response to
traumatic experience. Surprisingly, we found that mutations affecting a single gene, encoding a stress-regulated neuronal
protein, can cause claustrophobia. Gpm6a-deficient mice develop normally and lack obvious behavioral abnormalities. However,
when mildly stressed by single-housing, these mice develop a striking claustrophobia-like phenotype, which is not inducible in
wild-type controls, even by severe stress. The human GPM6A gene is located on chromosome 4q32-q34, a region linked to panic
disorder. Sequence analysis of 115 claustrophobic and non-claustrophobic subjects identified nine variants in the noncoding
region of the gene that are more frequent in affected individuals (P¼ 0.028). One variant in the 30untranslated region was linked
to claustrophobia in two small pedigrees. This mutant mRNA is functional but cannot be silenced by neuronal miR124 derived
itself from a stress-regulated transcript. We suggest that loosing dynamic regulation of neuronal GPM6A expression poses a
genetic risk for claustrophobia.
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Introduction
The neuronal tetraspan membrane glycoprotein Gpm6a
has been implicated in neurite outgrowth and dendritic
spine formation,1–3 but the lack of a mouse mutant has
prevented any in vivo analysis of Gpm6a function. Specifi-
cally, the observation that Gpm6a expression in rodent brain
is downregulated by cortisol or following physical restraint
stress4 has been puzzling. As stress is a key factor for
triggering mental disorders,5 we investigated the behavioral
consequences of resident-intruder stress in mice lacking the
Gpm6a gene. We report here the unexpected finding
that the neuronal gene Gpm6a constitutes a genetic cause
of a highly unusual ‘claustrophobia-like’ phenotype in null
mutant mice, which otherwise develop completely normally. In
fact, only Gpm6a mouse mutants that have experienced a
mild ‘social stress’ exhibit this ‘claustrophobia-like’ behavior.
Moreover, we translate this finding to human individuals,
where we find rare sequence variants in the GPM6A
gene associated with claustrophobia. Mechanistic insight is
provided by the demonstration of a human variant-specific
loss of GPM6A regulability. We conclude that regulability
of the GPM6A gene under stress is required to
avoid claustrophobia, which emerges as an unusual stress
response.
Materials and methods
Generation and characterization of Gpm6a null mutant
mice. All experiments were approved by the local Animal
Care and Use Committee in accordance with the German
Animal Protection Law. Mice with a targeted inactivation of
the Gpm6a gene were generated. First a gene-targeting
vector (Figure 1a) was constructed. From the cloned mouse
(129SV) Gpm6a gene, a 6.5-kb fragment of intron 2 became
the long homologous arm. A 1.5-kb fragment that included
the 30-part of intron 1 and 6 bp at the 50-end of exon 2 became
the short homologous arm. It was cloned with tailored PCR
primers introducing Hind3 (50) and BamH1 (30) restriction
sites. For negative selection, a neomycin-resistance gene
(neo) under control of the herpes simplex virus (HSV)
thymidine kinase (tk) promoter (kindly provided by R
Sprengel, MPI Heidelberg) was utilized. The neomycin
cassette was subcloned with tailored PCR primers introdu-
cing at both the 50- and the 30-end BamH1 restriction sites
and translation termination codons in all reading frames. For
positive selection, a Cla1 fragment of the HSV-tk under
control of the HSV-tk promoter was subcloned into the
vector. The construct was verified by molecular sequencing,
and the vector backbone (pKSþ bluescript, Stratagene
Heidelberg, Germany) was linearized with Not1. Using
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standard procedures,6 R1 mouse embryonic stem cells
(R1-ES, provided by A Nagy, Toronto, Canada), suspended
in phosphate-buffered saline (PBS) with 40 mg linearized
targeting vector, were electroporated using a Bio-Rad
GenePulser (240 V and 500 mF, Bio-Rad, Munich, Germany).
Transfected embryonic stem cells (2 107) were cultured on
gelatinized 10-cm dishes (Falcon, Heidelberg, Germany) for
1 day and then selected with 300 mg ml 1 G418 and 2 mM
Gancyclovir. On day 10 after electroporation, 386 resistant
clones were picked and one with homologous recombination
was identified by semi-nested PCR. Amplification was (1) with
forward primer (50-GGGCTGACTTTTGGATTTTGTGG-30)
and reverse primer (50-GCCTCTCCACCCAAGCGGCCG
GAGAACCTGCGTGC-30) and (2) on the first PCR product
with alternative reverse primer (50-GCAATCCATCTTGTT
CATGGC-30). Embryonic stem cells were microinjected into
C57Bl6/6J blastocysts that were transferred to pseudo-
pregnant foster mothers. Highly chimeric males (N¼ 4) were
obtained that were bred to C57Bl6/6J females. We interbred
heterozygous offspring to obtain homozygous mutant mice,
which were born at the expected Mendelian frequency.
Gpm6a null mutant mice are viable and fertile. For genotyp-
ing (Figure 1b), genomic DNA was isolated from tail biopsies
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Figure 1 Generation of Gpm6a null mutant mice and discovery of behavioral consequences following stress. (a) Strategy to inactivate the mouse Gpm6a gene.
A neomycin resistance cassette flanked by translation stop codons in all reading frames was fused into exon 2, which is the first exon present in all Gpm6a transcripts. (b) PCR
genotyping to identify wild-type (WT) and mutant Gpm6a alleles. (c) Immunoblot analysis of cortex homogenates using antibodies directed against Gpm6a or tubulin, with or
without prior deglycosylation using PNGaseF. Gpm6a was undetectable in Gpm6a null mutants. Note that the abundance of Gpm6a was considerably reduced in
heterozygous mice. (d) Immunohistochemistry of brain sections with antibodies directed against Gpm6a or the related proteolipid protein (PLP). Note that Gpm6a was not
detected in Gpm6a null mutant mice that showed unchanged PLP expression. (e) Elevated plus maze (EPM) behavior of psychosocially stressed (resident-intruder paradigm)
as well as of sham-stressed Gpm6a null mutants (KO) reveals a prominent claustrophobia-like phenotype (N¼ 17–19 per group). (f) Sample track recording of EPM
performance, illustrating a Gpm6a mutant spending much less time in closed arms compared with its WT littermate. (g) Single housing (a prerequisite of performing the
resident-intruder stress) is sufficient to induce a claustrophobia-like phenotype in Gpm6a mutants (N¼ 7–9 per group), which is absent upon group housing, and (f) to reveal a
clear genotype difference in the expression of a stress-regulated gene, Fkbp5, in mouse amygdala (N¼ 7–9 per group). Mean±s.e.m. presented. DAPI, 40-6-diamidino-2-
phenylindole; HSK-tk, herpes simplex virus-thymidine kinase.
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to manufacturer’s directions. In a PCR co-amplification
reaction, the presence of the Gpm6a wild-type (WT) allele
was shown using forward primer #1 (50-TTGCTCTTCTAC
AGGGTGCT-30) and reverse primer #2 (50-CCTCCA
TCCTCTGTCATTCC-30), which yielded a 560-bp fragment.
We identified the targeted allele with forward primer #1 and
reverse primer #3 (50-GCAATCCATCTTGTTCAATGGC-30),
yielding a 310-bp fragment. For protein analysis (Figure 1c),
we prepared total cortex lysates from WT, heterozygous and
homozygous mice and determined the protein concentration
according to Bradford, and boiled the samples (5 min) before
loading. For immunoblot, we separated 40mg lysate by 12%
SDS-polyacrylamide gel electrophoresis and transferred the
samples on poly(vinylidene fluoride) membranes (Hybond-P,
Amersham Biosciences, Glattbrugg, Switzerland). We
blocked the membrane in 5% milk powder in PBS with
0.1% Tween (30 min at 37 1C). Antibodies were directed
against the C-terminus of Gpm6a (#24983; 1:500) or tubulin
(Sigma, Heidelberg, Germany; 1:5000) and applied in
blocking buffer (over night, 4 1C). Following wash, membrane
was incubated with horseradish peroxidase-conjugated sec-
ondary antibody (Dianova, Hamburg, Germany, 1:5000 in
blocking buffer). Immunoreactive bands were visualized by
enhanced chemiluminescence (Pierce, Bonn, Germany). For
immunohistochemistry (Figure 1d), WT and Gpm6a null
mutant mice were anesthetized with Avertin (250 mg/kg body
weight; Sigma), perfused with Hank’s balanced salt solution,
followed by 4% formaldehyde in PBS and the isolated brains
were post-fixed for 1 h. Vibratome sections (thickness 12mm,
Leica VT 1000S, Leica Biosystems, Wetzlar, Germany) were
permeabilized with 0.4% Triton X-100 in PBS (30 min, room
temperature), blocked in 4% horse serum in PBS (30 min,
room temperature) and incubated with antibodies against
Gpm6a (M6, rat monoclonal, 1:25; kind gift by Carl Lagenaur,7
Pittsburgh, USA) or proteolipid protein (A431, rabbit
polyclonal, 1:500)8 at 4 1C for 24 h. After wash, sections were
incubated with appropriate fluochrome-coupled secondary
antibodies (Dianova, Hamburg, Germany; 2 h, room tempera-
ture) and washed three times. Sections were imaged with
Leica DMRXA and OpenLab 2.0 software (Improvision,
Tübingen, Germany).
Behavioral testing. For behavioral testing, mice were
housed in groups of three to five in standard plastic cages,
food and water ad libitum. The temperature in the colony
room was maintained at 20–22 1C, with a 12-h light/dark
cycle (light on at 0700 hours). Behavioral experiments were
conducted by an investigator, blinded to the genotype, during
the light phase of the day (between 0800 hours and 1700
hours). For behavioral experiments, eight different cohorts of
mice were used. The order of testing in the first cohort was as
follows: elevated plus maze (EPM), open field, hole board,
rotarod, pre-pulse inhibition, fear-conditioning, visual cliff. In
further cohorts, EPM release in closed arms, EPM in the
dark, mouse light/dark box test, mouse wide/narrow box test,
EPM retesting (‘exposure treatment’) and hearing were
performed. For electroretinogram, olfaction testing and
corticosterone determination upon metabolic cage exposure,
separate cohorts were used. Age of mice at the beginning of
testing was 19 weeks. Inter-test interval varied depending on
the degree of ‘test invasiveness’ but was at least 1 day. During
all tests, the investigator was ‘blinded’, that is, unaware of
mouse genotypes. For comprehensive test description of
basic tests, that is, EPM, open field, hole board, rotarod, visual
cliff test (vision), buried food finding test (olfaction), sucrose
preference test (motivation), pre-pulse inhibition, cued and
contextual fear-conditioning, and ultrasound vocalization
analysis, please see El-Kordi et al.9 Described in the following
are additional, modified or specifically designed tests.
EPM with release in closed arms. In this modified version,
mice were placed in the closed arms in the same plus-maze
described above. This test was done to address potential
motor factors influencing the time spent in arms. The test
was otherwise conducted in the same manner as the
classical EPM.
EPM in darkness. This test was again performed like the
classical EPM, just in full darkness to address potential
visual/perceptual factors affecting behavior in open/closed
space. The behavior of mice was monitored via infrared
camera.
Hot plate test. The hot plate test is used as a measure of
pain sensitivity. Mice were placed on a metal plate (Ugo
Basile, Comerio, Italy), preheated up to 55 1C. The latency of
hind paw licking or jumping was recorded. Mice were
removed from the platform immediately after showing the
response. A 40-s cutoff time was supposed to prevent
wounds, although none of the tested mice reached it.
Assessment of hearing by the acoustic startle response.
Individual mice were placed in small metal cages (90
40 40 mm3) to restrict major movements and exploratory
behavior. The cages were equipped with a movable platform
floor attached to a sensor that records vertical movements of
the floor. The cages were placed in four sound-attenuating
isolation cabinets (TSE GmbH, Bad Homburg, Germany).
Startle reflexes were evoked by acoustic stimuli delivered
from a loudspeaker that was suspended above the cage and
connected to an acoustic generator. The startle reaction to
an acoustic stimulus (pulse), which evokes a movement of
the platform and a transient force resulting from this
movement of the platform, was recorded with a computer
during a recording window of 100 ms and stored for further
evaluation. The recording window was defined from the
onset of the acoustic stimulus. An experimental session
consisted of a 2-min habituation to 65 dB background white
noise (continuous throughout the session), followed by a
baseline recording for 1 min at background noise. After
baseline recording, stimuli of different intensity and fixed
40 ms duration were presented. Stimulus intensity was varied
between 65 and 120 dB, such that 19 intensities from this
range were used with 3 dB step. Stimuli of the each intensity
were presented 10 times in a pseudorandom order with an
interval ranging from 8 to 22 s. The amplitude of the startle
response (expressed in arbitrary units) was defined as the
difference between the maximum force detected during a
recording window and the force measured immediately
before the stimulus onset. Amplitudes of responses for each
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stimulus intensity were averaged for individual animals.
Mean values for each experimental group were plotted on
the graph to provide the stimulus–response curves.
Mouse light/dark box test. The apparatus (36 20.5 19
cm3) consisted of two equal acrylic compartments, one
roofed, dark and one white, with a 300 lx light intensity in the
white compartment and separated by a divider with an
opening (size: 5.7 5 cm2) connecting both compartments.
Each mouse was tested by placing it in the black/dark area,
facing the white one, and was allowed to explore the novel
environment for 5 min. The roof of the dark compartment was
closed after releasing the mouse. The number of transfers
from one compartment to the other and the time spent in the
illuminated side were measured. This test exploited the
natural conflict between the animal’s drive to explore a new
environment and its tendency to rather stay in a closed, dark
and protected environment and to avoid bright light.
Mouse wide/narrow box test. This inhouse-made box (test
arena: length 60 cm, width 60 cm and height 30 cm)
consisted of two equal (each 30 cm length) gray plastic
compartments. One compartment was wide and open, the
other one narrow (consisting of 30 5 30 cm3 corridor).
Mice were placed in the wide compartment, facing the narrow
corridor. Light intensity in the wide compartment was 300 lx,
in the corridor 150 l . Time to enter the corridor was
recorded by a stopwatch. The behavior was recorded
throughout the 10 min testing period by a PC-linked overhead
video camera. ‘Viewer 2’ software was used to calculate
velocity, distance travelled, number of visits of and time spent
in both compartments.
Electroretinogram. Before the experiments, animals were
dark adapted for at least 12 h and all preparations were
carried out under dim red light.10 Mice were anaesthetized by
intraperitoneal injection of ketamine (0.125 mg g 1) and
xylazine (2.5 mg g 1). Supplemental doses of 1/4 the initial
dose were administered when changes in the constantly
monitored electrocardiogram or movements indicated that
the animals were waking up. Mice were placed on a heated
mat (Hugo Sachs Elektronik–Harvard Apparatus, March,
Germany) that kept the body temperature constant at 37 1C
under the control of a rectal thermometer. The head of the
mouse was placed inside a custom-designed Ganzfeld bowl
illuminated by a ring of 20 white light-emitting diode. The
pupil of the left eye was dilated with 1% atropine sulfate and a
silver wire ring electrode was coupled to the corneal surface
using electrode gel. The eye and electrode were kept moist
by a drop of 0.9% saline applied every 30 min. Subcutaneous
needle electrodes were inserted between the eyes (refer-
ence) and near the tail (ground). Electrical potentials were
amplified 1000 times, filtered between 0.1 and 8 kHz and
notch-filtered at 50 Hz using custom-designed hardware. The
Tucker Davis System III hardware and BioSig software
(Tucker-Davis Technology, Alachua, FL, USA) were used for
Elevated Plus Maze Exposure 'Therapy'
EPM

























































































































































Figure 2 Male Gpm6a mutants show a strong claustrophobia-like phenotype on top of mild anxiety features. (a) Behavior of Gpm6a knockout (KO) and wild-type (WT)
littermates in classical elevated plus maze (EPM); (b) in EPM performed in the darkness; and (c) in EPM upon release in closed arms. (d) Weekly exposure to EPM (over 3
weeks) led to reduction of closed arm aversion in Gpm6a KO. This adjustment also explains the weaker closed-arm avoidance seen in mice of b and c, which had had one
previous exposure to EPM. (e) In a newly developed wide/narrow box test, WT mice spent more time in the narrow area (left graph), whereas Gpm6a KO did not show narrow
space preference. (f) In the light/dark box, Gpm6a KO mice entered the light area faster; (g) explored less holes (requiring nose pokes in narrow holes); (h) spent less time in
the center of the open field, and (i) exerted higher baseline freezing in the fear-conditioning chamber. (j) Exposed to narrow metabolic cages for 3 h, Gpm6a KO excreted
higher levels of corticosterone via urine. (a–c): N¼ 17–18; (d): N¼ 8; (e): N¼ 32–35; (g–h): N¼ 17–18; (i, j): N¼ 12. Mean±s.e.m. presented.
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stimulus control and recordings. Scotopic responses to 10
white light flashes were averaged for each stimulus condi-
tion. Interstimulus intervals were 5 s for light intensities below
1 cds m 2 and 17 s for light intensities above 1 cds m 2. The
amplitude growth functions and latencies of the A-waves,
B-waves and oscillatory potentials in response to 0.1, 1 and
5 ms long-light flashes ranging between 0.0003 and
10 cds m 2 was analyzed using custom-written matlab
(Mathworks, Natick, MA, USA) software.
Corticosterone excretion. Urine samples were collected
using inhouse-made metabolic cages. Mice were placed in
small, narrow metal cages (90 40 40 mm3) to restrict
major movements and exploratory behavior, thus resulting in
stress-induced corticosterone release. These cages had a
wire-mesh floor enabling urine collection via a funnel. The
funnel was fixated on top of a collecting flask. Mice (12 per
genotype) were placed in the metabolic cages at 2200 hours
for 3 h each. Urine was collected at 0100 hours. Concentra-
tions of corticosterone were measured using a commercially
available EIA kit (BIOTREND, Cologne, Germany) according
to the manufacturer’s protocol. Urine creatinine was
determined photometrically (Jaffe method). Sample analysis
of WT and knockout (KO) animals was performed blinded
and in random order. Values were expressed as nmol per
day per g body weight.11
Resident-intruder (psychosocial stress) test. The procedure
is described in detail elsewhere.12,13 Briefly, male mice of
both genotypes (28 days old) were randomly assigned to
either the ‘stress’ or ‘sham stress’ group. As intruders, they
were subjected for 21 days (1 h daily, from 0900–1000 hours)
to resident male mice (male FVB, 2–3 months old, habituated
to resident cages for X10 days). To prevent injuries, direct
interaction was immediately terminated at the first attack
(usually occurring after a few seconds) by putting a grid cage
(140 75 60 mm3) over the intruder. Afterwards, intruder
mice were placed back in their home cage. Mice were
confronted with a different resident every day. Sham stress
consisted of placing the intruder mouse in an empty novel
cage for 1 h.
Restraint stress paradigm. Mice were kept undisturbed for at
least 1 week until a single 6-h restraint stress was performed
in a separate room (with mice left in their home cages and put
in wire mesh restrainers, secured at the head and tail ends
with clips) during the light period of the circadian cycle as
described.14 Control animals were left undisturbed.
Amygdala dissection. Mice were anaesthetized (intraperito-
neal sodium pentobarbital 50 mg kg 1) and perfused trans-
cardially (ice-cold PBS). Amygdalae were dissected from a
coronal slice  0.58 to  2.3 mm relative to Bregma and
stored in RNA later (Qiagen) at 4 1C until processed.14
Quantitative reverse transcription-PCR from amygdala.
Amygdala tissue was homogenized in Quiazol (Qiagen,
Hilden, Germany). Total RNA was isolated by using the
miRNeasy Mini Kit (Qiagen). First strand cDNA was
generated from total RNA using N9 random and Oligo(dT)
18 primers. The relative concentrations of mRNAs of interest
in different cDNA samples were measured out of three repli-
cates using the threshold cycle method (deltaCt) for each
dilution and were normalized to the normalization factor of
Hprt1 and H2afz genes calculated by the geNorm analysis
software. Reactions were performed using SYBR green PCR
master mix (ABgene, Foster City, CA, USA) according to the
protocol of the manufacturer. Cycling was done for 2 min at
50 1C, followed by denaturation at 95 1C for 10 min. The
amplification was carried out by 45 cycles of 95 1C for 15 s
and 60 1C for 60 s. The specificity of each primer pair was
controlled with a melting curve analysis. For quantitative











miR124. First strand cDNA synthesis and reactions were
generated from total RNA using the TaqMan MicroRNA RT
Kit, TaqMan MicroRNA Assay for hsa-miR124, TaqMan
MicroRNA Assay for sno-RNA142 as a housekeeper and
TaqMan 2 Universal PCR Master Mix (ABgene) according
to the manufacturer’s protocol. Cycling was done with 10 min
denaturation at 95 1C and amplification for 40 cycles at 95 1C
for 15 s and 60 1C for 60 s.
Human sample
Claustrophobic subjects. The present study was approved
by the Ethics Committee of the Georg-August-University. A
total of 47 subjects with clinical diagnosis of claustrophobia
according to Diagnostic and Statistical Manual of Mental
Disorders IV (DSM-IV)15 were included (Table 1). Healthy
subjects (N¼ 13) were recruited by e-mail announcements in
the Max Planck Institutes of Experimental Medicine (MPIEM)
and Biophysical Chemistry (MPBPC). Patients suffering from
psychiatric conditions other than psychotic disorders (N¼ 16;
that is, N¼ 7 affective disorder, N¼ 5 anxiety disorder, N¼ 2
substance use disorder, N¼ 2 others) were recruited from
the psychiatric hospital of the Georg-August-University
Göttingen. In addition, N¼ 18 schizophrenic individuals with
a claustrophobic phenotype were selected from the GRAS
data collection.16 Claustrophobic subjects were invited to the
outpatient unit of the MPIEM for examination. In the case of
GRAS patients, extensive telephone interviews were per-
formed instead. Subjects underwent detailed claustrophobia
relevant phenotyping, after validation of diagnoses using
DSM-IV criteria15 by a trained psychologist/psychiatrist. The
subsequent examination procedure comprised a short ques-
tionnaire regarding sociodemographic information, history of
physical and psychiatric diseases, specifically for this project
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developed abbreviated German version of the Claustropho-
bia Questionnaire (CLQ)17 (Short CLQ-G) and the screening
questions of the Structured Clinical Interview of Diseases18
for anxiety disorders.
Non-claustrophobic subjects. A total of 68 subjects, who did
not suffer from claustrophobia, were matched to the
claustrophobic subjects regarding age, gender and clinical
diagnosis where applicable (Table 1). Again, healthy subjects
(N¼ 14) were recruited by e-mail announcements in the
MPIEM and MPBPC. Patients suffering from psychiatric
conditions other than psychotic disorders (N¼ 29; that is,
N¼ 18 affective disorder, N¼ 4 general anxiety disorder,
N¼ 4 substance use disorder, N¼ 3 others) were recruited
Table 1. Comparison of sociodemographic, general clinical and anxiety/claustrophobia relevant parameters in claustrophobic and non-claustrophobic subjects









Mean±s.d. Mean± s.d. Mean± s.d.
Sociodemographics
Age in years 43.56±13.22 43.87±12.11 43.35±14.02 0.733
Education in years 14.43±3.55 14.31±3.85 14.52±3.35 0.830
N % N % N % Effect P b
Gender
Female 81 70.4 13 27.7 21 30.9 0.139 0.710
Male 34 29.6 34 72.3 47 69.1
Ethnicity
Caucasian 112 97.4 47 100.0 65 95.6 2.129 0.546
African 1 0.87 — — 1 1.47
Other 2 1.73 — — 2 9.94
Marital status
Single 57 49.6 24 51.1 33 48.5 3.545 0.471
Married 33 28.7 12 25.5 21 30.9
Divorced 19 16.5 11 23.4 11 16.2
Widowed 3 2.6 — — 3 4.4
Main diagnoses according to DSM-IV
No clinical diagnosis 27 23.5 13 27.7 14 20.6 1.135 0.567
Schizophrenia 43 37.4 18 38.3 25 36.8
Other clinical diagnoses 45 39.0 16 34.0 29 43
Prevalence of anxiety disorders
Comorbid anxiety disorderc 68 59.1 29 61.7 39 57.4 0.702
Panic disorder 29 25.2 15 31.9 14 20.6 0.194
Agoraphobiad 56 48.7 47 100.0 9 13.2 o0.0001
Ssocial phobia 18 15.7 9 19.1 9 13.2 0.440
Specific phobia 38 33.0 20 42.6 18 26.5 0.106
Generalized anxiety disorder 13 11.3 7 14.9 6 8.8 0.375
Obsessive compulsive disorder 18 15.7 9 19.1 9 13.2 0.440
Mean±s.d. Mean±s.d. Mean±s.d. P a
Claustrophobia Relevant Items (Short CLQ-G)
Subscale ‘restriction’
Dark room 2.18±1.66 3.25±1.22 1.44±1.51 o0.000001
Well-lit room 1.51±1.46 2.53±1.27 0.78±1.12 o0.000001
Sleeping bag 1.04±1.45 1.87±1.58 0.47±1.01 o0.000001
Trunk 2.18±1.67 3.53±1.04 1.25±1.36 o0.000001
MRI scanner 1.65±1.67 3.17±1.05 0.60± 1.11 o0.000001
Mean of subscale 1.71±1.36 2.87±0.87 0.91±1.00 o0.000001
Subscale ‘suffocation’
Elevator 1.07±1.39 2.13±1.36 0.34±0.84 o0.000001
Breathe 0.83±1.09 1.26±1.24 0.54±0.87 o0.001
Crowded room 1.82±1.57 3.04±1.12 0.97±1.25 o0.000001
Under a car 1.23±1.44 2.17±1.51 0.59±0.97 o0.000001
Sauna 1.00±1.44 2.04±1.56 0.28±0.75 o0.000001
Mean of subscale 1.19±1.08 2.13±0.83 0.54±0.70 o0.000001
Mean of questionnaire 1.45±1.17 2.50±0.74 0.73±0.82 o0.000001
Abbreviation: MRI, magnetic resonance imaging.
aMann–Whitney U-test.
bFisher’s exact test/w2-square test.
cAnxiety disorders other than agoraphobia.
dAgoraphobia includes claustrophobia.
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from the psychiatric clinic of the Georg-August-University
Göttingen. Furthermore, 25 schizophrenic non-claustropho-
bic individuals were selected from the GRAS data collec-
tion.16 The examination procedure comprised the same
battery of questionnaires as for the claustrophobic subjects
(above).
Pedigrees. To explore whether particular variations in
GPM6A are transmitted in families together with claustro-
phobia, we tried to contact all available family members of
the three claustrophobic individuals carrying the genetic
variation at locus c.*1834T4C. Only for two of the subjects,
SIWO and THKA (Figure 3b), it was possible to contact a
sufficient number of relatives. Claustrophobia diagnosis
according to DSM-IV criteria was confirmed by a telephone
interview carried out by a trained psychologist. Swabs for
genetic analysis and a short sociodemographic question-
naire, also containing items regarding the history of physical
and psychiatric diseases, the Short CLQ-G and the screen-
ing questions of the Structured Clinical Interview of Diseases
for anxiety disorders,18 were communicated via mail.
Abbreviated German version of the CLQ (Short CLQ-G).
To quantitatively assess the severity of claustrophobic
anxiety, nine items of the CLQ17,19 were selected and
translated into German language (Supplementary Table 1).
One item measuring fear experienced during magnetic
resonance imaging was added to the restriction subscale
because this situation may induce claustrophobia.20,21 The
CLQ is the most commonly used questionnaire for the
psychological assessment of claustrophobia and has excel-
lent psychometric properties (Cronbach’s a: 0.95; test–retest
reliability: 0.89).17 It is composed of two subscales measur-
ing two distinct but related fears: fear of restriction and fear of
suffocation. Anxiety severity is measured on a 5-point Likert
scale. To cover both subscales, five items from the
suffocation and four items from the restriction subscale with
high ecological validity were selected for construction of the
Short CLQ-G. Given the substantial reduction in item number
(B60%), the Short CLQ-G still achieves high internal
consistency (total scale: 0.932, restriction: 0.909, suffocation:
0.835) and split-half reliability (0.952, splits matched for
mean item difficulty) for the whole subject sample (N¼ 115;
N¼ 47 claustrophobic subjects; N¼ 68 non-claustrophobic
subjects; Supplementary Table 1).
GPM6A sequencing. DNA from all subjects participating
in this study (N¼ 115) was isolated from blood with the
Figure 3 Genetic analysis of GPM6A. (a) Sequencing strategy and overview of the detected variants. Displayed are the coding exons (filled boxes) and the noncoding
region of GPM6A (empty box). Arrows indicate rare variants found. Frequencies of rare variants in cases (black) versus controls (gray) are given. (b) Pedigrees of two
claustrophobic individuals (SIWO and THKA), carrying the mutation at locus c.*1834 (position 2882 in human GPM6A transcript variant 1, mRNA; NM_005277.3), suggesting
an association between this mutation and the claustrophobic phenotype. (c) Highly phylogenetically conserved genomic structure surrounding c.*1834T4C within the seed
sequence of miR124 in the 30untranslated region of GPM6A. (d) Expression analysis after miR124 nucleofection. Shown are the results of GPM6A RNA expression in
peripheral blood mononuclear cells (PBMCs) after nucleofection with miR124 from two patients and six controls (that is, not carrying the variant; age, gender and disease
matched; three controls per patient). Results were standardized to the results after just a pulse. (e) Restraint stress induces upregulation of miR124 in the amygdala of male
mice, identifying this miR as a stress-regulated transcript (N¼ 22 per group).
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JET Quick Kit (Genomed, Loehe, Germany). For analysis of
pedigree members (swabs), DNA was isolated with the
Isohelix DNA Swab Kit (Biolab Products, Goedenstorf,
Germany). PCR reaction: All exons, the putative promoter
region of Ex2B and the 30 untranslated region (30UTR) of
GPM6A were PCR-amplified from respective samples.
Primers are listed below. Sequencing: The PCR amplicons
were purified from unincorporated primers and deoxyribonu-
cleotide triphosphates by digesting with 1 U Shrimp Alkaline
Phosphatase und 5 U Exonuclease I (Exo) according to the
manufacturer’s instructions (USB Europe GmbH, Staufen,
Germany). Sequencing was carried out using the dideoxy
chain termination method with the BigDye Terminator v3.1
Cycle Sequencing Kit on a 3730XL DNA Analyzer (Applied
Biosystems, Foster City, CA, USA). Raw data were
processed with Sequencing Analysis 5.2 (Applied Biosys-
tems) and with different modules of the software package
Lasergene 7.0 (DNASTAR, Madison, WI, USA).
Primers for GPM6A sequencing approach
Amplified region Primer sequence (50-30) Size
(bp)






Exon 2b fw GAGGAGAGAAAAGGAAAACACAG 755
rv GAAACATTCATTAGCCTTACTGG
Exon 3 fw GAAAGTCTGGGTTGGGAAGGA 788
rv GATTTGTACCTGGCACTATTCTA
Exon 4 fw GAACCAGGGAAGAGGAGAAG 694
rv CCATACATCAATCAACAGTG
Exon 5 fw GCCAAGATATGATTTTCCAGCAG 709
rv GGGAGGATAAAAGTAGAATGC
Exon 6_7 fw GGAACTTGCTTAGATTTGATTAG 955
rv GACTTACTTACCCATTGTTTTCC
Exon 8* fw CGAGATAGCAAGGTGTAATGAAG 904
rv CATAAACATGAGTAATCTGAGG
30UTR* fw GAAGATCAGTGGCCATATTAC 1543
rv ATTGTACTTGAAAAGAATTCACAC
*For sequencing exon 8 and the associated 30UTR additional




Computational micro RNA (miRNA) search. To explore
putative miRNA-binding sites in the GPM6A 30UTR, several
analyses were performed. TargetScan, version 6.2 (http://
www.targetscan.org/) was used to identify miRNA-binding
sites. Screening and DDG prediction analysis for both alleles
of GPM6A were carried out using established algorithms
(http://genie.weizmann.ac.il/pubs/mir07/mir07_prediction.html).
Expression analysis after nucleofection. Peripheral blood
mononuclear cells (PBMCs) of claustrophobic patients with
the mutation in the 30UTR (N¼ 2) and three matches per
subject were freshly isolated using the standard Ficoll-Paque
Plus isolation procedure (GE Healthcare, Munich, Germany).
Using the Amaxa Nucleofector II Device (T-020), 6 106
cells were transfected with neg miRNA #2 or hsa-miR124
(Applied Biosystems) and cultured in RPMI supplemented
with 10% fetal calf serum. After 24 h, cells were harvested
and RNA extracted with the miRNeasy Mini Kit (Qiagen).
cDNA was synthesized using 200 U SuperScriptIII (Invitro-
gen, Karlsruhe, Germany). For quantification with quantita-
tive reverse transcription-PCR, the cDNA was used 1:10
diluted and four replicates per sample were performed; to 4ml
diluted cDNA, 5 ml Power SYBR mix (Applied Biosystems)
and 1 pmol of each primer (see below) were added.
Cycle threshold (CT) values for GPM6A were standardized





Statistical analyses. Data were analyzed using SPSS for
Windows version 17.0 (SPSS Inc., Chicago, IL, USA; http://
www.spss.com) (human data analyses) and Prism 4 for
Windows version 4.03 (GraphPad Software, Inc., La Jolla,
CA, USA) (mouse data analyses). Unless otherwise stated,
the data given in figures and text are expressed as
mean±s.e.m., and were compared by two- or three-way
analysis of variance with post-hoc planned comparisons or
by analysis of variance for repeated measurements,
Mann–Whitney U-test and w2 test, where appropriate.
Results
Gpm6a null mutant mice appear essentially normal in
development and basic behavior. We have generated
Gpm6a null mutant mice (KO) to explore the role of Gpm6a in
the behavioral response to stress (Figures 1a–d). Homo-
zygous KO mice were born at the expected Mendelian
frequency and are long-lived. By western blot analysis,
heterozygous mice expressed about 50% of the protein
(Figure 1c), demonstrating that Gpm6a abundance can be
regulated at the transcriptional level in vivo (see below).
Gpm6a KO mice reproduce well and exhibit no obvious
developmental defects (data not shown). Also, in a basic
behavioral test battery, which included the analysis of motor
and sensory functions, motivation and sensorimotor gating,
we found no difference from WT littermate controls
(Supplementary Figure 1).
Mild stress induces a claustrophobia-like phenotype in
Gpm6a null mutant mice. Unexpectedly, when applying
the resident-intruder paradigm13 in order to assess the
response to experimental stress, we noticed that sham-
stressed Gpm6a null mutant mice exhibit a prominent
phenotype in the EPM, consisting of a specific avoidance
of closed arms. To our knowledge, such a behavioral
response, which we like to term ‘claustrophobia’ in mice,
has not been reported before. This phenotype is specifically
striking, because normal rodents rapidly seek closed and
narrow spaces to hide, which is a protective trait. Interest-
ingly, the claustrophobia-like phenotype was only marginally
amplified in those mutant mice that had experienced the
resident-intruder stress (Figures 1e,f). As a prerequisite for
applying this stress paradigm is prior single housing (of all
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mice), we asked whether the relatively mild stress of social
withdrawal might have been sufficient to trigger the claus-
trophobia-like phenotype in Gpm6a mutants. Indeed, single-
housed, but not group-housed, Gpm6a mutants showed
claustrophobia (Figure 1g). In these experiments, 10 days of
single housing were sufficient to cause downregulation of the
stress-responsive gene Fkbp522,23 in the amygdala of WT
mice. Importantly, this downregulation was absent in Gpm6a
mutant mice, demonstrating a perturbation of the normal
stress response even at the molecular level (Figure 1h). A
comparable result was obtained for Npy5r as another marker
of stress (data not shown).24
Extra behavioral tests underline the claustrophobia-like
phenotype in Gpm6a / mice. As claustrophobia-like
behavior in mice has to our knowledge never been reported
before, we performed a large number of extra behavioral
tests in eight independent cohorts of male mice in order to
substantiate this unusual phenotype. In fact, claustrophobia
upon single housing was found in all cohorts of Gpm6a
mutants and maintained when EPM was performed in
darkness, using infrared cameras or when mice were
released in closed arms (Figures 2a–c). This behavioral
response did not rely on whisker functions or vocalizations,
as confirmed by whisker cutting and ultrasound recording,
respectively (data not shown). Similar to an ‘exposure
therapy’ in humans, repeated EPM testings of mutants
reduced and ultimately eliminated the claustrophobia-like
behavior (Figure 2d; note also the weaker closed arm
avoidance of mutants in Figures 1g and 2b,c;
Supplementary Figure 2B, showing cohorts that already
had one previous EPM test session). Also, other tests
confirmed our diagnosis of ‘claustrophobia’, such as a
specifically designed wide/narrow box, a light/dark box and
the hole board test, in all of which mutant mice lacked
preference for narrow and dark spaces (Figures 2e–g), that
is, displayed a highly abnormal behavior, considering
that rodents naturally prefer these spaces to hide and
thereby protect themselves from predators.
Further tests demonstrated slightly increased general
anxiety, again reminiscent of the known human claustropho-
bic phenotype. Mutants spent less time in the center of
the open field and showed increased ‘baseline freezing’ in the
fear-conditioning box (Figures 2h,i). The collection of urine
from mutant mice that were kept for 3 h in narrow metabolic
cages, revealed a significantly higher corticosterone excretion
compared with their WT littermates (at similar urine creatinine
values: WT 0.35±0.08 versus KO 0.39±0.06 mg per g body
weight and day; N¼ 12/group; P40.1), indicative of an
increased stress level (Figure 2j). As phobias/panic disorders
in humans are more prevalent in females than in males,25 we
additionally examined female mutant mice and confirmed a
very similar behavioral pattern as in male mice, that is, an
unaltered basic behavior and the avoidance of closed arms in
EPM (Supplementary Figure 2).
First considerations on a functional compensation for
loss of Gpm6a in null mutant mice. Interpreting stress at
the level of gene expression changes is difficult, because the
encoded proteins can be ‘upstream’ or ‘downstream’ of
stress perception, and either contribute to or protect from
abnormal stress response. This complicates the prediction of
cause and effect in a pathological situation. Gpm6a
mRNA is downregulated by chronic social stress and also
following prolonged cortisol treatment.26 As stimulation of
the hypothalamus–pituitary–adrenal (stress) axis leads to
cortisol release, it is likely that downregulated Gpm6a
expression mediates adaptation of the brain to stress and
is therefore a healthy response that serves a feedback
function in neuronal circuits exposed to stressful signals. The
loss of Gpm6a in null mutant mice is clearly tolerated,
presumably by the functional compensation of structurally
related membrane proteins that are co-expressed in devel-
opment (but are likely not stress regulated). One candidate
for functional compensation is the neuronal Gpm6b gene,
which encodes a highly related protein27 with a similar (but
not identical) spatio-temporal expression in brain28,29 and
which is, unlike Gpm6a, not among the identified stress-
regulated genes.26,30 In fact, this gene is upregulated under
basal conditions in the amygdalae of Gpm6a mutant mice
(KO: 1.04±0.06; WT: 0.86±0.05, normed to Hprt1 and
H2afz; Po0.05). To further investigate compensatory func-
tions between the two genes, we cross-bred Gpm6a mutant
mice with a newly generated line of Gpm6b null mutant
mice.31 The resulting double-mutant mice develop normally
and reproduce well, but show 20% unexplained mortality at
age 1 month. Further evidence that Gpm6a and Gpm6b have
overlapping functions was found in cultured cortical neurons,
in which the loss of both proteins reduced the collapse
response of growth cones to soluble ephrin-B5, a repulsive
signal.31 This significant but clearly limited evidence of
compensation strongly suggests that several (but not all)
Gpm6a functions are redundantly served by Gpm6b and
presumably other neuronal proteins. If stress-induced down-
regulation of Gpm6a expression in vivo were part of a
neuroprotective stress response, it would be plausible that
Gpm6a null mutant mice can develop normally but are
selectively affected at the behavioral level, simply because
Gpm6a compensating genes (such as Gpm6b) lack the
necessary downregulation following stress exposure.
Selected genomic sequencing of GPM6A reveals
associations with claustrophobia. As polymorphisms of
human GPM6A, specifically in the noncoding region, could
likewise interfere with dynamic gene regulation, we explored
the association of this gene with a predisposition to human
claustrophobia. A sample of 115 adult subjects (N¼ 47 self-
reported claustrophobics and N¼ 68 non-claustrophobic
controls) were recruited and interviewed with special
emphasis on general anxiety and claustrophobia (Table 1).
The sociodemographic description of the human sample
revealed similar distributions between claustrophobic and
non-claustrophobic individuals with regard to age, educa-
tional background, gender, ethnicity and marital status.
Moreover, cases and controls were well matched for co-
morbid disease state. The prevalence of DSM-IV anxiety
disorders other than claustrophobia (Table 1, included under
agoraphobia) did not substantially diverge between claus-
trophobic cases and controls. More than half of the total
sample (59%) reported to suffer from at least one (additional)
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anxiety disorder. Expectedly, most individuals suffered from
any kind of specific phobia (33%), followed by panic disorder
(25%), social phobia and obsessive-compulsive disorder
(both 16%). Generalized anxiety disorder was least frequent
in our sample (11%). Claustrophobic subjects displayed higher
severity ratings on all 10 items of an abbreviated German
version of the CLQ17 (Short CLQ-G; essentially all Po000001).
Despite a 60% reduction in item number, the Short CLQ-G
showed still very good psychometric properties comparable
to the original instrument (Supplementary Table 1).
On all 115 subjects, we performed genomic sequencing of
GPM6A covering all exons and flanking noncoding regions.
This identified nine single-base substitutions in GPM6A, all of
which were rare (most of them previously unreported) variants
in the noncoding regions. Interestingly, in claustrophobic
individuals, the sequenced regions were significantly more
polymorphic than in non-claustrophobic controls (P¼ 0.028;
Figure 3a). To investigate whether particular variants of
GPM6A are also genetically linked to claustrophobia, we
examined two families that shared sequence abnormalities in
the 30UTR. This allowed us to include information on more
than one family member (N¼ 10) within two small pedigrees
(Supplementary Table 2). Indeed, the sequence variants in
the 30UTR/noncoding region exon8 were consistently found in
claustrophobic (but not in non-claustrophobic) individuals
(Figure 3b). Unfortunately, the pedigrees were too small to
assess significance. Interestingly, however, when comparing
all mutation carriers in our sample of 115 individuals with all
non-mutation carriers (independent of the claustrophobia
diagnosis) significantly higher scores for most claustrophobia-
relevant items were found associated with the mutation
status (Supplementary Table 3).
A single-base substitution in the 30UTR of GPM6A
delivers first mechanistic insight. To gain mechanistic
insight into the possible role of GPM6A sequence variants in
the noncoding region, we focused on the newly identified
substitution T to C at position c.*1834 in the 30UTR of
exon8, consistently associated with claustrophobia in the two
pedigrees. In vertebrates, the c.*1834-T allele is conserved
from human to zebrafish (Figure 3c). Mechanistically, this
position is of particular interest because it is located within
the seed sequence of miR124. This miRNA is expressed in
brain and highly conserved.32 Indeed, in silico analysis of the
T-to-C substitution predicts the complete loss of miR124
binding (DDG¼ 8.11 kJ mol 1).
To assess the effect of miR124 on expression of the
endogenous human GPM6A gene, we obtained PBMCs, in
which the GPM6A transcript can be detected and quantified
by reverse transcription-PCR. When miR124 was over-
expressed by nucleofection of freshly isolated PBMCs,
steady-state levels of GPM6A mRNA were significantly
decreased in cells that were homozygous for the c.*1834-T
(WT) allele, but not in PBMCs from the heterozygous carriers
of the mutant c.*1834-C allele (Figure 3d). miR124 is
expressed in the adult brain, but has only been studied in
neuronal development32,33 and for its role in neuroplasti-
city.34,35 We asked whether miR124 is also found in the
amygdalae of mice and stress regulated. To this end, WT
mice were exposed to restraint stress for 6 h, followed
immediately by amygdala dissection. Indeed, we detected a
significant upregulation of miR124 (Figure 3e) under stress.
Discussion
The behavioral analysis of Gpm6a mutant mice has led to the
unexpected finding that a single neuronal gene can cause an
isolated behavioral defect, best described as claustrophobia.
Belonging to the category of agoraphobia/panic disorder,
claustrophobia is often assumed to be a conditioned
response, following a related traumatic experience.25,36 In
our model, claustrophobia-like behavior was observed in mice
with a strong genetic predisposition (that is, Gpm6a defi-
ciency) when combined with rather mild chronic stress.
Interestingly, there was no obvious relationship between the
quality of stress (that is, single-housing) and the very specific
avoidance behavior. This not only suggests that loss of
Gpm6a expression is a key genetic determinant of claus-
trophobia, but also sufficient to turn an unrelated stressor into
a trigger of a unique behavioral response. We note that
Gpm6a itself is widely expressed in the CNS, including
hippocampus and amygdala as known sites of fear condition-
ing. Thus, there are no reasons to believe that the encoded
membrane protein has evolved in the context of specific
behavioral functions. It is much more likely that membrane
protein Gpm6a, similar to other proteolipids,37,38 is a
cholesterol-associated tetraspan,39 that binds other neuronal
membrane proteins, which provide functional specificity. It is
thus intriguing that Gpm6a has been found to stimulate
endocytosis of m-opioid receptors from the surface of neuronal
cells.40,41 We note that opioids are well known to be involved
in regulation of fear/anxiety and their extinction in mouse
and man.24
Virtually nothing was known about the cause of claustro-
phobia. Typically, anectodal evidence suggested traumatic
experiences, such as in individuals that became trapped alive,
but these incidents cannot explain the high frequency
of claustrophobia in otherwise normal people. The cause or
trigger of some cases of claustrophobia may still be related
to exposure to narrow spaces,36 traumatic brain injury42 and
other traumatic experiences, such as surviving of mining
accidents, but these are mostly poorly documented.
Our report of a mutant mouse model for claustrophobia
suggests that also human claustrophobia can have a familial
predisposition. We could identify a genetic component of
claustrophobia, involving GPM6A expression and its post-
transcriptional regulation by the (stress-regulated) neuronal
miR124. These data suggest that GPM6A may contribute
to the normal stress response in mouse and human. Larger
studies in human samples would be required to assess
exactly to what extent variants of GPM6A act as a
claustrophobia-susceptibility gene.
At first glance, the two findings in mouse and human appear
contradictory, because the claustrophobic phenotype was
associated with the murine Gpm6a null mutation and the
human GPM6A c.*1834-C allele. The latter is predicted to
encode a more stable mRNA, due to the loss of its miR124-
binding site. However, both findings can be reconciled with the
compensation of Gpm6a (in the null mutant) by related
proteins, such as Gpm6b. These proteins substitute for
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Gpm6a in neurons and allow mutant animals to develop
and behave normally. However, when exposed to stress
the expression of these genes is not downregulated
(unlike Gpm6a), as evidenced by the gene expression
profiling that had identified and later confirmed Gpm6a as
the only stress-responsive proteolipid in the adult brain.1,30
Along these lines, we note that miR124, which acts as a
stress-regulated mediator of GPM6A downregulation, as
shown here, does not have comparable functional binding
sites in GPM6B. Thus, loss of dynamic proteolipid expression
in neurons (and the inability to downregulate these proteins)
may predispose to abnormal stress response, rather than the
loss of Gpm6a per se.
The detailed downstream mechanisms will have to be
explored in other conditional mouse mutants in the future.
Gpm6a drives the rate of endocytosis that downregulates the
steady-state level of m-opioid receptors at the surface of
neuronal cells.40,41 Thus, our data are compatible with a
hypothetical model, in which a stress-induced phobia/panic
disorder might be caused (in part) by a reduced feedback
regulation of endogenous opioid receptor signalling.
Obviously, interactions with other proteins that also influence
behavior may be functionally relevant, and we note that the
human serotonin transporter has been reported to interact in
cis with GPM6A and GPM6B43 (and Jana Haase, Dublin,
Ireland, personal communication), whereas another study has
implicated this serotonin transporter in human panic dis-
orders.44 In turn, GPM6A may also be relevant as a modifier of
other diseases, and it is intriguing that an association has
been found between GPM6A and the severity of depression in
patients with schizophrenia.45 The ramification of GPM6A
downstream mechanisms are therefore likely complex and
beyond the scope of this study. However, by placing the
dynamic expression of GPM6A/Gpm6a both upstream and
downstream of stress perception in the brain, we suggest a
working model of GPM6A/Gpm6a as a neuronal ‘brake’ for
maintaining a healthy stress response.
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38. Krämer-Albers EM, Gehrig-Burger K, Thiele C, Trotter J, Nave KA. Perturbed interac-
tions of mutant proteolipid protein/DM20 with cholesterol and lipid rafts in
oligodendroglia: implications for dysmyelination in spastic paraplegia. J Neurosci 2006;
26: 11743–11752.
39. Scorticati C, Formoso K, Frasch AC. Neuronal glycoprotein M6a induces filopodia
formation via association with cholesterol-rich lipid rafts. J Neurochem 2011; 119: 521–531.
40. Liang YJ, Wu DF, Stumm R, Hollt V, Koch T. Membrane glycoprotein M6A promotes mu-
opioid receptor endocytosis and facilitates receptor sorting into the recycling pathway. Cell
Res 2008; 18: 768–779.
41. Wu Q, Law PY, Wei LN, Loh HH. Post-transcriptional regulation of mouse mu opioid
receptor (MOR1) via its 30 untranslated region: a role for microRNA23b. Faseb J 2008; 22:
4085–4095.
42. Bryant RA, O’Donnell ML, Creamer M, McFarlane AC, Clark CR, Silove D. The psychiatric
sequelae of traumatic injury. Am J Psychiatry 2010; 167: 312–320.
43. Fjorback AW, Muller HK, Wiborg O. Membrane glycoprotein M6B interacts with the human
serotonin transporter. J Mol Neurosci 2009; 37: 191–200.
44. Schumacher J, Deckert J. Serotonin transporter polymorphisms and panic disorder.
Genome Med 2010; 2: 40.
45. Boks MP, Hoogendoorn M, Jungerius BJ, Bakker SC, Sommer IE, Sinke RJ et al. Do mood
symptoms subdivide the schizophrenia phenotype? Association of the GMP6A gene with a
depression subgroup. Am J Med Genet B Neuropsychiatr Genet 2008; 147B: 707–711.
Translational Psychiatry is an open-access journal
published by Nature Publishing Group. This work is
licensed under a Creative Commons Attribution-NonCommercial-
ShareAlike 3.0 Unported License. To view a copy of this license, visit
http://creativecommons.org/licenses/by-nc-sa/3.0/
Supplementary Information accompanies the paper on the Translational Psychiatry website (http://www.nature.com/tp)
Claustrophobia in Gpm6a null mutant mice







Olfaction Hearing Motivation Prepulse inhibitionPain sensation
A B C






































































































































































































































































































Supplementary Table 1 
 
Psychometric properties of the Short CLQ-G  
 
 TOTAL SAMPLE 
(N=115) 
CLAUSTROPHOBIC 




INTERNAL CONSISTENCY (CRONBACH´S ΑLPHA)   
CLQ total  0.932 0.764 0.909 
’RESTRICTION’ (SR) 0.909 0.739 0.870 
’SUFFOCATION’ (SS) 0.835 0.764 0.790 
SPLIT-HALF RELIABILITYA    
 0.952 0.803 0.947 
ITEM DISCRIMINATIONB    
SR    
to be locked in a small, dark room  0.821 0.688 0.787 
to be locked in a small, well-lit room  0.822 0.587 0.800 
to lie in a sleeping bag  0.651 0.413 0.628 
to lie in the trunk of a car 0.842 0.444 0.826 
to lie in an MRI scanner 0.773 0.371 0.578 
SS    
to be in an elevator 0.739 0.533 0.558 
having difficulties to breathe through nose 0.518 0.327 0.586 
to be in the middle of a crowded concert hall  0.789 0.409 0.715 
to work under a car 0.684 0.315 0.716 
to be in a sauna 0.655 0.296 0.592 
ITEM DIFFICULTY (MEAN ±SD)    
SR    
to be locked in a small, dark room  2.18 ± 1.66 3.25 ± 1.22 1.44 ± 1.51 
to be locked in a small, well-lit room  1.51 ± 1.46 2.53 ± 1.27 0.78 ± 1.12 
to lie in a sleeping bag  1.04 ± 1.45 1.87 ± 1.58 0.47 ± 1.01 
to lie in the trunk of a car 2.18 ± 1.67 3.53 ± 1.04 1.25 ± 1.36 
to lie in an MRI scanner 1.65 ± 1.67 3.17 ± 1.05 0.60± 1.11 
SS    
to be in an elevator 1.07 ± 1.39 2.13 ± 1.36 0.34 ± 0.84 
having difficulties to breathe through nose 0.83 ± 1.09 1.26 ± 1.24 0.54 ± 0.87 
to be in the middle of a crowded concert hall  1.82 ± 1.57 3.04 ± 1.12 0.97 ± 1.25 
to work under a car 1.23 ± 1.44 2.17 ± 1.51 0.59 ± 0.97 
to be in a sauna 1.00 ± 1.44 2.04 ± 1.56 0.28 ± 0.75 
ACorrelation between split a (elevator, breathe, sauna, dark room, trunk) and split b (crowded room, under a car, well-lit room, sleeping bag, MRI scanner).
Both splits matched for mean item difficulty; BCorrelation between each item and the mean of the respective subscale. Indicates how well a certain item 





Cronbach’s alpha coefficients are given as measures of the internal consistency of the items included 
in the claustrophobia questionnaire. To calculate the split-half reliability (Spearman-Brown correlation 
between 2 test halves) reflecting the questionnaires’ homogeneity, the 10 single items were divided 
into 2 clusters such that both splits did not differ in mean item difficulty (split a: elevator, breathe, 
sauna, dark room, trunk and split b: crowded room, under a car, well-lit room, sleeping bag, MRI 
scanner). Item discrimination represents the correlation of a single item and the mean of the total 
scale or the subscale the item belongs to. It indicates how much a single test item influences the 
overall result, i.e. how representative the item is for the entire measure. Item difficulties are given as 






Supplementary Table 2  Description of the pedigree sample with respect to sociodemographic and anxiety/claustrophobia relevant readouts 



























(mean of subscale 
‚suffocation’) 
Pedigree 1          




acrophobia YES 2.40 3.40 1.40 
BEWO Mother 54 13.5 Married No clinical diagnosis 
Specific phobia; 
acrophobia YES 2.10 2.40 1.80 
ERWO Father 57 12.5 Married No clinical diagnosis None NO 0.40 0.20 0.60 
KRVO Sister 32 13.5 Married No clinical diagnosis 
Specific phobia; 
acrophobia YES 0.80 1.00 0.60 
KEEN Aunt 48 12 Married No clinical diagnosis 
Specific phobia; 
acrophobia YES 0.80 1.20 0.40 
ILSP Aunt 58 12 Married No clinical diagnosis Specific phobia YES 5.70 8.80 2.60 
MAJA Uncle 43 12 Single No clinical diagnosis None YES 1.50 2.40 0.60 
Pedigree 2          
THKA Included in  study sample 46 13 Divorced 
Affective 
disorder None YES 3.40 3.40 3.40 
REWI Mother 66 12 Married No clinical diagnosis None YES 0.50 0.80 0.20 
TIKA Son 8 - - No clinical diagnosis None NO 0.0 0.0 0.0 
aDegree of familial relationship to subject included in the study sample (SIWO & THKA) 
 
 
Supplementary Table 3  
Comparison of sociodemographic and anxiety/claustrophobia relevant parameters  





NON- MUTATION  
CARRIERS (N=93) STATISTICS 
SOCIODEMOGRAPHICS    
 Mean ± SD Mean  ± SD pa
Age in years 46.26±13.64  42.92±13.64 0.221 
Education in years  15.11±3.50  14.27±3.56 0.367 
 N % N % Effect  pb
Gender      
female 19 86.4 62 66.7 
male 3 13.6 31 33.3 
3.315 0.069 
Ethnicity     
caucasian 22 100.0 90 96.8 
african - - 1 1.1 
other - - 2 2.1 
0.729 0.866 
Marital status     
single 11 50.0 46 49.5 
married 4 18.2 29 31.2 
divorced 7 31.8 15 16.1 
widowed - - 3 3.2 
4.035 0.399 
MAIN DIAGNOSES ACCORDING TO DSM-IV  
 N % N % Effect  pb
no clinical diagnosis  4 18.2 23 24.7 
schizophrenia 9 40.9 34 36.6 
other clinical diagnoses 9 40.9 36 38.7 
0.437 0.804 
PREVALENCE OF ANXIETY DISORDERS  
 N % N % pb
comorbid anxiety disorderc 14 63.6 54 58.1 0.810 
panic disorder 9 40.9 20 21.5 0.098 
agoraphobia 14 63.6 42 45.2 0.156 
claustrophobia 14 63.6 33 35.5 0.028 
social phobia 3 13.6 15 16.1 1.00 
specific phobia 9 40.9 29 31.2 0.452 
generalized anxiety disorder 3 13.6 10 10.8 0.712 
obsessive-compulsive disorder 6 27.3 12 12.9 0.109 
CLAUSTROPHOBIA RELEVANT ITEMS (SHORT CLQ-G)   
 Mean ±  SD Mean  ±  SD pa
Subscale ’restriction’    
dark room 3.00±1.45 1.99±1.65 0.005 
well-lit room 2.00±1.57 1.38±1.41 0.085 
sleeping bag 1.73±1.55 0.88±1.38 0.012 
trunk 2.77±1.57 2.04±1.67 0.057 
magnetic resonance imaging scanner 2.32±1.46 1.49±1.68 0.023 
mean of subscale  2.36±1.27 1.56±1.33 0.010 
Subscale ‘suffocation’      
elevator 1.73±1.55 0.91±1.32 0.018 
breathe 1.31±.132 0.72±1.00 0.035 
crowded room 2.50±1.54 1.66±1.54 0.030 
under a car 1.77±1.54 1.11±1.39 0.059 
sauna 1.45±1.60 0.89±1.39  0.089 
mean of subscale 1.75±1.07 1.08±1.05 0.006 
Mean of questionnaire  2.06±1.08 1.31±1.16 0.006 
aMann-Whitney U-Test; b Fisher’s exact test/ Chi-square test; cAnxiety disorders other than agoraphobia;  
 1
 
Supplementary Figure 1: Basic behavior of male Gpm6a KO mice as well as visual 
function determined by electroretinography is normal. (A) Body weight; (B) Vision (visual 
cliff test); (C) Electroretinography; this was performed to exclude potential developmental 
alterations in the retina1 of mutant mice affecting visual perception (N=6 per group); grand 
averages±SEM of electroretinograms evoked by 0.075cds/m2 light flashes recorded from M6A 
mutant mice and wildtype littermates (n=6 each); over a range of 7 light intensities between 
0.0003cds/m2 and 10cds/m2, amplitudes and latencies of A- and B-waves (reflecting 
synchronous activity of photoreceptors and bipolar/retinal ganglion cells, respectively), as well 
as the amplitude and frequency of oscillatory potentials overlying the ascending B-wave 
(reflecting electric activity of amacrine cells), were normal in M6A mutants. No significant 
differences were obtained for any of the intensities tested. (D) Open field pattern (except for 
time spent in the center); (E) Rotarod; (F) Olfaction (buried food finding); (G) Pain sensation 
(hot plate); (H) Acoustic startle response (hearing); (I) Motivation (sucrose preference test); (J) 
Sensorimotor gating, measured by prepulse inhibition (PPI), and startle response are all 
indistinguishable between KO and WT. N=13-28 per group except for (C). Mean±SEM 
presented. 
 
Supplementary Figure 2: Brief behavioral characterization of female Gpm6a KO mice also 
reveals a claustrophobia-like phenotype. (A) Comparable to male KO mice, female KO have 
an aversion towards closed arms in the classical EPM as well as (B) in EPM conducted in 




Supplementary Table 1: Psychometric properties of the 'short German version' of the CLQ 
 
Supplementary Table 2: Description of the pedigree sample with respect to sociodemographic 
and anxiety/claustrophobia relevant readouts 
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5. Slightly modified expression of the gene encoding methyl-CpG binding 
protein-2 influences impulsivity in mouse and man 
  
5.1 Overview of project IV 
 
The gene encoding methyl-CpG binding protein-2 (MECP2) maps to chromosome Xq28 and  
is one of the most dosage-sensitive genes transcriptionally regulating genes associated with 
neuronal functional integrity (Chahrour et al. 2008). Loss-of-function mutations of MECP2 
lead to Rett syndrome, characterized by a gender- and mutation-type-dependent array of 
symptoms ranging from loss of speech and acquired motor skills to autistic symptoms, severe 
mental retardation and neonatal encephalopathy (Bienvenu et al. 2006). Interestingly, gene 
duplication can cause very similar symptoms (Ramocki et al. 2010), which points to the 
necessity of a tight regulation of gene expression. Accumulating evidence from studies with 
transgenic mouse models of complete loss-of-function, reduced expression or overexpression 
of Mecp2, further substantiates that certain levels of the protein are required for the neuronal 
system to maintain its inhibitory and excitatory balance (Ramocki et al. 2008). Very mild 
overexpression of Mecp2 (~1.5-fold) already disrupts neuronal homeostasis resulting in 
higher seizure propensity together with alterations in neuronal branching sites and increased 
spine density (Bodda et al. 2013). Behaviorally, disturbed neuronal homeostasis across 
different Mecp2 mouse models expresses as abnormal social behavior and increased 
aggression (Shahbazian et al. 2002, Moretti et al. 2005, Fyffe et al. 2008, Kerr et al. 2008, 
Samaco et al. 2009, Chao et al. 2010, Pearson et al. 2012, Samaco et al. 2012, Bodda C 2013). 
Interestingly, behavioral effects of altered Mecp2 levels vary dependent of the genetic 
background (C57Bl6 versus FVB) of the mice.  
 
Our first aim of the present study was to explore the impact of the genetic background on 
basic behaviors, seizure propensity and spontaneous home cage behavior in transgenic mice 
with mild overexpression of Mecp2. Indeed, increased aggression in transgenic mice as 
compared to wildtype littermates could only be detected for the FVB/N background but not 
for C57Bl6/N mice. We further observed that while mild Mecp2 overexpression in FVB and 
C57Bl/6 mice left most basic behaviors unaltered, it modulated seizure propensity (gender-





In humans, data on aggression/impulsivity in Rett or MECP2 gene duplication syndrome are 
scarce. A family study characterizing the neuropsychiatric phenotypes of 9 males and 9 
females carrying MECP2 duplications revealed a high prevalence of hostility (63%) in the 
carrier females. Strikingly, females exhibited mild psychiatric symptoms despite 100% 
skewing of inactivation of the mutation carrying allele and normal MECP2 mRNA levels 
(Ramocki et al. 2009). Moreover, one of three very mild cases of Rett syndrome  who carried 
a mutation located in the deletion hotspot of the 3’ end of the MECP2 gene, has been reported 
to experience episodes of uncontrolled aggression (Huppke et al. 2006). Consequently, also in 
humans, very mild loss and gain of function of MECP2 might result in a range of 
neuropsychiatric symptoms including aggression.  
 
Surprisingly, despite the obvious importance of MECP2 for nervous system development and 
function, the effect of common genetic variations of this gene on human behavior remains 
widely unknown. It was previously shown that common genetic variants such as 3’ UTR SNP 
rs2734647 of MECP2 alter the risk for autism (Loat et al. 2008). Moreover, carriers of the 
minor allele of SNP rs2239464 have decreased cortical surface area in brain regions such as 
the cuneus (Joyner et al. 2009). Interestingly, this brain region has been shown to be 
associated with inhibitory control in patients suffering from bipolar disorder (Haldane et al. 
2008). In the framework of the present project, we wondered whether slight MECP2 
expression differences mediated by common genetic variations would also be associated with 
aggression relevant behavioral phenotypes in humans and how possible genotype-phenotype 
relationships would be mechanistically mediated.  
 
Two MECP2 SNPs, rs2239464 and rs2734647, were considered for the phenotype-based 
association study (inclusion criterion r²<0.8). Translating our findings from the Mecp2 
overexpressing mouse model to humans, we selected impulse control, excitement and 
uncooperativeness (Positive and Negative Syndrome Scale, PANSS) as aggression 
equivalents from the GRAS data collection (Ribbe et al. 2010). Our PGAS approach was 
applied to the three target measures and possible sociodemographic and clinical confounders 
such as age and educational level. Significant genotype-dependent group differences for both 
selected SNPs were shown for male patients with respect to poor impulse control while only 
nominal significances/tendencies could be observed for excitement and uncooperativeness. In 
women, no statistically significant results were obtained. Importantly, no genotype 
differences withstanding correction for multiple testing were observed for the 
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sociodemographic and clinical measures. In terms of functional implications of the 3’UTR 
SNP rs2734647, we identified two microRNAs (miR) with seed binding sites including the 
3’UTR SNP position. In vitro luciferase assays demonstrated a loss of down-regulation upon 
co-transfection with these miRs in case of the allele associated with higher impulsivity. A co-
evolutionary effect on one specific miR sequence, adapting for binding to the respective 
3'UTR sequence in mouse and man, may emphasize the importance of this regulatory 
interaction. As a conclusion, well in line with the aggression phenotype observed in 
transgenic FVB mice, already mildly elevated MECP2 levels seem to be sufficient to 
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Our current psychiatric classification largely relies on the operationalization of categories 
introduced by experienced diagnosticians from the 19th century such as Emil Kraepelin, 
Eugen Bleuler or Kurt Schneider. They highlighted few salient clinical features which they 
determined to signify separate nosologic entities (Kendler 2009). However, many clinical 
features such as psychotic symptoms, mood dysregulation or anxiety transcend diagnostic 
categories (Craddock et al. 2005) (also compare schizophrenic, depressive and autistic  
patients Figure 1). DSM-IV (APA 1994) lists 522 criteria for diagnosing 201 distinct 
psychiatric conditions. Hence, several symptoms function as criteria for more than one 
disorder which challenges the view of psychiatric conditions as entirely distinct entities 
(Borsboom et al. 2011, Rosen et al. 2012). Also from a genetic point of view, the boundaries 
between different psychiatric diagnostic categories begin to blur. In the last years, support for 
genetic risk factors simultaneously associating with several psychiatric diseases accumulated 
(Burbach et al. 2009, Carroll et al. 2009, Purcell et al. 2009, Smoller et al. 2013).  
 
Evidence challenging the symptomatic demarcation between autism spectrum disorders 
(ASD) and schizophrenia exemplify phenomenological similarities described for various 
psychiatric conditions (Kendler et al. 1993, Craddock et al. 2007). Interestingly, the following 
findings seem to mark the beginning of a reinstatement of previous conceptualizations of 
autism as a schizophrenia subtype (Kanner 1943, Crespi 2010). Since it was shown that 
autistic individuals often report psychotic experiences in adolescence or early adulthood, a 
diagnosis of autism does not exclude symptoms typical for schizophrenia (Stahlberg et al. 
2004, Bevan Jones et al. 2012). Recent evidence illustrates that 10 out of 18 cases with early-
onset schizophrenia also fulfilled symptom criteria for Asperger’s syndrome (Waris et al. 
2013). Some argue that symptomatic similarities of ASD and schizophrenia are only 
superficial and do not reflect overlapping underlying pathogenic factors, due to supposedly 
diverse developmental trajectories and ages of onset (Sasson et al. 2011). In contrast to autism 
spectrum disorder (ASD), schizophrenia is still widely considered as adult onset mental 
illness (Häfner et al. 1997). To strengthen the case for altered neurodevelopment in 
schizophrenia, a plethora of neuropathological findings implicating developmentally reduced 




2011). Longitudinal studies have revealed that neurodevelopmental abnormalities such as a 
delay in motor development or impairments in receptive language are found to prevail in 
those later diagnosed with schizophrenia (Jones et al. 1994, Cannon et al. 2002, Rapoport et 
al. 2009). Relationship and adjustment difficulties in childhood, core features of autism, have 
also been reported to be prevalent in this condition (Cannon et al. 2001, Rutter et al. 2006). 
Along the same lines, recent studies convincingly demonstrate that childhood-onset 
schizophrenia is preceded by a diagnosis of an autism spectrum disorder in 30%-50% of the 
cases (Rapoport et al. 2009). Most importantly, however, among those patients suffering from 
schizophrenia, some exhibit a prominent autistic phenotype while psychotic symptoms are 
less prominent (King et al. 2010, Bastiaansen et al. 2011). This autistic subgroup of 
schizophrenic patients can be characterized by behavioral abnormalities such as difficulties in 
social interaction, communication, emotion processing, and motor abnormalities (Cheung et 
al. 2010, King et al. 2010). Additionally, schizophrenic individuals predominantly suffering 
from negative symptoms obtain high scores on the Autism Diagnostic Observation Schedule 
(ADOS); an instrument developed to support the diagnosis of ASD (Bastiaansen et al. 2011). 
Taken together, the strong phenotypic relationship supports overlapping genetic susceptibility 
and pathogenesis of ASD and a subgroup of schizophrenic individuals.  
 
Aims of thesis project V 
To provide the ground for investigating biological pathways common to ASD and a subgroup 
of schizophrenic patients, project V is aimed at defining an autistic subgroup of schizophrenic 
patients using specific highly intercorrelated readouts from the GRAS data collection (Ribbe 
et al. 2010). These autism relevant items were merged into a composite score reflecting the 
overall severity of autistic behaviors. As the selected items have not originally been designed 
to assess autistic behaviors, a validation study in an ASD sample has been initiated to evaluate 
construct (convergent and discriminant validity) and criterion-related validity. Although the 
recruitment of ASD patients will be ongoing, preliminary results from the validation study 
will be reported in the following.  
 
Methods 
Operationalization of autistic symptoms using the GRAS data collection 
From the detailed phenotyping of the GRAS sample (Ribbe et al. 2010), items indicative of 
autistic behavior (covering all three symptom domains according to DSM-IV) (APA 1994) 
were selected from the Positive and Negative Syndrome Scale (PANSS) (Kay et al. 1987) and 
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the Cambridge Neurological Inventory (CNI) (Chen et al. 1995). Both are standardized third-
party clinical observation tools, well-evaluated and widely applied to assess positive, 
negative, general psychopathology and neurological symptom severity in schizophrenia (Kay 
et al. 1988, Chen et al. 2000, Bottlender et al. 2013, Salavera et al. 2013). The severity 
scoring of PANSS items ranges from 1 (definition does not apply) to 7 (severe dysfunction) 
whereas CNI item scores can vary between 0 (normal function), 2 and 3 (function grossly 
abnormal). To cover the diagnostic domain of difficulties in social interaction, items 1 
(‘blunted affect’); 3 (‘poor rapport’) and 4 (‘social withdrawal’) of the PANSS negative 
subscale were used. Difficulties in communication were measured employing items 5 
(‘difficulties in abstract thinking’) and 6 (‘lack of spontaneity and flow of conversation’) of 
the PANSS negative subscale as well as the CNI items ‘aprosodic speech’, ‘echophenomena’ 
and ‘perseveration’. The third diagnostic symptom cluster assessing limited, repetitive and 
stereotypic patterns of behavior was accounted for by using item 5 (‘mannerism’) and 15 
(‘preoccupation’) of the PANSS general subscale and item 7 of the negative subscale 
(‘stereotyped thinking’) as well as the item ‘mannerism’ assessed by the CNI. 
 
Creation of an autism severity score for every schizophrenic GRAS patient 
To generate an integrative measure reflecting the overall severity of autistic behaviors (autism 
severity score), a composite score was created (mean of all items) for every schizophrenic 
GRAS patient. Prior to merging single items, phenotypes were standardized to zero mean and 
variance one by rank based Blom transformation (Blom 1958).  
 
Participants of the validation study 
So far, 53 probands (36 males, 17 females) have been included in the validation study. They 
were partly recruited to the outpatient unit of the Max Planck Institute of Experimental 
Medicine, Göttingen by public announcements or to the Autism Diagnosis Center of the 
University Hospital of Rostock and the Psychiatric Clinic in Taufkirchen. Some probands 
presented with an assured ASD diagnosis, while others had not been diagnosed before. For 44 
individuals (29 males, 15 females; age [mean±SD]: 34.27±10.35) an ASD diagnosis based on 
DSM-IV criteria (infantile autism [N=12], Asperger’s syndrome [N=24]; atypical autism 
[N=8]) (APA 1994) could be confirmed by an invariant team of specially trained and 
experienced psychiatrists and psychologists. Nine individuals (7 males, 2 females; age 
[mean±SD]: 35.9±12.60) did not receive an ASD diagnosis and were included in the control 




but were classified as suffering from personality disorder (N=6), attention deficit 
hyperactivity disorder (N=1) or as healthy control (N=2). Besides an established ASD 
diagnosis, inclusion criteria consisted in average intelligence (Hamburger-Wechsler 
Intelligence scale (Tewes 1994)), legal age (≥ 18 years) and language abilities permitting the 
conductance of anamnestic interviews.  
 
Measures and procedure of the validation study 
As both PANSS and CNI have not been developed and evaluated for the assessment of autism 
relevant behaviors, construct validity and criterion-related validity of the autism severity score 
were evaluated. Construct validity is assured, if it can be demonstrated that the autism 
severity score specifically measures autism relevant behavior. One possibility is to show that 
the newly developed score correlates substantively with a clinical rating of autistic behaviors 
with already established construct validity (convergent validity). A high correlation results if 
a person who scores high on the established instrument also obtains high values on the new 
measure and vice versa. At the same time, the new tool should not correlate with an 
established measure assessing a construct different from autism (discriminant validity). The 
items contained in the autism severity score were rated on the basis of a semi-structured 
interview which was also designed to explore developmental delays and abnormalities as well 
as current symptoms relevant for the confirmation or exclusion of an ASD diagnosis. To 
provide convergent validity, module 4 of the Autism Diagnostic Observation Schedule 
(ADOS) (Lord et al. 2000) was scored based on the ‘original algorithm’ relying on the social 
interaction and communication domain only (Lord et al. 2000). The ADOS is a standardized 
clinical rating instrument assessing social interaction, communication and imagination during 
a semi-structured interaction with an examiner. Modul 4 has been developed for adolescents 
and adults with fluent speech and has good criterion-related validity (Lord et al. 2000, 
Bastiaansen et al. 2011). All ADOS raters of the present study received a special training to 
guarantee standardized administration and scoring. To assure discriminant validity, the 
positive symptoms subscale score of the PANSS was used because it comprises items very 
different from core features of autism. Additionally, criterion-related validity referring to the 
quality of differentiation between diagnosed and non-diagnosed individuals should be 
assessed for the autism severity score. Importantly, the ADOS and the autism severity items 
were always scored by two different examiners both of which were blind to the clinical 











































































Figure 2 Operationalization of autistic symptoms in the schizophrenic GRAS sample. (A) Intercorrelation 
pattern of 6 autism relevant variables created from 12 individual items extracted from the Positive and Negative 
Syndrome Scale (PANSS) and the Cambridge Neurological Inventory (CNI) of the GRAS data collection. As 
revealed by the substantial internal consistency all variables are very likely to be indicative of the same 
underlying psychological construct. (B) Relative frequency distribution of the autism severity score in the 
schizophrenic GRAS sample. The autism severity score is composed of the 6 variables presented in panel A 
and  provides the ground for future genetic approaches. The latter will involve a comparison of the extremes of 
the distribution (phenotypic cases versus phenotypic controls) with respect to constellations of common 
variants of genes implicated in certain biological pathways such as synaptic transmission. 
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Spearman rank correlation coefficients are reported for the individual PANSS and CNI items 
and the ADOS (Figure 3A). Pearson correlation coefficients were calculated for the z-
standardized autism severity score and the ADOS (Figure 3B; convergent validity) and the 
PANSS positive subscale (Figure 3C; discriminant validity). In the present study, criterion-
related validity refers to the degree to which ADOS and autism severity score ratings are in 
agreement with the clinical diagnosis of having ASD or not. Logistic regression was used to 
predict dichotomous ASD status based on both scores. The continuous scores instead of cut-
off based status were used as for the autism severity score no such cut-off has been defined 
yet. Receiver Operating Characteristic (ROC) curves were calculated to provide information 




autism severity score (Figure 3D). In addition, Area under the Curve (AuC) statistics 
representing the overall level of agreement between criterion (i.e. clinical diagnosis of ASD) 
and instrument (i.e. ADOS and autism severity score) were determined. The higher the AuC 
(1 = perfect agreement), the higher the probability for a randomly chosen ASD patient to 
score higher on the respective instrument than a randomly chosen proband without ASD. 
Group differences were assessed by Mann-Whitney U tests (Figure 3E).  
 
Results 
Autism severity score in the GRAS sample allows extreme group definition  
The high internal consistency (Cronbach’s alpha, N=1079: 0.806) of all individual autism 
variables (Figure 2A) indicated that they are very likely to be indicative of one underlying 
construct. Hence, they were integrated into an autism severity score supposed to reflect the 
overall severity of the dimensional trait. The distribution of the autism severity score in the 
schizophrenic GRAS cohort (range: -1.15 to 2.5) allows the definition of extreme groups 
contrasting maximally with respect to the severity of autistic symptoms (Figure 2B).  
 
First evidence for construct and criterion-based validity of the autism severity score 
As the items used to operationalize autistic features have not originally been developed for 
this purpose, the autism severity score was construct validated in a sample of ASD patients 
and controls. Construct validity can be assessed by evaluating the convergence between a 
newly developed rating scale and a measure with established construct validity for the trait of 
interest. For this purpose the ADOS was chosen, which has high diagnostic validity for the 
diagnosis of ASD. Almost all single items included in the autism severity score correlated 
with the ADOS (Figure 3A) although both measures had been rated by independent 
examiners. Strongest correlations (0.4<r<0.7) were observed for the items belonging to the 
diagnostic domains difficulties in social interaction and communication. Its highly significant 
correlation with the ADOS (r=0.654; Figure 3B) and the lack thereof with the positive 
symptom subscale of the PANSS (r=0.044; Figure 3C), points towards high construct validity 
of the autism severity score. As revealed by logistic regression analysis based on ASD 
diagnosis, the autism severity score was able to correctly classify 83% of the probands 
whereas the ADOS classified 86.8% of the probands correctly. ROC curves for the ADOS 
and autism severity scores resulted in AuC values of 0.832 and 0.745, respectively (Figure 
3D). Lastly, significant score differences between the control group and the ASD group were 
observed for both the ADOS (p=0.001) and the autism severity score (p=0.02). Taken 
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together, the high convergence between the autism severity scores and the ADOS supports its 
high construct validity and criterion-related validity. 
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Pearson correlation coefficient r = 0.654; p<0.0002
Figure 3 Results of the construct and criterion-related validation of the autism severity score in a sample of 
ASD patients and controls. (A) Intercorrelations of individual autism severity score items and the Autism Diagnostic 
Observation Schedule (ADOS). The strength of correlation (Spearman rank correlation) is symbolized by the 
thickness of the horizontal bars. (B) Convergent validity of the autism severity score is underlined by a highly 
significant correlation of z-standardized ADOS and autism severity scores (Pearson correlation). (C) Discriminant 
validity of the autism severity score is supported by a lack of correlation between the z-standardized Positive and 
Negative Syndrome Scale (PANSS) positive subscale and autism severity score. (D) Receiver Operating 
Characteristic curves for the ADOS and the autism severity score illustrate high Area under the Curve (AuC) statistics 
which indicates that both scores adequately predict whether someone has an ASD diagnosis or not.  (E) Scatterplots 
reveal significant group differences (autism spectrum disorder [ASD] group versus control group) for the ADOS and 
the autism severity score. P-values were obtained from Mann-Whitney U test. 
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A multitude of genetic and clinical studies converge on the notion that similar biological 
pathways may be involved in the etiology of ASD and a subgroup of schizophrenic 
individuals. Selected items from clinical rating instruments originally developed to assess the 
severity of schizophrenia psychopathology (PANSS) and neurological symptoms (CNI) were 
used to characterize autistic symptoms in the schizophrenic GRAS sample. Probands with a 
clinical ASD diagnosis as well as control subjects were recruited to evaluate construct and 
criterion-related validity of the autism severity score. As could be demonstrated by the 
correlation with the ADOS and the lack of co-variation with the PANSS positive symptoms 
score, first evidence for the autism severity score to be a construct valid instrument could be 
obtained. In addition, the autism severity score was shown to have good general criterion-
related validity. It is able to correctly classify the majority of individuals and higher scores on 
the autism severity score predict a higher probability of having a clinical ASD diagnosis. 
Moreover, group comparisons between ASD and a control group demonstrate that the autism 
severity score is able to differentiate between ASD cases and individuals who themselves 
suspected to deserve a clinical diagnosis of ASD and therefore participated in the study but 
for whom a clinical ASD diagnosis according to DSM-IV criteria could not be confirmed. As 
a consequence, the items developed to assess the severity of negative symptomatology in 
schizophrenia might also be useful to evaluate autistic symptoms in individuals diagnosed 
with ASD. 
 
Interestingly, correlations strengths of ADOS and individual autism score items largely 
varied. Single measures representing the stereotypies and restricted interest domain (i.e. 
‘mannerism’, ‘perseveration’) were least comparable to the ADOS score. This might be due 
to the fact that the original ADOS algorithm used to generate the score in the present study 
does not contain items covering this symptom domain (Lord et al. 2000). In future studies, a 
revised algorithm will be used to decide whether the lack of co-variation is due to the 
respective items not being valid or to the ADOS not covering this behavioral aspect. Not 
surprisingly, as correspondent ratings are included in the ADOS, the items ‘blunted affect’, 
‘poor rapport’ and ‘aprosodic speech’ correlated substantively with the ADOS. Although 
there is no direct equivalent contained in the ADOS, highest correlations were obtained for 
the PANSS item ‘preoccupation’. This measure assesses the state of being absorbed with 
“internally generated thoughts and feelings and with autistic experiences to the detriment of 
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reality orientation and adaptive behavior” Thus, in follow-up evaluation studies, this item 
might turn out to complement the revised ADOS algorithm.  
 
Across all measures, better criterion-related validity was obtained for the ADOS as compared 
to the autism severity score. However, this could be based on the fact that the clinical 
diagnosis of ASD is often assisted by the ADOS due to the lack of an established diagnostic 
tradition for ASD in adults (Bastiaansen et al. 2011). Thus, both parameters might not be 
completely independent from each other.  
 
Several limitations should be taken into account when interpreting the results of the study. 
First of all, data on psychometric properties of ADOS, module 4 are scarce. Existing studies 
demonstrating good psychometric properties rely on very small samples (Lord et al. 2000, 
Bastiaansen et al. 2011). Thus, it can be questioned whether the ADOS is an adequate 
comparison standard. Nevertheless, to date, the ADOS is the only standardized third-party 
clinical rating instrument available. Second, samples sizes in the present study are quite small. 
To substantiate the preliminary findings reported here, recruitment of the ASD patients and 
controls is still ongoing. Moreover, because our semi-structured interviews relied on full 
speech capacity, the ASD group studied is likely biased towards the high-functioning end of 
the autistic spectrum. Besides the small sample size, this limits generalizability of the results. 
Also, raters were blind to ASD diagnosis for only 66% of recruited individuals. Hence, for the 
remaining part, their severity ratings could have been influenced by their awareness about the 
diagnosis.  
 
Our findings are well in line with a previous study illustrating that some patients with 
treatment-resistant schizophrenia have autistic symptoms and that these co-vary with negative 
but not with positive symptoms (Sheitman et al. 2004). Importantly, this subgroup of patients 
did not respond to neuroleptic treatment which strongly points to an involvement of biological 
pathways not targeted by conventional dopaminergic agents. The definition of extreme groups 
based on the here presented autism severity score, permits a future investigation of genetic 
constellations reflecting the integrity of biological pathways shared by individuals suffering 
from ASD and a subgroup of schizophrenic individuals. This might stimulate the 
development of novel pharmacological targets resulting in therapeutic benefits for 
phenotypically defined subgroups of schizophrenic patients. 
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7. Summary and conclusions 
 
Applying a phenotype-based genetic association approach, the present thesis work provides 
evidence for several genes modulating rather specific behavioral dimensions in a 
schizophrenic sample. This complements existing genetic paradigms by elucidating possible 
relationships between common genetic variants, mildly altered biological networks and 
behavioral phenotypes relevant for psychiatric disorders. We could show that the endogenous 
EPO/EPOR system has a role in aspects of cognitive functioning in schizophrenic patients 
and cognitively inferior healthy controls (project I). Moreover, an association of the well-
replicated schizophrenia risk gene neuregulin1 with central olfactory processing could be 
detected (project II). The gene encoding glycoprotein M6a was identified to be involved in 
the risk to develop claustrophobia (project III). Lastly, common genetic variants in the 
transcriptional regulator MECP2 were identified to influence the severity of impulsivity and 
aggression (project IV). The functional relevance of certain candidate genes for specific 
aspects of behavior could be further substantiated by mouse models of loss and gain of 
function of the respective proteins. Mechanistic insight was obtained by studying the 
influence of SNPs located in the regulatory regions (5’ and 3’ regions) of the genes on the 
regulability of expression. Behavior has to be highly flexible in order to be adaptive in a 
constantly changing social environment. Thus, loss of dynamic regulation of the expression of 
certain genes might give rise to dysfunctional behaviors. Projects I, III and IV converge on 
the finding that those genotypes associated with superior expression of the phenotype 
(superior cognition, no claustrophobia, less impulsivity) showed elevated flexibility in gene 
expression. For project I (EPO/EPOR variants), this higher regulability might potentially be 
mediated by genotype-dependent transcription factor binding whereas for projects III and IV 
flexible regulation of gene expression was shown to be influenced by certain brain-expressed 
microRNAs.   
 
Prior to analyzing specific subphenotypes of schizophrenia, schizophrenic GRAS patients and 
healthy blood donors were compared with respect to differential distributions of certain alleles 
of the respective markers of interests (data not reported in the overview sections). 
Importantly, none of the presented candidate genes (EPO, EPOR, neuregulin1, MECP2) was 
found to be associated with an overall disease risk for schizophrenia. Researchers in favor of 
this case-control approach might ascribe this result to the GRAS sample lacking the statistical 
power to detect the presumably small effects. We believe that a concept such as ‘overall 
disease risk’ does not exist. We rather expect different genes to differentially associate with 
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particular phenotypes/inter-correlated phenotypes more or less pronounced in individuals 
carrying a psychiatric diagnosis which can also be assessed in ‘healthy’ subjects (‘healthy’ 
meaning non-diagnosed). The considerable variability in symptom composition and severity 
likely obscures potential effects of variants playing a role in a subsample of schizophrenic 
individuals only. Thus, ultimately, an understanding of the genetic architecture of 
schizophrenia bearing relevant therapeutic implications requires the definition of more 
homogeneous disease subgroups based on highly intercorrelated quantitative phenotypes that 
share common etiologies. These biologically relevant subgroups might represent the extremes 
of continuously distributed phenotype severity scores. Project V of the present thesis gave a 
description of the operationalization of a prevailing autistic phenotype in a subset of 
schizophrenic patients. Future studies will have to reveal whether the severity of autistic traits 
in schizophrenic individuals is modulated by genes implicated in the etiology of autism 
spectrum disorders. Loci or pathways mainly involving synaptic proteins also implicated in 
familial forms of autism might be interesting candidates (Garber 2007, Carroll et al. 2009).  
 
As a conclusion, the present thesis work comprises several examples highlighting the 
importance of defining subphenotypes of schizophrenia to reduce intra-group variability and 
to be able to genetically compare phenotypic cases and controls. The introduced phenotype-
genotype association approach may eventually assist the description of biological pathways 
contributing to the emergence of dysfunctional behaviors. This is crucial for the development 





Abhary, S., Burdon, K. P., Casson, R. J., Goggin, M., Petrovsky, N. P. and Craig, J. E. (2010). 
"Association between erythropoietin gene polymorphisms and diabetic retinopathy." Arch 
Ophthalmol 128(1): 102-106. 
Adamson, J. (1996). "Erythropoietin, iron metabolism, and red blood cell production." Semin 
Hematol 33(2 Suppl 2): 5-7; discussion 8-9. 
Alfonso, J., Fernandez, M. E., Cooper, B., Flugge, G. and Frasch, A. C. (2005). "The stress-
regulated protein M6a is a key modulator for neurite outgrowth and filopodium/spine 
formation." Proc Natl Acad Sci U S A 102(47): 17196-17201. 
Alfonso, J., Pollevick, G. D., Van Der Hart, M. G., Flugge, G., Fuchs, E. and Frasch, A. C. 
(2004). "Identification of genes regulated by chronic psychosocial stress and antidepressant 
treatment in the hippocampus." Eur J Neurosci 19(3): 659-666. 
APA (1994). Diagnostic and statistical manual of mental disorders, 4th edition (DSM-IV). 
Washington, DC, American Psychiatric Association. 
Arcasoy, M. O., Degar, B. A., Harris, K. W. and Forget, B. G. (1997). "Familial erythrocytosis 
associated with a short deletion in the erythropoietin receptor gene." Blood 89(12): 4628-
4635. 
Atanasova, B., Graux, J., El Hage, W., Hommet, C., Camus, V. and Belzung, C. (2008). 
"Olfaction: a potential cognitive marker of psychiatric disorders." Neurosci Biobehav Rev 
32(7): 1315-1325. 
Barnes, A., Isohanni, M., Barnett, J. H., Pietilainen, O., Veijola, J., Miettunen, J., Paunio, T., 
Tanskanen, P., Ridler, K., Suckling, J., Bullmore, E. T., Jones, P. B. and Murray, G. K. 
(2012). "Neuregulin-1 genotype is associated with structural differences in the normal human 
brain." Neuroimage 59(3): 2057-2061. 
Bartels, C., Spate, K., Krampe, H. and Ehrenreich, H. (2008). "Recombinant Human 
Erythropoietin: Novel Strategies for Neuroprotective/Neuro-regenerative Treatment of 
Multiple Sclerosis." Ther Adv Neurol Disord 1(3): 193-206. 
Bassett, A. S., Scherer, S. W. and Brzustowicz, L. M. (2010). "Copy number variations in 
schizophrenia: critical review and new perspectives on concepts of genetics and disease." Am 
J Psychiatry 167(8): 899-914. 
Bastiaansen, J. A., Meffert, H., Hein, S., Huizinga, P., Ketelaars, C., Pijnenborg, M., Bartels, A., 
Minderaa, R., Keysers, C. and de Bildt, A. (2011). "Diagnosing autism spectrum disorders in 
adults: the use of Autism Diagnostic Observation Schedule (ADOS) module 4." J Autism Dev 
Disord 41(9): 1256-1266. 
Benarroch, E. E. (2010). "Olfactory system: functional organization and involvement in 
neurodegenerative disease." Neurology 75(12): 1104-1109. 
Berger, S. (1998). "The WAIS-R factors: usefulness and construct validity in neuropsychological 
assessments." Appl Neuropsychol 5(1): 37-42. 
Bevan Jones, R., Thapar, A., Lewis, G. and Zammit, S. (2012). "The association between early 
autistic traits and psychotic experiences in adolescence." Schizophr Res 135(1-3): 164-169. 
Bienvenu, T. and Chelly, J. (2006). "Molecular genetics of Rett syndrome: when DNA 
methylation goes unrecognized." Nat Rev Genet 7(6): 415-426. 
Bleuler, M. (1979). "On schizophrenic psychoses." Am J Psychiatry 136(11): 1403-1409. 
Blom, G. (1958). Statistical estimates and transformed beta-variables. New York, Wiley. 
Bodda, C., Tantra, M., Mollajew, R., Arunachalam, J., Can, K., Rosenberger, A., Mironov, S., 
Ehrenreich, H. and Mannan, A. U. (2013). "Mild overexpression of Mecp2 in mice causes a 
higher susceptibility toward seizures." Am Journal of Pathology. 
Bodda C, T. M., Mollajew R, Arunachalam JP, Can K, Rosenberger A,. Mironov SL, Ehrenreich 
H and Mannan AU (2013). "Mild overexpression of Mecp2 in mice causes a higher 
susceptibility toward seizures." Am J Pathol  
Bibliography_________________________________________________________________ 
 108
Boks, M. P., Hoogendoorn, M., Jungerius, B. J., Bakker, S. C., Sommer, I. E., Sinke, R. J., 
Ophoff, R. A. and Kahn, R. S. (2008). "Do mood symptoms subdivide the schizophrenia 
phenotype? Association of the GMP6A gene with a depression subgroup." Am J Med Genet 
B Neuropsychiatr Genet 147B(6): 707-711. 
Bondy, B. (2011). "Genetics in psychiatry: are the promises met?" World J Biol Psychiatry 12(2): 
81-88. 
Borsboom, D., Cramer, A. O., Schmittmann, V. D., Epskamp, S. and Waldorp, L. J. (2011). "The 
small world of psychopathology." PLoS One 6(11): e27407. 
Bottlender, R., Strauss, A. and Moller, H. J. (2013). "Association between psychopathology and 
problems of psychosocial functioning in the long-term outcome of patients diagnosed with 
schizophrenic, schizoaffective and affective disorders." Eur Arch Psychiatry Clin Neurosci 
263(2): 85-92. 
Brines, M. and Cerami, A. (2005). "Emerging biological roles for erythropoietin in the nervous 
system." Nat Rev Neurosci 6(6): 484-494. 
Burbach, J. P. and van der Zwaag, B. (2009). "Contact in the genetics of autism and 
schizophrenia." Trends Neurosci 32(2): 69-72. 
Cannon, M., Caspi, A., Moffitt, T. E., Harrington, H., Taylor, A., Murray, R. M. and Poulton, R. 
(2002). "Evidence for early-childhood, pan-developmental impairment specific to 
schizophreniform disorder: results from a longitudinal birth cohort." Arch Gen Psychiatry 
59(5): 449-456. 
Cannon, M., Walsh, E., Hollis, C., Kargin, M., Taylor, E., Murray, R. M. and Jones, P. B. (2001). 
"Predictors of later schizophrenia and affective psychosis among attendees at a child 
psychiatry department." Br J Psychiatry 178: 420-426. 
Cardno, A. G., Marshall, E. J., Coid, B., Macdonald, A. M., Ribchester, T. R., Davies, N. J., 
Venturi, P., Jones, L. A., Lewis, S. W., Sham, P. C., Gottesman, II, Farmer, A. E., McGuffin, 
P., Reveley, A. M. and Murray, R. M. (1999). "Heritability estimates for psychotic disorders: 
the Maudsley twin psychosis series." Arch Gen Psychiatry 56(2): 162-168. 
Carroll, L. S. and Owen, M. J. (2009). "Genetic overlap between autism, schizophrenia and 
bipolar disorder." Genome Med 1(10): 102. 
Chahrour, M., Jung, S. Y., Shaw, C., Zhou, X., Wong, S. T., Qin, J. and Zoghbi, H. Y. (2008). 
"MeCP2, a key contributor to neurological disease, activates and represses transcription." 
Science 320(5880): 1224-1229. 
Chao, H. T., Chen, H., Samaco, R. C., Xue, M., Chahrour, M., Yoo, J., Neul, J. L., Gong, S., Lu, 
H. C., Heintz, N., Ekker, M., Rubenstein, J. L., Noebels, J. L., Rosenmund, C. and Zoghbi, H. 
Y. (2010). "Dysfunction in GABA signalling mediates autism-like stereotypies and Rett 
syndrome phenotypes." Nature 468(7321): 263-269. 
Chen, E. Y., Shapleske, J., Luque, R., McKenna, P. J., Hodges, J. R., Calloway, S. P., Hymas, N. 
F., Dening, T. R. and Berrios, G. E. (1995). "The Cambridge Neurological Inventory: a 
clinical instrument for assessment of soft neurological signs in psychiatric patients." 
Psychiatry Res 56(2): 183-204. 
Chen, Y. L., Chen, Y. H. and Mak, F. L. (2000). "Soft neurological signs in schizophrenic patients 
and their nonpsychotic siblings." J Nerv Ment Dis 188(2): 84-89. 
Cheung, C., Yu, K., Fung, G., Leung, M., Wong, C., Li, Q., Sham, P., Chua, S. and McAlonan, G. 
(2010). "Autistic disorders and schizophrenia: related or remote? An anatomical likelihood 
estimation." PLoS One 5(8): e12233. 
Cichon, S., Craddock, N., Daly, M., Faraone, S. V., Gejman, P. V., Kelsoe, J., Lehner, T., 
Levinson, D. F., Moran, A., Sklar, P. and Sullivan, P. F. (2009). "Genomewide association 
studies: history, rationale, and prospects for psychiatric disorders." Am J Psychiatry 166(5): 
540-556. 
Conrad, C. D. (2006). "What is the functional significance of chronic stress-induced CA3 
dendritic retraction within the hippocampus?" Behav Cogn Neurosci Rev 5(1): 41-60. 
________________________________________________________________Bibliography 
 109
Craddock, N., O'Donovan, M. C. and Owen, M. J. (2007). "Symptom dimensions and the 
Kraepelinian dichotomy." Br J Psychiatry 190: 361; author reply 361-362. 
Craddock, N. and Owen, M. J. (2005). "The beginning of the end for the Kraepelinian 
dichotomy." Br J Psychiatry 186: 364-366. 
Crespi, B. J. (2010). "Revisiting Bleuler: relationship between autism and schizophrenia." Br J 
Psychiatry 196(6): 495; author reply 495-496. 
de Haan, L. and Bakker, J. M. (2004). "Overview of neuropathological theories of schizophrenia: 
from degeneration to progressive developmental disorder." Psychopathology 37(1): 1-7. 
de la Chapelle, A., Sistonen, P., Lehvaslaiho, H., Ikkala, E. and Juvonen, E. (1993). "Familial 
erythrocytosis genetically linked to erythropoietin receptor gene." Lancet 341(8837): 82-84. 
Domschke, K., Hohoff, C., Jacob, C., Maier, W., Fritze, J., Bandelow, B., Krakowitzky, P., 
Kastner, F., Rothermundt, M., Arolt, V. and Deckert, J. (2008). "Chromosome 4q31-34 panic 
disorder risk locus: association of neuropeptide Y Y5 receptor variants." Am J Med Genet B 
Neuropsychiatr Genet 147B(4): 510-516. 
Doty, R. L., Shaman, P., Kimmelman, C. P. and Dann, M. S. (1984). "University of Pennsylvania 
Smell Identification Test: a rapid quantitative olfactory function test for the clinic." 
Laryngoscope 94(2 Pt 1): 176-178. 
Duan, J., Sanders, A. R. and Gejman, P. V. (2010). "Genome-wide approaches to schizophrenia." 
Brain Res Bull 83(3-4): 93-102. 
Ehrenreich, H., Bartels, C., Sargin, D., Stawicki, S. and Krampe, H. (2008). "Recombinant human 
erythropoietin in the treatment of human brain disease: focus on cognition." J Ren Nutr 18(1): 
146-153. 
Ehrenreich, H., Fischer, B., Norra, C., Schellenberger, F., Stender, N., Stiefel, M., Siren, A. L., 
Paulus, W., Nave, K. A., Gold, R. and Bartels, C. (2007). "Exploring recombinant human 
erythropoietin in chronic progressive multiple sclerosis." Brain 130(Pt 10): 2577-2588. 
Ehrenreich, H., Hasselblatt, M., Dembowski, C., Cepek, L., Lewczuk, P., Stiefel, M., Rustenbeck, 
H. H., Breiter, N., Jacob, S., Knerlich, F., Bohn, M., Poser, W., Ruther, E., Kochen, M., 
Gefeller, O., Gleiter, C., Wessel, T. C., De Ryck, M., Itri, L., Prange, H., Cerami, A., Brines, 
M. and Siren, A. L. (2002). "Erythropoietin therapy for acute stroke is both safe and 
beneficial." Mol Med 8(8): 495-505. 
Ehrenreich, H., Hinze-Selch, D., Stawicki, S., Aust, C., Knolle-Veentjer, S., Wilms, S., Heinz, G., 
Erdag, S., Jahn, H., Degner, D., Ritzen, M., Mohr, A., Wagner, M., Schneider, U., Bohn, M., 
Huber, M., Czernik, A., Pollmacher, T., Maier, W., Siren, A. L., Klosterkotter, J., Falkai, P., 
Ruther, E., Aldenhoff, J. B. and Krampe, H. (2007). "Improvement of cognitive functions in 
chronic schizophrenic patients by recombinant human erythropoietin." Mol Psychiatry 12(2): 
206-220. 
Ehrenreich, H., Kästner, A., Weissenborn, K., Streeter, J., Sperling, S., Wang, K. K., Worthmann, 
H., Hayes, R. L., von Ahsen, N., Kastrup, A., Jeromin, A. and Herrmann, M. (2011). 
"Circulating damage marker profiles support a neuroprotective effect of erythropoietin in 
ischemic stroke patients." Mol Med 17(11-12): 1306-1310. 
Eiland, L. and McEwen, B. S. (2012). "Early life stress followed by subsequent adult chronic 
stress potentiates anxiety and blunts hippocampal structural remodeling." Hippocampus 22(1): 
82-91. 
Furukawa, T., Narita, M., Sakaue, M., Otsuka, T., Kuroha, T., Masuko, M., Azegami, T., Kishi, 
K., Takahashi, M., Utsumi, J., Koike, T. and Aizawa, Y. (1997). "Primary familial 
polycythaemia associated with a novel point mutation in the erythropoietin receptor." Br J 
Haematol 99(1): 222-227. 
Fyffe, S. L., Neul, J. L., Samaco, R. C., Chao, H. T., Ben-Shachar, S., Moretti, P., McGill, B. E., 
Goulding, E. H., Sullivan, E., Tecott, L. H. and Zoghbi, H. Y. (2008). "Deletion of Mecp2 in 
Sim1-expressing neurons reveals a critical role for MeCP2 in feeding behavior, aggression, 
and the response to stress." Neuron 59(6): 947-958. 
Bibliography_________________________________________________________________ 
 110
Garber, K. (2007). "Neuroscience. Autism's cause may reside in abnormalities at the synapse." 
Science 317(5835): 190-191. 
Girard, S. L., Dion, P. A. and Rouleau, G. A. (2012). "Schizophrenia genetics: putting all the 
pieces together." Curr Neurol Neurosci Rep 12(3): 261-266. 
Gottesman, II and Shields, J. (1967). "A polygenic theory of schizophrenia." Proc Natl Acad Sci 
U S A 58(1): 199-205. 
Gurling, H. (1986). "Candidate genes and favoured loci: strategies for molecular genetic research 
into schizophrenia, manic depression, autism, alcoholism and Alzheimer's disease." Psychiatr 
Dev 4(4): 289-309. 
Häfner, H. and an der Heiden, W. (1997). "Epidemiology of schizophrenia." Can J Psychiatry 
42(2): 139-151. 
Hall, J., Whalley, H. C., Job, D. E., Baig, B. J., McIntosh, A. M., Evans, K. L., Thomson, P. A., 
Porteous, D. J., Cunningham-Owens, D. G., Johnstone, E. C. and Lawrie, S. M. (2006). "A 
neuregulin 1 variant associated with abnormal cortical function and psychotic symptoms." Nat 
Neurosci 9(12): 1477-1478. 
Hartl, D. L. and Clark, A. G. (1997). Principles of population genetics, Sunderland: Sinauer 
Associates. 
Hudry, J., Saoud, M., D'Amato, T., Dalery, J. and Royet, J. P. (2002). "Ratings of different 
olfactory judgements in schizophrenia." Chem Senses 27(5): 407-416. 
Huppke, P., Maier, E. M., Warnke, A., Brendel, C., Laccone, F. and Gartner, J. (2006). "Very 
mild cases of Rett syndrome with skewed X inactivation." J Med Genet 43(10): 814-816. 
Jedlickova, K., Stockton, D. W. and Prchal, J. T. (2003). "Possible primary familial and 
congenital polycythemia locus at 7q22.1-7q22.2." Blood Cells Mol Dis 31(3): 327-331. 
Jones, P., Rodgers, B., Murray, R. and Marmot, M. (1994). "Child development risk factors for 
adult schizophrenia in the British 1946 birth cohort." Lancet 344(8934): 1398-1402. 
Kaabi, B., Gelernter, J., Woods, S. W., Goddard, A., Page, G. P. and Elston, R. C. (2006). 
"Genome scan for loci predisposing to anxiety disorders using a novel multivariate approach: 
strong evidence for a chromosome 4 risk locus." Am J Hum Genet 78(4): 543-553. 
Kamath, V., Moberg, P. J., Kohler, C. G., Gur, R. E. and Turetsky, B. I. (2011). "Odor Hedonic 
Capacity and Anhedonia in Schizophrenia and Unaffected First-Degree Relatives of 
Schizophrenia Patients." Schizophr Bull. 
Kamath, V., Turetsky, B. I. and Moberg, P. J. (2011). "Identification of pleasant, neutral, and 
unpleasant odors in schizophrenia." Psychiatry Res 187(1-2): 30-35. 
Kanner, L. (1943). "Autistic disturbances of affective contact." Nervous Child 2: 217-250. 
Kay, S. R., Fiszbein, A. and Opler, L. A. (1987). "The positive and negative syndrome scale 
(PANSS) for schizophrenia." Schizophr Bull 13(2): 261-276. 
Kay, S. R., Opler, L. A. and Lindenmayer, J. P. (1988). "Reliability and validity of the positive 
and negative syndrome scale for schizophrenics." Psychiatry Res 23(1): 99-110. 
Kendler, K. S. (2009). "An historical framework for psychiatric nosology." Psychol Med 39(12): 
1935-1941. 
Kendler, K. S., Neale, M. C., Kessler, R. C., Heath, A. C. and Eaves, L. J. (1993). "Major 
depression and phobias: the genetic and environmental sources of comorbidity." Psychol Med 
23(2): 361-371. 
Kerr, B., Alvarez-Saavedra, M., Saez, M. A., Saona, A. and Young, J. I. (2008). "Defective body-
weight regulation, motor control and abnormal social interactions in Mecp2 hypomorphic 
mice." Hum Mol Genet 17(12): 1707-1717. 
Kimura, M. (1976). "Population genetics and molecular evoulution." Johns Hopkins Med J 
138(6): 253-261. 




Kralovics, R., Sokol, L., Broxson, E. H., Jr. and Prchal, J. T. (1997). "The erythropoietin receptor 
gene is not linked with the polycythemia phenotype in a family with autosomal dominant 
primary polycythemia." Proc Assoc Am Physicians 109(6): 580-585. 
Lagenaur, C., Kunemund, V., Fischer, G., Fushiki, S. and Schachner, M. (1992). "Monoclonal M6 
antibody interferes with neurite extension of cultured neurons." J Neurobiol 23(1): 71-88. 
Larsson, M. and Willander, J. (2009). "Autobiographical odor memory." Ann N Y Acad Sci 1170: 
318-323. 
Law, A. J., Lipska, B. K., Weickert, C. S., Hyde, T. M., Straub, R. E., Hashimoto, R., Harrison, P. 
J., Kleinman, J. E. and Weinberger, D. R. (2006). "Neuregulin 1 transcripts are differentially 
expressed in schizophrenia and regulated by 5' SNPs associated with the disease." Proc Natl 
Acad Sci U S A 103(17): 6747-6752. 
Lee, S. H., DeCandia, T. R., Ripke, S., Yang, J., Sullivan, P. F., Goddard, M. E., Keller, M. C., 
Visscher, P. M. and Wray, N. R. (2012). "Estimating the proportion of variation in 
susceptibility to schizophrenia captured by common SNPs." Nat Genet 44(3): 247-250. 
Lee, Y. H., Kim, J. H. and Song, G. G. (2013). "Pathway analysis of a genome-wide association 
study in schizophrenia." Gene. 
Loat, C. S., Curran, S., Lewis, C. M., Duvall, J., Geschwind, D., Bolton, P. and Craig, I. W. 
(2008). "Methyl-CpG-binding protein 2 polymorphisms and vulnerability to autism." Genes 
Brain Behav 7(7): 754-760. 
Lord, C., Risi, S., Lambrecht, L., Cook, E. H., Jr., Leventhal, B. L., DiLavore, P. C., Pickles, A. 
and Rutter, M. (2000). "The autism diagnostic observation schedule-generic: a standard 
measure of social and communication deficits associated with the spectrum of autism." J 
Autism Dev Disord 30(3): 205-223. 
Luo, X., Huang, L., Jia, P., Li, M., Su, B., Zhao, Z. and Gan, L. (2013). "Protein-Protein 
Interaction and Pathway Analyses of Top Schizophrenia Genes Reveal Schizophrenia 
Susceptibility Genes Converge on Common Molecular Networks and Enrichment of 
Nucleosome (Chromatin) Assembly Genes in Schizophrenia Susceptibility Loci." Schizophr 
Bull. 
Ma, W., Kantarjian, H., Zhang, K., Zhang, X., Wang, X., Chen, C., Donahue, A. C., Zhang, Z., 
Yeh, C. H., O'Brien, S., Garcia-Manero, G., Caporaso, N., Landgren, O. and Albitar, M. 
(2010). "Significant association between polymorphism of the erythropoietin gene promoter 
and myelodysplastic syndrome." BMC Med Genet 11: 163. 
Magarinos, A. M. and McEwen, B. S. (1995). "Stress-induced atrophy of apical dendrites of 
hippocampal CA3c neurons: involvement of glucocorticoid secretion and excitatory amino 
acid receptors." Neuroscience 69(1): 89-98. 
Marti, H. H. (2004). "Erythropoietin and the hypoxic brain." J Exp Biol 207(Pt 18): 3233-3242. 
McClellan, J. and King, M. C. (2010). "Genetic heterogeneity in human disease." Cell 141(2): 
210-217. 
McEwen, B. S. (2001). "Plasticity of the hippocampus: adaptation to chronic stress and allostatic 
load." Ann N Y Acad Sci 933: 265-277. 
McEwen, B. S. (2008). "Central effects of stress hormones in health and disease: Understanding 
the protective and damaging effects of stress and stress mediators." Eur J Pharmacol 583(2-3): 
174-185. 
Meyer-Lindenberg, A. and Weinberger, D. R. (2006). "Intermediate phenotypes and genetic 
mechanisms of psychiatric disorders." Nat Rev Neurosci 7(10): 818-827. 
Michibata, H., Okuno, T., Konishi, N., Kyono, K., Wakimoto, K., Aoki, K., Kondo, Y., Takata, 
K., Kitamura, Y. and Taniguchi, T. (2009). "Human GPM6A is associated with differentiation 
and neuronal migration of neurons derived from human embryonic stem cells." Stem Cells 
Dev 18(4): 629-639. 
Miskowiak, K., O'Sullivan, U. and Harmer, C. J. (2007). "Erythropoietin enhances hippocampal 
response during memory retrieval in humans." J Neurosci 27(11): 2788-2792. 
Bibliography_________________________________________________________________ 
 112
Mitra, R., Jadhav, S., McEwen, B. S., Vyas, A. and Chattarji, S. (2005). "Stress duration 
modulates the spatiotemporal patterns of spine formation in the basolateral amygdala." Proc 
Natl Acad Sci U S A 102(26): 9371-9376. 
Moberg, P. J., Arnold, S. E., Doty, R. L., Kohler, C., Kanes, S., Seigel, S., Gur, R. E. and 
Turetsky, B. I. (2003). "Impairment of odor hedonics in men with schizophrenia." Am J 
Psychiatry 160(10): 1784-1789. 
Moretti, P., Bouwknecht, J. A., Teague, R., Paylor, R. and Zoghbi, H. Y. (2005). "Abnormalities 
of social interactions and home-cage behavior in a mouse model of Rett syndrome." Hum Mol 
Genet 14(2): 205-220. 
Morishita, E., Masuda, S., Nagao, M., Yasuda, Y. and Sasaki, R. (1997). "Erythropoietin receptor 
is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in 
vitro glutamate-induced neuronal death." Neuroscience 76(1): 105-116. 
Murray, R. M. L., S.W. (1987). "Is schizophrenia a neurodevelopmental disorder?" British 
Medical Journal 295: 681-682. 
Myers, R. A., Casals, F., Gauthier, J., Hamdan, F. F., Keebler, J., Boyko, A. R., Bustamante, C. 
D., Piton, A. M., Spiegelman, D., Henrion, E., Zilversmit, M., Hussin, J., Quinlan, J., Yang, 
Y., Lafreniere, R. G., Griffing, A. R., Stone, E. A., Rouleau, G. A. and Awadalla, P. (2011). 
"A population genetic approach to mapping neurological disorder genes using deep 
resequencing." PLoS Genet 7(2): e1001318. 
Owen, M. J., Craddock, N. and O'Donovan, M. C. (2010). "Suggestion of roles for both common 
and rare risk variants in genome-wide studies of schizophrenia." Arch Gen Psychiatry 67(7): 
667-673. 
Owen, M. J., O'Donovan, M. C., Thapar, A. and Craddock, N. (2011). "Neurodevelopmental 
hypothesis of schizophrenia." Br J Psychiatry 198(3): 173-175. 
Papiol, S., Begemann, M., Rosenberger, A., Friedrichs, H., Ribbe, K., Grube, S., Schwab, M. H., 
Jahn, H., Gunkel, S., Benseler, F., Nave, K. A. and Ehrenreich, H. (2011). "A phenotype-
based genetic association study reveals the contribution of neuregulin1 gene variants to age of 
onset and positive symptom severity in schizophrenia." Am J Med Genet B Neuropsychiatr 
Genet 156B(3): 340-345. 
Papiol, S., Malzahn, D., Kästner, A., Sperling, S., Begemann, M., Stefansson, H., Bickeboller, H., 
Nave, K. A. and Ehrenreich, H. (2011). "Dissociation of accumulated genetic risk and disease 
severity in patients with schizophrenia." Transl Psychiatry 1: e45. 
Pearson, B. L., Defensor, E. B., Pobbe, R. L. H., Yamamoto, L. H. L., Bolivar, V. J., Blanchard, 
D. C. and Blanchard, R. J. (2012). "Mecp2 Truncation in Male Mice Promotes Affiliative 
Social Behavior." Behavior Genetics 42(2): 299-312. 
Percy, M. J., McMullin, M. F. and Lappin, T. R. (1997). "Sequence analysis of the 3' hypoxia-
responsive element of the human erythropoietin gene in patients with erythrocytosis." 
Biochem Mol Med 62(1): 132-134. 
Petersen, K. B., Hokland, P., Petersen, G. B. and Nyvold, C. G. (2004). "Erythropoietin receptor 
defect: a cause of primary polycythaemia." Br J Haematol 125(4): 537-538. 
Plailly, J., d'Amato, T., Saoud, M. and Royet, J. P. (2006). "Left temporo-limbic and orbital 
dysfunction in schizophrenia during odor familiarity and hedonicity judgments." Neuroimage 
29(1): 302-313. 
Plomin, R., Haworth, C. M. and Davis, O. S. (2009). "Common disorders are quantitative traits." 
Nat Rev Genet 10(12): 872-878. 
Purcell, S. M., Wray, N. R., Stone, J. L., Visscher, P. M., O'Donovan, M. C., Sullivan, P. F. and 
Sklar, P. (2009). "Common polygenic variation contributes to risk of schizophrenia and 
bipolar disorder." Nature 460(7256): 748-752. 
Radomsky, A. S., Rachman, S., Thordarson, D. S., McIsaac, H. K. and Teachman, B. A. (2001). 
"The Claustrophobia Questionnaire." J Anxiety Disord 15(4): 287-297. 
________________________________________________________________Bibliography 
 113
Ramocki, M. B., Peters, S. U., Tavyev, Y. J., Zhang, F., Carvalho, C. M., Schaaf, C. P., Richman, 
R., Fang, P., Glaze, D. G., Lupski, J. R. and Zoghbi, H. Y. (2009). "Autism and other 
neuropsychiatric symptoms are prevalent in individuals with MeCP2 duplication syndrome." 
Ann Neurol 66(6): 771-782. 
Ramocki, M. B., Tavyev, Y. J. and Peters, S. U. (2010). "The MECP2 duplication syndrome." Am 
J Med Genet A 152A(5): 1079-1088. 
Ramocki, M. B. and Zoghbi, H. Y. (2008). "Failure of neuronal homeostasis results in common 
neuropsychiatric phenotypes." Nature 455(7215): 912-918. 
Rapoport, J. and Ahn, K. (2011). "Rare variants and risk for schizophrenia: more support." Biol 
Psychiatry 70(12): 1102-1103. 
Rapoport, J., Chavez, A., Greenstein, D., Addington, A. and Gogtay, N. (2009). "Autism spectrum 
disorders and childhood-onset schizophrenia: clinical and biological contributions to a 
relation revisited." J Am Acad Child Adolesc Psychiatry 48(1): 10-18. 
Ribbe, K., Friedrichs, H., Begemann, M., Grube, S., Papiol, S., Kastner, A., Gerchen, M. F., 
Ackermann, V., Tarami, A., Treitz, A., Flogel, M., Adler, L., Aldenhoff, J. B., Becker-Emner, 
M., Becker, T., Czernik, A., Dose, M., Folkerts, H., Freese, R., Gunther, R., Herpertz, S., 
Hesse, D., Kruse, G., Kunze, H., Franz, M., Lohrer, F., Maier, W., Mielke, A., Muller-
Isberner, R., Oestereich, C., Pajonk, F. G., Pollmacher, T., Schneider, U., Schwarz, H. J., 
Kroner-Herwig, B., Havemann-Reinecke, U., Frahm, J., Stuhmer, W., Falkai, P., Brose, N., 
Nave, K. A. and Ehrenreich, H. (2010). "The cross-sectional GRAS sample: a comprehensive 
phenotypical data collection of schizophrenic patients." BMC Psychiatry 10: 91. 
Risch, N. and Merikangas, K. (1996). "The future of genetic studies of complex human diseases." 
Science 273(5281): 1516-1517. 
Risch, N. and Merikangas, K. R. (1993). "Linkage studies of psychiatric disorders." Eur Arch 
Psychiatry Clin Neurosci 243(3-4): 143-149. 
Rosen, C., Marvin, R., Reilly, J. L., Deleon, O., Harris, M. S., Keedy, S. K., Solari, H., Weiden, P. 
and Sweeney, J. A. (2012). "Phenomenology of first-episode psychosis in schizophrenia, 
bipolar disorder, and unipolar depression: a comparative analysis." Clin Schizophr Relat 
Psychoses 6(3): 145-151. 
Rutter, M., Kim-Cohen, J. and Maughan, B. (2006). "Continuities and discontinuities in 
psychopathology between childhood and adult life." J Child Psychol Psychiatry 47(3-4): 276-
295. 
Salavera, C., Puyuelo, M., Antonanzas, J. L. and Teruel, P. (2013). "Semantics, pragmatics, and 
formal thought disorders in people with schizophrenia." Neuropsychiatr Dis Treat 9: 177-183. 
Samaco, R. C., Mandel-Brehm, C., Chao, H.-T., Ward, C. S., Fyffe-Maricich, S. L., Ren, J., 
Hyland, K., Thaller, C., Maricich, S. M., Humphreys, P., Greer, J. J., Percy, A., Glaze, D. G., 
Zoghbi, H. Y. and Neul, J. L. (2009). "Loss of MeCP2 in aminergic neurons causes cell-
autonomous defects in neurotransmitter synthesis and specific behavioral abnormalities." 
Proceedings of the National Academy of Sciences 106(51): 21966-21971. 
Samaco, R. C., Mandel-Brehm, C., McGraw, C. M., Shaw, C. A., McGill, B. E. and Zoghbi, H. Y. 
(2012). "Crh and Oprm1 mediate anxiety-related behavior and social approach in a mouse 
model of MECP2 duplication syndrome." Nat Genet 44(2): 206-211. 
Saoud, M., Hueber, T., Mandran, H., Dalery, J. and d'Amato, T. (1998). "Olfactory identification 
deficiency and WCST performance in men with schizophrenia." Psychiatry Res 81(2): 251-
257. 
Sargin, D., Friedrichs, H., El-Kordi, A. and Ehrenreich, H. (2010). "Erythropoietin as 
neuroprotective and neuroregenerative treatment strategy: comprehensive overview of 12 
years of preclinical and clinical research." Best Pract Res Clin Anaesthesiol 24(4): 573-594. 
Sasson, N. J., Pinkham, A. E., Carpenter, K. L. and Belger, A. (2011). "The benefit of directly 
comparing autism and schizophrenia for revealing mechanisms of social cognitive 
impairment." J Neurodev Disord 3(2): 87-100. 
Bibliography_________________________________________________________________ 
 114
Savic, I. (2001). "Processing of odorous signals in humans." Brain Res Bull 54(3): 307-312. 
Schab, F. R. (1990). "Odors and the remembrance of things past." Journal of Experimental 
Psychology: Learning, Memory, and Cognition 16(4): 648-655. 
Shahbazian, M., Young, J., Yuva-Paylor, L., Spencer, C., Antalffy, B., Noebels, J., Armstrong, 
D., Paylor, R. and Zoghbi, H. (2002). "Mice with truncated MeCP2 recapitulate many Rett 
syndrome features and display hyperacetylation of histone H3." Neuron 35(2): 243-254. 
Sheitman, B. B., Kraus, J. E., Bodfish, J. W. and Carmel, H. (2004). "Are the negative symptoms 
of schizophrenia consistent with an autistic spectrum illness?" Schizophr Res 69(1): 119-120. 
Shin, L. M. and Liberzon, I. (2010). "The neurocircuitry of fear, stress, and anxiety disorders." 
Neuropsychopharmacology 35(1): 169-191. 
Siren, A. L., Fasshauer, T., Bartels, C. and Ehrenreich, H. (2009). "Therapeutic potential of 
erythropoietin and its structural or functional variants in the nervous system." 
Neurotherapeutics 6(1): 108-127. 
Slater, E. (1958). "The monogenic theory of schizophrenia." Acta Genet Stat Med 8(1): 50-56. 
Smoller, J. W., Craddock, N., Kendler, K., Lee, P. H., Neale, B. M., Nurnberger, J. I., Ripke, S., 
Santangelo, S. and Sullivan, P. F. (2013). "Identification of risk loci with shared effects on 
five major psychiatric disorders: a genome-wide analysis." Lancet 381(9875): 1371-1379. 
Sokol, L., Prchal, J. and Prchal, J. T. (1993). "Primary familial and congenital polycythaemia." 
Lancet 342(8863): 115-116. 
Sokol, L. and Prchal, J. T. (1994). "Two microsatellite repeat polymorphisms in the EPO gene." 
Hum Mol Genet 3(1): 219. 
Soudry, Y., Lemogne, C., Malinvaud, D., Consoli, S. M. and Bonfils, P. (2011). "Olfactory 
system and emotion: common substrates." Eur Ann Otorhinolaryngol Head Neck Dis 128(1): 
18-23. 
Stahlberg, O., Soderstrom, H., Rastam, M. and Gillberg, C. (2004). "Bipolar disorder, 
schizophrenia, and other psychotic disorders in adults with childhood onset AD/HD and/or 
autism spectrum disorders." J Neural Transm 111(7): 891-902. 
Stefansson, H., Ophoff, R. A., Steinberg, S., Andreassen, O. A., Cichon, S., Rujescu, D., Werge, 
T., Pietilainen, O. P., Mors, O., Mortensen, P. B., Sigurdsson, E., Gustafsson, O., Nyegaard, 
M., Tuulio-Henriksson, A., Ingason, A., Hansen, T., Suvisaari, J., Lonnqvist, J., Paunio, T., 
Borglum, A. D., Hartmann, A., Fink-Jensen, A., Nordentoft, M., Hougaard, D., Norgaard-
Pedersen, B., Bottcher, Y., Olesen, J., Breuer, R., Moller, H. J., Giegling, I., Rasmussen, H. 
B., Timm, S., Mattheisen, M., Bitter, I., Rethelyi, J. M., Magnusdottir, B. B., Sigmundsson, 
T., Olason, P., Masson, G., Gulcher, J. R., Haraldsson, M., Fossdal, R., Thorgeirsson, T. E., 
Thorsteinsdottir, U., Ruggeri, M., Tosato, S., Franke, B., Strengman, E., Kiemeney, L. A., 
Genetic, R., Outcome in, P., Melle, I., Djurovic, S., Abramova, L., Kaleda, V., Sanjuan, J., de 
Frutos, R., Bramon, E., Vassos, E., Fraser, G., Ettinger, U., Picchioni, M., Walker, N., 
Toulopoulou, T., Need, A. C., Ge, D., Yoon, J. L., Shianna, K. V., Freimer, N. B., Cantor, R. 
M., Murray, R., Kong, A., Golimbet, V., Carracedo, A., Arango, C., Costas, J., Jonsson, E. 
G., Terenius, L., Agartz, I., Petursson, H., Nothen, M. M., Rietschel, M., Matthews, P. M., 
Muglia, P., Peltonen, L., St Clair, D., Goldstein, D. B., Stefansson, K. and Collier, D. A. 
(2009). "Common variants conferring risk of schizophrenia." Nature 460(7256): 744-747. 
Stefansson, H., Sigurdsson, E., Steinthorsdottir, V., Bjornsdottir, S., Sigmundsson, T., Ghosh, S., 
Brynjolfsson, J., Gunnarsdottir, S., Ivarsson, O., Chou, T. T., Hjaltason, O., Birgisdottir, B., 
Jonsson, H., Gudnadottir, V. G., Gudmundsdottir, E., Bjornsson, A., Ingvarsson, B., Ingason, 
A., Sigfusson, S., Hardardottir, H., Harvey, R. P., Lai, D., Zhou, M., Brunner, D., Mutel, V., 
Gonzalo, A., Lemke, G., Sainz, J., Johannesson, G., Andresson, T., Gudbjartsson, D., 
Manolescu, A., Frigge, M. L., Gurney, M. E., Kong, A., Gulcher, J. R., Petursson, H. and 




Stein, D. J. and Matsunaga, H. (2006). "Specific phobia: a disorder of fear conditioning and 
extinction." CNS Spectr 11(4): 248-251. 
Steinberg, S., de Jong, S., Irish Schizophrenia Genomics, C., Andreassen, O. A., Werge, T., 
Borglum, A. D., Mors, O., Mortensen, P. B., Gustafsson, O., Costas, J., Pietilainen, O. P., 
Demontis, D., Papiol, S., Huttenlocher, J., Mattheisen, M., Breuer, R., Vassos, E., Giegling, 
I., Fraser, G., Walker, N., Tuulio-Henriksson, A., Suvisaari, J., Lonnqvist, J., Paunio, T., 
Agartz, I., Melle, I., Djurovic, S., Strengman, E., Group, Jurgens, G., Glenthoj, B., Terenius, 
L., Hougaard, D. M., Orntoft, T., Wiuf, C., Didriksen, M., Hollegaard, M. V., Nordentoft, M., 
van Winkel, R., Kenis, G., Abramova, L., Kaleda, V., Arrojo, M., Sanjuan, J., Arango, C., 
Sperling, S., Rossner, M., Ribolsi, M., Magni, V., Siracusano, A., Christiansen, C., 
Kiemeney, L. A., Veldink, J., van den Berg, L., Ingason, A., Muglia, P., Murray, R., Nothen, 
M. M., Sigurdsson, E., Petursson, H., Thorsteinsdottir, U., Kong, A., Rubino, I. A., De Hert, 
M., Rethelyi, J. M., Bitter, I., Jonsson, E. G., Golimbet, V., Carracedo, A., Ehrenreich, H., 
Craddock, N., Owen, M. J., O'Donovan, M. C., Wellcome Trust Case Control, C., Ruggeri, 
M., Tosato, S., Peltonen, L., Ophoff, R. A., Collier, D. A., St Clair, D., Rietschel, M., Cichon, 
S., Stefansson, H., Rujescu, D. and Stefansson, K. (2011). "Common variants at VRK2 and 
TCF4 conferring risk of schizophrenia." Hum Mol Genet 20(20): 4076-4081. 
Steinberg, S., Mors, O., Borglum, A. D., Gustafsson, O., Werge, T., Mortensen, P. B., 
Andreassen, O. A., Sigurdsson, E., Thorgeirsson, T. E., Bottcher, Y., Olason, P., Ophoff, R. 
A., Cichon, S., Gudjonsdottir, I. H., Pietilainen, O. P., Nyegaard, M., Tuulio-Henriksson, A., 
Ingason, A., Hansen, T., Athanasiu, L., Suvisaari, J., Lonnqvist, J., Paunio, T., Hartmann, A., 
Jurgens, G., Nordentoft, M., Hougaard, D., Norgaard-Pedersen, B., Breuer, R., Moller, H. J., 
Giegling, I., Glenthoj, B., Rasmussen, H. B., Mattheisen, M., Bitter, I., Rethelyi, J. M., 
Sigmundsson, T., Fossdal, R., Thorsteinsdottir, U., Ruggeri, M., Tosato, S., Strengman, E., 
Genetic, R., Outcome in, P., Kiemeney, L. A., Melle, I., Djurovic, S., Abramova, L., Kaleda, 
V., Walshe, M., Bramon, E., Vassos, E., Li, T., Fraser, G., Walker, N., Toulopoulou, T., 
Yoon, J., Freimer, N. B., Cantor, R. M., Murray, R., Kong, A., Golimbet, V., Jonsson, E. G., 
Terenius, L., Agartz, I., Petursson, H., Nothen, M. M., Rietschel, M., Peltonen, L., Rujescu, 
D., Collier, D. A., Stefansson, H., St Clair, D. and Stefansson, K. (2011). "Expanding the 
range of ZNF804A variants conferring risk of psychosis." Mol Psychiatry 16(1): 59-66. 
Sullivan, P. (2012). "Don't give up on GWAS." Mol Psychiatry 17(1): 2-3. 
Sullivan, P. F., Kendler, K. S. and Neale, M. C. (2003). "Schizophrenia as a complex trait: 
evidence from a meta-analysis of twin studies." Arch Gen Psychiatry 60(12): 1187-1192. 
Tewes, U. (1994). HAWIE-R. Hamburg-Wechsler-Intelligenztest für Erwachsene, Revision 1991 
; Handbuch und Testanweisung. Bern; Göttingen; Toronto; Seattle, Verlag Hans Huber. 
Tong, Z., Yang, Z., Patel, S., Chen, H., Gibbs, D., Yang, X., Hau, V. S., Kaminoh, Y., Harmon, J., 
Pearson, E., Buehler, J., Chen, Y., Yu, B., Tinkham, N. H., Zabriskie, N. A., Zeng, J., Luo, L., 
Sun, J. K., Prakash, M., Hamam, R. N., Tonna, S., Constantine, R., Ronquillo, C. C., Sadda, 
S., Avery, R. L., Brand, J. M., London, N., Anduze, A. L., King, G. L., Bernstein, P. S., 
Watkins, S., Jorde, L. B., Li, D. Y., Aiello, L. P., Pollak, M. R. and Zhang, K. (2008). 
"Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney 
complications." Proc Natl Acad Sci U S A 105(19): 6998-7003. 
Tronson, N. C., Schrick, C., Fischer, A., Sananbenesi, F., Pages, G., Pouyssegur, J. and 
Radulovic, J. (2008). "Regulatory mechanisms of fear extinction and depression-like 
behavior." Neuropsychopharmacology 33(7): 1570-1583. 
Turetsky, B. I., Hahn, C. G., Borgmann-Winter, K. and Moberg, P. J. (2009). "Scents and 
nonsense: olfactory dysfunction in schizophrenia." Schizophr Bull 35(6): 1117-1131. 
van den Oord, E. J., Kuo, P. H., Hartmann, A. M., Webb, B. T., Moller, H. J., Hettema, J. M., 
Giegling, I., Bukszar, J. and Rujescu, D. (2008). "Genomewide association analysis followed 
by a replication study implicates a novel candidate gene for neuroticism." Arch Gen 
Psychiatry 65(9): 1062-1071. 
Bibliography_________________________________________________________________ 
 116
van Nierop, M., van Os, J., Gunther, N., Myin-Germeys, I., de Graaf, R., ten Have, M., van 
Dorsselaer, S., Bak, M. and van Winkel, R. (2011). "Phenotypically continuous with clinical 
psychosis, discontinuous in need for care: evidence for an extended psychosis phenotype." 
Schizophr Bull 38(2): 231-238. 
van Os, J. and Linscott, R. J. (2012). "Introduction: The extended psychosis phenotype--
relationship with schizophrenia and with ultrahigh risk status for psychosis." Schizophr Bull 
38(2): 227-230. 
Visscher, P. M., Brown, M. A., McCarthy, M. I. and Yang, J. (2012). "Five years of GWAS 
discovery." Am J Hum Genet 90(1): 7-24. 
Visscher, P. M., Goddard, M. E., Derks, E. M. and Wray, N. R. (2012). "Evidence-based 
psychiatric genetics, AKA the false dichotomy between common and rare variant 
hypotheses." Mol Psychiatry 17(5): 474-485. 
Waris, P., Lindberg, N., Kettunen, K. and Tani, P. (2013). "The relationship between Asperger's 
syndrome and schizophrenia in adolescence." Eur Child Adolesc Psychiatry 22(4): 217-223. 
Watowich, S. S., Xie, X., Klingmuller, U., Kere, J., Lindlof, M., Berglund, S. and de la Chapelle, 
A. (1999). "Erythropoietin receptor mutations associated with familial erythrocytosis cause 
hypersensitivity to erythropoietin in the heterozygous state." Blood 94(7): 2530-2532. 
Wüstenberg, T., Begemann, M., Bartels, C., Gefeller, O., Stawicki, S., Hinze-Selch, D., Mohr, A., 
Falkai, P., Aldenhoff, J. B., Knauth, M., Nave, K. A. and Ehrenreich, H. (2011). 
"Recombinant human erythropoietin delays loss of gray matter in chronic schizophrenia." 






9.1 Accepted co-author publications 
 
Co-author publication I 
Ribbe, K.*, Friedrichs, H.*, Begemann, M., Grube, S., Papiol, S., Kästner, A., Gerchen, M. 
F., Ackermann, V., Tarami, A., Treitz, A., Flogel, M., Adler, L., Aldenhoff, J. B., Becker-
Emner, M., Becker, T., Czernik, A., Dose, M., Folkerts, H., Freese, R., Gunther, R., Herpertz, 
S., Hesse, D., Kruse, G., Kunze, H., Franz, M., Lohrer, F., Maier, W., Mielke, A., Muller-
Isberner, R., Oestereich, C., Pajonk, F. G., Pollmacher, T., Schneider, U., Schwarz, H. J., 
Kroner-Herwig, B., Havemann-Reinecke, U., Frahm, J., Stuhmer, W., Falkai, P., Brose, N., 
Nave, K. A. and Ehrenreich, H. (2010). "The cross-sectional GRAS sample: a comprehensive 
phenotypical data collection of schizophrenic patients." BMC Psychiatry 10: 91. 
 
Personal contribution 
I performed a substantial part of the data entry and participated in the continuous 
improvement of data validation and quality control.  
 
Co-author publication II 
Ehrenreich, H., Kästner, A., Weissenborn, K., Streeter, J., Sperling, S., Wang, K. K., 
Worthmann, H., Hayes, R. L., von Ahsen, N., Kastrup, A., Jeromin, A. and Herrmann, M. 
(2011). "Circulating damage marker profiles support a neuroprotective effect of 
erythropoietin in ischemic stroke patients." Mol Med 17(11-12): 1306-1310. 
 
Personal contribution 
I carried out the statistical analyses and designed the figures and tables. 
 
Co-author publication III 
Papiol, S.*, Malzahn, D.*, Kästner, A., Sperling, S., Begemann, M., Stefansson, H., 
Bickeboller, H., Nave, K. A. and Ehrenreich, H. (2011). "Dissociation of accumulated genetic 







I contributed to the data acquisition, participated in the analysis and interpretation of data and 
assisted in the design of the figures.  
 
Co-author publication IV 
Hagemeyer, N.*, Goebbels, S.*, Papiol, S.*, Kästner, A., Hofer, S., Begemann, M., Gerwig, 
U. C., Boretius, S., Wieser, G. L., Ronnenberg, A., Gurvich, A., Heckers, S. H., Frahm, J., 
Nave, K. A. and Ehrenreich, H. (2012). "A myelin gene causative of a catatonia-depression 
syndrome upon aging." EMBO Mol Med 4(6): 528-539. 
 
Personal contribution 
I coordinated and supervised the recruitment of subjects for the diffusion tensor imaging 
study and performed the human genetic association analyses. I participated in the writing of 
the manuscript. 
 
Co-author publication V 
El-Kordi, A.*, Winkler, D.*, Hammerschmidt, K., Kästner, A., Krueger, D., Ronnenberg, A., 
Ritter, C., Jatho, J., Radyushkin, K., Bourgeron, T., Fischer, J., Brose, N. and Ehrenreich, H. 
(2013). "Development of an autism severity score for mice using Nlgn4 null mutants as a 
construct-valid model of heritable monogenic autism." Behav Brain Res. 
 
Personal contribution 
I created the gender-specific autism composite scores, carried out the linear regression based 
multiple imputation and performed the autism composite score related statistical analyses. 







*These authors contributed equally to the work. 
 
RESEARCH ARTICLE Open Access
The cross-sectional GRAS sample: A comprehensive
phenotypical data collection of schizophrenic patients
Katja Ribbe1†, Heidi Friedrichs1†, Martin Begemann1†, Sabrina Grube1, Sergi Papiol1,30, Anne Kästner1, Martin F Gerchen1,
Verena Ackermann1, Asieh Tarami1, Annika Treitz1, Marlene Flögel1, Lothar Adler2, Josef B Aldenhoff 3,
Marianne Becker-Emner4, Thomas Becker5, Adelheid Czernik6, Matthias Dose7, Here Folkerts8, Roland Freese9,
Rolf Günther 10, Sabine Herpertz11, Dirk Hesse12, Gunther Kruse13, Heinrich Kunze14, Michael Franz14, Frank Löhrer15,
Wolfgang Maier16, Andreas Mielke17, Rüdiger Müller-Isberner18, Cornelia Oestereich19, Frank-Gerald Pajonk20,
Thomas Pollmächer21, Udo Schneider22, Hans-Joachim Schwarz23, Birgit Kröner-Herwig24,
Ursula Havemann-Reinecke25,30, Jens Frahm26,30,31, Walter Stühmer27,30,31, Peter Falkai25,30,31, Nils Brose28,30,31,
Klaus-Armin Nave29,30,31, Hannelore Ehrenreich1,30,31*
Abstract
Background: Schizophrenia is the collective term for an exclusively clinically diagnosed, heterogeneous group of
mental disorders with still obscure biological roots. Based on the assumption that valuable information about
relevant genetic and environmental disease mechanisms can be obtained by association studies on patient cohorts
of ≥1000 patients, if performed on detailed clinical datasets and quantifiable biological readouts, we generated a
new schizophrenia data base, the GRAS (Göttingen Research Association for Schizophrenia) data collection. GRAS is
the necessary ground to study genetic causes of the schizophrenic phenotype in a ‘phenotype-based genetic
association study’ (PGAS). This approach is different from and complementary to the genome-wide association
studies (GWAS) on schizophrenia.
Methods: For this purpose, 1085 patients were recruited between 2005 and 2010 by an invariable team of
traveling investigators in a cross-sectional field study that comprised 23 German psychiatric hospitals. Additionally,
chart records and discharge letters of all patients were collected.
Results: The corresponding dataset extracted and presented in form of an overview here, comprises biographic
information, disease history, medication including side effects, and results of comprehensive cross-sectional
psychopathological, neuropsychological, and neurological examinations. With >3000 data points per schizophrenic
subject, this data base of living patients, who are also accessible for follow-up studies, provides a wide-ranging and
standardized phenotype characterization of as yet unprecedented detail.
Conclusions: The GRAS data base will serve as prerequisite for PGAS, a novel approach to better understanding
‘the schizophrenias’ through exploring the contribution of genetic variation to the schizophrenic phenotypes.
Background
Schizophrenia is a devastating brain disease that affects
approximately 1% of the population across cultures [1].
The diagnosis of schizophrenia or - perhaps more correctly
- of ‘the schizophrenias’ is still purely clinical, requiring the
coincident presence of symptoms as listed in the leading
classification systems, DSM-IV and ICD-10 [2,3].
Notably, one of the core symptoms of schizophrenia,
namely cognitive deficits, from mild impairments to
full-blown dementia, has not yet been considered in
these classifications. Biologically, schizophrenia is a
‘mixed bag’ of diseases that undoubtedly have a strong
genetic root. Family studies exploring relative risk of
schizophrenia have led to estimates of heritability of
about 64-88% [4,5]. Monozygotic twin studies showing
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concordance rates of 41-65% [6,7] indicate a considerable
amount of non-genetic causes, in the following referred
to as ‘environmental factors’. Already in the middle of
the twentieth century, schizophrenia was seen as a ‘poly-
genetic’ disease [8] and, indeed, in numerous genetic stu-
dies since, ranging from segregation or linkage analyses,
genome scans and large association studies, no major
‘schizophrenia gene’ has been identified [9]. Even recent
genome-wide association studies (GWAS) on schizophre-
nia confirm that several distinct loci are associated with
the disease. These studies concentrated on endpoint
diagnosis and found odds ratios for single markers in dif-
ferent genomic regions ranging from 0.68 to 6.01 [10],
essentially underlining the fact that - across ethnicities -
in most cases these genotypes do not contribute more to
the disease than a slightly increased probability.
We hypothesize that an interplay of multiple causative
factors, perhaps thousands of potential combinations of
genes/genetic markers and an array of different environ-
mental risks, leads to the development of ‘the schizo-
phrenias’, as schematically illustrated in Figure 1. There
may be cases with a critical genetic load already present
without need of additional external co-factors, however,
in most individuals, an interaction of a certain genetic
predisposition with environmental co-factors is appar-
ently required for disease onset. In fact, not too much
of an overlap may exist between genetic risk factors
from one schizophrenic patient to an unrelated other
schizophrenic individual, explaining why it is basically
impossible to find common risk genes of schizophrenia
with appreciable odds ratios. One GRAS working
hypothesis is that in the overwhelming majority of cases,
schizophrenia is the result of a ‘combination of unfortu-
nate genotypes’.
If along the lines of traditional human genetics all
attempts to define schizophrenia as a ‘classical’ genetic
disease have largely failed, how can we learn more about
the contribution of genes/genotypes to the disease phe-
notype? Rather than searching by GWAS for yet other
schizophrenia risk genes, we designed an alternative and
widely complementary approach, termed PGAS (pheno-






























Critical "genetic load" for spontaneous disease onset?
Later onset including atypical 
schizophrenic psychosis
'The schizophrenias'
Figure 1 Schizophrenia is a complex multigenetic disease. Schizophrenia may be seen as the result of a multifaceted interplay between
multiple causative factors, including several genetic markers and a variety of different environmental risks. Cases with a critical genetic load may
not need additional external/environmental co-factors, whilst in others, the interaction of a certain genetic predisposition with environmental co-
factors is required for disease onset (modified from [84]).
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explore the contribution of certain genes/genetic mar-
kers to the schizophrenic phenotype. To launch PGAS,
we had to establish a comprehensive phenotypical data
base of schizophrenic patients, the GRAS (Göttingen
Research Association for Schizophrenia) data collection.
Very recently, we have been able to demonstrate proof-
of-concept for the PGAS approach [[11], and Grube
et al: Calcium-activated potassium channels as regulators
of cognitive performance in schizophrenia, submitted].
Large data bases of schizophrenic patients have been
instigated for decades to perform linkage/family studies,
treatment trials, genetic or epidemiological studies
applying either a cross-sectional or a longitudinal design
(e.g. [12-20]). However, for the above introduced PGAS
approach, another type of data base is required, and
only few of the existing data banks are suited for pheno-
typical analyses. An example is the ‘Clinical Antipsycho-
tic Trial of Intervention Effectiveness (CATIE)’,
originally set up as a treatment study comparing a first
generation antipsychotic drug with several second gen-
eration antipsychotics in a multisite randomized double-
blind trial [17,21]. The huge amount of data accumu-
lated in the frame of this trial serves now also for
GWAS and genotype-phenotype association studies
[22-25]. Disadvantages may be that the CATIE data
were collected by different examiners in 57 US sites and
that comprehensive data for phenotypical analyses are
only available for subsamples of the originally included
1493 patients. Another example of a large data base
with considerable phenotypical power is the ‘Australian
Schizophrenia Research Bank (ASRB)’ [26]. ASRB oper-
ates to collect, store and distribute linked clinical, cogni-
tive, neuroimaging and genetic data from a large sample
of patients with schizophrenia (at present nearly 500)
and healthy controls (almost 300) [27,28]).
The present paper has been designed (1) to introduce
the GRAS data collection, set up as prerequisite and
platform for PGAS; (2) to exemplify on some selected
areas of interest the potential of phenotypical readouts
derived from the GRAS data collection and their inter-
nal consistency; (3) to provide a first panel of epidemio-
logical data as a ‘side harvest’ of this data base; and (4)
to enable interested researchers worldwide to initiate
scientific collaborations based on this data base.
Methods
Ethics
The GRAS data collection has been approved by the ethical
committee of the Georg-August-University of Göttingen
(master committee) as well as by the respective local regu-
latories/ethical committees of all collaborating centers
(Table 1). The distribution of the centers over Germany
together with information on the numbers of recruited
patients per center is presented in Figure 2.
GRAS patients
From September 2005 to July 2008, a total of 1071
patients were examined by the GRAS team of traveling
investigators after giving written informed consent, own
and/or authorized legal representatives. Since then, low-
rate steady state recruitment has been ongoing, among
others to build up a new cohort for replicate analyses of
genotype-phenotype associations. As of July 2010, 1085
patients have been entered into the data base. They
were examined in different settings: 348 (32.1%) as out-
patients, 474 (43.7%) as inpatients in psychiatric hospi-
tals, 189 (17.4%) as residents in sheltered homes, 54
(5%) as patients in specific forensic units, and 20 (1.8%)
as day clinic patients. Inclusion criteria were (1) con-
firmed or suspected diagnosis of schizophrenia or schi-
zoaffective disorder according to DSM-IV and (2) at
least some ability to cooperate. Recruitment efficiency
over the core travel/field study time from 2005 to 2008
and patient flow are shown in Figures 3a and 3b. Of the
1085 patients entered into the data base, a total of 1037
fulfilled the diagnosis of schizophrenia or schizoaffective
disorder. For 48 patients the diagnosis of schizophrenia
could not be ultimately confirmed upon careful re-check
and follow-up. Of the schizophrenic patients, 96% com-
pleted the GRAS assessment whereas about 4% dropped
out during the examination. Almost all patients agreed
to be re-contacted for potential follow-up studies, only
1.5% were either lost to follow-up (present address
unknown or deceased) or did not give consent to be
contacted again.
Healthy control subjects
(1) For genetic analyses, control subjects, who gave writ-
ten informed consent, were voluntary blood donors,
recruited by the Department of Transfusion Medicine at
the Georg-August-University of Göttingen according to
national guidelines for blood donation. As such, they
widely fulfill health criteria, ensured by a broad pre-
donation screening process containing standardized
questionnaires, interviews, hemoglobin, blood pressure,
pulse, and body temperature determinations. Of the
total of 2265 subjects, 57.5% are male (n = 1303) and
42.5% female (n = 962). The average age is 33.8 ± 12.2
years, with a range from 18 to 69 years. Participation as
healthy controls for the GRAS sample was anonymous,
with information restricted to age, gender, blood donor
health state and ethnicity. Comparable to the patient
population (Table 2), almost all control subjects were of
European Caucasian descent (Caucasian 97.8%; other
ethnicities 2%; unknown 0.2%). (2) For selected cognitive
measures and olfactory testing, 103 additional healthy
volunteers were recruited as control subjects (matched
with respect to age, gender, and smoking habits). These
healthy controls include 67.0% male (n = 69) and 33.0%
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Table 1 GRAS data collection manual: Table of contents
category content reference in the paper
legal documents/ethical requirements patient information, informed consent form, confidentiality form, and others...
patient history general information (age, sex, ethnicity,...) ® table 2
education/employment ® table 2
living situation ® table 2
legal history
medication including side effects ® table 4
medical history
family history
global quality of lifea ® table 2 and figure 6
birth history/traumatic brain injury
stressful life events
suicidal thoughts/suicide attempts
hospitalization history ® table 2 and figure 6
clinical interviews/ratings parts of SCID-I: addiction, anxiety, affective disorders, psychotic disorders*b
Positive and Negative Syndrome Scale* (PANSS)c ® table 2 and figure 6
Clinical Global Impression* (CGI)d ® table 2 and figure 6
Global Assessment of Functioning* (GAF)e ® table 2 and figure 6
questionnaires State-Trait-Anxiety-Inventory* (STAI)f ® table 2 and figure 6
Brief Symptom Inventory* (BSI)g ® table 2 and figure 6
Toronto Alexithymia Scale* (TAS)h ® table 2
cognitive tests premorbid IQ (MWT-B)i, j ® table 3 and figure 7
reasoning (LPS-3)k ® table 3 and figure 7
letter-number-span (BZT)l ® table 3 and figure 7
finger dotting and tappingm ® table 3 and figure 7
trail making tests (TMT-A and TMT-B)n ® table 3 and figure 7
verbal fluency (DT/RWT)o, p
digit-symbol test (ZST)q ® table 3 and figure 7
verbal memory* (VLMT)r ® table 3 and figure 7
physical examination Testbatterie zur Aufmerksamkeitsprüfung (TAP)s ® table 3 and figure 7
general physical examination
Cambridge Neurological Inventory (CNI)t ® table 5 and figure 8
Contralateral Co-Movement Test (COMO)u
Barnes Akathisia Rating Scale (BARS)v ® figure 8
Simpson-Angus Scale (SAS)w ® figure 8
Tardive Dyskinesia Rating Scale (TDRS)x ® figure 8
Abnormal Involuntary Movement Scale (AIMS)y ® figure 8
odor testing (ORNI Test)z
blood sampling (DNA, serum)
*questionnaires and cognitive tests in respective German versions
a Based on a visual analogue scale (Krampe H, Bartels C, Victorson D, Enders CK, Beaumont J, Cella D, Ehrenreich H: The influence of personality factors on disease progression
and health-related quality of life in people with ALS. Amyotroph Lateral Scler 2008, 9:99-107). bWittchen H-U, Zaudig, M. and Fydrich, T.: SKID-I (Strukturiertes Klinisches
Interview für DSM-IV; Achse I: Psychische Störungen). Göttingen: Hogrefe; 1997. cKay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS) for
schizophrenia. Schizophr Bull 1987, 13(2):261-276. dGuy W: Clinical Global Impression (CGI). In ECDEU Assessment manual for psychopharmacology, revised National Institue of
Mental Health. Rockville, MD; 1976. eAmericanPsychiatricAssociation: Diagnostic and statistical manual of mental disorders, 4th edition (DSM-IV). Washington, DC: American
Psychiatric Press; 1994. fLaux L, Glanzmann P, Schaffner P, Spielberger CD: Das State-Trait-Angstinventar (STAI). Weinheim: Beltz; 1981. gFranke GH: Brief Symptom Inventory
(BSI). Goettingen: Beltz; 2000. hKupfer J, Brosig B, Braehler E: Toronto Alexithymie-Skala-26 (TAS-26). Goettingen: Hogrefe; 2001. iLehrl S, Triebig G, Fischer B: Multiple choice
vocabulary test MWT as a valid and short test to estimate premorbid intelligence. Acta Neurol Scand 1995, 91(5):335-345. jLehrl S: Mehrfach-Wortschatz-Intelligenztest MWT-B.
Balingen: Spitta Verlag; 1999. kHorn W: Leistungsprüfsystem (LPS). 2 edition. Goettingen: Hogrefe; 1983. lGold JM, Carpenter C, Randolph C, Goldberg TE, Weinberger DR:
Auditory working memory and Wisconsin Card Sorting Test performance in schizophrenia. Arch Gen Psychiatry 1997, 54(2):159-165. mChapman RL: The MacQuarrie test for
mechanical ability. Psychometrika 1948, 13(3):175-179. nWar-Department: Army Individual Test Battery. Manual of directions and scoring. Washington, D.C.: War Department,
Adjutant General’s Office; 1944. oKessler J, Denzler P, Markowitsch HJ: Demenz-Test (DT). Göttingen: Hogrefe; 1999. pAschenbrenner S, Tucha O, Lange KW: Der Regensburger
Wortflüssigkeits-Test (RWT). Göttingen: Hogrefe; 2000. qTewes U: Hamburg-Wechsler Intelligenztest fuer Erwachsene (HAWIE-R). Bern: Huber; 1991. rHelmstaedter C, Lendt M,
Lux S: Verbaler Lern- und Merkfåhigkeitstest (VLMT). Goettingen: Beltz; 2001. sZimmermann P, Fimm B: Testbatterie zur Aufmerksamkeitsprüfung (TAP). Version 1.02c.
Herzogenrath: PSYTEST; 1993. tChen EY, Shapleske J, Luque R, McKenna PJ, Hodges JR, Calloway SP, Hymas NF, Dening TR, Berrios GE: The Cambridge Neurological Inventory:
a clinical instrument for assessment of soft neurological signs in psychiatric patients. Psychiatry Res 1995, 56(2):183-204. uBartels C, Mertens N, Hofer S, Merboldt KD, Dietrich J,
Frahm J, Ehrenreich H: Callosal dysfunction in amyotrophic lateral sclerosis correlates with diffusion tensor imaging of the central motor system. Neuromuscul Disord 2008, 18
(5):398-407. vBarnes TR: The Barnes Akathisia Rating Scale - revisited. J Psychopharmacol 2003, 17(4):365-370. wSimpson GM, Angus JW: A rating scale for extrapyramidal side
effects. Acta Psychiatr Scand Suppl 1970, 212:11-19. xSimpson GM, Lee JH, Zoubok B, Gardos G: A rating scale for tardive dyskinesia. Psychopharmacology (Berl) 1979, 64
(2):171-179. yGuy W: Abnormal involuntary movement scale (AIMS). In ECDEU Assessment manual for psychopharmacology, revised National Institute of Mental Health.
Rockville, MD; 1976. zORNI Test (Odor Recognition, Naming and Interpretation Test; developed for the purpose of odor testing in schizophrenics; manuscript in preparation)
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(n = 34) female subjects with an average age of 39.02 ±
13.87 years, ranging from 18 to 71 years.
Traveling team
The GRAS team of traveling investigators consisted of 1
trained psychiatrist and neurologist, 3 psychologists and
4 medical doctors/last year medical students. All investi-
gators had continuous training and calibration sessions
to ensure the highest possible agreement on diagnoses
and other judgments as well as a low interrater variabil-
ity regarding the instruments applied. Patient contacts
were usually prepared by colleagues/personnel in the
respective collaborating psychiatric centers (Figure 2) to
make the work of the travel team as efficient as possible.
The GRAS manual
A standardized procedure for examination of the
patients has been arranged with the GRAS manual,
composed for the purpose of the GRAS data collection.
Table 1 presents its contents, including established
instruments, such as clinical interviews/ratings, ques-
tionnaires, cognitive and neurological tests [2,29-53].
GRAS operating procedure
The GRAS data base operating procedure leading from
the large set of raw data provided by the travel team
to the data bank with its several-fold controlled and
verified data points is illustrated in Figure 4. Already
during the time when the travel team examined
patients all over Germany, a team of psychologists
started to work on the development of the GRAS data
base, integrating the raw data to ultimately result in
over 3000 phenotypic data points per patient (total of
over 3.000 000 data points at present in the data col-
lection) (Figure 5). Most importantly, the chart
records/medical reports of all patients were carefully
screened, missing records identified and, in numerous,
sometimes extensive and repeated, telephone and writ-
ten conversations, missing psychiatric discharge letters
of every single patient organized. After careful study
and pre-processing of raw data and chart records, the
confirmation of the diagnoses, determination of age of
onset of the disease and prodrome as well as other














































numbers of recruited patientscenter (city)
Figure 2 Collaborating centers and patient numbers. Map of Germany displaying the locations of all 23 collaborating centers that were
visited by an invariable team of traveling investigators. The table next to the map provides numbers of patients examined in each center. Some
centers were visited more than once.
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Statistical analyses
For the establishment of the data base and for basic sta-
tistical analyses of the data, SPSS for Windows version
17.0 [54] was used. Comparisons of men and women in
terms of sociodemographic and clinical picture as well
as neurological examination were assessed using either
Mann-Whitney-U or Chi-square test. Prior to correla-
tion and regression analyses, selected metric phenotypic
variables were standardized by Blom transformation
[55]. The Blom transformation is a probate transforma-
tion into ranks and the resulting standardized values are





























































































































Figure 3 Patient recruitment and flow: (a) Recruitment efficiency 2005 - 2008. Cumulative numbers of recruited patients per quarter of the
year are shown in bar graphs. Note that steady-state recruitment is ongoing. (b) Patient flow. Of 1085 patients examined, the diagnosis of
schizophrenia or schizoaffective disorder could not be confirmed for 48. Instead, alternative diagnoses had to be given.
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Table 2 GRAS sample description
total men women statistics
N % mean (sd) median N % mean (sd) median N % mean (sd) median c 2/Z P
sociodemographics
total n 1037 100 693 100 344 100










11.94 (3.37) 12.00 11.71 (3.34) 12.00 12.42 (3.39) 12.00 Z = -2.714 0.007*
ethnicity: caucasian 992 95.66 661 95.38 331 96.20
african 7 0.68 6 0.87 1 0.30
mixed 10 0.96 7 1.01 3 0.90 c2 = 1.202 0.753
unknown 28 2.70 19 2.74 9 2.60
native tongue: German 902 86.98 591 85.71 311 90.67
bi-lingual German 46 4.44 38 4.33 8 1.46 c2 = 6.899 0.032*
other 89 8.58 64 9.96 25 7.87
marital status: single 748 72.13 575 82.97 173 50.44
married 129 12.44 48 6.93 81 23.32




widowed 13 1.25 3 0.43 10 2.92
unknown 23 2.22 10 1.44 13 3.79
living situation: alone 292 28.16 201 29.00 91 26.45
alone with children 17 1.64 0 0 17 4.94
with partner (± children) 137 13.20 50 7.22 87 25.29
With parents 157 15.14 121 17.46 36 10.47
with others (family members,
friends)




sheltered home 282 27.19 212 30.59 70 20.35
forensic hospital 54 5.21 43 6.20 11 3.20
homeless 4 0.39 4 0.58 0 0




















age of onset of first psychotic
episode
25.75 (8.81) 23.00 24.49 (7.71) 22.00 28.28
(10.23)
26.00 Z = -5.705 <
0.001*






13.02 Z = -2.600 0.009*
hospitalization (number of
inpatient stays)
























450.00 Z = -2.428 0. 015*
PANSSa: positive symptoms 13.76 (6.32) 12.00 13.94 (6.16) 12.00 13.92 (6.64) 12.00 Z = -0.130 0.990
negative symptoms 18.23 (7.85) 17.00 18.14 (7.57) 17.00 18.11 (8.44) 17.00 0.886 0.376














Clinical Global Impression scaleb 5.57 6.00 5.57 (1.03) 6.00 5.57 (1.18) 6.00 Z = -0.121 0.894




45.00 Z = -0.323 0.747
global quality of life d 5.41 (2.37) 5.00 5.43 (2.31) 5.00 5.38 (2.49) 5.00 Z = -0.378 0.705
Brief Symptom Inventory e: general severity index 0.88 (0.68) 0.71 0.87 (0.66) 0.71 0.92 (0.72) 0.71 Z = -0.687 0.492














Toronto Alexithymia Scale g 2.59 (0.56) 2.61 2.58 (0.54) 2.55 2.60 (0.60) 2.66 Z = -0.607 0.544
aKay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull1987,13(2):261-276. bGuy W: Clinical Global Impressions (CGI). In ECDEU Assessment manual for
psychopharmacology, revised NationalInstitue of Mental Health. Rockville, MD; 1976. cAmericanPsychiatricAssociation: Diagnostic and statistical manual of mental disorders, 4th edition (DSM-IV). Washington, DC:
American Psychiatric Press; 1994. dBased on a visual analogue scale (Krampe H, Bartels C, Victorson D, Enders CK, Beaumont J, Cella D, Ehrenreich H: The influence of personality factors on disease progression and
health-related quality of life in people with ALS. Amyotroph Lateral Scler 2008, 9:99-107). eFranke GH: Brief Symptom Inventory (BSI). Goettingen: Beltz; 2000. fLaux L, Glanzmann P, Schaffner P, Spielberger CD: Das

















Comparisons of men and women in terms of cognitive
performance were assessed by analyses of covariance,
using age, duration of disease, years of education and
chlorpromazine equivalents as covariates. For all inter-
correlation patterns, correlations of the particular target
variables were assessed using Pearson product-moment
correlation. Cronbach’s alpha coefficient was determined
for estimation of internal consistency of the target vari-
ables within a defined intercorrelation pattern. Multiple
regression analyses using the enter method were con-
ducted to evaluate the contribution of selected disease
related variables (duration of disease, positive symptoms,
negative symptoms, catatonic signs and chlorpromazine
equivalents) to 3 dependent variables: basic cognition/
fine motor functions, cognitive functions and global
functioning (GAF) [2]. The dependent variables basic
cognition/fine motor functions and cognitive functions
are both composite score variables. The basic cognition/
fine motor function score comprises alertness (TAP),
dotting and tapping (Cronbach’s alpha = .801) [39,46]
and the cognition score consists of reasoning (LPS3), 2
processing speed measures (TMT-A and digit-symbol
test, ZST), executive functions (TMT-B), working mem-
ory (BZT), verbal learning & memory (VLMT) and
divided attention (TAP) [37,38,41,44-46] (Cronbach’s
alpha = .869). For both scores, a Cronbach’s alpha >.80
indicates a high internal consistency as prerequisite for
integrating several distinct items into one score. Multi-
ple regression analyses were conducted for the total
sample and separated for men and women.
Results
Biographic and clinical data
The GRAS data collection comprises presently (as of
August 2010) 1037 patients with confirmed diagnosis of
schizophrenia (82.2%) or schizoaffective disorder
(17.8%). A total of 693 men and 344 women fulfilled the
respective diagnostic requirements of DSM-IV. Table 2
provides a sample description, both total and separated
for male and female patients, with respect to sociode-
mographic data and clinical picture. There are some dif-
ferences between genders in the GRAS sample: Women
are older, less single, have more years of education,
more diagnoses of schizoaffective disorders, longer dura-
tion of disease, later age of onset of first psychotic epi-
sode and lower doses of antipsychotics. However,
regarding determinants of the clinical picture, e.g.




meticulous double-check of entered data
confirmation of consensus diagnosis based on 
chart records (e.g. first diagnosis, first psychotic 
episode, current diagnosis, differential diagnosis)
determination of age of onset, duration of 
prodromal symptoms, medication history, pattern 
of course, psychiatric and medical comorbidity
continuous training and calibration sessions
of all raters and research assistants
analysis and entering of questionnaire data, rating 




letters of every 
single patient














Figure 4 Development of the GRAS data bank. Raw data, brought to Göttingen by the traveling team of examiners, were only entered into
the data base after careful and comprehensive data re-checking, also based on patient charts and discharge letters. During the whole process,
continuous calibration sessions and repeated re-checking of the entered data took place.
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An intercorrelation pattern of selected clinical readouts,
obtained by (1) clinical ratings and (2) self-ratings of the
patients and complemented by (3) ‘objective data’, in
this case medication and hospitalization, is presented in
Figure 6. The Cronbach’s alpha of .753 suggests that
items derived from the 3 different perspectives harmo-
nize well. Whereas patient ratings of quality of life and
state anxiety (STAI) [32] are only weakly correlated with
professional clinical ratings and objective data, the
patients’ self-estimated symptom burden as measured
with the BSI [33] shows moderate to good correlation.
Cognition
For the ongoing/planned genetic analyses, not only the
clinical picture with its schizophrenia-typical positive
and negative symptoms, but particularly cognition plays
an important role. The cognitive tests applied in the
GRAS data collection show an intercorrelation pattern
that further underlines quality and internal consistency
of the data obtained by the invariable team of investiga-
tors (Figure 7). Table 3 represents the cognitive perfor-
mance data of the complete GRAS sample in the
respective domains. In addition, the performance level
of men and women is given as well as - for comparison
- available normative data of healthy individuals. Since
for dotting and tapping [39], no normative data were
available in the literature, the values shown in Table 3
were obtained from the healthy GRAS control popula-
tion for cognitive measures (n = 103; see patients and
methods).
Comparing cognitive performance of schizophrenic
men and women, analyses of covariance have been con-
ducted, with age, duration of disease, years of education
and chlorpromazine equivalents as covariates, which
revealed significant gender differences in discrete cogni-
tive domains. Men performed better in reasoning (F =
17.62, p <.001), alertness (F = 28.30, p <.001 for reaction
time and F = 10.39, p = .001 for lapses), and divided
attention (F = 14.07 p <.001 for reaction time and F =
22.12, p <.001 for lapses). In contrast, female schizo-
phrenic patients were superior in verbal memory tasks
(F = 12.38, p <.001) and digit symbol test (F = 19.24, p
<.001). With respect to normative data obtained from
healthy controls, cognitive data of all schizophrenic
patients are in the lower normal range (percentile rank
= 16 for digit symbol test) or even below (percentile
family history: prevalence of 
spectrum disorders…
sociodemographic characteristics:
education, training, forensic information…
psychopathology: psychiatric ratings, subjective symptoms, course, 
diagnostic categories, hallucination and delusion phenomena…
neurological examination: neurological standard exam, 
soft signs, odor testing, saccadic eye movements…
neuropsychology / cognition: speed of processing, attention / vigilance, 
working memory, verbal learning, reasoning / problem solving (executive functioning), motor 
function, crystalline / fluid intelligence…
birth complications: prolonged birth, 
asphyxia, premature birth…
psychiatric comorbidity: anxiety, depression, mania, 
substance abuse, e.g. alcohol, cannabis… 
medication history: type, combination, 
dose of antipsychotic medication during 
disease course, side effects...
physical examination:
minor abnormalities, comorbidity… social functioning: living skills, employment, 
social network, quality of life…
disease history: age of onset, duration of 
prodromal symptoms, first diagnosis, first 
psychotic episode…
neuro- and psychotrauma: cerebral contusion, 
loss of consciousness, abuse during childhood, migration…
phenotype
overview
hospitalization: number and duration 
of psychiatric inpatient stays and forensic stays…
Figure 5 Phenotype overview. Various different domains covered by the GRAS data collection are displayed. These domains will also deliver
the basis for further sophistication of phenotypical readouts.
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ranks 10 for verbal memory, TMT-A, TMT-B, alertness
and divided attention). Only for reasoning (LPS) [37]
and premorbid intelligence (MWT-B) [36], schizophre-
nic subjects lie in the average range (percentile ranks of
31 and 43.5 respectively).
Antipsychotic medication and side effects
Another important feature of schizophrenic patients that
may influence their every-day functioning and perfor-
mance, and result in a considerable number of side effects,
is their antipsychotic medication. The GRAS data collec-
tion contains information on type, dose, duration of medi-
cation and drugs prescribed over the years. The mean
dose of present antipsychotic medication of the whole
GRAS population, expressed as chlorpromazine equiva-
lents [56] amounts to 687.36 (± 696.85). Chlorpromazine
equivalents in male are significantly higher as compared to
female patients (Table 2). An overview of self-reported
side effects of current antipsychotic medication in the
GRAS sample, again sorted by gender, is given in Table 4.
Of the 1037 patients with confirmed diagnosis of schizo-
phrenia/schizoaffective disorder, 24 were presently not on
antipsychotic drugs, whilst for 1 patient the current medi-
cation was unknown. Of the remaining 1012 patients who
currently receive antipsychotic medication (16.5% first
generation antipsychotics, 54.1% second generation anti-
psychotics and 29.4% mixed) and were all explicitly inter-
viewed regarding medication side effects, only 423
reported any. The discrepancy between side effects mea-
sured versus side effects based on patients’ reports
becomes obvious when considering for instance the num-
ber of patients with clear extrapyramidal symptoms: A
total of 335 subjects measured by Simpson-Angus Scale
(mean score >.3) [50] contrasts only 117 patients self-
reporting extrapyramidal complaints. External rating of
extrapyramidal side effects in the GRAS population was
comprehensively performed, utilizing a number of respec-
tive instruments which all showed significant


























Figure 6 Clinical intercorrelation pattern. Correlations between measures of the clinical picture derived from different approaches: Patient
self-ratings, clinical rater judgement and ‘objective data’. Thickness of the lines represents the strength of correlation between two measures;
only significant correlations are displayed. Note the strong internal consistency expressed by a Cronbach’s alpha of .753.
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intercorrelation (Figure 8) [47,49-52,57]. A composite
score of the 6 Blom transformed scales, used for testing
potential gender effects, yielded no significant differences
in extrapyramidal symptoms in men versus women (Z =
-0.022, p = 0.982).
Neurological symptoms
Similar to cognitive readouts, evaluation of inherent
neurological symptoms in the schizophrenic patient
population are of tremendous interest, not only for
understanding the contribution of particular genes/
genetic markers and/or environmental factors to the
schizophrenic phenotype but also for estimating the
impact of potential neurological comorbidities. Table 5
provides an overview of neurological symptoms based
on the Cambridge Neurological Inventory (CNI) [47].
Only in the subscale ‘Failure to suppress inappropriate
response’, significant differences between men and
women (Z = -3.175, p = 0.001) became evident. Women
were less able to hold respective responses back, e.g. to
blink with one eye, leaving the other eye open, or to
perform saccadic eye movements without moving the
head.
Prediction of functioning
In order to delineate the influence of disease on func-
tioning in the GRAS sample, multiple regression ana-
lyses have been employed. These procedures assessed
the contribution of 5 disease-related variables, i.e. dura-
tion of disease, PANSS positive and negative scores [30],
catatonic signs [47], and dose of antipsychotic medica-
tion, to 3 dependent performance variables: (a) basic
cognition/fine motor functions, (b) cognitive perfor-
mance and (c) global functioning (Table 6). Regarding
basic cognition/fine motor function, multiple regression


































.6 < r < .9
Figure 7 Cognitive intercorrelation pattern. Shown are all neuropsychological tests performed, together with their respective cognitive
domain. Thickness of the lines represents the strength of correlation between two tests; only significant correlations are displayed. Tests for
higher cognitive functions are labelled in orange; tests for basic (mainly basic cognition/fine motor dependent) functions in grey. Measures of
higher cognitive functions as well as measures of basic cognition/fine motor functions show powerful internal consistency (Cronbach’s alpha of
.819 and .801 respectively).
Ribbe et al. BMC Psychiatry 2010, 10:91
http://www.biomedcentral.com/1471-244X/10/91
Page 12 of 20
32.4% of variance in the total sample. In fact, duration
of disease, negative symptoms, catatonic signs, and med-
ication (chlorpromazine equivalents) contributed signifi-
cantly to basic cognition/fine motor function, whereas
positive symptoms did not (b = -.006, p = .856). Accord-
ing to the standardized regression coefficients, duration
of disease and negative symptoms are the best
predictors of basic cognition/fine motor function (b =
-.346, p < .001 and b = -.334, p < .001). For higher cog-
nitive functions, the set of disease-related variables
explained 33% of variance in the total sample. Again,
duration of disease and negative symptoms are the best
predictors of higher cognitive functions (b = -.335, p <
.001 and b = -.351, p < .001). Positive symptoms did not
Table 3 Cognitive performance of GRAS patients. For comparison, normative data are presented wherever available2.
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° Higher scores reflect better performance, except for TMT-A, TMT-B, Alertness and Divided Attention (TAP)
* For statistical comparison (ANCOVA) between men and women values are corrected for age, duration of disease, chlorpromazine equivalents and years of
education (except MWT-B).
1) Non-native and non-bilingual German speaking patients are excluded (n = 89).
2) Percentile ranks (PR) < 15 indicate that the mean or the median of the total sample is below average in comparison to a normative sample.
aHorn W: Leistungsprüfsystem (LPS). 2 edition. Goettingen: Hogrefe; 1983. bGold JM, Carpenter C, Randolph C, Goldberg TE, Weinberger DR: Auditory working
memory and Wisconsin Card Sorting Test performance in schizophrenia. Arch Gen Psychiatry 1997, 54(2):159-165. cPerianez JA, Rios-Lago M, Rodriguez-Sanchez
JM, Adrover-Roig D, Sanchez-Cubillo I, Crespo-Facorro B, Quemada JI, Barcelo F: Trail Making Test in traumatic brain injury, schizophrenia, and normal ageing:
sample comparisons and normative data. Arch Clin Neuropsychol 2007, 22(4):433-447. dHelmstaedter C, Lendt M, Lux S: Verbaler Lern- und Merkfähigkeitstest
(VLMT). Goettingen: Beltz; 2001. eLehrl S: Mehrfach-Wortschatz-Intelligenztest MWT-B. Balingen: Spitta Verlag; 1999. fZimmermann P, Fimm B: Testbatterie zur
Aufmerksamkeitsprüfung (TAP). Version 1.02c. Herzogenrath: PSYTEST; 1993. gTewes U: Hamburg-Wechsler Intelligenztest fuer Erwachsene (HAWIE-R). Bern: Huber;
1991. hHealthy controls recruited for selected cognitive and olfactory testing (unpublished data).
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reach significance (b = - .015, p = .658). With respect to
global functioning, all chosen disease-related factors
accounted for 59.6% of variance in the total sample.
Only duration of disease per se did not reach signifi-
cance (b = -.028, p = .198). Positive and negative symp-
toms were the strongest predictors of global functioning
(b = - .441, p < .001 and b = -.380, p < .001).
Discussion
The present paper provides an overview of the GRAS
data collection, including (1) study logistics and proce-
dures, (2) sample description regarding sociodemo-
graphic data, disease-related variables, cognitive
performance and neurological symptoms, paying parti-
cular attention to gender differences, and (3) a first pre-
sentation of intercorrelation patterns for selected areas
of interest to phenotype studies. (4) In addition, disease-
related factors influencing important criteria of daily
functioning are evaluated in the >1000 GRAS patients.
Overall, the GRAS sample represents a typical schizo-
phrenic population in contact with the health system
and is - last not least due to its homogeneous data
acquisition - ideally suited for the ongoing and planned
phenotype-based genetic association studies (PGAS) (e.g.
[[11], and Grube et al: Calcium-activated potassium
channels as regulators of cognitive performance in schi-
zophrenia, submitted]).
The GRAS data collection has several remarkable
advantages, two of which are of major importance for
its ultimate goal, PGAS: (i) Different from other studies
dealing with the establishment of a schizophrenia data
base, all data for GRAS were collected by one and the
same traveling team of examiners, who frequently per-
formed calibrating sessions and rater trainings. This
effort has clearly paid off in terms of reliability and qual-
ity of the data, considering the internal consistencies of
the GRAS phenotypes, as exemplified in the displayed
correlation patterns. (ii) Even though the GRAS study
has been implemented as a cross-sectional investigation,
the GRAS data collection also includes solid longitudinal
information derived from the almost complete psychia-
tric chart records/discharge letters of all schizophrenic
patients. This longitudinal set of data has been essential
to e.g. reliably estimate prodrome versus disease onset, i.
e. occurrence of the first psychotic episode.
Comparable to other schizophrenia samples, the
GRAS sample comprises around two thirds of male and
one third of female patients [17,58]. Assuming that the
gender ratio in schizophrenia were 1:1 as claimed in
text books, but recently also questioned [59,60], then
two principal reasons may account for the gender distri-
bution observed here: (1) Schizophrenic women gener-
ally seem to have less contact with the health system
due to being better socially settled (later age of onset of
Table 4 Self-reported medication side effects of patients (N = 423)* according to treatment type
FGA1 SGA2
men women men women
Parkinson symptoms 17% 15.6% 3.8% 11.6%
dyskinetic/dystonic symptoms 35.8% 31.3% 9.4% 9.7%
akathisia 22.6% 12.5% 6% 6.8%
hyperprolactinaemia - - - 1.9%
hormonal dysfunctions (gynecomastia, absence/changes of menorrhea) - 9.4% - 5.8%
sexual dysfunction 7.5% - 10.3% -
vertigo (incl. hypotonia) 5.7% 12.5% 5.1% 8.7%
weight gain 9.4% 18.7% 38.3% 39.8%
diabetes mellitus - - 0.4% -
sialorrhea (’drooling’) - - 20.4% 6.8%
skin abnormalities, loss of hair 1.9% - 1.7% 5.8%
gastrointestinal symptoms 1.9% 6.3% 5.9% 7.8%
hyperhidrosis - - 2.6% -
psychological symptoms (loss of concentration, no drive, tiredness) 33.9% 28.1% 44.2% 31.1%
cardiovascular symptoms (tachycardia, hypertension) - - 1.3% 1.9%
impaired vision - - 1.7% 3.9%
dry mouth 5.7% 9.4% 5.1% 4.9%
urinary retention - 3.1% 1.3% -
number of patients who reported side effects 53 32 235 103
1FGA - first generation antipsychotics, typical antipsychotics
2SGA - second generation antipsychotics, atypical antipsychotics
*Only N = 423 patients (out of 1012 patients who were on antipsychotic medication) reported side effects (see text for details).
Ribbe et al. BMC Psychiatry 2010, 10:91
http://www.biomedcentral.com/1471-244X/10/91
Page 14 of 20
disease) and protected within their families [61]; (2) A
certain (smaller) recruitment bias may be explained by
the fact that the traveling team of examiners visited
some institutions with an overrepresentation of males, e.
g. specialized forensic units or a hospital for psychotic
patients with co-morbid substance use disorders.
With the purposeful strategy to visit several different
facilities of psychiatric health care covering inpatients,
outpatients, residents of sheltered homes and forensic
patients, the GRAS approach tried to avoid biases inher-
ent to pure inpatient samples [58]. Nevertheless, patients
who are not in contact with the health care system are
unlikely to be integrated in any comparable data bases.
For instance, only 4 of the 1085 examined patients are
currently homeless, whereas among homeless people a
considerable proportion suffers from schizophrenia [62].
To reach them as well, different and more cost intensive
recruitment strategies would be required [13]. On the
other hand, the schizophrenic phenotype required for
the GRAS-PGAS studies pursued here, might be veiled
in this severely affected subsample of patients that is
additionally characterized by other specific problems, e.
g. a highly elevated incidence of multiple substance use
disorders and severe downstream medical comorbidities
[63,64].
Gender differences in schizophrenia as obvious from
the present data collection have been known for a long
time [65]. In agreement with the literature, men and
women in the GRAS sample differ by diagnosis, with
women having a higher rate of schizoaffective disorders
[66,67]. With respect to age of onset, education, indica-
tors of social integration (e.g. marital status, living situa-
tion) and medication, the present results are also in




















Figure 8 Extrapyramidal intercorrelation pattern. Shown are correlations between different neurological tests for measuring extrapyramidal
symptoms. Thickness of the lines represents the strength of correlation between two tests; only significant correlations are displayed. Cronbach’s
alpha of .675 shows that these measures have a decent internal consistency.
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are younger when the first psychotic episode occurs, are
more frequently single, more often dependent on sup-
ported living conditions (e.g. residential homes) and
show lower educational status [61,67,68]. Among the
explanations for the observed gender differences in schi-
zophrenia are the protective role of female hormones
[69] and social aspects like earlier marriage of young
women leading to a more protected environment at dis-
ease onset [13]. In line with these considerations is the
work of Häfner and colleagues [12]. In a prospective
design he could show that ‘the social course (of schizo-
phrenia) is determined by individual stage at illness
onset and by early illness course’ [70].
With respect to psychopathology and premorbid func-
tioning, the GRAS sample may be slightly different from
other schizophrenia samples reported in the literature
[67]. Several studies published in this area show that men
exhibit more negative symptoms, even in a geriatric sam-
ple [71,72], and that females have poorer premorbid cogni-
tive functioning than males [73]. In the GRAS patients,
there are no gender differences regarding psychopathology
and premorbid cognition. Importantly, clear support for a
comparable severity of psychopathology in men and
women of the GRAS sample is provided by the lack of
gender differences in numbers of hospitalizations, clinical
severity ratings, including global functioning (CGI, GAF
[2,31]), and self-ratings of symptom severity and anxiety.
One potential explanation for the discrepancies between
the GRAS sample and other studies regarding psycho-
pathology may be that patient numbers in some of the
other studies have been too low to give conclusive results.
In the assessment of premorbid cognitive functioning of
the GRAS sample, a methodological limitation could be
the retrospective determination of premorbid intelligence
using a so-called ‘hold’ measure, i.e. a multiple choice
vocabulary test [35]. Even though this is an accepted and
valid instrument to retrospectively estimate premorbid
intelligence [74], a prospective procedure might be more
accurate. In fact, Weiser and colleagues had the opportu-
nity to base their assessments on cognitive testing per-
formed on adolescents before starting their military
service [73], potentially explaining the deviating results.
Gender differences regarding current cognitive perfor-
mance are similar within the GRAS sample (even though
Table 5 Cambridge Neurological Inventory (CNI)a subscale sum scores (N = 893-942)
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0.0 (0-5) -1.363 n.s
Tardive dyskinesia
dyskinetic, sustained or manneristic face and head movement, simple or








0.0 (0-7) -0.132 n.s
Catatonic signs
gait mannerism, gegenhalten, mitgehen, imposed posture, exaggerated or







0.0 (0-7) -1.717 n.s
Parkinsonism
increased tone in upper and lower limb (le/ri), decreased associated
movements in walking, shuffling gait, arm dropping, tremor postural or














Failure to suppress inappropriate response








1.0 (0-6) -3.175 .001*
*le/ri - left and right
aChen EY, Shapleske J, Luque R, McKenna PJ, Hodges JR, Calloway SP, Hymas NF, Dening TR, Berrios GE: The Cambridge Neurological Inventory: a clinical
instrument for assessment of soft neurological signs in psychiatric patients. Psychiatry Res 1995, 56(2):183-204.
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at a lower functioning level [75]) compared to healthy con-
trols [76] after considering age of onset, duration of dis-
ease, education and medication as covariates. Men
perform better in reasoning, alertness and divided atten-
tion but worse in verbal memory, confirming reports on
first-episode as well as chronically ill schizophrenic
patients [77].
Women in the GRAS study receive significantly lower
doses of chlorpromazine equivalents, confirming that
they require less medication to achieve a reasonable
treatment effect [78]. Importantly, regarding medication
side effects, there were no gender differences in extra-
pyramidal symptoms. There were also no differences in
the overall proportion of men and women who self-
reported side effects, but the pattern of complaints was
slightly different. For instance, women mentioned more
often hormonal dysfunction and vertigo (or related
symptoms like hypotonia), whilst men complained
mainly about sexual dysfunction. Altogether, it is worth
pointing out that the percentage of patients self-report-
ing side effects is low when compared to that with
objectively measured side effects, e.g. extrapyramidal
symptoms (11.3% versus 32.3%).
Explicit studies on gender differences in antipsychotic
medication side effects found a somewhat different dis-
tribution of complaints, e.g. more weight gain, diabetes
and specific cardiovascular diseases in females [78,79].
Here, one reason is certainly the still preliminary data
set of the GRAS collection evaluated, based at this point
exclusively on cross-sectional patient reports. For a
more appropriate coverage of medication side effects, all
charts/discharge letters of every GRAS patient (also of
those patients who did/could not report them), will have
to be screened and entered into the data base. Compre-
hensive information on antipsychotic (and other) drugs
and their side effects in the GRAS sample has been col-
lected and is waiting for analyses to support e.g. future
pharmacogenomic approaches, perhaps also in colla-
boration with industry partners.
In line with the findings of a recent meta-analysis [80],
positive symptoms of the GRAS patients do not influ-
ence higher cognitive function or basic cognition/fine
Table 6 Multiple regression analyses predicting a) basic cognition/fine motor functions, b) cognitive performance, c)
global functioning
total male female
b t p b t p b t p
a) basic cognition/fine motor functions1
duration of disease (years) -.346 -11.92 < .001 -.353 -9.68 < .001 -.318 -6.59 < .001
positive symptoms (PANSS) -.006 -0.18 .856 -.028 -0.69 .489 .065 1.08 .283
negative symptoms (PANSS) -.334 -10.05 < .001 -.293 -7.32 < .001 -.415 -7.01 < .001
catatonic signs (CNI) -.126 -4.26 < .001 -.128 -3.45 .001 -.161 -3.27 .001
medication (CPZ-equivalents) -.080 -2.70 .007 -.066 -1.83 .068 -.147 -2.84 .005







duration of disease (years) -.335 -11.54 < .001 -.356 -9.72 < .001 -.294 -6.12 < .001
positive symptoms (PANSS) -.015 -0.44 .658 -.033 -0.80 .427 .023 0.38 .704
negative symptoms (PANSS) -.351 -10.47 < .001 -.320 -7.92 < .001 -.396 -6.56 < .001
catatonic signs (CNI) -.132 -4.46 < .001 -.103 -2.76 .006 -.204 -4.16 < .001
medication (CPZ-equivalents) -.082 -2.74 .006 -.060 -1.62 .105 -.140 -2.70 .007







duration of disease (years) -.028 -1.29 .198 -.008 -0.28 .780 -.062 -1.78 .076
positive symptoms (PANSS) -.441 -17.33 < .001 -.458 -14.45 < .001 -.415 -9.60 < .001
negative symptoms (PANSS) -.380 -15.02 < .001 -.345 -10.97 < .001 -.430 -10.0 < .001
catatonic signs (CNI) -.060 -2.67 .008 -.050 -1.71 .088 -.093 -2.58 .011
medication (CPZ-equivalents) -.106 -4.71 < .001 -.122 -4.29 < .001 -.078 -2.07 .040






1A basic cognition/fine motor composite score was used as a dependent variable comprising alertness (TAP), tapping, and dotting (Chronbachs alpha = .801).
2A cognitive composite score was used as a dependent variable consisting of reasoning (LPS3), 2 processing speed measures (TMT -A and digit-symbol test, ZST),
executive functions (TMT-B), working memory (BZT), verbal memory (VLMT) and divided attention (TAP) (Chronbachs alpha = .869).
3Global assessment of functioning (GAF) was used as a dependent variable.
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motor performance, whilst negative symptoms, catatonic
signs, duration of disease and antipsychotic medication
have a significant effect on both. The clinical ratings of
global functioning, however, strongly rely on positive as
well as negative symptoms, medication and catatonic
signs [81-83].
Conclusion
GRAS enables a novel phenotype-based approach to
understand the molecular-genetic architecture of schizo-
phrenia. The GRAS data collection encompasses a large
sample of comprehensively phenotyped, moderately to
severely affected schizophrenic patients. Proof-of-princi-
ple for the suitability of the GRAS data collection for
PGAS has already been demonstrated [[11], and Grube
et al: Calcium-activated potassium channels as regula-
tors of cognitive performance in schizophrenia, sub-
mitted]. Further extensive analyses of the accumulated
information on every single patient are ongoing.
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INTRODUCTION
Since 1998, nearly 200 preclinical stud-
ies have proven erythropoietin (EPO) to
have neuroprotective and neuroregenera-
tive potential, ranging from ischemia and
neurotrauma to inflammation and neu-
rodegeneration. Essentially all of the few
clinical studies performed in the neuro-
science field have yielded positive results
with respect to EPO treatment effects (re-
viewed in [1,2]). The first encouraging
clinical study was the Göttingen EPO
Stroke Study, which showed beneficial
outcome of ischemic stroke patients
upon EPO (3).
Unfortunately, the respective follow-
up study, the German Multicenter EPO
Stroke Trial (ClinicalTrials.gov identifier
NCT00604630), building on these posi-
tive results, turned out to be a formally
negative trial, because of the unexpect-
edly large percentage of recombinant
tissue plasminogen activator (rtPA)
treatments with a high violation rate of
thrombolysis contraindications (4). Pa-
tients with rtPA application despite
prior anticoagulation had inferior out-
come under additional EPO, whereas
patients treated with rtPA “lege artis”
(“correctly”; “by law of art”) did not
have any disadvantage of EPO treat-
ment (www.epo-study.de) (4). Potential
mechanisms explaining a negative inter-
play between EPO and rtPA were re-
cently reported in preclinical work (5,6).
In contrast, patients who did not receive
rtPA likely benefitted from EPO with a
clinical course/outcome (National Insti-
tutes of Health Stroke Scale [NIHSS])
comparable to that obtained in the first
EPO stroke study (3,4). In the absence of
any other neuroprotective or neurore-
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generative strategy available for stroke
patients, this promising signal encour-
ages further work along these lines.
Circulating biomarkers of brain dam-
age are increasingly considered as addi-
tional outcome measures for stroke com-
plementing clinical and imaging data.
Among the markers selected for the pres-
ent analysis, the glial damage markers
S100B and glial fibrillary acidic protein
(GFAP) have been in clinical use for
many years, whereas the neuronal
marker ubiquitin C-terminal hydrolase
(UCH-L1) has been integrated recently in
the repertoire of stroke biomarkers. All
these damage markers correlate well
with clinical severity, course and out-
come of brain injury (7,8).
UCH-L1 is a highly abundant protein
that resides in almost all neurons and
averages between 1% and 5% of total
soluble brain proteins. It has been sug-
gested that UCH-L1 plays a critical role
in the removal of excessively oxidized
or misfolded proteins both during nor-
mal and neuropathological conditions
(9–12). On the basis of this important
neuronal function and its high speci-
ficity and abundance in the central
nervous system, we selected UCH-L1
here as a candidate biomarker for
 poststroke brain injury and readout of
neuroprotection.
S100B is a low-molecular-weight glial
protein of a multigenic family of cal-
cium-binding proteins, highly specific
to the nervous system and found in
abundance in the astroglia compartment
in the cerebral cortex, in peripheral
Schwann cells, but also extra-neuronally
in melanocytes, adipocytes and chondro-
cytes (13). In previous studies, we could
show that S100B release was associated
with stroke severity and clinical outcome
(14). S100B was also postulated to be a
marker of generalized blood-brain bar-
rier dysfunction, rather than of specific
glia damage only (15).
GFAP is a monomeric filament protein
localized to astrocytes in the brain.
GFAP is involved in various neuronal
processes, including maintenance of the
blood-brain barrier (reviewed in [16]). In-
creased serum concentrations of GFAP
were described after ischemic stroke and
traumatic brain injury and to correlate
with clinical severity and outcome (17,18).
About 10 years ago, we argued that
molecular markers of brain damage might
be a useful tool in translational stroke re-
search and that the analysis of the release
patterns of biomarkers might be a promis-
ing strategy to evaluate neuroprotective
approaches in stroke treatment (19). Here
we report poststroke  biomarker profiles of
an exploratory subgroup comprising per-
protocol treated  ischemic stroke patients
of the German Multicenter EPO Stroke
Trial who did not receive rtPA.
MATERIALS AND METHODS
Patients
The present predefined exploratory
subgroup analysis is based on all pa-
Table 1. Patient characteristics on inclusion.
Patients included in subgroup analysis (n = 163)
Variable EPO (n = 76) Placebo (n = 87) P
Age (years) (mean ± SD) 71.14 ± 11.45 71.37 ± 10.78 1.00a
Sex (M/F ratio) (%) 40/36 (52.6/47.4) 44/43 (50.6/49.4) 0.875
Number of deaths (%) 6 (7.9) 8 (9.2) 1.00
Hemisphere [n (%)]
Left 35 (46.1) 40 (46.0) 0.879
Right 41 (53.9) 46 (52.9)
Both 0 (0.0) 1 (1.1)
Stroke subtype [n (%)]
Cardiogenic embolism 34 (44.7) 42 (48.3) 0.985
Arterial embolism 18 (23.7) 17 (19.5)
Large artery occlusion 13 (17.1) 14 (16.1)
Paradox embolism 2 (2.6) 2 (2.3)
Lacunar infarction 5 (6.6) 6 (6.9)
Unknown 4 (5.3) 6 (6.9)
Prior anticoagulation 
[n (%)]
No 42 (55.3) 45 (51.7) 0.601
Yes 34 (44.7) 41 (47.1)
Unknown 0 (0.0) 1 (1.1)
Hypertension [n (%)]
No 18 (23.7) 22 (25.3) 0.246
Yes 58 (76.3) 62 (71.3)
Subclinical/borderline 0 (0.0) 3 (3.4)
Unknown 0 (0.0) 0 (0.0)
Diabetes [n (%)]
No 58 (76.3) 60 (69.0) 0.503
Yes 15 (19.8) 24 (27.6)
Subclinical/borderline 3 (3.9) 3 (3.4)
Unknown 0 (0.0) 0 (0.0)
NIHSS
Mean ± SD (range) 12.08 ± 5.90 (4–27) 11.47 ± 5.52 (4–27) 0.539a
MRI diffusion-weighted 
imaging (cm3)
Mean ± SD (range) 34.84 ± 44.11 (0–186) 42.39 ± 65.52 (0.2–298) 0.688a
MRI FLAIR (cm3)
Mean ± SD (range) 4.06 ± 12.10 (0–77) 2.26 ± 4.9 (0–23) 0.895a
Time to treatment (min)
Mean ± SD (range) 275.32 ± 79.10 (42–442) 278.98 ± 65.85 (78–485) 0.977*
aP values from group comparison by Mann-Whitney U test. All other P values obtained from
the two-sided χ2 test or Fisher exact test.
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tients of the randomized, double-blind,
placebo-controlled German Multicenter
EPO Stroke Trial (4) who fulfilled the fol-
lowing requirements: (a) they were
treated per-protocol, (b) they had not re-
ceived rtPA, and (c) they had at least two
out of five follow-up blood samples for
circulating damage markers drawn, re-
sulting in a total of n = 163 patients (ex-
clusion of n = 3 due to missing serum
samples). Main inclusion criteria were
acute ischemic stroke in the middle cere-
bral artery territory leading to a score ≥4
in the NIHSS.
Study Intervention
Intravenous infusion of recombinant
human EPO (Epoetin-α, 40,000 IU) or
placebo was given within 6 h after symp-
tom onset (day 1) and repeated 24 and
48 h later (4). The dose was chosen ac-
cording to the previous EPO study (3).
Biomarker Assays
Blood for biomarker analysis was
drawn on d 1, 2, 3, 4 and 7. Serum was
stored at –80°C. Enzyme-linked immuno -
sorbent assays of S100B, GFAP and
UCH-L1 were performed blindly (that is,
without clinical information) using anti-
bodies from Banyan (Alachua, FL, USA),
Sigma (St. Louis, MO, USA) and Dako
(Carpentaria, CA, USA).
Statistical Analysis
For each marker, a linear regression–
based multiple imputation (10 itera-
tions) model of missing data (UCH-L1
5.8%; S100B 6.5%; GFAP 20.6% missing)
was applied, if at least two out of five
values per subject were present (result-
ing in n = 163 subjects for UCH-L1 and
S100B and n = 154 for GFAP). All per-
protocol treated non-rtPA individuals
not meeting this criterion were excluded
from further analysis (UCH-L1 and
S100B n = 3; GFAP n = 12). Areas under
the curve (AUCs) for every marker were
determined for each imputation matrix
by the composite trapezoidal rule for
numerical integration. The pooled AUC
represents the mean of the 10 AUC ma-
trices per marker. Two composite scores
were  calculated reflecting the mean of
the z-standardized pooled AUC values
for UCH-L1, S100B and GFAP (Cron-
bach α = 0.811) and for S100B and GFAP
(Cronbach α = 0.755). For a total of n = 9
individuals, the composite scores had to
be based on the z-standardized pooled
AUC values for UCH-L1 and S100B
only. Mann-Whitney U tests (two-tailed)
and χ2 tests or Fisher exact test were
used for intergroup comparisons. Anal-
ysis of variance for repeated measures
was applied to compare EPO versus
placebo with respect to Δ NIHSS
Figure 1. Course of circulating brain damage markers after ischemic stroke. All three bio-
markers measured in serum over time increase after stroke (placebo white, left panels;
EPO black, right panels). Note the logarithmic scale of presentations. Medians are given.
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(NIHSS at baseline – NIHSS day 90).
Analysis of covariance with NIHSS
score at baseline as the  covariate com-
pared both groups with respect to
pooled single-marker AUC values and
AUC composite scores. Further, a corre-
lation analysis (Pearson) of Δ NIHSS
and UCH-L1 AUC was performed. 
Data are presented as mean ± SD in
text/tables and median or mean ± SEM
in figures.
RESULTS
Patient characteristics at inclusion were
well balanced between EPO and placebo
groups in all important baseline vari-
ables, representative of a typical stroke
population (Table 1). Biomarker profiles
in serum displayed the expected in-
creases between d 2 and 4 poststroke,
with peak time points varying consider-
ably among different markers and indi-
vidual patients (Figure 1).
The clinical course of included per-
protocol treated non-rtPA patients (n =
163) demonstrates a slightly better out-
come of the EPO compared with the pla-
cebo group (mean Δ NIHSS of 5.3 ± 5.3 in
EPO versus 3.3 ± 6.5 in placebo; P =
0.039) (Figure 2A). As a best estimate of
the total increase in circulating damage
marker concentrations, AUCs were cal-
culated for each marker in all patients.
AUCs, corrected for NIHSS d 1 (severity
of stroke symptoms upon inclusion, that
is, before any study drug treatment),
turned out to be significantly lower in
EPO versus placebo patients for UCH-L1
and showed a similar tendency for S100B
and GFAP (Figure 2B).
To make use of the complete bio-
marker information, a z-standardization
of the AUC scores for each marker was
performed. AUC composite scores of the
two glial markers and of all three bio-
markers were calculated. The internal
consistency of these composite scores
turned out to be sufficiently high (n =
154; Cronbach α = 0.755; and n = 154;
Cronbach α = 0.811, respectively) to jus-
tify their use as composites. Figure 2C
 illustrates z-standardized biomarker
AUC levels for all single markers and the
two composites showing that all three
biomarkers discriminate between EPO
and placebo groups, with UCH-L1 as a
single marker and the three-marker com-
posite score reaching statistical signifi-
cance. Correlation coefficients of
Δ NIHSS and UCH-L1 AUC were found
to be significant for both treatment
groups, with a numerically higher value
in EPO patients (Figure 2D). This result
again emphasizes the neuroprotective
property of EPO in stroke.
DISCUSSION
The present exploratory subgroup
study builds on the observation that
stroke patients of the German Multicen-
ter EPO Stroke Trial, nonqualifying for
rtPA treatment, seemed to have a better
clinical course/outcome under EPO than
placebo (4). This observation is further
supported here by respective stroke bio-
marker profiles. The blunted increase in
the neuronal damage marker UCH-L1
under EPO especially points to neuro-
protection. The results obtained with this
marker may actually suggest its ex-
tended use as a surrogate marker of
stroke severity in future neuroprotection
trials.
Similar to the first EPO stroke study
(3), the S100B increase tended to be
lower in EPO patients but failed to reach
statistical significance here. The third
evaluated marker, GFAP, turned out to
be the least responsive one in the present
analysis, perhaps due to the necessity
(insufficient sample volume left) to im-
Figure 2. Biomarkers substantiate the positive signal on clinical outcome of EPO com-
pared with placebo patients. (A) EPO patients show improved clinical outcome (NIHSS)
after stroke compared with the placebo group. AUC mean ± SEM values (B) and AUC 
z-standardized values (C) demonstrate differences in biomarkers poststroke between EPO
and placebo patients. (D) Δ NIHSS and UCH-L1 AUC correlate in both treatment groups
with a numerically higher correlation coefficient in EPO patients.
pute circa 20% of missing data (as com-
pared with only around 6% for S100B
and UCH-L1). The composite score of
both glial markers, S100B and GFAP, pro-
duced a “near-significant” result. The
composite of all three markers, although
different between treatment groups, does
at first look not add to the information
obtainable with the neuronal marker
UCH-L1 alone. However, both composite
scores reveal that all contributing mark-
ers, be it of glial or neuronal origin, es-
sentially behave synergistically.
In conclusion, stroke is a very com-
mon, devastating and frequently se-
verely disabling condition with only
thrombolysis and supportive measures
presently available for treatment. The
former still reaches just a small percent-
age of patients, and the increasing viola-
tion of rtPA contraindications (as also ex-
perienced in the German Multicenter
EPO Stroke Trial) reflects desperation
and fatalism of treating personnel in the
absence of alternative therapeutic op-
tions. Importantly, stroke patients are ex-
tremely heterogeneous with respect to
genetic and environmental predisposing
factors, including comorbidities, explain-
ing why huge effects of novel treatment
strategies can never be expected over all
patients. Therefore, even the slightest
signal of benefit of neuroprotective treat-
ment strategies has to be vigorously pur-
sued. In this regard, the course of circu-
lating brain damage markers upon EPO
(in association with the documented
 clinical improvement) should encourage
further work on EPO or EPO variants/
analogs in ischemic stroke patients who
are not eligible for thrombolysis.
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Dissociation of accumulated genetic risk and disease
severity in patients with schizophrenia
S Papiol1,2,3, D Malzahn4, A Kästner1, S Sperling1, M Begemann1, H Stefansson5, H Bickeböller4, K-A Nave2,3 and H Ehrenreich1,3
Genotype–phenotype correlations of common monogenic diseases revealed that the degree of deviation of mutant genes from
wild-type structure and function often predicts disease onset and severity. In complex disorders such as schizophrenia, the
overall genetic risk is still often 450% but genotype–phenotype relationships are unclear. Recent genome-wide association
studies (GWAS) replicated a risk for several single-nucleotide polymorphisms (SNPs) regarding the endpoint diagnosis of
schizophrenia. The biological relevance of these SNPs, however, for phenotypes or severity of schizophrenia has remained
obscure. We hypothesized that the GWAS ‘top-10’ should as single markers, but even more so upon their accumulation, display
associations with lead features of schizophrenia, namely positive and negative symptoms, cognitive deficits and neurological
signs (including catatonia), and/or with age of onset of the disease prodrome as developmental readout and predictor of disease
severity. For testing this hypothesis, we took an approach complementary to GWAS, and performed a phenotype-based genetic
association study (PGAS). We utilized the to our knowledge worldwide largest phenotypical database of schizophrenic patients
(n41000), the GRAS (Göttingen Research Association for Schizophrenia) Data Collection. We found that the ‘top-10’ GWAS-
identified risk SNPs neither as single markers nor when explored in the sense of a cumulative genetic risk, have any predictive
value for disease onset or severity in the schizophrenic patients, as demonstrated across all core symptoms. We conclude that
GWAS does not extract disease genes of general significance in schizophrenia, but may yield, on a hypothesis-free basis,
candidate genes relevant for defining disease subgroups.
Translational Psychiatry (2011) 1, e45; doi:10.1038/tp.2011.43; published online 4 October 2011
Introduction
In complex disorders lacking clearly identifiable disease-
causing factors, such as schizophrenia, the overall genetic
risk is often 450%1 but genotype–phenotype relationships
are obscure. Recent genome-wide association studies
(GWAS) on schizophrenia, building on very large cohorts of
cases and controls, have uncovered and replicated a risk for
several single-nucleotide polymorphisms (SNPs). Among the
10 ‘top hits’, reaching genome-wide significance in different
populations after multiple-testing correction (even though with
low odds ratios), are markers in the major histocompatibility
complex region and in TCF4, ZNF804A and NRGN genes.2–6
The biological relevance of these SNPs, however, for
phenotypes or severity of schizophrenia has remained
unclear.
All current GWAS data on schizophrenia rely on endpoint
diagnosis only and do not allow for genotype–phenotype
correlations. In an approach complementary to GWAS, we
employed the ‘top-10’ schizophrenia-associated SNPs that
have emerged as genome-wide significant from several
GWAS, and explored their potential contribution to the
disease phenotype, including positive and negative symp-
toms, cognitive deficits and neurological signs (including
catatonia), and age of onset of the prodrome as develop-
mental readout and predictor of disease severity. For this
phenotype-based genetic association study (PGAS), we
utilized the GRAS (Göttingen Research Association for
Schizophrenia) Data Collection.7,8
Materials and methods
Schizophrenic patients. The GRAS study was approved
by the Ethics Committees of the Georg-August-University of
Göttingen and of participating centers, and comprises at
present 1041 patients with confirmed Diagnostic and Statis-
tical Manual of Mental Disorders, fourth edition (DSM-IV)9
diagnosis of schizophrenia (82.2%) or schizoaffective
disorder (17.8%), examined between 2005 and 2010 in 23
collaborating centers all over Germany (Supplementary
Table 1).7,8
Healthy subjects. Healthy subjects for the case–control
study were blood donors (n¼ 1144), recruited according to
national guidelines for blood donation.7 Comparable to the
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patient population (Caucasian 95.5%; other ethnicities 1.8%;
unknown 2.7%), almost all controls were of European–
Caucasian descent (Caucasian 97.8%; other ethnicities 2%;
unknown 0.2%).
Phenotyping. Comprehensive interviews, testing and
clinical ratings were conducted by an invariable team of
trained examiners (psychiatrists and psychologists) using the
‘GRAS Manual’.7,8 Diagnoses of schizophrenia/schizo-
affective disorders were based on the structured clinical
interview for DSM-IV (SCID),10 substantiated by information
from medical records/discharge letters of all the patients.
Psychopathological state, symptom severity and functional
outcome were evaluated by clinical ratings (positive and
negative syndrome scale (PANSS)11 and global assessment
of functioning (GAF).9) Neuropsychological testing (subtest
3 of Leistungsprüfsystem,12 Trail-Making Test,13,14 Verbal
Learning and Memory test15) including pre-morbid intelligence
(Mehrfachwahl-Wortschatz-lntelligenz test-B16) and neuro-
logical examination (Cambridge Neurological Inventory17)
yielding respective composite scores, are described in detail
elsewhere.7,8
Genotyping. SNP genotyping was performed with
SimpleProbes (TIB Molbiol, Berlin, Germany) on
LightCycler480 (Roche, Mannheim, Germany). All markers
fulfilled the Hardy–Weinberg equilibrium.
Statistical methods. PGAS : Phenotype data were
standardized to be normally distributed with expectation
zero and variance one, and presented such that higher
values always indicate better performance. Expected values
of univariate and multivariate phenotypes were analyzed with
linear models (Rv2.12.0), covariate adjusted and tested for
additive effects of GWAS risk alleles with single-locus
models (Table 1) and with a 10-loci model (Table 2). The
latter simultaneously estimates for all the 10 loci regression
coefficients with number of respective GWAS risk alleles.
To assess statistical significance, the commonly used
Bonferroni correction was employed; however, raw
P-values are given.
Results
First, we proved in a case–control study (cases n¼ 1041;
healthy controls n¼ 1144) that the GRAS population (for
patient characteristics see Supplementary Table 1) provides a
‘genetic data matrix’ that essentially replicates the GWAS
results (Table 1, upper part). In fact, screening of the 10
genome-wide hits resulted in a significant association of
markers rs6913660, rs13211507 and rs3131296 in the major
histocompatibility complex region (chromosome 6), and
marker rs2312147 in chromosome 2 (VRK2 gene) with an
increased risk for the disease. Due to the smaller sample size
compared with the GWAS studies, leading to lower power
(power 70–90% for the SNPs found to reach allelic P-values
p0.05, average power of 43% over all markers), not all SNPs
turned out to be significantly associated with the schizo-
phrenia risk. Nevertheless, all of them exhibit the same
direction of association as reported in GWAS.2–6 In fact, the
GRAS sample has been included in a recent large GWAS
follow-up study.6
We next conducted PGAS single-locus and PGAS multi-
locus quantitative association analyses. In both the proce-
dures we searched for the hypothesized association of
markers with the lead symptoms of schizophrenia including
developmental readouts/disease severity, both in the form of
a composite construct (multivariate phenotype) and of its
components separately (individual phenotypes), that is,
positive and negative symptoms (PANSS), cognitive deficits
(composite of executive function, reasoning, verbal learning
and memory) and neurological signs (including catatonia),
and/or with the age of onset of the disease prodrome.
We further hypothesized that, if the markers were disease
specific, they should not be associated with the schizo-
phrenia-unrelated, general disease control variables.
Hence, such variables referring to symptoms that are not in
any way specific for schizophrenia were also included
PANSS general psychopathology (depression, anxiety and
others), global assessment of functioning and pre-
morbid intelligence (basic cognitive capabilities of an indivi-
dual before disease onset) (Tables 1 and 2; Supplementary
Table 2).
With 41000 patients, the single-locus analysis found
none of the schizophrenia phenotypes, neither individual
nor multivariate, significantly influenced by any of the markers
after multiple-testing correction by Bonferroni (Table 1).
We thus wondered whether—instead of single genotypes—
the ‘genetic load’ of a patient, that is, the accumulation of risk
genotypes, would give us a clearer signal regarding the
contribution of genetic risk to disease phenotype and severity.
As illustrated in Figure 1, the composite severity score, built on
the basis of the five core symptom variables (see inset),
shows an essentially equal distribution of schizophrenia
severity from the lowest to the highest genetic load group.
As more symptoms do not necessarily reflect more
severe disease and certain symptom groups may better
associate with genetic load, all five variables were considered
separately, too. But again, for the 10 top hits of GWAS, none
of the schizophrenia symptom groups was dependent
regarding its severity on the increase in the ‘genetic load’
(Supplementary Table 2, and Supplementary Figure 1). This
becomes evident when the composite score data are
presented alternatively as percentage severity over all the
genetic load groups; there is no tendency of an increase
in severe cases with an increase in the number of risk
markers (Supplementary Figure 2). Interestingly, grouping the
distribution of accumulated risk genotypes in the Icelandic
GWAS sample (n¼ 582 schizophrenic individuals) yields a
pattern of overall risk distribution that is comparable to that
of the GRAS database (Supplementary Figure 3), further
supporting the validity of our sample for the PGAS approach to
the GWAS hits.
We now pursued the question whether better insight into the
phenotypical contribution of the GWAS hits could be obtained
by performing a multilocus additive joint model analysis. This
analysis weighs each marker according to its estimated
relative importance as a risk genotype. Also this approach
failed to uncover statistically significant associations after
multiple-testing correction. Close to significance are two
GWAS SNPs and schizophrenia severity
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associations, one between the marker rs3131296 in NOTCH4
(chromosome 6) and prodromal onset (developmental
readout), the other between rs12807809 in chromosome 11
(near NRGN gene) and severity of the neurological signs
(Table 2). In fact, when ignoring the multiple-testing issue, the
latter marker which has a relatively low odds ratio in our case–
control study (OR 1.13 here and 1.15 in the GWAS study of
Stefansson et al. 5), shows several association ‘signals’ that
make it attractive for follow-up in future subgroup analyses.
However, this marker did not associate with the cognition of
schizophrenic subjects in a recent study.18
Discussion
How can the overall negative result regarding the phenotypi-
cal significance of basically all GWAS ‘top-10’ genotypes be
explained? First, in clear contrast to monogenic diseases,19
the genetic risk for schizophrenia may not simply be reflected
by phenotypical disease severity or by core symptoms of the
disease. Here, an array of environmental risk factors that
cannot easily be controlled for might also have a modulating
role.20 Second, the genotype –to phenotype translation may
only be visible and valid for a relatively small subgroup of
individuals, but still leads to significant (even though low)
genetic risk odds ratios in very large GWAS samples.
Third, one risk genotype may partly ‘neutralize’ another one,
resulting in risk reduction upon combination rather than
accumulation of the genetic load. This latter, seemingly
paradox interaction is supported by the observation that the
few effects on phenotypes found here in marker rs12807809
(chromosome 11; near NRGN) unexpectedly go into the
opposite direction (risk genotype shows less severity). Fourth
and finally, we cannot rule out that for some analyses the
GRAS sample may not have enough power to detect the
(certainly weak if any) phenotypical consequences of the ‘top
10’ GWAS hits. In this context, however, the general question
Table 1 GWAS replication and PGAS single-locus quantitative association analysis
Abbreviations: CNI, Cambridge neurological inventory; CI, confidence interval; Chr, chromosome; GAF, global assessment of functioning; GWAS, genome-wide
association studies; MHC, major histocompatibility complex; OR, odds ratio; PGAS, phenotype-based genetic association study; PANSS, positive and negative
syndrome scale; SNP, single-nucleotide polymorphism; SNP ID, SNP identifier.
GRAS sample of schizophrenic patients, n¼1041; healthy control sample, n¼1144. Upper part shows the case–control genetic association study essentially
replicating previous GWAS results. SNPs are presented from left to right in the order of OR (odds ratio). Pearson w2-test and Fisher’s exact test (both two sided) were
used for genotypic and allelic comparisons, respectively. Lower part (PGAS) gives additive effect per copy of GWAS risk allele on expected value of schizophrenia-
relevant quantitative phenotypes. The multivariate phenotype combines five schizophrenia core features (positive PANSS, negative PANSS, cognitive score, total
CNI and prodromal onset). All phenotypes were standardized to zero mean and variance one and presented such that larger values correspond to better performance
(for this purpose, PANSS scores and total CNI were multiplied by 1). General PANSS, GAF and premorbid intelligence were included in the analyses as disease
control variables. The estimate of allele effect is negative if carriers of a GWAS risk variant perform worse. It is positive, if carriers of a GWAS risk variant perform better
with respect to the expected trait value for the schizophrenic sample. Allele effect size on mean trait is quantified relative to trait variability (standard deviation). P-
values below 0.05 were highlighted for optical guidance but are not significant after multiple-testing adjustment.
aCorrected for age: PANSS negative, cognitive score and total CNI (for separate analyses and within multivariate phenotype), GAF.
bCorrected for language problems: pre-morbid intelligence (898 with no language problems and 108 with correction for language problems).
Exploratory exclusion of non-Caucasian subjects from the GRAS sample (n¼ 48; 4.5%) did not qualitatively alter any of the main findings in this Table.
GWAS SNPs and schizophrenia severity
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arises of how much clinical significance a genetic association
may have if several thousand patients are needed to reveal a
tiny effect on disease severity or phenotype. Thus, building on
41000 patients, one would at least have expected some
more signals to pop up (that is, more nominal P-values around
0.05 in the PGAS part of Table 1). In fact, the estimated power
assessed according to Lettre et al.,21 who performed simula-
tions in a similar context (sample size, normally distributed
phenotype), amounts to overall around 80% at the a¼ 0.05
level for the PGAS approach. The presented additive model,
chosen to match our hypothesis of cumulated risk, performed
similarly to a co-dominant one but appeared to be slightly
more powerful.
After all, we note that entirely different genotypes that were
never found to be significantly associated with any schizo-
phrenia risk in GWAS, still may profoundly modulate the
schizophrenic phenotype, for example, of genes encoding
neuregulin-1, complexin 2 or COMT.7,22,23 On the other hand,
GWAS finds may be of general rather than disease-specific
significance. Several studies have for instance suggested
that schizophrenia and affective disorders are on a continuum
of liability. Genetic linkage and association studies have
proposed common disease loci for both the disorders.2,24
Likewise, family studies show that first-degree relatives of
bipolar patients have a higher risk for schizophrenia compared
with first-degree relatives of healthy controls.25,26 Also other
psychiatric diseases like alcoholism or major depression have
been found to be associated with certain schizophrenia risk
genes, for example, DISC1.27 Thus, exploration of many other
phenotypes available in the GRAS database, including
candidate intermediate phenotypes28,29 or those reflecting a
more dimensional approach to the disease,30 might potentially
be interesting. Purpose of the present study, however, was to
cover the lead symptoms of schizophrenia in the first place.
To conclude, GWAS approaches in diseases as complex as
schizophrenia do not lead to the reconstruction of a ‘common
disease mechanism’ or to the discovery of ‘classical disease
genes’, as such genes obviously do not exist. What makes our
study important for the clinician is that we can show, for the
first time, that the combination of a whole battery of genetic
pre-disposing factors (the ‘top 10’ GWAS finds in schizo-
phrenia) in individual patients will not make their schizo-
phrenic phenotype any different or worse than that of those
patients who do not carry these genetic factors. Importantly,
however, GWAS results may guide, on a hypothesis-free
basis, to the identification of totally unexpected candidate
genes involved in certain disease aspects in subgroups of
patients, as they can be defined by PGAS. In order to get
closer to understanding the disorders as complex and
heterogeneous as schizophrenia, GWAS and PGAS will have
to go hand in hand.
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Supplementary Table 1: GRAS patient sample description. 
 
Variable Mean ± s.d. Median 
Age in GRAS patients (years) 39.54 ± 12.55 39.05 
PANSS positive 13.76 ± 6.32 12.00 
PANSS negative 18.23 ± 7.86 17.00 
Cognitive score -0.01 ± 0.85 0.02 
Total CNI 19.76 ± 18.63 15.00 
Prodromal Age of Onset (years) 22.81 ± 8.70 20.00 
PANSS general 33.73 ± 11.83 32.00 
GAF 45.73 ± 17.26 45.00 









Gender proportion 66.7% men / 33.3% women - 
 
 
Gender and age distribution in the sample of patients (GRAS, n=1041). Mean ± s.d. and Median of the 



























Supplementary Table 2:  PGAS: Association between cumulative genetic load 
and expected value of quantitative schizophrenia-relevant phenotypes 
 
Effect per unit increase of genetic load 0.0083 
Multivariate phenotype# 
 P value 0.3391 
Effect per unit increase of genetic load 0.0106 
PANSS positive 
 P value 0.4557 
Effect per unit increase of genetic load 0.0333 
PANSS negative# 
 P value 0.0220 
Effect per unit increase of genetic load 0.0033 
Cognitive score# 
 P value 0.7745 
Effect per unit increase of genetic load 0.0111 
Total CNI# 
 P value 0.4163 
Effect per unit increase of genetic load -0.0051 
Prodromal Onset 
 P value 0.7502 
Effect per unit increase of genetic load 0.0216 PANSS general 
 P value 0.1445 
Effect per unit increase of genetic load 0.0122 
GAF# 
 P value 0.4073 




Premorbid Intelligence‡  
 P value 0.9248 
 
#Corrected for age: PANSS negative, cognitive score, total CNI (for separate analyses and within multivariate phenotype); GAF. 
‡Corrected for language problems: premorbid intelligence (886 with no language problems, 107 with correction for language 
problems). 
  
Analysis based on the GRAS sample of schizophrenic patients, i.e. n=1010 individuals with complete 
genotype information for 10 GWAS loci. The cumulative genetic load is defined as sum of the number 
of all GWAS risk variants at the 10 loci of Table 1. Estimated was the mean effect of the genetic load 
per unit increase (additive model with equal weighting of risk variants at each locus). Phenotypes were 
standardized to zero mean and variance one and presented such that larger values correspond to 
better performance (i.e. PANSS scores and total CNI were multiplied by -1). General PANSS, GAF 
and premorbid intelligence were included in the analyses as disease control variables. A positive 
estimate of the effect of increased genetic load suggests a milder phenotype, a negative estimate a 
more severe phenotype. Effect size is quantified relative to trait variability (standard deviation). P 
values below 0.05 were highlighted for optical guidance but are not significant due to multiple-testing 
adjustment. Exploratory exclusion of non-Caucasian subjects from the GRAS sample (n=48; 4.5%) did 


















Supplementary Figure 1 
 
Distribution of phenotype severity and cumulative genetic load with respect to the 
number of GWAS-identified ‘top-10’ risk SNP alleles in the GRAS population (bar graph). Phenotype 
severity in each of the figures is based on one of the 5 core items of schizophrenia. Score range for 










Supplementary Figure 2 
 
Percentage distribution of phenotype severity in genetic load groups with respect 
to the number of GWAS-identified ‘top-10’ risk SNP alleles in the GRAS population. Phenotype 
severity is based on a composite score of 5 core features of schizophrenia (compare inset of Figure 
1). Score range in the GRAS sample is divided into 3 equal parts and ranked as mild, medium and 















Supplementary Figure 3 
 
Distribution of cumulative genetic load in Icelandic and German populations 
Grouping the distribution of accumulated risk genotypes in the Icelandic GWAS sample (n=582 
schizophrenic individuals) yields a pattern similar to the GRAS population (n=1041), further supporting 
the validity of the GRAS sample for the PGAS approach to the GWAS hits. German healthy controls 
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Severe mental illnesses have been linked to white matter abnormalities, docu-
mented by postmortem studies. However, cause and effect have remained difficult
to distinguish. CNP (20,30-cyclic nucleotide 30-phosphodiesterase) is among the
oligodendrocyte/myelin-associated genes most robustly reduced on mRNA and
protein level in brains of schizophrenic, bipolar or major depressive patients. This
suggests that CNP reduction might be critical for a more general disease process
and not restricted to a single diagnostic category. We show here that reduced
expression of CNP is the primary cause of a distinct behavioural phenotype, seen
only upon aging as an additional ‘pro-inflammatory hit’. This phenotype is strik-
ingly similar in Cnp heterozygous mice and patients with mental disease carrying
the AA genotype at CNP SNP rs2070106. The characteristic features in both species
with their partial CNP ‘loss-of-function’ genotype are best described as ‘catatonia-
depression’ syndrome. As a consequence of perturbed CNP expression, mice show
secondary low-grade inflammation/neurodegeneration. Analogously, in man, dif-
fusion tensor imaging points to axonal loss in the frontal corpus callosum. To
conclude, subtle white matter abnormalities inducing neurodegenerative changes
can cause/amplify psychiatric diseases.
INTRODUCTION
The CNP gene encodes the enzyme 20,30-cyclic nucleotide 30-
phosphodiesterase (CNP) which is present in non-compacted
myelin areas such as the inner mesaxon, paranodal loops and
Schmidt-Lantermann incisures (Braun et al, 2004; Yu et al,
1994), and accounts for about 4% of total central nervous
system myelin proteins (Braun et al, 2004). CNP is expressed
early in development of oligodendrocytes (Yu et al, 1994),
increases with onset of myelination and remains detectable in
these cells throughout life (Scherer et al, 1994). In vitro and
in vivo studies demonstrated a regulatory function of CNP for
process outgrowth in oligodendrocytes (Gravel et al, 1996; Lee
et al, 2005; Yin et al, 1997), as well as an interaction with
microtubules, cytoskeleton and RNA (Bifulco et al, 2002; De
Angelis & Braun, 1996; Gravel et al, 2009; Lee et al, 2005).
Studies employing homozygous Cnp-null mutant mice
revealed that Cnp is essential for axonal survival but not for
myelin assembly (Lappe-Siefke et al, 2003). In fact, Cnp/
mice show progressive axonal swellings and brain inflammation
with first motor deficits occurring at 4 months that progress to
severe hindlimb paralysis and death at 8–15 months (Lappe-
Siefke et al, 2003). In contrast, Cnpþ/ mice with a 50%
reduced Cnp expression do not exhibit any signs of inflamma-
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tion nor of abnormalities in neurological scoring or behaviour at
least until the age of 12 months (Lappe-Siefke et al, 2003;Wieser
et al, in preparation), indicating that lower Cnp levels can be
fully compensated for.
Nevertheless, decreased CNP expression could have patho-
physiological significance. CNP is among the oligodendrocyte/
myelin-associated genes identified to be most robustly reduced
both on mRNA and protein level in postmortem brains of
schizophrenic, bipolar or major depressive patients (Aston et al,
2005; Mitkus et al, 2008; Tkachev et al, 2003). These findings
suggest that CNP reduction might be critical in a more general
disease process and that the potential role of this molecule is not
restricted to a single diagnostic category but of global relevance
for severe mental disorders.
Several genetic association studies have explored a potential
impact of genetic variability in the CNP gene (chr17q21.2, 11Kb)
on the overall risk for schizophrenia, with inconclusive results
so far (Che et al, 2009; Peirce et al, 2006). Interestingly,
however, a synonymous (Gly/Gly) single nucleotide poly-
morphism (SNP), localized in the fourth exon of the gene
(rs2070106), influences CNP expression in the human cortex,
especially in frontal areas, with the rarer A-allele showing lower
expression in comparison to the G-allele (Iwamoto et al, 2008;
Mitkus et al, 2008; Peirce et al, 2006).
Recent work indicates that in major psychiatric disorders like
schizophrenia and depression, low-grade inflammation con-
stitutes a crucial mechanism in the final common disease
pathway (reviewed in Monji et al, 2009). Already the normal
aging process is associated with slightly increased brain
inflammation characterized by, for example, enhanced levels
of pro-inflammatory cytokines, higher microglial numbers and
increased reactivity with augmented expression of microglial
surface markers (reviewed in, e.g. Miller & Streit, 2007;
Sparkman & Johnson, 2008; Streit, 2006).
To address the pathophysiological relevance of reduced CNP
expression, we chose CNP partial ‘loss-of-function’ genotypes
with aging as an additional ‘pro-inflammatory hit’. We
examined old Cnpþ/ mice and schizophrenic patients with
the AA versus GG genotype in the CNP SNP rs2070106. We
report here the surprising association of CNP partial loss-of-
function with a catatonia-depression syndrome both in mouse
and man upon aging. Importantly, we provide evidence for late-
onset low-grade inflammation in mice as a plausible pathophy-
siological mechanism. In patients carrying the low-expression
genotype (AA), a comparable process might be reflected by
axonal loss in the frontal corpus callosum as detectable by
neuroimaging.
RESULTS
Brains of aging CnpR/ mice are characterized by enhanced
inflammation, astrogliosis and axonal degeneration
Immunohistochemical analysis of mouse brains from age 4 to
26 months revealed an age-related increase in the number of
ionized calcium-binding adapter molecule 1 (IBA-1) and Mac-3
positive microglia, infiltrating T-lymphocytes (cluster of
differentiation 3; CD3) and astrocytes (glial fibrillary acidic
protein, GFAP) in corpus callosum, striatum and anterior
commissure (month 4 vs. month 26: all p 0.01; for wild-type
(Wt) as well as Cnpþ/ mice). This increase was significantly
more pronounced in old Cnpþ/ as compared to Wt mice
(Fig 1A–H). Axonal swellings (spheroids) as readout of
neurodegenerationwere determined in corpus callosum, striatum
and anterior commissure using amyloid precursor protein (APP)
immunoreactivity (Fig 1I/J). At the age of 4 months, no positive
APP stainingwas detected. Thereafter, an age-dependent increase
in axonal swellings became evident, again more prominent in
Cnpþ/mice (Fig 1I/J). Determination of CnpmRNA expression
in brains of young versus oldmice revealed a remarkable decrease
upon aging in Wt mice, which, however, still maintained levels
above those in Cnpþ/ mice (Fig 1K). In both Wt and Cnpþ/
mice, we found a corresponding age-dependent reduction of
Cnp protein in purified myelin membranes, with the lowest
overall level in aged Cnpþ/ (Fig 1L). Proteolipid protein (Plp), a
control protein for compact myelin, also decreased with age but
independent of the Cnp genotype (Fig 1L). Taken together, old
Cnpþ/mice show a more pronounced low-grade inflammatory
phenotype with axonal degeneration compared to Wt mice.
Aged CnpR/ mice have a slightly elevated anxiety profile
but normal motor activity, coordination and strength
To test whether the pronounced histological changes upon
aging are associated with any behavioural consequences, we
investigated aged (24 months old) Cnpþ/ and Wt mice
employing a comprehensive test battery. In the open field test, a
measure for general locomotor activity and anxiety, Cnpþ/
mice tended to spend less time in the centre thanWt (p¼ 0.096;
Fig 2A). Velocity and total distance travelled in the open field
were comparable in both genotypes (Fig 2B and C), indicating
normal activity. In the elevated plus maze, a classical anxiety
test, open arm visits were reduced in Cnpþ/ mice (p¼ 0.036;
Fig 2D), whereas, the light/dark-box did not yield differences in
the time spent in light (Fig 2E). Freezing behaviour is seen as
another indicator of anxiety/fear in rodents. Cnpþ/ mice
showed higher percentage of freezing in the fear conditioning
chamber already at baseline, that is before measurement of
conditioned or cued memory (p¼ 0.007; Fig 2F), precluding the
use of fear conditioning for memory assessment in these mice.
Like basic motor activity, which proved to be normal, motor
performance, coordination andmotor learning, as evaluated in a
2-day rota-rod testing, were not different between genotypes
(Fig 2G). Also, gait analysis detected no motor abnormalities or
ataxia (see, e.g. Fig 2H depicts forelimb stride of left and right
paw) and muscle strength, measured by the grip strength test,
did not differ between genotypes (Fig 2I). To summarize,
24 months old Cnpþ/ mice show normal overall motor
performance and a mildly elevated anxiety profile in different
anxiety-relevant tests compared to Wt mice.
Aged CnpR/ mice show impaired social and
exploratory behaviour
Social behaviour of aged Wt and Cnpþ/ mice was tested in a
three-partite chamber. This test measures the preference of a
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Figure 1. Low-grade brain inflammation and axonal degeneration in aged CnpR/ mice.
A. Representative microscopic images of the corpus callosum from 4 months (upper panels) and 26 months (lower panels) old Wt and Cnpþ/ mice,
immunostained for IBA-1; scale bar 20mm.
B. Bar graph gives the age-dependent quantification of the total number of IBA-1 positive microglia in the corpus callosum of Wt and Cnpþ/ mice. For all
quantifications (B, D, F, H, J), n numbers indicated; mean s.e.m. presented; two-sided Student’s t-test used.
C. Representative microscopic images of the corpus callosum from 4 months (upper panels) and 26 months (lower panels) old Wt and Cnpþ/ mice,
immunostained for Mac-3; scale bar 20mm.
D. Bar graph gives the age-dependent quantification of the total number of Mac-3 positive microglia in the corpus callosum of Wt and Cnpþ/ mice.
E. Representative microscopic images of the corpus callosum from 4 months (upper panels) and 26 months (lower panels) old Wt and Cnpþ/ mice,
immunostained for CD3; black arrows exemplify respective positive cells; scale bar 20mm.
F. Bar graph gives the age-dependent quantification of the total number of CD3 positive T-lymphocytes in the corpus callosum, striatum and anterior
commissure of Wt and Cnpþ/ mice.
G. Representative microscopic images of the corpus callosum from 4 months (upper panels) and 26 months (lower panels) old Wt and Cnpþ/ mice,
immunostained for GFAP; scale bar 20mm.
H. Densitometrical quantification of the GFAP positive area in the corpus callosum.
I. Representative microscopic images of the striatum from 4 months (upper panels) and 26 months (lower panels) old Wt and Cnpþ/mice, immunostained for
APP; black arrows exemplify respective positive cells; scale bar 20mm.
J. Bar graph gives the age-dependent quantification of the APP positive axonal swellings in the corpus callosum, striatum and anterior commissure of Wt and
Cnpþ/ mice.
K. CnpmRNA expression level of Wt and Cnpþ/mice at months 2 and 24, normalized to mean value of ATP synthase subunit beta (Atp5b) and acidic ribosomal
phosphoprotein P0 (Rplp0) as housekeeper genes and to 2 months old Wt (1.0); mean s.e.m. presented; two-sided Student’s t-test used.
L. Cnp protein expression of Wt and Cnpþ/mice at months 2 and 24, compared to Plp as control protein of compact myelin;  low-size band detected in aged
brain myelin with the Plp antibody directed against the C-terminus of PLP/DM20.
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mouse for a chamber containing a small wire cage with a
stranger mouse in comparison to a chamber with an empty wire
cage. Aged Wt mice displayed the expected behaviour, that is
spent significantly more time close to the cage with the stranger
mouse compared to the empty wire cage (p¼ 0.019), whereas,
Cnpþ/ mice did not show preference. To control for altered
olfaction as a potential confounder of social behaviour in mice,
the buried-food-finding test was performed, confirming normal
olfactory function in both groups (Fig 2K). In the hole board test,
measuring exploratory behaviour of mice, old Cnpþ/ mice
had significantly less head dips (p¼ 0.011; Fig 2L), indicating
loss of interest (in the absence of any signs of altered basic motor
activity). To conclude, old Cnpþ/ mice demonstrate several
facets of a loss of interest in the outside world.
Aged CnpR/ mice exhibit features of depression and
catatonia
In the Morris water maze task, Cnpþ/ mice displayed
prominent floating behaviour, precluding analysis of this test
for learning and memory. Analysis of the time mice spent
floating within a swim trial of 90 s yielded threefold higher
floating rates of Cnpþ/ mice in comparison to Wt, which we
interpret as a potential sign of depression (p¼ 0.016; Fig 2M).
To further consolidate this hypothesis, we performed an
Research Article
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Figure 2. Aged CnpR/ mice show a phenotype composed of catatonia, depression, loss of interest, impaired social interaction and anxiety.
A-C Open arm parameters.
D. Elevated plus maze.
E. Light/dark box paradigm.




J. Sociability testing in the three-partite chamber.
K. Buried-food finding test – latency to find hidden versus visible food pellets.
L. Hole board.
M. Floating rate in a 90 s swim trial.
N. Tail suspension test.
O. Bar test for catatonia.
P. Typical posture of a catatonic Cnpþ/ mouse during the bar test; see also videos of Supporting Information.
Q. Behavioural composite score displayed as intercorrelation network of Z-transformed items. Line thickness indicates the degree of correlation between 2
respective items. The composite score differs between genotypes (p¼ 0.0001). For all behavioural experiments, 24 months old mice were used: Wt n¼ 9–11
and Cnpþ/ n¼ 10–16; mean s.e.m. presented; two-sided or paired t-tests used where applicable.
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established test to measure depression in rodents, the tail
suspension test, which determines over 6min the time mice
spend immobile. Fractionated analysis revealed that Cnpþ/
mice had a higher duration of immobility in the second and last
third of the test period compared to Wt (p¼ 0.025; Fig 2N),
consistent with the typical ‘give up’ behaviour of depressed
individuals. A phenotype, thus far observed in mice only upon
induction (e.g. body pinch or drug exposure; Amir, 1986;
Chaperon & Thiebot, 1999) is catatonia/catalepsy, a state of
immobility where mice persist in an externally imposed
abnormal posture for a prolonged time period. Mice are put
into a position where they have to grab a bar while standingwith
their hind paws on the floor (as illustrated in Fig 2P; for a
striking example see videos of Supporting Information). Wt
mice swiftly left this position, whereas, Cnpþ/mice persisted
in this posture (p¼ 0.005; Fig 2O). Taken together, old Cnpþ/
mice exhibit a catatonia-depression syndrome.
Creating a mouse behavioural composite, the ‘catatonia-
depression score’
For translational purposes and confirmation of the internal
consistency of our behavioural readouts in aged mice, we
calculated intercorrelations between the observed behavioural
sub-phenotypes catatonia, depression, loss of interest, impaired
social interaction and anxiety as target variables. These
variables, put together in a composite score, were internally
consistent (Cronbach’s a¼ .686; Fig 2Q). Operationalization of
the score items is detailed in the Materials and Methods Section.
Expectedly, the score was significantly higher in Cnpþ/
(0.32 0.44) than in Wt mice (0.43 0.41; p¼ 0.0001). Based
on these findings, we wondered whether reduced expression of
the CNP gene in aging human patients may have a similar
influence on the phenotype.
Exploiting the GRAS data base for a phenotype-based genetic
association study on the role of CNP genotypes in a
‘catatonia-depression syndrome’
To search for potential behavioural consequences of a
previously described CNP loss-of-function genotype in humans
(Iwamoto et al, 2008; Mitkus et al, 2008; Peirce et al, 2006), we
conducted a phenotype-based genetic association study (PGAS)
targeting the CNP SNP rs2070106 (A/G; Fig 3A) in >1000
schizophrenic patients of the Göttingen Research Association
for Schizophrenia (GRAS) data collection (Begemann et al,
2010; Ribbe et al, 2010). As a first step, we performed a case–
control analysis (schizophrenic patients vs. healthy controls)
and found that this genetic marker does not contribute to an
increased risk of schizophrenia in our population, as proven by
the genotypic and the allelic chi-square comparison (p> 0.05;
Table I of Supporting Information).
Next, a composite score including all variables represented in
the mouse behaviour composite was created that also yielded
good internal consistency with a Cronbach’s a¼ .695 (Fig 3B).
The operationalization of the score items is explained in the
Materials and Methods Section. As illustrated in Fig 3C, the
composite score shows a clear age and genotype (rs2070106)
association: AA subjects develop a significantly higher score
with increasing age as compared to GG carriers, with the
dissociation of the regression lines starting at around the age of
40 years. We therefore set a cut-off of 40 years and focused on
the older schizophrenic patients with our further PGAS analysis.
The characteristics of the GRAS patients with an age 40
years, separated by AA versus GG genotype of rs2070106, are
presented in Table 1. These data demonstrate that both
genotype groups are comparable with respect to basic socio-
demographic and clinical/disease control variables but differ
highly significantly in the composite score measuring the
catatonia-depression syndrome. Interestingly, heterozygote
individuals (GA) are very similar to GG subjects. They do not
show an intermediate phenotype in the composite score (Table
II of Supporting Information). Importantly, when screening all
items of the composite separately, a significant age-associated
genotype (GG vs. AA) effect, comparable to the mouse findings,
becomes evident for all (Fig 1 of Supporting Information).
CNP rs2070106 genotypes influence myelin/axon integrity in
the frontal corpus callosum fibres, a candidate region of
catatonia-depression
Based on clinical observation of the affected individuals – both
mouse and man – and the scarce information in the literature on
brain areas potentially involved in the catatonic phenomenon
(Arora & Praharaj, 2007; Northoff et al, 2004), we hypothesized
that aging AA individuals displaying the catatonia-depression
syndrome, in contrast to GG subjects, should show differences
in axonal integrity of frontal crossing fibres. To prove this
hypothesis, a subset of older patients of both genotypes (GG
n¼ 11; AA n¼ 10) from the GRAS sample was selected and
matched according to age, gender and duration of disease
(Table 1). These patients, living all over Germany, were re-
invited to Göttingen for diffusion tensor imaging (DTI). Indeed,
DTI identified higher axial diffusivity (AD) and a higher
apparent diffusion coefficient (ADC) in the frontal part of the
corpus callosum (genu) of AA subjects as compared to GG
patients (p 0.005 for both values; Fig 3E), consistent with a
more progressed axonal loss/degeneration. This effect was
specific for the frontal commissural fibres and was not observed
in the posterior corpus callosum taken as a control region
(Fig 3F). ADC values in the genu were generally correlated with
age but, despite the small number of imaged subjects, resulted in
a significant difference between genotypes upon linear dis-
criminant analysis (LDA; p< 0.05; Fig 3G). Importantly, there
were no global brain volume differences detectable between GG
and AA subjects that could have accounted for DTI results
(p> 0.05 for all comparisons; Fig 3H).
DISCUSSION
We report here the unexpected finding that CNP loss-of-function
genotypes are causative of a mental syndrome, consisting of
catatonia, depression, mild anxiety/social withdrawal, impaired
social interaction and reduced interest in the outside world,
which is remarkably similar in mouse and man. In both species,
age becomes an important cofactor, supporting the view that the
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underlying mechanism of this mental syndrome is a slowly
progressive neurodegeneration, beginning in subcortical white
matter, as described for the more rapid axonal loss in Cnp null
mutant mice (Edgar et al, 2009; Lappe-Siefke et al, 2003).
Importantly, the CNP loss-of-function genotype is causative of
the here described behavioural syndrome but not of schizo-
phrenia where it may only shape the aging phenotype.
In fact, the human part of this study has been obtained from a
phenotypically extremely well characterized schizophrenic
population (the ‘GRAS data collection’), which was accessible
and where all assessed items of the catatonia-depression
syndrome are potentially relevant for disease subphenotypes.
If a similar database on patients with, for example major
depression had been available, the study would have been
extended to this population. We expect that in individuals
suffering from other mental disorders and even to some
(perhaps mild) degree in healthy subjects, the phenotypical
consequence of the CNP rs2070106 AA genotype will be
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Figure 3. Age- and genotype-dependent association of the CNP rs2070106 SNP with a catatonia-depression syndrome in the GRAS sample of
schizophrenic patients.
A. Schematic view of the human CNP gene structure and location of the synonymous SNP rs2070106 (A/G).
B. Intercorrelation network of all Z-transformed items of the catatonia-depression composite in the GRAS population. Line thickness indicates the degree of
correlation between two respective items.
C. Correlation of genotypes with the catatonia-depression composite score across age groups. Grey bars in the background display the age distribution of the
total GRAS sample of schizophrenic patients (n¼1048). Red or white circles denote mean values of the composite score for the respective age group and
genotype (red, AA; black, GG). Linear regression lines of the genotypes dissociate after the age of 40 years. Pearson product-moment correlation applied.
D. Diffusion tensor imaging (DTI) study selecting the frontal (genu) and caudal (splenium) areas of the corpus callosum as regions of interest.
E,F ADC and AD values plotted according to rs2070106 homozygosity status in genu (E, target region) and splenium (F, control region) of the corpus callosum in a
subgroup of schizophrenic individuals >40 years of age (GG n¼ 11 and AA n¼ 10); results corrected for chlorpromazine equivalents (CPZ). Mean s.e.m.
presented and ANCOVA applied.
G. Correlation of ADC and age in AA and GG genotypes; linear discriminant analysis (LDA) with genotype as grouping variable and ADC and age as independent
variables. Pearson product-moment correlation applied.
H. Magnetic resonance imaging (MRI) volumetric comparison of brain matter, ventricular system and corpus callosum between genotypes. Mean s.e.m.
presented; two-sided Student’s t-test applied.
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comparable. Along these lines, we show that many schizo-
phrenic patients (and virtually all patients younger than
40 years) lack this syndrome. We would therefore like to stress
again that this syndrome is independent of the diagnosis
schizophrenia, which is also supported by the behavioural
homology of the Cnp mouse model.
Several studies have suggested that schizophrenia and
affective disorders are on a continuum of liability. Genetic
linkage and association studies have proposed common disease
loci for both disorders (Berrettini, 2000; O’Donovan et al, 2008).
Family studies document that first-degree relatives of bipolar
patients have a threefold higher risk for schizophrenia
compared with first-degree relatives of healthy controls (Sham
et al, 1994; Valles et al, 2000). Psychopathological syndromes,
as the catatonia-depression syndrome shown here, shared by
subgroups of both patient populations, would also be
compatible with this overlap. Indeed, catatonia has been found
to be highly prevalent in elderly patients with major depression
(Starkstein et al, 1996). It will be interesting to determine
whether depressed individuals that exhibit catatonic signs are
also preferentially carriers of the CNP rs2070106 AA genotype.
To our knowledge, no spontaneous catalepsy in mice has as
yet been reported, in contrast to pinch- or drug-induced
catalepsy/catatonia (for review see, e.g. Amir, 1986; Chaperon
& Thiebot, 1999). The here observed Cnpþ/ associated
catalepsy/catatonia represents, therefore, the first clearly
defined genetic catatonia model. Catatonia as a prominent
phenotype has been extensively described by Karl Kahlbaum in
1874 (Kahlbaum, 1874) and entered the Diagnostic and Statistic
Manual of Mental Disorders (APA, 2000) from its first edition in
1952 on, where it appears until now in connection with mood
disorders, schizophrenia, and general medical conditions
(Heckers et al, 2010). Nevertheless, reports on potential brain
areas involved in this phenomenon in man are still scarce and
point to frontal regions, based on, for example pronounced
catatonia in a case with butterfly glioma of the frontal corpus
callosum (Arora and Praharaj, 2007) or on a functional magnetic
resonance imaging (MRI) study in akinetic catatonic patients
during negative emotional stimulation (Northoff et al, 2004).
We hypothesized that genotype-dependent axonal degeneration
should be detectable in the frontal commissural fibres of the
corpus callosum. These considerations were supported by the
fact that the catatonia presented here in the context of a
syndrome is characterized by several features of a primarily
executive control (frontal lobe) deficiency in the absence of any
‘classical’ motor dysfunction. Indeed, we could localize axonal
degeneration, determined by an increased axonal diffusivity in
DTI, selectively to the genu corporis callosi.
The CNP rs2070106 AA genotype leads to reduced expression
of CNP (Mitkus et al, 2008; Peirce et al, 2006), constituting
‘partial loss-of-function’. Since there is an appreciable degree of
linkage disequilibrium across the CNP gene (www.hapmap.
org), the effects seen with the synonymous SNP rs2070106
might well be due to the influence of another genetic variant in
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Table 1. Sociodemographic variables, composite score (target variable) and clinical/disease control variables of the GRAS sample of schizophrenic patients
40 years with homozygosity in CNP SNP rs2070106 (A/G) and – for comparison – in the subset of patients selected for DTI
GRAS sample 40 years Pb (F/x2) DTI subsample
AA (n¼45) GG (n¼235) AA (n¼10) GG (n¼11)
Sociodemographic variables
Age, years, mean SD (range) 51.047.65 (40.44–69.93) 50.168.42 (44.03–79.49) 0.515 52.074.74 (44.08–60.30) 49.505.34 (40.66–58.71)
Gender, No. (%), male 26 (57.8%) 142 (60.4%) 0.740 7 (70%) 8 (72.7%)
Ethnicity, No. (%), Caucasian 43 (95.6%) 225 (95.7%) 0.892 10 (100%) 11 (100%)
Years of educationa,
mean SD (range)
12.273.82 (0–21) 12.323.36 (0–27) 0.933 12.453.39 (9–19.5) 14.143.16 (8–19)
Target variable
Catatonia-depression composite
score, mean SD (range)
0.380.86 (1.13–1.91) 0.030.74 (1.20–2.44) 0.009
0.006c
0.720.94 (0.99–1.85) 0.020.76 (0.97–0.97)
Clinical/disease control variables
Age at first episode, years,
mean SD (range)
29.7710.18 (15.26–55.61) 30.719.58 (14.73–57.35) 0.533 30.8011.03 (19.35–49.61) 30.8011.03 (22.10–41.89)
Duration of disease (1st episode),
years, mean SD (range)
21.0210.27 (0.16–47.35) 19.3910.86 (0.04–58.23) 0.359 21.2711.26 (0.16–39.13) 19.269.19 (3.30–34.18)
CPZ, mean SD (range) 650.68515.35 (37.5–2295.0) 805.76915.14 (0–7375.0) 0.271 525.93276.29 (175–940) 352.61338.62 (0–1200)
PANSS pos, mean SD (range) 14.006.81 (7–36) 14.556.63 (7–35) 0.619 12.96.01 (7–25) 11.273.66 (7–17)
PANSS neg, mean SD (range) 19.798.48 (7–38) 18.868.21 (7–46) 0.503 21.18.94 (7–35) 17.555.87 (7–27)
PANSS gen, mean SD (range) 35.6614.17 (16–68) 34.6512.54 (16–82) 0.644 35.111.20 (20–55) 29.829.97 (17–51)
PANSS total, mean SD (range) 69.2227.27 (30–128) 68.1024.70 (30–160) 0.795 69.123.64 (37–115) 58.6416.35 (31–90)
GAF, mean SD (range) 42.6820.22 (11–90) 43.8217.56 (10–90) 0.703 43.8014.21 (25–63) 56.5517.41 (35–85)
CGI, mean SD (range) 5.751.35 (3–8) 5.621.13 (2–8) 0.488 6.000.94 (5–7) 5.091.14 (3–7)
CPZ, chlorpromazine equivalents as measure of antipsychotic drug dose; PANSS, positive and negative syndrome scale (consisting of three parts: pos; positive
symptoms; neg, negative symptoms; gen, general psychopathology); GAF, global assessment of functioning; CGI, clinical global impression (see Ribbe et al, 2010
for further details).
Due to missing data upon phenotyping, sample size varies between n¼ 242 and 280 in the sample of individuals with age equal to or above 40 years.
aRating according to graduation/certificate; patients currently in school or in educational training are excluded.
bStatistical methods used: ANOVA or x2-test.
cResult after correction for CPZ.
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close vicinity (e.g. in the 30-untranslated region (30-UTR) of
the CNP gene). Alternatively, according to previous studies,
synonymous SNPs may modify translational timing due to
differential codon usage (Kimchi-Sarfaty et al, 2007) or inactivate
an exonic splicing silencer that compensates for other genetic
variations in exonic splicing enhancers (Nielsen et al, 2007).
We demonstrated increased numbers of inflammatory cells,
gliosis and axonal degeneration in old Cnpþ/mice suggesting
an important role of low-grade inflammation in the described
syndrome. Even though brain sections of human patients with
the respective CNP genotypes were not available in the present
study, the axonal degeneration detected by DTI is an intriguing
observation that might point to the hypothesis of a comparable
disease mechanism in mouse and man. Mechanistic details on
the subcellular functions of CNP in myelinating oligodendro-
cytes have been reported (Gravel et al, 2009) and are under
further investigation. The secondary neuroinflammation is a
well-known cause of nitric oxide-mediated axonal stress and
neurodegeneration (for review see Amor et al, 2010; Smith &
Lassmann, 2002). We note that a diverse group of inherited
myelinopathies in the nervous system of mice can trigger the
recruitment of microglia/macrophages and T-cells (Ip et al,
2006; Kassmann et al, 2007; Martini & Toyka, 2004),
demonstrating that low-grade inflammation is a rather unspe-
cific response of myelinating glial cells to cellular stress,
possibly related to perturbed lipid metabolism (Dumser et al,
2007). Interestingly, low-grade inflammation has been found to
be associated with behavioural consequences in mouse studies
(Bercik et al, 2010) and hypothesized to play a role in mental
diseases (Gardner & Boles, 2011; Monji et al, 2009; Muller &
Schwarz, 2008; Schnieder & Dwork, 2011). Respective first
clinical trials employing antiinflammatory strategies in bipolar
disease and schizophrenia yielded positive signals (Laan et al,
2010; Muller et al, 2010). Having information available on a
predisposing genotype, individualized preventive and thera-
peutic approaches may be possible in the future.
To conclude, the major finding of the present study is the
proof-of-principle that subtle changes of subcortical white
matter can be the cause, rather than merely the consequence, of
a complex neuropsychiatric syndrome. This distinction is
extremely difficult in human patients with a psychiatric disease
of unknown etiology, specifically when pharmacologically
treated and only diagnosed (by MRI) with minor abnormalities
of white matter tracts (Davis et al, 2003). Our analysis was
possible by building on genetic variants of the cell type-specific
CNP gene that lead to a partial loss-of-function genotype in both
mouse and man. Importantly, Cnp heterozygosity (in mice) and
moderately reduced CNP expression levels (in humans) are well
tolerated until an advanced age. At that point, however, haplo-
insufficiency causes a striking phenotype inmice and shapes the
phenotype of a complex psychiatric disease in humans.
Although we have no ultimate proof that moderately reduced
CNP levels in any individual (diseased or healthy) suffice to
trigger a catatonia-depression syndrome upon aging, they
clearly add to other genetic factors (here in patients diagnosed
with schizophrenia) such that the catatonia-depression syn-
drome can be well defined and emerges as remarkably similar to
the isolated behavioural phenotype of aged Cnp heterozygous
mice. This amazing similarity of the behavioural phenotype
in two different species emphasizes the relevance of glial
dysfunction in psychiatric disorders, and supports the explora-





Blood donors (n¼1045; Begemann et al, 2010) were recruited for the
case-control study. Ethnicity (Caucasian 97.8%; other ethnicities 2%;
unknown 0.2%) was comparable to the patient population (Caucasian
95.5%; other ethnicities 1.8%; unknown 2.7%).
Schizophrenic patients
The GRAS data collection was approved by Ethics Committees of the
Georg-August-University of Göttingen and participating centres, and
comprises at present 1048 patients with Diagnostic and Statistical
Manual of Mental Disorders-IV (DSM-IV; APA, 2000) diagnosis of
schizophrenia (81.7%) or schizoaffective disorder (18.3%), examined
between 2005–2010 in 23 centres all over Germany (for details see
Ribbe et al, 2010). Interviews, testing and ratings were conducted by
an invariable team of trained examiners using the ‘GRAS Manual’
(Begemann et al, 2010; Ribbe et al, 2010).
Catatonia-depression composite
The score consists of five phenotype domains: Depression was
operationalized by items 3 (guilt feelings) and 6 (depression) of
general psychopathology subscale of Positive and Negative Syndrome
Scale (PANSS) (Kay et al, 1987). Catatonia was based on catatonic
signs subscale of the Cambridge Neurological Inventory (gait
mannerism, gegenhalten, mitgehen, imposed posture, abrupt or
exaggerated spontaneous movements, iterative movements, automatic
obedience and echopraxia; Chen et al, 1995). Deficits in social
interaction were built on items 1 (blunted affect) and 3 (poor rapport)
of PANSS negative subscale, combined with item 44 (never feeling
close to another person) of Brief Symptom Inventory (Derogatis &
Melisaratos, 1983). Social withdrawal/anxiety was assessed by item 4
(social withdrawal) of PANSS negative subscale and item 12 (suddenly
scared for no reason) of Brief Symptom Inventory. Loss of interest in the
outside world was estimated by item 7 (self-centred attitude) of PANSS
negative and item 15 (preoccupation) of general subscale. Phenotype
domains were Z-standardized to be normally distributed with
expectation zero and variance one. Higher values indicate worse
outcome. Composite calculation was based on subjects without
missing data (n¼929). Correlations of the five target phenotypes were
assessed using Pearson product–moment correlation and internal
consistency was determined using Cronbach’s a.
Genotyping
Genotyping of SNP rs2070106 was performed using SimpleProbes
(TIB Molbiol, Berlin, Germany) on LightCycler480 (Roche Diagnostics,
Basel, Switzerland).
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MRI/DTI
For MRI/DTI analyses, a subset of patients ‡40 years of both genotypes
(GG n¼11; AA n¼10) from the GRAS sample was selected and
matched according to age, gender and duration of disease. Studies
were conducted at 3T (Tim Trio, Siemens Healthcare, Erlangen,
Germany) using a 32-channel head coil. DTI was performed at
2mm isotropic resolution using diffusion-weighted single-shot
stimulated echo acquisition mode (STEAM) sequences (Hofer et al,
2010; Karaus and Frahm, 2009) combining 6/8 partial Fourier
encoding and parallel imaging. Protocol comprised 24-independent
diffusion gradient directions and b-values of 0 and 900 smm2. A total
of 55 transverse sections (2mm thickness) covered brain parts dorsal
and ventral to the corpus callosum. To increase signal-to-noise ratio,
acquisition was repeated three times (17min). Anatomic images were
based on T1-weighted 3D fast low angle shot (FLASH) MRI sequence
(repetition time TR¼11ms, echo time TE¼4.9ms, flip angle 15-).
DTI regions of interest (ROI)
Before calculation of diffusion tensor, diffusion-weighted MRI data
sets were interpolated to 1mm isotropic resolution and smoothed
with a 3D Gaussian filter (half width 1mm). Individual ROIs were
manually defined on colour-coded maps of the main diffusion
direction without thresholding. ROIs for the corpus callosum were
placed in the midsagittal plane as well as in two directly neighbouring
parasagittal sections covering central portions of genu and most
posterior part of splenium (Hofer & Frahm, 2006). Mean values of
fractional anisotropy (FA), ADC, AD and radial diffusivity (RD) were
calculated.
MRI volumetry
Analyses were performed with an automatic brain segmentation tool
for surface-based cortical thickness (http://surfer.nmr.mgh.harvard.e-
du). T1-weighted images underwent corrections for intensity inhomo-
geneity, skull strip and registration into Talairach space followed by
segmentation into grey matter, white matter and various brain areas.
Regional differences of cortical thickness between patient groups were
investigated using Qdec (FreeSurfer for multiple comparisons and
voxel-based morphometry). Statistics relied on p £0.05 (false discovery
rate corrected for multiple comparisons). Visualization employed an
inflated pial surface model.
Mouse studies
Mouse mutants
Experiments were carried out according to animal policies of the
German Federal State of Niedersachsen. CnpR/ mice were geno-
typed with primers Cnp-E3s, 5(-GCCTTCAAACTGTCCATCTC-3(; Cnp-
E3as, 5(-CCCAGCCCTTTTATTACCAC-3( and puro3, 5(-CATAGCCTGAA-
GAACGAGA-3(.
Immunostaining
Mice were anesthetized with Avertin (Sigma–Aldrich, Taufkirchen,
Germany) and perfused through the left ventricle with 15ml of Hank’s
balanced salt solution (Lonza, Basel, Switzerland), followed by 50ml of
4% paraformaldehyde in phosphate buffered saline (PBS). Brains were
harvested and postfixed in 4% paraformaldehyde overnight at 4-C and
then embedded in Paraplast (Surgipath Paraplast; Leica, Wetzlar,
Germany). Microtome sections of 5mm (Microm HM400, Walldorf,
Germany) were prepared. For diaminobenzidine (DAB)-based immu-
nostaining of paraffin sections, Dako-LSAB2 system or Vectastain Elite
ABC kit (Vector laboratories, Burlingame, CA, USA) were used according
to manufacturer’s instructions. Primary antibodies were directed
against APP (1:750, Chemicon (Millipore) Billerica, MA, USA), CD3
(1:150, Serotec, Oxford, UK), GFAP (1:200, Novocastra (Leica) New-
castle Upon Tyne, UK), IBA-1 (1:1000, Wako, Neuss, Germany) and
Mac-3 (1:400, BD Pharmingen, Franklin Lakes, NJ, USA).
Quantitative real time polymerase chain reaction (qRT-PCR)
qRT-PCR was performed using SYBR green master mix (Applied
Biosystems, Foster City, CA, USA) and 7500 Fast Real-Time PCR System
(Applied Biosystems). Specific qRT-PCR primers were designed by
Roche Universal ProbeLibrary Assay Design Center (Cnp, forward 5(-
TAACCCTCCCTTAGCCCCTG-3(, reverse 5(-GTCCCTAGCATGTGGCAGCT-3(;
for normalization: Atp5b forward 5(-GGATCTGCTGGCCCCATAC-3(,
reverse 5(-CTTTCCAACGCCAGCACCT-3(, Rplp0 forward 5(-GATGCC-
CAGGGAAGACAG-3(, reverse 5(-ACAATGAAGCATTTTGGATAATCA-3().
Data were analysed with Microsoft Excel 2010.
Western blot
Myelin purified from protein lysates was performed according to
(Norton & Poduslo, 1973). For Western blotting, proteins were size-
separated in 12% sodium dodecyl sulphate (SDS)–polyacrylamide gels
(0.2mg/ml), blotted onto polyvinylidene difluoride membranes (Hy-
bond P; GE Healthcare, München, Germany), blocked with 5% milk
powder in Tris-buffered saline (TBS) and Tris-buffered salineR Triton X-
100 (TBST; 150mM NaCl, 10mM Tris/HCl, pH 7.4; 0.1% Tween20),
and incubated with primary antibodies (CNPase, 1:5000, Sigma, Saint
Louis, MO, USA; Plp (A431), 1:5000; Jung et al, 1996), overnight at 4-C.
Blots were washed with TBS/0.05% Tween20, incubated with
appropriate secondary horseradish peroxidase-conjugated antibodies
(Dianova, Hamburg, Germany), washed with TBS/0.05% Tween20 and
developed by enhanced chemiluminescence (Pierce, Rockford, IL, USA).
Morphometry
Digitized overlapping light microscopic images (20T if not otherwise
stated), fused to a continuous image of a complete corpus callosum
(bregma 0.74mm) by using Photoshop CS5 and ImageJ software were
analysed for absolute numbers of IBA-1 and Mac-3 positive cells. To
quantify GFAP positive areas, a plug-in for the ImageJ software for
semi-automated analysis was implemented (http://www1.em.mpg.de/
wieser). APP positive axonal spheroids (analysed at 40T magnifica-
tion) and CD3 positive T-cells are expressed as total numbers
quantified in corpus callosum, anterior commissure and striatum.
For all stainings, two sections per mouse were quantified.
Behavioural testing
Tests were performed as described in detail previously, using the
following order: Elevated plus maze (Radyushkin et al, 2010), open field
(Radyushkin et al, 2010), light/dark box (Finn et al, 2003), rota-rod
(Radyushkin et al, 2010), gait analysis (Brooks & Dunnett, 2009), grip
strength (Radyushkin et al, 2010), hole board (Radyushkin et al, 2009),
sociability (Moy et al, 2004), buried-food-finding test for olfaction
(Radyushkin et al, 2009), floating behaviour (analysis of swimming/
floating during a 90s trial in the Morris water maze pool; Morris, 1984;
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Stone & Lin, 2011), tail suspension test (Cryan et al, 2005), bar test
(Kuschinsky & Hornykiewicz, 1972; see Fig 2P and videos of Supporting
Information) and fear conditioning (Radyushkin et al, 2009).
Mouse score
For the catatonia-depression score, five phenotype domains were
created: (I) Depression was operationalized by floating time and tail
suspension (delta time of immobility in the last 2min minus first
2min), (II) catatonia by time on bar, (III) deficit in social interaction by
delta time spent with stranger versus empty compartment, (IV) anxiety
by open field-duration in centre, elevated plus maze – open arm visits,
and fear conditioning – freezing at baseline in cue task and (V) loss of
interest by hole board – number of head dips. Composite score
calculation was done in analogy to the human score and based on
mice with not more than two variables missing (n¼27).
Statistical analysis
Statistical analyses were performed using SPSS for Windows version
17.0 (https://www.spss.com/de) and Prism5 (GraphPad Software, San
Diego, CS, USA). Exact procedures are indicated in the respective sections.
Note: All experiments/analyses in both men and mice were performed
by persons unaware of genotypes (‘blinded’).
Author contributions
NH, SG, SP, KAN and HE developed study concept and design;
NH performed all behavioural analysis of Cnpþ/mice; SP and
AK carried out human genetic analyses and performed the
human association study; UCG and GLW performed the
histological analyses of Cnpþ/ mice under supervision of
SG; DTI study with human subjects was performed by SH and
analysed under the supervision of SB and JF; Administrative,
technical and material support was provided by MB, AR and AG
in different aspects of the study; MB and AK coordinated and
supervised the recruitment of subjects for the DTI study; SHH,
SB and JF gave input to data analysis, interpretation, and
manuscript preparation; NH, SG, SP, AK, KAN and HE wrote the
manuscript; KAN and HE had full access to all of the data in the
study and take responsibility for the integrity of the data and
the accuracy of the data analysis.
Acknowledgements
We are indebted to all patients for their participation in the
GRAS (Göttingen Research Association for Schizophrenia) study
and all collaborating GRAS centres for their support. We are
grateful to all colleagues who contributed to the GRAS data
collection. This work was supported by the Max Planck
Society, the DFG-Research Center for Molecular Physiology of
the Brain (CMPB) and the Bernstein Center for Computational
Neuroscience (BCCN) (Grant 01GQ0431). K.A.N. acknowl-
edges grant support from ERA-Net Neuron (Grant 01EW1102)
and is recipient of an ERC Advanced Grant (Axoglia).
Supporting Information is available at EMBO Molecular
Medicine online.
Research Article
CNP genotypes are associated with catatonia-depression
The paper explained
PROBLEM:
Myelin and white matter abnormalities have been documented
in neuropsychiatric diseases such as schizophrenia, major
depression and bipolar disorder. However, their significance for
disease mechanisms, pathogenesis or phenotypes is still obscure.
A considerable number of postmortem studies found reduced
expression of several myelin genes, including 20,30-cyclic
nucleotide 30-phosphodiesterase (CNP), in the brains of indivi-
duals with severe mental disease. In the present translational
approach, we report for the first time phenotypical consequences
of moderate CNP ‘loss-of-function’ genotypes, that is genetic
variants leading to decreased CNP expression, both inman (single
nucleotide polymorphism rs2070106) and mouse (heterozygous
Cnp null mutant mice).
RESULTS:
We show that reduced CNP expression causes a distinct
behavioural abnormality, seen only upon aging as an additional
‘pro-inflammatory hit’. This phenotype is strikingly similar
between Cnp heterozygous mice and patients with mental
disease, carrying the AA genotype at CNP SNP rs2070106. The
characteristic features in both species are best described as a
‘catatonia-depression’ syndrome and include bizarre posturing,
depression, anxiety, loss of interest in the outside world and
social withdrawal. As a consequence of perturbed CNP expres-
sion, mice show secondary low-grade inflammation and
degeneration of nerve fibres. Analogously, in man, diffusion
tensor imaging points to axonal loss in the frontal corpus
callosum.
IMPACT:
Our genetic data demonstrate that subtle white matter
abnormalities can be the cause of a psychiatric syndrome. To our
knowledge, CNP is the first gene identified to be associated with
catatonia, and aged heterozygous null mutant mice are the first
animal model of spontaneous catatonia. Moderately reduced
CNP expression contributes to a distinct phenotype, which is not
restricted to a single diagnostic category but could explain
features of catatonia-depression in different mental disorders
and possibly – to a milder degree – even in aging healthy
individuals. This knowledge will help defining subgroups of
(aging) subjects who may profit from novel, more specific
therapeutic approaches including anti-inflammatory strategies.
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Supporting Table I 
 
 
Case-control analysis for SNP rs2070106 in exon 4 of 2',3'-cyclic nucleotide 3'-phosphodiesterase 
(CNP) human gene. No statistically significant differences were observed between schizophrenic 
/schizoaffective cases and controls with respect to genotypic and allelic frequencies. 
 
 
Case-control   
 Genotypes P-value 
 GG GA AA Genotypic 
Controls (n=1045) 459 (43.9%) 476 (45.6%) 110 (10.5%) 
0.716 
Cases (n=1048) 477 (45.5%) 459 (43.8%) 112 (10.7%) 
 Alleles P-value 
 G allele A allele Allelic 
Controls (2n=2090) 1394 (66.7%) 696 (33.3%) 
0.622 
Cases (2n=2096) 1413 (67.4%) 683 (32.6%) 
 










Supporting Table II 
 
 
Catatonia-depression composite score: Descriptives and ANOVA results upon inclusion of all 3 
genotypes. The data show that heterozygous (GA) subjects have very similar composite score to GG 






Composite score  
  N Mean 
Std. 
Deviation Std. Error 
95% Confidence 
Interval for Mean Minimum Maximum 




Bound     
AA 40 .3794 .86258 .13639 .1036 .6553 -1.13 1.91 
GA 188 .0497 .76584 .05585 -.0605 .1599 -1.20 2.72 
GG 202 .0308 .74461 .05239 -.0725 .1341 -1.20 2.44 




Composite score  
  
Sum of 
Squares df Mean Square F Sig. 
Between 
Groups 4.217 2 2.108 3.599 .028 
Within Groups 250.138 427 .586     

























































































































































































































































































































































































































































































































































































































































































































Supporting Videos:  
 
 
1 - Catalepsy Test Cnp+/- 
 
2 - Catalepsy Test Wt 
 
 
A phenotype, thus far observed in mice only upon pinching or drug exposure (cannabinoids) is 
catatonia/catalepsy, a state of immobility where mice persist in an externally imposed abnormal posture for a 
prolonged time period. In the bar test, 24 months old male mice are put into a position where they have to grab a 
bar while standing with their hind paws on the floor. Cnp+/- mice persisted in this posture (Video 1), whereas Wt 
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a  b  s  t  r  a  c  t
Autism  is  the  short  name  of  a  complex  and  heterogeneous  group  of  disorders  (autism  spectrum  disorders,
ASD)  with  several  lead  symptoms  required  for classification,  including  compromised  social  interaction,
reduced  verbal  communication  and  stereotyped  repetitive  behaviors/restricted  interests.  The  etiology  of
ASD  is  still  unknown  in  most  cases  but monogenic  heritable  forms  exist  that  have  provided  insights  into
ASD  pathogenesis  and  have  led to the  notion  of  autism  as a ‘synapse  disorder’.  Among  the  most  frequent
monogenic  causes  of  autism  are  loss-of-function  mutations  of  the  NLGN4X  gene  which  encodes  the  synap-
tic  cell  adhesion  protein  neuroligin-4X  (NLGN4X).  We  previously  described  autism-like  behaviors  in  male
Nlgn4  null  mutant  mice,  including  reduced  social  interaction  and ultrasonic  communication.  Here,  we
extend  the  phenotypical  characterization  of  Nlgn4  null  mutant  mice to both  genders  and  add  a  series  of
additional  autism-relevant  behavioral  readouts.  We now  report  similar  social  interaction  and  ultrasonic
communication  deficits  in  females  as  in  males.  Furthermore,  aggression,  nest-building  parameters,  as
well  as  self-grooming  and  circling  as indicators  of  repetitive  behaviors/stereotypies  were  explored  inender  differences
SD
both  genders.  The  construction  of  a gender-specific  autism  severity  composite  score  for  Nlgn4  mutant
mice  markedly  diminishes  population/sample  heterogeneity  typically  obtained  for  single  tests,  resulting
in  p  values  of <0.00001  and  a genotype  predictability  of 100%  for male  and  of  >83%  for  female  mice.  Taken
together,  these  data  underscore  the  similarity  of  phenotypical  consequences  of  Nlgn4/NLGN4X  loss-of-Please cite this article in press as: El-Kordi A, et al. Development of an autism
model  of heritable monogenic autism. Behav Brain Res (2013), http://dx.do
function  in  mouse  and  man,  a
model  with  both  construct  and
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nd  emphasize  the high  relevance  of  Nlgn4  null  mutant  mice  as  an  ASD
 face  validity.
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. Introduction
The term autism spectrum disorders (ASD) describes a group
f etiologically heterogeneous conditions, forced under a common
abel according to presently used clinical classification systems
f psychiatric diseases. The purely phenotypical diagnosis – with
ll its pitfalls and differential diagnoses on top – blinds out the
remendous heterogeneity of ASD and likely also accounts for
he low interrater reliability achieved in the clinical diagnosis of
dult autism [1,2]. The discovery of monogenic heritable forms of
he disorder involving mutations in genes encoding neuroligin-4X
NLGN4X), neurexin-1 (NRXN1), neuroligin-3 (NLGN3), SHANK2,
nd SHANK3, has not only strengthened the notion that autism
ight be a disease of the synapse but also led to the development
f urgently needed mouse models with proven construct valid-
ty [3–9]. In the past, only animal models with some face validity
ould be used to study ASD and to search for therapeutic strategies
10] but no effective treatment for humans is available to date that
ould measurably improve core symptoms of ASD. More adequate
nimal models are expected to improve this situation.
Strikingly, several monogenic mouse models with disruption
f only one synaptic gene display an array of entirely different
ymptoms, reminiscent of autism, i.e. compromised verbal and
on-verbal communication, disturbed social interaction and social
kills, narrowed interests and stereotypical repetitive behaviors
‘routines’), impulsivity and altered aggression (e.g. for review, see
11–13]). Comparable to humans, however, the presentation of
ymptoms with respect to their severity varies considerably among
ndividual mice even if they carry the same ASD-related mutation.
herefore, an autism severity composite score rather than the selec-
ion of single readouts might better assist in the search for new
reatments addressing the core features of the disorder.
The  present study has been designed (1) to comprehensively
haracterize the behavior of Nlgn4 null mutant mice, a construct-
alid model of monogenic heritable autism, extending previous
ork [4] to a greater variety of symptoms, particularly to repet-
tive stereotyped behaviors, and to the female gender which has
ever been studied; (2) to develop an autism composite score with
ighest power of contrasting between autistic and non-autistic
ndividuals as an important basis for future therapeutic strategies.
. Materials and methods
.1.  Mice
For all experiments reported here, male and female Nlgn4 null mutant
Nlgn4−/−)  and wildtype (WT) C57BL/6J mice (littermates) were used. They were
erived  from revitalized frozen embryos that originated from a C57BL/6J-SV129
osaic  Nlgn4−/− line that had been backcrossed into C57BL/6J for 6 generations
4].  After revitalization, Nlgn4−/+ mice were bred with C57BL/6J for 2 further gen-
rations, and then Nlgn4−/+ mice were interbred for colony expansion to generate
ice  for experiments. The revitalization was initiated since there had been con-
erns raised by others regarding a potential loss of phenotypical changes in these
ice  with increasing numbers of generations (‘phenotype bleaching’). See also the
aper by [14]. These concerns even led us to prematurely unblind an 8-arm pre-
linical treatment study with Nlgn4−/− versus WT  mice (littermates) of generation
3,  which had been running in our lab. Due to the still small number of untreated
control)  mice available for behavioral analysis at the time point of unblinding this
tudy, we cannot make any firm conclusions regarding reduction or stability of the
riginally reported phenotype [4]. The tendencies obtained, however, clearly do not
upport a loss of phenotypic changes in Nlgn4−/− (see Supplementary Figures 1–3).
evertheless, such gradual ‘bleaching’ of phenotypic changes over generations with
espect to higher brain functions may  well happen, as illustrated by our follow-
p  studies of another mouse strain, cEPOR transgenic mice, where the transgene
xpression  remained stable over the respective generations, but the initially supe-
ior spatial learning and memory, reversal learning/cognitive flexibility and activityPlease cite this article in press as: El-Kordi A, et al. Development of an autism
model  of heritable monogenic autism. Behav Brain Res (2013), http://dx.do
radually returned to control levels ([15]; Supplementary Figure 4).
Mouse genotyping: WT and Nlgn4−/− littermates were obtained from
lgn4+/−  heterozygous breeding pairs. Genotypes of the offspring were ana-
yzed  by PCR of tail genomic DNA using the following primers: Forward primer
′-CTTCCTATCCTGTTACTCTCAC-3′ , WT reverse primer 5′-TAGGGAAAGCGGAAT PRESS
 Research xxx (2013) xxx– xxx
TGAGTGTAAC-3′ (yielding a 475 bp product) and KO reverse primer 5′-
ACACTCCAACCTCCGCAAACTCCT-3′ (yielding a 183 bp product). PCR amplification
of  the DNA was  carried out with the following conditions: 5 min, 94 ◦C (1 cycle);
30  s, 94 ◦C; 30 s, 64 ◦C; 1 min, 72 ◦C (30 cycles), followed by final extension at 72 ◦C
for  7 min.
2.2.  Behavioral testing
All  experiments were approved by the local Animal Care and Use Committee in
accordance with the German Animal Protection Law. For behavioral testing, mice
were housed in groups of 3–5 (except where otherwise specified) in standard plas-
tic cages, with food and water ad libitum. The temperature in the colony room
was  maintained at 20–22 ◦C, with a 12 h light–dark cycle (light on at 7:00 am). All
behavioral  experiments were conducted by investigators, unaware of the genotype
(‘blinded’), during the light phase of the day (between 8:00 am and 5:00 pm). Basic
behavioral functions were assessed in 2 large consecutive cohorts of male and female
mice (genders tested separately) in the following order: elevated plus maze, open
field, hole board, rota-rod, pre-pulse inhibition of the startle response (PPI), social
interaction in pairs, ultrasound vocalization, and LABORAS spontaneous home cage
behavioral assessment. The second cohort (again genders tested separately) was
additionally evaluated in LABORAS, in a modified version of social interaction in
the tripartite chamber [16], olfaction, marble burying, nest building, induced self-
grooming in LABORAS as well as in enriched environment, and finally aggression,
using  the resident-intruder paradigm. The age of mice at the beginning of test-
ing was 11–12 weeks. Inter-test interval varied depending on the degree of ‘test
invasiveness’ but was at least 1 day.
Elevated Plus Maze Test: Individual animals were placed on the central plat-
form  facing an open arm of the plus-maze (made of gray Perspex with a
5  cm × 5 cm central platform, 2 open arms of 30 cm × 5 cm,  and 2 closed arms of
30  cm × 5 cm × 15 cm,  with overall illumination at 135 lx). Behavior was recorded
for  5 min by an overhead video camera and a computer equipped with Viewer 2
software (BIOBSERVE GmbH, St. Augustin, Germany) to calculate the time each ani-
mal spent in open or closed arms. The proportion of time spent in open arms was
used for the estimation of open arm aversion, which is an indicator of fear.
Open Field Test: Spontaneous activity in the open field was tested in a gray circu-
lar  Perspex arena (120 cm in diameter, 25 cm high). Individual animals were placed
in the center of the open field and were allowed to explore it for 7 min. The behav-
ior  was recorded by a computer-linked overhead video camera. Viewer 2 software
(BIOBSERVE  GmbH) was used to calculate the distance traveled and the time spent
in the central, intermediate, and peripheral zones of the open field.
Hole Board Test: Individual mice were placed in the center of the hole board
(transparent  Perspex chamber (50 cm × 50 cm × 36 cm), with a non-transparent
floor  raised 3 cm above the bottom of the chamber with 16 equally spaced holes
of  2.2 cm diameter), and allowed to explore the chamber for 5 min. The number of
holes explored (head dips) was  monitored by 2 layers of infrared photo beams con-
nected to a computer with the AKS software (TSE Systems GmbH, Bad Homburg,
Germany).
Rota-Rod  Test: The rota-rod (Ugo Basile Srl, Comerio, Italy) comprised a rotating
drum  which was  accelerated from 4 to 40 rpm over the course of 5 min. Individual
mice  were placed on the drum, and once they were balanced, the drum was accel-
erated. The time in seconds at which the respective animal fell from the drum was
recorded using a trip switch. Each animal went through 3 consecutive trials, one
trial per day.
Pre-Pulse Inhibition Test: Individual mice were placed in small metal cages
(82  mm × 40 mm × 40 mm)  to restrict major movements and exploratory behav-
ior.  The cages were equipped with a movable platform floor attached to a sensor
that  recorded vertical movements of the floor. The cages were placed in 4 sound-
attenuating  isolation cabinets (TSE Systems GmbH). Startle reflexes were evoked by
acoustic stimuli delivered from a loudspeaker that was suspended above the cage
and connected to an acoustic generator. The startle reaction to an acoustic stimu-
lus,  which evokes a movement of the platform and a transient force resulting from
this movement of the platform, was recorded with a computer during a recording
window  of 260 ms  and saved for further evaluation. The recording window was
defined from the onset of the acoustic stimulus. An experimental session consisted
of  a 2 min  habituation to 65 dB background white noise (continuous throughout
the  session), followed by a baseline recording for 1 min  at background noise. After
baseline recording, 6 pulse-alone trials using startle stimuli of 120 dB intensity and
40 ms  duration were applied to decrease influence of within-session habituation.
These  data were not included in the 120 dB/40 ms  analysis of the pre-pulse inhibi-
tion.  For tests of pre-pulse inhibition, the startle pulse was  applied either alone or
preceded by a pre-pulse stimulus of 70 dB, 75 dB, or 80 dB intensity and 20 ms dura-
tion. An interval of 100 ms  with background white noise was used between each
pre-pulse and pulse stimulus. The trials were presented in a pseudorandom order
with an interval ranging from 8 to 22 s. Amplitude of the startle response (expressed severity score for mice using Nlgn4 null mutants as a construct-valid
i.org/10.1016/j.bbr.2012.11.016
in  arbitrary units) was defined as a difference between the maximum force detected
during a recording window and the force measured immediately before the stimu-
lus onset. Amplitudes were averaged for each individual animal, separately for both
types of trials (i.e. stimulus alone or stimulus preceded by a pre-pulse). Pre-pulse
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ormula: % pre-pulse inhibition = 100 − [(startle amplitude after pre-pulse)/(startle
mplitude  after pulse only) × 100].
Sociability and Social Memory Tests: Sociability and social memory were tested
s  described [16] with small modifications. The social testing arena was  a rectan-
ular, 3-chambered box. Each chamber was 40 cm × 20 cm × 22 cm in size. Dividing
alls  were made from clear Plexiglas, with rectangular openings (35 mm × 220 mm)
llowing access into each chamber. The chambers of the arena were cleaned and
resh wood-chip bedding was added between trials. The test mouse was first
laced  in the middle chamber and allowed to explore for 5 min. The openings
nto  the 2 side chambers were obstructed by plastic boxes during this habitua-
ion  phase. After the habituation period, a C57BL/6N male mouse of the same age
stranger 1) without prior contact with the test mouse was  placed in one of the
ide chambers. The location of stranger 1 in the left versus right side chamber was
ystematically alternated between trials. The stranger mouse was  enclosed in a
mall (140 mm × 75 mm × 60 mm),  rectangular wire cage, which allowed nose con-
act through the bars but prevented fighting. The animals serving as strangers had
reviously been habituated to placement in the small cage. An identical empty wire
age was placed in the opposite chamber. A weighted cup was placed on the top
f the small wire cages to prevent climbing by the test mice. Both openings to the
ide chambers were then unblocked and the subject mouse was  allowed to explore
he entire social test arena for a 10 min  session. The amount of time spent in each
hamber and the number of entries into each chamber were recorded by the video-
racking system Viewer 2 (BIOBSERVE GmbH). An entry was  defined as all 4 paws
n one chamber. At the end of the first 10 min, each mouse was  tested in a second
0 min  session where stranger 1 changed the side to avoid bias by side preference.
t  the end of this session, mice were tested in a third 10 min episode to quantify
ocial  preference for a new stranger. A second, unfamiliar mouse of the same age
stranger 2) was  placed into the previously empty wire cage. The test mouse had a
hoice between the already familiar stranger 1, and the novel unfamiliar stranger
.  As described above, time spent in each chamber and the number of transitions
etween  chambers of the apparatus during the first (social preference) and third
0 min  session (social memory) were analyzed. Based on the amount of time spent
n each chamber, a ‘sociability index’ and a ‘social memory index’ were calculated
ccording  to the following formulas:
ociability index = timestranger
timestranger + timeempty
× 100
emory  index = timenovel
timenovel + timefamiliar
× 100
Test  of Social Interaction in Pairs, i.e. ‘Social Approach’: The social interaction test
as performed in a neutral cage (gray Plexiglas box, 30 cm × 30 cm × 30 cm). During
 consecutive days, each individual mouse went through one 10 min session in the
eutral cage to habituate to the testing conditions. On day 3 (test day), pairs of
nfamiliar  mice of the same genotype were placed into the neutral cage for 10 min.
ehavior of mice was recorded by a computer and the video-tracking system Viewer
 (BIOBSERVE GmbH). The time spent in social interaction (defined as staying in close
ontact) was  registered.
Buried  Food Finding Test: Starting 6 days before testing, mice were habituated
o  clear cages (29.5 cm × 18.5 cm × 13 cm) for 20 min, 4× per day. Starting 4 days
efore  testing, mice received a piece of chocolate cookie (1.6 g) with water ad libi-
um at each habituation. Additionally, mice received 3–5 cookies in their home cage
ver night which they consumed within 24 h. When mice consumed also the cook-
es during the habituation phase, testing was performed on the next day. Starting
2  h before testing, mice were deprived of food with water ad libitum. For testing,
ndividual  mice were placed into clear cages, in which a piece of chocolate cookie
as  hidden under 1.5 cm standard bedding at the end of the cage. The mouse was
ositioned in the right corner at the opposite end of the cage, and the food finding
ime,  i.e. the time from the moment the mouse was placed into the cage to the time
t located the cookie and initiated burrowing, was  recorded. As soon as the cookie
as  detected, the mouse was removed from the cage. Fresh bedding was  used for
ach trial; all mice underwent identical testing procedures.
Resident-Intruder Test: Inter-male aggression was  studied using the
esident–intruder paradigm (e.g. [17,4]). Previously group housed male mice
ere  separated and housed individually for 21 days before testing. As standard
pponent  males, we  used group-caged males of the same age (4 months) from
he  C57BL/6N strain (Charles River, Sulzfeld, Germany). A standard opponent was
ntroduced into the cage of the tested resident male and observation started when
 tested resident male sniffed the opponent for the first time. The observation was
topped immediately after the first attack (an attack being defined as a bite) to
revent wounding, but lasted 10 min  if no attack occurred. The latency to attack
as  recorded by a stop watch.
Ultrasound Vocalization Analysis: We  recorded ultrasonic vocalizations (USVs)
f  male mice using the recording software Avisoft Recorder 4.2 at a sampling fre-Please cite this article in press as: El-Kordi A, et al. Development of an autism
model  of heritable monogenic autism. Behav Brain Res (2013), http://dx.do
uency of 300 kHz. The microphone (UltraSoundGate CM16) was  connected to a
reamplifier (UltraSoundGate 116), which was connected to a computer (all sound
ecording hardware and software was  from Avisoft Bioacoustics, Berlin, Germany).
or  the recording, resident mice (males and females) were housed in single cages.
t the day of the recording, mice in their own home cage were placed on the desk PRESS
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in  the recording room for 60 s. Subsequently, the intruder mouse was put into the
home cage of the resident, and the vocalization behavior was recorded for 3 min.
We recorded male mice with unfamiliar female mice in estrous. Female mice were
tested with anaesthetized unfamiliar females (anesthetic: intraperitoneal injection
of 0.25% tribromoethanol, 0.1 ml/10 g body weight). We counted the number of calls
per recording session and separated USVs from other sounds using the whistles
detection  algorithm of AVISOFT RECORDER 4.2 with following selection criteria: Pos-
sible changes per step = 4 (4687 Hz), minimal continuity = 8 ms,  possible frequency
range  = 35–150 kHz. These criteria had been tested in former studies of mouse USVs
[4,18].
LABORAS: The LABORASTM system (Metris b.v., Hoofddorp, The Netherlands)
consists  of a triangular shaped sensor platform (Carbon Fiber Plate
1000  mm × 700 mm × 700 mm × 30 mm,  Metris b.v.), positioned on 2 orthogonally
placed  force transducers (Single Point Load Cells) and a third fixed point attached
to  a heavy bottom plate (Corian Plate 980 mm × 695 mm × 695 mm × 48 mm,
Metris  b.v.). The whole structure stands on 3 spikes, which are adjustable in height
and absorb external vibrations. Mice are housed in clear polycarbonate cages
(Makrolon  type II cage, 22 cm × 16 cm × 14 cm)  with a wood-chip bedding covered
floor.  The cage is placed directly onto the sensing platform, with the upper part
of  the cage (including the top, food hopper and drinking bottle) suspended in a
height-adjustable frame separate from the sensing platform. Resultant electrical
signals  caused by the mechanical vibrations of the movement of the animal are
transformed by each force transducer, amplified to a fixed signal range, filtered
to  eliminate noise, digitized and then stored on a computer. The computer then
processes the stored data using several signal analysis techniques to classify the
signals into the behavioral categories of eating, drinking, scratching, circling,
climbing,  immobility, locomotor activity and grooming (for details see [19]). The
behavior which dominates is scored. Spontaneous mouse behavior was  assessed
from  5:00 pm until 9:00 am,  with 1 h habituation to the cages before the initiation
of  recording. Behaviors during the light as well as the dark cycle were analyzed
separately.
Marble  Burying Test: This test is used to assess stereotypies and
obsessive–compulsive behaviors in mice [20]. Mice were tested in plastic
cages  (34.5 cm × 56.5 cm × 18 cm)  filled with 5 cm deep wood-chip bedding. Evenly
spaced  (4 cm apart) 24 glass marbles were placed on the surface. Individual mice
were put in the cage and left there for 30 min. Illumination was dimmed (6 lx). The
number of buried marbles (to 2/3 their depth) during this time was counted. Two
groups of mice with different housing conditions were tested. Mice were single
housed  for at least 10 days. Another group was left in the group housing cages.
Nest Building: Nest construction is an important indicator of social and reproduc-
tive  behavior [21,22]. The nest building test was conducted according to a previously
reported protocol [21]. Approximately 1 h before the dark phase, group housed mice
were transferred to single housing cages with wood-chip bedding and nesting tow-
els, but no environmental enrichment items. After 2 nights of habituation, nesting
towels  were removed and nestlets (pressed cotton squares, weighing ∼3 g) placed
in  the single housing cages. Nest building was  assessed on the next morning using
a rating scale where high scores indicate an almost perfect nest.
Induced  Self-Grooming in LABORAS and Enriched Environment: Grooming is a com-
mon and robust behavior in rodents. Excessive grooming has been observed in
animal models of obsessive-compulsive disorders as well as ASD [23,8]. The natural
tendency to groom might be amplified by various experimental procedures [24].
We used water induced self-grooming according to a previously described protocol
[24] with slight modifications. Mice were misted with water and placed on the LAB-
ORAS platforms (see above) under red light for a 30 min recording session. Behavior
was  simultaneously video-recorded. The misting procedure was as follows: Mice
were taken by their tail and lifted over a table, then misted with a spray bottle filled
with water at room temperature. The misting pattern was 3× on the back (distance
30  cm), 3× on the abdomen and again 3× on the back. The analysis of LABORAS data
was  done as described above. Video-recorded grooming duration was estimated by
2 independent raters, unaware of the genotype. After an interval of 2 weeks, ani-
mals were placed into cages with enriched environment (with paper towel, toilet
rolls, running wheel) and kept there for 72 h. Then grooming was  induced again as
described above and behavior was  recorded (under red light in the enriched envi-
ronment cages) with a video camera. Video ratings were conducted in the same
manner  as described above.
Statistical  Analysis: Unless stated otherwise, the data given in figures and text
are expressed as mean ± SEM, and were compared by 2-way analysis of variance
(ANOVA)  with post hoc planned comparisons, or by ANOVA for repeated measure-
ments,  Mann–Whitney U and 2 test where appropriate, using SPSS v.17 Software,
San Diego, USA. A p value below 0.05 was considered to indicate significance.
Autism Composite Score: For the autism composite score, selected single readouts
were  z-standardized and presented such that higher values represent higher symp-
tom severity. Relevant items were selected based on significant Mann–Whitney U
test results. To build the scores on complete data sets, for each behavioral test, a
linear regression based multiple imputations (10 iterations) model of missing data severity score for mice using Nlgn4 null mutants as a construct-valid
i.org/10.1016/j.bbr.2012.11.016
(males: vocal calls 17.6%, nesting score 23.5%, social approach 11.8%, marble burying
23.5%, circling 35.3%, aggression 32.4%; females: vocal calls 2.8%, novelty index 2.8%,
social approach 11.1%, marble burying 16.7%, circling 52.8%) was applied to the z-
standardized single tests for male and female mice separately. A total of 17 male mice
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 out of 6 readouts were missing. Altogether 4 female mice (N = 4 WT)  were excluded
ecause  more than 3 out of 5 readouts were lacking. Thus, the imputation models
ere  based on 34 (N = 16 WT and N = 18 KO) male and 36 (N = 21 WT and N = 15 KO)
emale  individuals. Note that missing values are mainly due to test logistics (limi-
ations of mouse numbers running in a certain test); there was no other systematic
eason  for exclusion of animals from particular tests, and exclusions were all ran-
om. Gender specific composite scores were calculated by integrating the means
f the imputation matrices of all behavioral readouts. Genotype dependent group
omparisons were conducted by Mann–Whitney U tests. Intercorrelation patterns
pairwise  Pearson correlations) were based on available sets of z-standardized raw
cores.
. Results
.1. Basic behaviors are normal in male and in female Nlgn4 null
utant  mice
Basic  behavioral test results for activity, anxiety, motor perfor-
ance, exploratory behavior and sensorimotor gating of both male
nd female Nlgn4 null mutant mice are shown separately in Sup-
lementary Figures 5 and 6. Genotypes did not differ in elevated
lus maze, open field, rota-rod, hole board, startle response and
PI performance.
.2. Nlgn4 null mutants of both genders display broadly impaired
ocial  behaviors and communication
To comprehensively characterize the social phenotype in adult
lgn4 null mutants of both genders, we assessed social approach
ehavior, vocalization, aggression and nest building (Fig. 1). Con-
istent with our previously reported findings in male Nlgn4 null
utants only [4], we again saw significantly reduced interaction
ime in males (Fig. 1A; p = 0.0006). This observation was  now also
ade independently in female mutants (Fig. 1B; p = 0.015). Addi-
ionally, the number of calls was significantly reduced in both
enders of Nlgn4 null mutants (Fig. 1C, D; p = 0.006 and p = 0.0097,
espectively). Again, as shown earlier [4] male Nlgn4 null mutants
ad a higher attack latency in the resident-intruder paradigm
Fig. 1E; p = 0.025). In a newly performed test, nest building, only
ale mutants had a higher proportion of untouched nesting mate-
ial (Fig. 1F, inset, p = 0.049) and built significantly less functional
ests (Fig. 1G; p = 0.006). Female mutants showed the same ten-
ency as the males. Their potential performance deficits, however,
id not reach statistical significance (Fig. 1F, H).
.3. Deficits in social functions of Nlgn4 null mutants as
etermined in the tripartite chamber are mild and look different
ependent on gender
As  reported previously [4], male Nlgn4 null mutants showed
 deficit in the first trial of social interaction in the tri-
artite chamber (Supplementary Figure 7A; 2-way ANOVA
M, Finteraction(1,39) = 8.935, p = 0.0048; Fcompartment(1,39) = 94.45,
 < 0.0001; Fgenotype(1,39) = 0.6493, p = 0.4253). Post hoc single com-
arisons revealed that mutant mice spent less time in the
ompartment with the stranger mouse, and more time in the
mpty compartment (mouse compartment: p = 0.018; empty com-
artment: p = 0.02). Consequently, male mutant mice had a
ignificantly lower sociability index as compared to WT  animals
Supplementary Figure 7C; p = 0.0058). In contrast, in the present
eries of tests, social novelty was indistinguishable between WT
nd mutant males (Supplementary Figure 7E,G). On the other
and, sociability was not affected in female Nlgn4 null mutantsPlease cite this article in press as: El-Kordi A, et al. Development of an autism
model  of heritable monogenic autism. Behav Brain Res (2013), http://dx.do
Supplementary Figure 7B,D) which, however, showed a deficit
n social memory (Supplementary Figure 7F; 2-way ANOVA
M, Finteraction(1,37) = 6.444, p = 0.0155; Fcompartment(1,37) = 3.163,
 = 0.0835; Fgenotype(1,37) = 3.826, p = 0.0581). Post hoc single PRESS
 Research xxx (2013) xxx– xxx
comparisons revealed a significantly reduced time spent with the
new mouse in the female mutant group (Supplementary Figure 7F,
p = 0.015) and thus a reduction in their novelty index (Supplemen-
tary Figure 7H; p = 0.036).
3.4. Stereotyped repetitive behaviors are detectable in Nlgn4 null
mutant  mice of both genders
Since  stereotypies are an important feature of ASD, we decided
to study this trait in Nlgn4 null mutants and their WT  littermates
in more detail. To this end, we assessed marble burying both in
single and group housed mice. Single housing has previously been
used as an environmental stressor leading to subtle alterations in
behavior [25]. Interestingly, only single housed null mutants of both
genders had an increased number of buried marbles (Fig. 2A, B, left
panels; Mann–Whitney U tests, p = 0.0281 and 0.0093 respectively).
Group housed mice did not demonstrate a genotype effect (Fig. 2A,
B, right panels). Spontaneous homecage behavior assessed via LAB-
ORAS revealed other compulsive features: Nlgn4 null mutants of
both genders had more circling episodes (Fig. 2C, D, left pan-
els; Mann–Whitney U tests, p = 0.0244 and p = 0.0424 respectively),
with general locomotion being unaffected (Fig. 2C, D, right panels).
Grooming is considered to be an ecologically relevant behav-
ioral trait in mice [26]. Excessive grooming has been reported
in various mouse lines [23,27,28] and is regarded to be anal-
ogous to human obsessive–compulsive behaviors (e.g. [29]). To
analyze grooming under standardized conditions, we  misted
mice with tap water and recorded self-grooming for 30 min
under standard single housing conditions which revealed a sig-
nificant interaction effect in female mice (Fig. 2F, left panel:
Finteraction(2,54) = 5.888, p = 0.0049; Ftime(2,54) = 303.8, p < 0.0001;
Fgenotype(1,27) = 0.5509, p = 0.4644). There were no significant differ-
ences between male Nlgn4 null mutants and WT littermates (Fig. 2E,
left panel: Finteraction(2,48) = 0.3685, p = 0.6937; Ftime(2,54) = 254.9,
p  < 0.0001; Fgenotype(1,24) = 0.9074, p = 0.3503). Post hoc single com-
parison detected a significant difference between female mutants
and WT  in the second 10 min  interval (Fig. 2F, left panel;
p = 0.009), indicating increased grooming time in the mutant
group. Since autism is also characterized by reduced inter-
ests and higher resistance towards environmental distractors,
we tested whether mice generally groomed less in a more
attractive and stimulating environment – perhaps paying more
attention to the environmental enrichment instead of compul-
sive self-grooming. Surprisingly, however, induced self-grooming
under enriched conditions was  even more pronounced and did
not differ between genotypes in any of the genders (Fig. 2E,
right panel; Finteraction(2,46) = 1.621, p = 0.2088; Ftime(2,46) = 53.59,
p  < 0.0001; Fgenotype(1,23) = 1.422, p = 0.2453. Fig. 2F, right panel;
Finteraction(2,46) = 0.123, p = 0.8847; Ftime(2,46) = 96.26, p < 0.0001;
Fgenotype(1,24) = 0.1202, p = 0.7318).
3.5.  Development of an autism severity composite score for mice
Comparable  to a known form of a human monogenic herita-
ble autism, where mutations of the NLGN4X gene can lead to a
variety of ASD typical symptoms, we  found readouts of social inter-
action, ultrasound communication, and stereotyped behaviors also
altered in Nlgn4 null mutant mice. Thus, disruption of only one
single gene results in a diverse array of behavioral abnormali-
ties. To account for individuality of discrete symptom severity in
the autistic syndrome as a whole as well as for gender differ-
ences, we  created an autism severity score, separately for male severity score for mice using Nlgn4 null mutants as a construct-valid
i.org/10.1016/j.bbr.2012.11.016
and female mice. For this autism composite score, selected sin-
gle symptom readouts were z-standardized and genotype groups
were contrasted by Mann–Whitney U tests (Fig. 3A, B). Behav-
ioral tests with a clear genotype dependent dissociation of means
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Nesting ma teria l H
Fig. 1. Diverse features of social behaviors are affected in Nlgn4 null mutants (KO) of both genders as compared to wildtype (WT) mice. (A, B) Male as well as female Nlgn4
null mutant mice spent less time in direct social contact with a stranger mouse from the same genotype and gender (♂: WT = 36; KO = 26; ♀: WT = 30; KO = 22). (C, D) Null
mutants had significantly fewer calls in the ultrasound vocalization paradigm (♂: WT = 29; KO = 24; ♀: WT  = 36; KO = 23). (E) Male Nlgn4 KO mice had longer attack latency
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esting material untouched and built significantly less functional nests (♂: WT  = 13; KO 














































































































































ig. 2. Nlgn4 null mutant mice demonstrate increased stereotyped behaviors (A, B) Bo
O = 13; ♀: WT = 15; KO = 15) – buried more marbles in contrast to WT mice. This significa
T  = 24; KO = 13). (C, D) Spontaneous circling behavior (left) in LABORAS was  increased i
right) (♂: WT = 17; KO = 16; ♀: WT = 14; KO = 15). (E, F) Water misting induced self-gr
ompared to WT  (left: normal environment: ♂: WT = 13; KO = 13; ♀: WT = 15; KO = 14; rig
resented. severity score for mice using Nlgn4 null mutants as a construct-valid
i.org/10.1016/j.bbr.2012.11.016




































































































































































th male and female Nlgn4 mutants–when single housed (left panel: ♂: WT = 13;
nt difference disappeared upon group housing (right panel: ♂: WT  = 13; KO = 7; ♀:
n Nlgn4 mutants of both genders without alterations in general locomotor activity
ooming, which showed an increase in female, but not in male Nlgn4 KO mice as
ht: enriched environment, ♂: WT = 12; KO = 13; ♀: WT  = 13; KO = 13). Mean ± SEM
ARTICLE IN PRESSG ModelBBR-7988; No. of Pages 9















1.20 WT (N=8-2 5)
KO (N =9-15)





















p=0.00 1 p=0.38 3 p=0.00 7 p=0.03 5 p=0.00 8 p=0.24 8
-0.5<r< 0.1 0.1<r<0.3
0.3<r<0.5 0.5 <r<0.7
Cronbach’s alp ha:  0.65 0
Cronbach’s alp ha:  0.63 2
Communication Social fun ctions Re petitive behaviors,  stereo typies
















































































Fig. 3. Transformation and preparation of data for the development of an autism severity composite score (A) Male mice: Contrasting of 7 autism-relevant single behavioral
readouts (mean ± SEM) following z-standardization allows all but one (novelty index) to be integrated into the composite score based on a very good Cronbach’s alpha of


























onsisting of all 3 lead domains of ASD (B) Female mice: Contrasting of 6 autism-r
ut  one (nesting score) to be integrated into the composite score based on a very g
ubstantiating the integration of all readouts into one score. Intercorrelations are d
group comparison significant or at least showing a strong ten-
ency) were selected with the aim of building gender specific
omposite scores for each individual mouse, assuring coverage of
ll 3 diagnostic domains of ASD (i.e. communication, social func-
ions, repetitive behaviors/stereotypies). These composite scores
hould reflect the overall severity of autistic behaviors in a continu-
us fashion with higher values indicating higher severity of autistic
ehaviors. For male mice, the composite score was  based on vocal
alls, aggression, nesting, social approach, marble burying and cir-
ling (resulting in a Cronbach’s  ̨ = 0.632). For female mice, vocal
alls, social approach, novelty index, marble burying, and circling
Cronbach’s  ̨ = 0.650) were included in the composite score. Inter-
orrelations between single score items are displayed in Fig. 3A,
. Gender specific autism severity composite scores, calculated by
ntegrating the means of all behavioral readouts (following impu-
ations as described in materials) yielded highly significant results
p < 0.0001) for both genders for contrasting between mutant and
T mice (Fig. 4A, B). The relative frequency distribution of thePlease cite this article in press as: El-Kordi A, et al. Development of an autism
model  of heritable monogenic autism. Behav Brain Res (2013), http://dx.do
utism severity composite score discriminates well between WT
nd null mutant mice, with a slightly higher overlap seen for female
s compared to male subjects (Fig. 4C, D). Individual animals can
e assigned to the correct genotype with nearly 100% predictionnt single behavioral readouts (mean ± SEM) following z-standardization allows all
ronbach’s alpha of >0.6. This value supports a high internal consistency of the data
ed in the construct, consisting of all 3 lead domains of ASD.
accuracy  in males (75% of phenotypic variance explained; calcula-
tions based on a binary logistic regression model using the imputed
complete data set). In female mice, 54% of phenotypic variance is
explained by the respective model and >83% of predictions of geno-
type status are correct (73% of mutants correctly identified as such
and 91% of WT  correctly assigned to the WT  group by the model)
(Fig. 4E, F).
4.  Discussion
The present study provides a comprehensive phenotypical
characterization of Nlgn4 null mutant mice, thereby essentially
reproducing our own  previous work on Nlgn4−/− males [4] and
extending it – independently – also to females and, notably, to a
number of new ASD relevant tests, most of which turned out to
be informative. The results show that both genders of Nlgn4 null
mutants display a multifaceted autistic-like syndrome consisting
of distinctive symptoms for all 3 lead features of the disorder: severity score for mice using Nlgn4 null mutants as a construct-valid
i.org/10.1016/j.bbr.2012.11.016
Disturbed social interactions, compromised verbal (ultrasound)
communication and repetitive behaviors/restricted interests. Most
importantly, based on these typical behavioral symptoms (as
evaluated by the most informative tests), we have been able to
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everity) based on the z-transformed raw data of selected tests with significant di
n materials), gives highest significance levels for both genders. (C, D) Relative freq
verlap in males than in females. (E, F) The autism score of individual mice striking
evelop for the first time an autism severity composite score
or mice. This score allows a highly significant discrimination
etween autistic and non-autistic Nlgn4−/− mice, with an accu-
acy of 100% for males and of >83% for females to predict the
enotype status from the behavioral readouts. In the meanwhile,
his same score has already been successfully applied to other
enetic mouse models of autism analyzed in our lab (manuscript in
reparation).
Compared to the other tests of social behavior with their
onsistently robust findings (social approach behavior, vocaliza-
ion, aggression and nest building), demonstrated again in the
resent work, the discriminatory power of the tripartite cham-
er tests [16] remains delicate and difficult to reproduce, at least
n our hands. In fact, we made similar observations with these
ests in various different mouse lines that we  have analyzed over
he years. Lab-to-lab variations including differences in breed-
ng, upbringing and maintenance or even differential effects of
odifier genes may  explain at least part of these difficulties. In
he present work, these problems of the tripartite chamber tests
re reflected by the partly divergent results in male mice (i.e.
n social memory) when comparing the previously published [4]
nd the present cohort. The reason for this discrepancy remains
nknown but all other findings of the previous study were entirely
eproducible.
The fact that the prediction of genotype from behavior is less
ccurate for female mice reflects the overall milder and slightly
ifferent ASD-like phenotype found here in female as compared toPlease cite this article in press as: El-Kordi A, et al. Development of an autism
model  of heritable monogenic autism. Behav Brain Res (2013), http://dx.do
ale mice, despite the use of mostly higher n-numbers for test-
ng of females. It has to be mentioned, however, that due to space,
ersonnel and logistic limitations, male and female mice were not
trictly tested in parallel. Therefore, a direct statistical comparisonce between genotypes (Fig. 3) and imputed values for missing data (as explained
 distribution of autism composite score bins separates WT and mutants, with less
riminates between genotypes.
is  not justified. The comparison provided here is descriptive and
looks separately at the test results obtained with both genders.
Particularly in nesting but also in induced self-grooming
and social interaction readouts, genders differ clearly. Of note,
gender-specific findings have been reported in several other
mouse models of autism (e.g. [30,9]) and, also in humans, autis-
tic symptom severity and distribution show gender differences
[31–36].
Moreover, individuality is an important issue in ASD. Despite
having the same mutation, persons affected by the disorder can
show different severity and different lead symptom distribution
[37–43]. This observation may  partly be explained by genetic and
environmental modulation of the syndrome. Interestingly, how-
ever, the same still holds true for mice where almost identical
environmental conditions (cage, group, food, etc.) on top of the
highly inbred background tremendously diminish variability as
compared to humans.
Nevertheless, a fascinating example of how environment can
modify behavior is shown by our results on marble burying behav-
ior in both genders. Here, group housing alleviates the compulsive
phenotype. Interestingly, social enrichment and environmental
complexity have been reported to improve the autistic phenotype
in e.g. fragile X mice [44] as well as in humans [45,46], supporting
the important role of the social context and of behavioral psy-
chotherapy in autistic individuals [47–49].
As shown here, the development of an autism severity score
has delivered a more robust ground for future treatment studies severity score for mice using Nlgn4 null mutants as a construct-valid
i.org/10.1016/j.bbr.2012.11.016
than single readouts with their higher heterogeneity in the popu-
lation and their smaller effect sizes. The score provides a powerful
and unitary measure for the overall severity of autistic symptoms,
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ompounds for the treatment of autism should always happen in
oth genders and across a wide range of autism-relevant tests.
pplying integrative gender-specific scores will largely simplify the
uantification and validation of treatment outcomes in both male
nd female experimental groups.
Since autism is usually diagnosed in children before the age of
 years, assessment of neurobehavioral developmental milestones
n neonatal mice up to the age of 3–4 weeks will be interesting for
urther characterization of the Nlgn4−/− mouse model of autism. In
he present work, we did not yet address these questions. Moreover,
evelopmental disturbances (e.g. seizures, learning and memory
mpairments) will have to be assessed. The good construct and face
alidity of the present mouse model may  now encourage in depth
tudies on the issue of predictive validity e.g. by using pharma-
ological agents or genetic rescue of the phenotype. In the case
tudied here, one gene aberration causes the syndrome. There-
ore, ideally, a causal treatment should also combat all features
f the disorder. In the present study, group in contrast to sin-
le housing of Nlgn4 null mutants obviously attenuated selected
ompulsive/stereotypic traits, indicating a social component of
ymptom severity. Further work will have to elucidate the effect
f potential modifying environmental factors, e.g. environmental
omplexity and social enrichment, in the Nlgn4 null mutant model.
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